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Abstract 
The proteoglycan aggrecan, which is a major structural component of cartilage, has 
been identified as a candidate autoantigen in rheumatoid arthritis (RA). This is 
principally due to its degradation early in the disease pathology, its ability to induce 
an RA-like disease in mouse models and the presence of elevated numbers of reactive 
T and B cells in RA patients. Studies have also defined an essential requirement for 
autoantigen-specific B cells as antigen presenting cells (APC) in RA although the 
cellular mechanisms involved in antigen processing and presentation of joint-derived 
autoantigens by B cells remains unknown.  
 
To investigate the role of autoreactive B cells as APC in RA, I have used two 
complimentary approaches to generate B cells expressing an aggrecan-specific B cell 
receptor (BCR). The first was based on a modified monoclonal antibody production 
protocol and the second involved the transfection of B lymphoma cells with newly 
generated plasmids encoding an aggrecan-specific BCR.  
 
Using the second approach, I have successfully generated aggrecan-specific B cell 
lines (C71-4C5 and C71-5F10). I have shown that these B cells specifically bind 
aggrecan leading to efficient processing and the generation of the immunogenic T cell 
epitope 84-103 that is recognised by both aggrecan-specific T cell hybridomas and 
CD4+ T cells isolated from an aggrecan-specific TCR transgenic mouse. The 
aggrecan-specific B cells are able to present aggrecan at least 10
4
 fold more 
efficiently than non-specific B cells, 10
2
 fold more efficiently than macrophages and 
comparable to that seen by dendritic cells. 
 
By using a panel of inhibitors, I have also shown that the generation of the 84-
103/MHC complex by aggrecan-specific B cells requires an acidic environment, 
proteolysis by aspartic, serine and metalloproteinases and the “classical” pathway of 
MHC class II biosynthesis.  
 
During this PhD, I have highlighted a novel role for aggrecan-specific B cells as 
important APC involved in aggrecan-presentation, as well as elucidating a role for 
metalloproteinases in aggrecan processing and presentation by APC. 
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 1 
1. Introduction 
 
1.1 Rheumatoid arthritis. 
Rheumatoid arthritis (RA) is a systemic autoimmune disease affecting approximately 
1% of the population and causing significant morbidity and mortality (Lee and 
Weinblatt 2001). Incidence increases with age and affects 3 times more women than 
men. (Rooney and Silman 1999). The clinical presentation of the disease varies 
between patients but common symptoms include joint pain and swelling 
predominantly in the metacarpophalangeal, proximal interphalangeal and wrist joints 
and accompanying feelings of malaise and fatigue (Joseph, Brasington et al.). The 
swelling and pain experienced in RA joints are the results of the synovitis caused by 
an infiltration of immune cells such as neutrophils, macrophages, B cells and T cells 
into the joint lining (synovium) (Firestein 2003). Local production of inflammatory 
mediators such as TNFα, IL-1, IL-6, IL-23 and IL-2, tissue degrading enzymes such 
as metalloproteinases, immune complex deposition and angiogenesis leads to 
hyperplasia of the synovium (pannus formation), cartilage destruction and eventually 
erosion of the underlying bone (see Figure 1.1) (Brennan and McInnes 2008). 
Although it is predominantly the joints which are affected by the disease, patients 
often develop extra-articular manifestations including the formation of rheumatoid 
nodules, vasculitis, anaemia and problems in other organs such as the lungs, eyes and 
heart (Turesson, Jacobsson et al. 1999). Once severe damage to the joints has 
occurred it is, in many cases irreversible. Therefore, most treatment is aimed at 
dealing with inflammation and preventing further damage to the joint.  
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Figure 1.1 A schematic of a healthy joint (upper) and an arthritic joint (lower). 
The synovium forms a thin layer encapsulating the healthy joint with no inflammation depicted in the 
upper picture. In the arthritic joint the synovium becomes infiltrated with immune cells, inflamed and 
hyperplastic encroaching on the articular cartilage and underlying bone depicted in the lower panel. 
http://www.arc.org.uk/arthinfo/patpubs/6033/6033.asp 
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The cause of rheumatoid arthritis is not fully understood and may vary from patient to 
patient due to various genetic, environmental, hormonal and infectious factors.  
 
Early findings identified that many patients with RA were seropositive for the anti-
IgG autoantibodies known as rheumatoid factor (RF), leading to the view that RA is 
an autoimmune disease caused by autoantibodies (Franklin, Holman et al. 1957; 
Zvaifler 1973). It was later discovered that although RF had the potential to bind to 
immune complexes within the joint and potentiate inflammation it was not necessarily 
a marker of disease as it is also present in the serum of healthy individuals and 
patients with other chronic inflammatory diseases (Dorner, Egerer et al. 2004). More 
recently antibodies reactive against citrulline-containing proteins have been identified 
in the inflamed joints of RA patients. These anti-cyclic citrullinated peptide antibodies 
(anti-CCP) appear early on in the disease process; furthermore, they are rarely found 
in healthy individuals and their presence is associated with a more severe disease 
prognosis (van Gaalen, Ioan-Facsinay et al. 2005). The discovery of autoantibodies in 
RA initiated unsuccessful attempts at preventing antibody production or removing 
antibodies from the circulation of patients (Goronzy and Weyand 2003). However, 
initial studies involving the use of the anti-CD20 therapy Rituximab to deplete B cells 
resulted in a 70% improvement in RA disease activity (Edwards and Cambridge 
2001). The role of B cells in RA is multifunctional and not limited to antibody 
production which may provide an explanation for the success of a B cell depletion 
therapy as opposed to antibody removal. Antigen-specific B cells are very efficient 
antigen presenting cells (APC) able to concentrate low doses of antigen generally 
sequestered from the immune system for presentation to autoreactive T cells (Mamula 
and Janeway 1993). In addition, B cells are found in abundance in the rheumatoid 
synovium often forming germinal centre like aggregates with T cells, implying a role 
for B cells in antigen-mediated T cell activation during RA pathogenesis (Weyand, 
Goronzy et al. 2000). 
 
Current therapy has come a long way from the early treatment of patients with gold 
salts, non steroidal anti-inflammatory drugs (NSAID) and anti-malarial drugs such as 
chloroquine (Isaacs 2010). Disease modifying anti-rheumatic drugs (DMARDS) such 
as Methotrexate are also used which inhibit immune cell proliferation and induce 
apoptosis, inhibit pro-inflammatory cytokines and indirectly incurs effects on joint 
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degradatitve enzymes (Cutolo, Sulli et al. 2001). Therapies aimed at targeting pro-
inflammatory cytokines such as TNFα (Etanercept, Infliximab and Adalimumab), IL-
6 (Tocilizumab) and IL-1 (Anakinra) work best in combination with methotrexate 
(Buch; Senolt, Vencovsky et al. 2009).  T and B cell directed therapies such as 
Rituximab and Abatacept (Orencia, Bristol Myers-Squibb) have both been relatively 
successful where other biological therapies such as anti-TNFα have failed, details of 
which are discussed in Sections 1.3.3 and 1.4.1. However, as yet there is no gold 
standard treatment for some patients and no known cure for RA. Therefore, 
identifying early disease markers and novel targets for RA therapy is an ongoing 
process.   
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1.2 The synovial joint 
The synovial joints (diathroidal joints) are the most moveable joints in the body. They 
differ from the cartilaginous and fibrous joints which do not have a cavity (O'Rahilly 
1957). The structure of the synovial joint is formed at the extremities of 2 spongy 
cancellous bones. The surfaces of the bones are coated in a layer of denser 
subchondral bone which provides support for the overlying articular cartilage (Li, 
Marshall et al. 1999).  
 
1.2.1 Articular cartilage 
 Articular cartilage is of the hyaline variety, it forms a coating over the subchondral 
bone and its elasticity and smooth surface helps to support skeletal shape and aid 
freedom of movement and the loadbearing forces of the joint. Articular cartilage is 
avascular and is made up of extracellular matrix synthesised and maintained by a 
sparsely distributed homogeneous population of cartilage cells called chondrocytes. 
95% of the cartilage extracellular matrix consists of the components collagen II (60%) 
and the major proteoglycan aggrecan (35%) (Dudhia 2005). Type II collagen provides 
tensile strength and a mesh network to immobilise structural proteins while the highly 
negative charge of aggrecan allows cartilage to have a high water content which 
contributes to its compressive resilience during joint loading (Dudhia 2005).  
 
The cartilage receives nutrients from the neighbouring bone and the synovial 
membrane which lines the joint capsule (Gray 1918). During the progression of RA, 
cartilage destruction is mediated by inflammatory cytokines such as IL-1 and TNFα 
and cartilage degrading components such as matrix metalloproteinases (MMPs) and 
cathepsins which can mediate both the initiation and maintenance of inflammation 
and extracellular matrix (ECM) breakdown (Choy and Panayi 2001). These factors 
are released within the cartilage by activated chondrocytes and invading synoviocytes 
and within the inflamed synovium and surrounding synovial fluid by activated 
synoviocytes and infiltrating immune cells  (Yoshihara, Nakamura et al. 2000; Pope 
2002; McInnes and Schett 2007; Otero and Goldring 2007) ( Figure 1.2) 
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Figure 1.2 Overview of RA pathogenesis mediated by monocytes, synovial 
fibroblasts and activated chondrocytes.  Extracted from (Pope 2002) 
 
The extremities of the 2 bones comprising the joint are enclosed in a capsule which 
provides the joint with stability by limiting movement of the bones. The joint capsule 
consists of a fibrous outer layer which attaches to the bone and is itself lined by a 
softer internal layer termed the synovium (Ralphs and Benjamin 1994).   
 
1.2.2 Synovium 
The synovium is a bilayer composed of an outer layer of fat cells, blood vessels and 
fibroblasts and a lining layer consisting of loose connective tissue interspersed with 
blood vessels and a layer of 2 different types of synoviocytes 1-2 cells thick. Type a 
synoviocytes are macrophage like cells and type b synoviocytes are fibroblast like   
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cells (Lories, Derese et al. 2003; FitzGerald 2007). The lining layer of the synovium 
is the initiating site for RA characterized by increased vasculature, hyperplasia and an 
infiltration of immune cells and mesenchymal cells (Kraan, Versendaal et al. 1998; 
Marinova-Mutafchieva, Taylor et al. 2000; Tak and Bresnihan 2000). As the volume 
of the synovium  increases (pannus formation) it begins to encroach on the cartilage 
and the pannus residing cells invade and destroy it both directly and by activating 
chondrocyte mediated cartilage destruction (Otero and Goldring 2007). 
 
The synovium secretes fluid into the joint space which provides nutrients and 
lubrication to the avascular articular cartilage. Normal synovial fluid consists of 
plasma derived from synovial vessels, a few cells infiltrating from the neighbouring 
cartilage and synovium, and hyaluronate which gives the synovial fluid its viscosity 
(Freemont 1996). During RA progression both the volume and contents of the 
synovial fluid increases. Synovial fluid from RA patients is highly inflammatory and 
has been shown to contain high levels of the inflammatory mediators IL-1, IL-6, 
TNFα, IL-8, IL-17 and IL-21 (Brennan and McInnes 2008). In addition, the fluid 
contains a large influx of inflammatory cells which are predominantly neutrophils but 
also contains lymphocytes, granulocytes and monocytes (Harris 1990). However, 
variability between the cellular composition of the arthritic synovial fluid can occur in 
individual patients probably due to the nature of the initiating inflammatory stimulus 
and the individuals immune response to the causative agent (Davis, Denton et al. 
1988; Freemont 1991).  
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1. 3 The role of T cells in RA 
The role of T cells in rheumatoid arthritis has been reviewed (Lundy, Sarkar et al. 
2007; Isaacs 2008; Mauri and Carter 2009). The discovery of  genetic links  between 
T cell activation and disease susceptibility have highlighted T cells as playing a 
central role in the disease pathogenesis.  
 
Earlier studies involving the analysis of synovial tissues and fluid revealed the 
prominence of T cell infiltrates in the RA synovium and their accumulation in 
synovial fluid (Van Boxel and Paget 1975; Iannone, Corrigall et al. 1994). However, 
low levels of the Th1 cytokines IFNγ, IL-2 and IL-3 in synovial fluid and tissue 
suggested that T cells were not activating macrophages via IFNγ and IL-2 (Firestein 
and Zvaifler 1987; Firestein, Xu et al. 1988). This led to the dogma that the T cell 
infiltrate found in the joints of RA patients was not responsible for disease 
pathogenesis. However, more recently several animal models of RA have identified 
an essential role for T cells in the development of arthritis in RA disease models. 
Additionally, genetic linkage with T cell dependent factors discussed below in 
Section 1.3.1 and the efficacy of RA drugs targeting T cell activation have provoked a 
new interest in their role as central mediators in disease pathogenesis.  One possible 
explanation for the finding that there are low levels of IFNγ yet a prominent infiltrate 
of T cells in the synovium is that synovial T cells are activating macrophages 
independently of IFNγ. Indeed, it has been previously shown that the cytokine IL-15 
which is found at increased levels in the RA synovium can activate synovial T cells to 
produce the RA associated cytokine TNFα. More importantly, these IL-15 activated T 
cells are able to induce significant TNFα by macrophages in a cell contact dependent 
manner which is mediated by the cell surface molecules LFA-1, ICAM1 and CD69 
(McInnes, Leung et al. 1997).  
 
1.3.1 Genetic evidence for T cell involvement 
The human leukocyte antigen (HLA) DP, DQ and DR loci and their murine 
equivalent I-A and I-E encode the highly polymorphic αβ major histocompatibility 
complex (MHC) heterodimers found on the surfaces of antigen presenting cells (Al-
Daccak, Mooney et al. 2004). A genetic association with a conserved amino acid 
sequence known as the „shared epitope‟ from within the third hypervariable region of 
MHC DRβ chains is found in 90% of RA patients (Firestein 2003). 
 9 
The shared epitope (
70
QKRAA
74
 or 
70
QRRAA
74
) forms the fourth anchoring pocket of 
the peptide binding groove of complete MHC class II HLA-DR molecules which DRβ 
chains contribute to. Several DRB1 alleles are associated with RA including *0401, 
*0404, *0405 and *0101, the products of which contribute to HLA-DR molecules of 
the DR4 and DR1 subtypes (Tsark, Wang et al. 2002; Hill, Southwood et al. 2003; 
Svendsen, Andersen et al. 2004). In addition it has been shown that certain alleles 
such as the RA associated HLA-DR4 form less stable CLIP interactions (Patil, 
Pashine et al. 2001). Therefore, peptide loading of HLA-DR4 molecules may not be 
as tightly regulated as non-RA associated alleles providing a possible explanation for 
DR4 association with RA pathology. 
 
As T cells recognise protein-derived peptide fragments in association with MHC class 
II molecules, this genetic association with MHC strongly implies that the disease is 
antigen driven and T cell mediated.  In support of this, more recently identified 
genetic factors such as PTPN22, a gene involved in regulating T cell receptor 
signalling threshold and CTLA-4, which negatively regulates activated T cells, have 
both been implicated in RA susceptibility (Begovich, Carlton et al. 2004; Plenge, 
Padyukov et al. 2005). As previously described anti-CCP autoantibodies are common 
immunogenic determinants in patients with RA. In addition, anti-CCP antibodies are 
associated with a genetic linkage to the shared epitope and a more aggressive disease 
prognosis (Meyer, Labarre et al. 2003). The amino acid at position 71 of the shared 
epitope has a positive charge. However, the same amino acid in the 70-74 sequence of 
non-disease associated DRβ chains do not have a positive charge. Therefore, as the 
70-74 sequence contributes to the peptide anchoring pocket, the charges of the amino 
acids at these positions will influence what peptides can bind HLA II. In contrast to 
non disease associated HLA II, disease associated HLA II which have shared epitope 
containing DRβ chains have positive charge and will favour binding of more 
negatively charged peptides. Citrullination removes a positive charge from peptides 
and makes them more negative. Therefore, individuals expressing the HLA II RA 
susceptibility alleles are more likely to produce responses to more negatively charged 
or citrullinated peptides. In support of this hypothesis, other genetic factors such as 
peptidylarginine deiminase 4 (PAD14), an enzyme involved in protein citrullination is 
another recently identified genetic determinant of RA. Furthermore, environmental 
factors such as smoking have been shown to increase the rate at which proteins are 
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citrullinated in individuals expressing the HLA II RA susceptibility alleles 
(Klareskog, Stolt et al. 2006). Therefore, it is possible that the association between 
citrullination and the HLA II RA susceptibility alleles identifies citrullinated proteins 
as potential RA autoantigens for T cell activation. 
 
1.3.2 T cell depletion therapy in RA  
Early attempts aimed at T cell depletion were unsuccessful due to unwanted side 
effects such as lymphopenia, skin rashes and in the case of the T cell superagonist 
monoclonal antibody (mAb) TGN142 even life threatening adverse affects (Isaacs and 
Waldmann 1998; Stebbings, Findlay et al. 2007; Isaacs 2010). However, the success 
of T cell directed therapies such as Abatacept have taught us a lot about their role in 
RA. Abatacept is a soluble fusion protein containing the extracellular domain of 
CTLA-4 linked to the modified Fc domain of human IgG targeted at switching off 
activated T cells and blocking the interaction between T cell CD28 and APC via its 
high affinity for CD80/86. In addition, Abatacept can also mediate its effects via 
modulation of tryptophan metabolism in APC (Grohmann, Orabona et al. 2002). 
Abatacept is currently an efficacious licensed therapy shown to slow disease 
progression and slowly ameliorate symptoms in ~50% of RA patients in which anti-
TNF therapy has failed (Genovese, Becker et al. 2005, Maxwell #506). The efficiency 
of therapies that prevent antigen presentation to T cells uncovers a role for both APC 
and activated T cells in the disease process. However, it does not tell us which APC or 
antigen is important in T cell activation. Future possibilities for the targeting of T 
cells as RA therapies are the isolation, in vitro expansion and autologous 
transplantation of Tregs or cellular therapies involving autologous transplant of other 
regulatory cells to manipulate the T cell response (Isaacs 2008; Mauri and Carter 
2009).  
 
The processes leading to the activation of >30% of the T cell population within the 
synovium and also whether they are activated locally or distally is not fully 
understood. Genetic data in favour of T cell activation via antigen presentation is well 
known yet the antigen presenting cell population responsible and indeed the antigen 
itself is not known. Although, it is likely that T cells play a key role, the pathogenesis 
of RA is complex and T cells alone are unlikely to be solely responsible for the 
initiation and /or perpetuation of the disease. 
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1.3.3 CD4+ T cell activation and tolerance   
CD4+, CD8+ NKT cells and CD4+ CD25+ naturally occurring T regs (nTreg) 
develop within the thymus. There are several CD4+ subtypes of T cells based on 
cytokine production including Th1, Th2, Th17 and iTreg generated in the periphery 
each playing a distinct role in immune responses to a variety of intracellular and 
extracellular pathogens, or in the case of autoimmunity, self antigens (Zhu and Paul 
2008). Prolonged or serial TCR stimulation via MHC class II peptide complexes is 
central to the activation and differentiation of CD4+ T cells (Lanzavecchia and 
Sallusto 2001). In addition to this, the fate of the cognate T cell relies on the delivery 
of subsequent signals by the APC. A second activation signal delivered by the APC 
via co-stimulatory molecules such as CD80/86 via T cell CD28, CD70 via T cell 
CD27, or OX40L via T cell OX40 is required to prevent T cell anergy (Akiba, 
Oshima et al. 1999; Linton, Bautista et al. 2003). Additionally, a third „danger signal‟ 
is required which is usually delivered to the APC by inflammatory cytokines or 
foreign/endogenous ligands recognised by a variety of cytokine receptors or pattern 
recognition receptors such as IL1r and TLRs (Curtsinger, Schmidt et al. 1999). This 
third signal ensures physiological changes required by the APC for efficient T cell 
activation are induced only when necessary. Thus, the cytokine environment and 
activation status of the APC/T cell dictates the type and level of CD4+ T cell 
response. Th1 differentiation is mediated by the cytokines IFNγ and IL-12, Th2 by 
IL-4 and IL-2, Th17 by TGFβ, IL-6, IL-21, IL-23 and iTreg by TGFβ, IL-2 and IL-10 
(Zhu, Yamane et al. 2010).  
 
Therefore, the location and type of APC presenting the antigen may affect the delicate 
balance between T cell responses and could be essential in providing the right 
response at the right time and with the desired kinetics (Stockinger, Zal et al. 1996). 
 
1.3.4 T cell tolerance 
The αβ TCR consists of an α and β chain generated in the thymus by somatic 
recombination of the variable and joining gene segments of the α chain and 
recombination of variable, diversity and joining gene segments of the β chain. 
Humans have approximately 3 x 10
11
 naïve  T cells and TCR rearrangement leads to a 
possible >10
13
  different TCR specificities (Jenkins, Chu et al. 2010). This diverse 
repertoire of T cells must be controlled to prevent autoreactive T cells entering the 
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peripheral circulation and causing an autoimmune response in the periphery. Central 
T cell tolerance involves both the positive and negative selection of T cells. TCR that 
recognise self MHC/peptide complexes with a low affinity within the thymus receive 
a survival signal and become committed to either a CD4+ or CD8+ lineage. 
Alternately, self-recognition of MHC class II peptide complexes with a stronger 
affinity can lead to the positive selection and development of forkhead box P3 
(FoxP3) expressing CD4+ nTreg (10%) (Starr, Jameson et al. 2003; Josefowicz and 
Rudensky 2009). Negative selection of CD4+ T cells involves the deletion of 
immature T cells that recognize self MHC class II peptide complexes with high 
affinity in the thymus and this ensures that potentially self-reactive T cells are deleted 
during development.  However, a certain percentage of self-reactive T cells may still 
reach the periphery. Self-reactive peripheral T cells have been identified in patients 
suffering from autoimmune diseases including multiple sclerosis, insulin dependent 
diabetes mellitus and rheumatoid arthritis as well as healthy individuals, indicating a 
possible lack of peripheral tolerance in autoimmune patients (de Jong, Berlo et al.; 
Scholz, Patton et al. 1998; Viglietta, Kent et al. 2002). Possible explanations for their 
escape from the thymus include, the self antigen or the specific epitope recognised by 
the TCR may not have been presented within the thymus for negative selection and 
secondly negative section may not be stringent enough to delete T cells with a low 
affinity for self antigen (Walker and Abbas 2002; Abbas, Lohr et al. 2004). However, 
positive selection of self reactive T cells may be important in maintaining a broad-
specificity T cell repertoire in the periphery which is controlled by various immune 
mechanisms to prevent autoimmunity. It has been suggested that subtle mechanisms 
such as destructive antigen processing and presentation by resting APC, are in place 
to „fine tune‟ the sensitivity of these self-reactive T cells to antigenic stimulation 
causing their ignorance, desensitisation or death within the periphery (Anderton and 
Wraith 2002).  
 
Peripheral tolerance can be achieved by various mechanisms including T cell 
ignorance, anergy, suppression or apoptosis. T cell ignorance occurs when 
autoreactive T cells do not encounter their antigen either because it is either 
sequestered from the immune system or it is only available at very low levels, 
suppression via regulatory immune cells and to a lesser extent apoptosis via activation 
induced death (Walker and Abbas 2002). 
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T cell anergy occurs via recognition of MHC class II peptide complexes and either a 
lack of co-stimulation or signals via inhibitory T cell receptors such as CTLA-4 and 
PD-1 (Greenwald, Boussiotis et al. 2001; Latchman, Wood et al. 2001).  Anergic T 
cells fall into two categories T cell clonal anergy which results in growth arrest and T 
cell adaptive tolerance which results in the inhibition proliferation and effecter 
functions (Schwartz 2003). 
 
Recent evidence also highlights a role for T cell revision as a peripheral tolerance 
mechanism, this results from T cells whose autoreactive TCR has undergone 
rearrangement within the periphery thought to be due to a loss of signal via TCR, 
resulting in the expression of a new TCR with different specificity (Hale and Fink 
2010). This tolerance mechanism is most likely in place to re-arrange self-reactive 
TCR that has not encountered its ligand due to mechanisms mentioned. However, it is 
possible that recombination may also result in the expression of a higher avidity self 
reactive TCR resulting in a potentially dangerous population of self-reactive cells able 
to cause autoimmunity. The mechanisms involved in regulating this process to 
prevent autoimmunity are not known and whether they are involved in promoting or 
preventing autoimmunity remains to be determined (Huang, Golub et al. 2002; Serra, 
Amrani et al. 2002; Waid, Vaitaitis et al. 2004; Wagner 2007).  
 
Central to peripheral T cell tolerance is a group of regulatory immune cells, B regs, 
nTregs, iTregs, tolerogenic DC and suppressive macrophages (Mauri and Carter 
2009).  Tregs activated via TCR recognition of MHC class II peptide complexes on 
APC can subsequently suppress other autoreactive effecter T cells (Thornton and 
Shevach 2000). Mechanisms by which Tregs mediate suppressor function include 
ligation of CTLA-4 with CD86 and the production of the immunomodulatory 
cytokines IL-10 and IL-35 (Collison, Workman et al. 2007). IL-10 has been shown to 
inhibit antigen presentation, cytokine production and expression of co-stimulatory 
molecules on dendritic cells (Moore, de Waal Malefyt et al. 2001). The mechanisms 
by which IL-10 exert its effects are unclear. However, recent studies have identified 
that IL-10 can effect APC function via degradation of TLR adapter MyD88 dependent 
signalling molecules, resulting in a lack of MyD88 signalling and cytokine production 
(Chang, Kunkel et al. 2009). The suppressive activity of Bregs is mediated via IL-10 
production and most likely by their ability to induce the differentiation of Tregs via 
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antigen presentation (Blair, Chavez-Rueda et al. 2009). Regulatory dendritic cells are 
thought to exert their effects via the differentiation of iTregs (Weiner 2001). 
Suppressor macrophages are thought to develop in the presence of Tregs and can 
suppress T cell autoreactivity via production of IL-10 and tryptophan catabolism and 
can also induce iTreg differentiation via antigen presentation (Mauri and Carter 
2009). 
 
Severe autoimmune conditions occur when major components of the tolerance system 
are missing. Examples include the autoimmune disease immunodysregulation 
polyendocrinopathy X-linked (IPEX) in which there is a lack of FoxP3 causing severe 
autoimmunity in both animals and humans (Ochs, Gambineri et al. 2007) and 
polymorphisms in the genes IL-10, IL-2 and CTLA-4 have been linked to the 
autoimmune disease primary biliary cirrhosis (Invernizzi, Selmi et al. 2005). In 
humans breakdown of tolerance mechanisms by combinations of genetic 
susceptibility such as the shared epitope and environmental triggers such as smoking 
can result in T cell activation in response to the presentation of self-antigens and 
ultimately autoimmunity.  
 
Infection or mechanical insult can result in cartilage degradation in RA uncovering 
antigens from a previously immunopriviledged site (Doran, Goodstone et al. 1995). 
Exogenously degraded forms of antigen may be processed differently by APC 
producing „cryptic epitopes‟ against which there is no T cell tolerance (Lehmann, 
Forsthuber et al. 1992). In these circumstances it is possible to envisage how disease 
could be perpetuated by auto-reactive T and B cells against joint antigens and how 
recognition of antigen would cause T and B cell proliferation, cytokine and 
immunoglobulin (Ig) production causing further damage that leads to the release of 
more sequestered joint antigen.  
 
1.3.5 The role of Th17/Treg cells in RA 
The low levels of Th1 cytokines found in RA synovium may be due to the 
involvement of Th17 cells, which have been shown to negatively regulate Th1 cell 
development providing a possible explanation for the low levels of IFNγ (Smeets, 
Dolhain et al. 1998; Harrington, Hatton et al. 2005). Th17 cells produce IL-17A, IL-
21 and IL-22. Elevated levels of both IL-17A and IL-17A producing CCR6+ Th17 
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cells have been found in the synovial fluid of RA patients and high levels of IL-22 in 
synovial tissues (Chabaud, Durand et al. 1999; Ziolkowska, Koc et al. 2000; Ikeuchi, 
Kuroiwa et al. 2005; Hirota, Yoshitomi et al. 2007).  However, results are 
controversial with other groups demonstrating low levels of Th17 cells within the 
rheumatoid synovium and the finding that other cell types such as mast cells may be 
the major source of IL-17A (Yamada, Nakashima et al. 2008; Hueber, Asquith et al. 
2010). Studies using mouse models have shown Th17 cytokines to have effects on 
osteoclastogenesis, angiogenesis and inflammation and they have pro-inflammatory 
effects on various cells of the synovium including osteoclasts, chondrocytes and 
fibroblasts (Muller-Ladner, Ospelt et al. 2007; Otero and Goldring 2007; Schett 
2007). However, results using animal models are contradictory with proteoglycan 
induced arthritis (PGIA) generating a Th17 independent disease (Doodes, Cao et al. 
2008), and collagen induced arthritis (CIA) generating a Th17 dependent disease 
(Lubberts, Koenders et al. 2004). The contribution of Th17 cells to human arthritis is 
still unclear.   
 
Another possible role for T cells in RA is the activation or deregulated activation of 
Treg cells whose role in central tolerance is most clearly demonstrated by the 
previously mentioned IPEX linked to mutations in FoxP3 causing severe 
autoimmunity in both animals and humans. There are 2 main types of Treg,  naturally 
occurring FoxP3+ generated in the thymus and peripherally activated CD4+ CD25+ 
iTreg which can acquire FoxP3 expression upon antigen recognition in the periphery 
(Chen, Jin et al. 2003). CD4+ CD25+ T cells have been implicated as playing a role in 
RA as there are lower numbers found in patients and /or they are defective in their 
ability to suppress TNFα and IFNγ production by T lymphocytes and monocytes 
(Ehrenstein, Evans et al. 2004; Lawson, Brown et al. 2006). However, their exact 
mechanism of tolerance induction is not known. Experiments by van Bilsen et al into 
the mechanisms of Treg mediated suppression in RA have indicated that suppression 
is an antigen-specific balance between pro-inflammatory and regulatory responses. 
Using the candidate autoantigen human cartilage glycoprotein 39 (Hcgp39) van 
Bilsen et al showed that PBMC responses from normal individuals to Hcgp39 were 
biased towards anti-inflammatory IL-10 mediated Treg responses, whereas PBMC 
from RA patients responded in a pro-inflammatory way producing a more Th1 
phenotype (van Bilsen, van Dongen et al. 2004).  This data suggests that during the 
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initiation/perpetuation of RA there may be a dysregulation in the balance between 
pro-inflammatory cells and regulatory cells such as Tregs, B regs, regulatory DC and 
regulatory macrophages which results in a switch from self-tolerance to 
autoimmunity. 
 
Th1, Th17 and Tregs have all been identified as playing a role in RA but it is not 
known the relative contribution of each to disease pathology. T regs and Th17 can 
rapidly become IFNγ producing Th1 T cells in vitro following the addition of IL-12 
(Lee, Turner et al. 2009). Therefore, it is also possible that T cell plasticity occurs in 
RA and conversion from one cell type to another may upset the balance between self 
tolerance and autoimmunity. 
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1.4 The role of B cells in RA 
Several autoimmune diseases are characterised by the presence of autoantibodies and 
hence the implications for B cell involvement in disease pathogenesis. Coupled with 
the successful treatment of RA patients with the B cell depleting therapy Rituximab 
(Rituxan, Genentech) this implicates B cells as important mediators of RA 
pathogenesis and excellent candidates with which to explore the potential of improved 
and novel drug targets.  
 
1.4.1 B cell depletion therapy 
Rituximab is an anti-CD20 therapy originally designed to treat non-Hodgkins 
lymphoma (Grillo-Lopez, White et al. 1999). It has shown clinical benefit in ~80% 
RA patients with major improvements observed in ~50% with complete resolution of 
inflammation observed in some cases (Edwards and Cambridge 2006). Rituximab is a 
chimeric IgG1 κ mAb containing mouse heavy (H) and light (L) chain variable 
regions and human constant regions directed against CD20 found on the surface of 
pre and mature B cells but not on plasma cells or pro-B cells (Edwards and 
Cambridge 2001; Emery, Fleischmann et al. 2006; Genentech 2007 ). Germinal centre 
marginal zone B cells also appear to be resistant to Rituximab mediated cell death 
possible due to protection conferred from the microenvironment (Gong, Ou et al. 
2005). Although the exact mechanisms of B cell death are not known it is thought to 
be largely due to antibody-dependent cell-mediated cytotoxicity (ADCC) (Uchida, 
Hamaguchi et al. 2004). B cell depletion and clinical benefits of Rituximab last 
approximately 7-8 months before B cell numbers begin to increase replenished by the 
undepleted pre-B cell pool. Other agents aimed at targeting B cells in RA are the B-
cell survival factor (BAFF) specific antibody Belimumab (human genome sciences 
and Glaxosmithkline) and the neutralizing recombinant fusion protein Atacicept 
(EMD Serono and Zymogenetics Amgen) that targets the B lymphocyte stimulator 
BLyS and APRIL a proliferation-inducing ligand, both involved in B cell survival, 
proliferation, antigen presentation and class switching (Tak, Thurlings et al. 2008). 
Although Belimumab was well tolerated it showed limited efficacy in clinical trials 
(Looney 2006). In contrast, Atacicept which contains the human IgG1 Fc fused with 
the extracellular portion of TACI binds to and neutralizes BLyS and APRIL has 
recently shown promising effects in initial small trials and larger trials are now 
underway (Bracewell, Isaacs et al. 2009). 
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1.4.2 Autoantibodies and their role in disease  
As previously mentioned in rheumatoid arthritis there is evidence of autoantibodies 
reactive against several self-antigens including glucose-6-phosphate isomerise (GPI), 
a ubiquitous enzyme thought to be deposited in the synovium, post translationally 
modified citrullinated peptides (CCP) and the Fc region of human IgG (RF) 
(Silverman and Carson 2003) (Huang, Kearney et al. 2006). Mechanisms of action of 
autoantibodies have been shown in experiments with K/BxN mice. The K/BxN mouse 
models which express the TCR transgene (KRN) developed by Mathis and Benoist 
were crossed with non obese diabetic mice to generate the K/BxN strain (Kouskoff, 
Korganow et al. 1996). K/BxN mice develop a spontaneous arthritis at the age of 3-5 
weeks which is localised to the joints and results from the presence of GPI specific 
autoantibodies and autoreactive T cells (Korganow, Ji et al. 1999). The disease was 
antibody dependent and could be transferred to healthy recipients by serum alone. 
Knockout experiments confirm that the disease is dependent on FcRyIII (Corr and 
Crain 2002) and anti-C5 administration confirms an essential role for complement (Ji, 
Ohmura et al. 2002). The K/BxN model has taught us a lot about the pathogenic 
potential of autoantibodies in complement activation and Fc mediated antigen uptake 
by APC. Whether autoantibodies play a central role in disease pathology or whether 
they are simply good diagnostic markers for RA is not known. However, the fact 
remains that populations of autoreactive B cells are present in most RA patients and 
are under constant activation to become antibody secreting plasma cells. The role of B 
cells is not limited to antibody production alone. Indeed, following their activation via 
antigen recognition, T cell help and TLR signalling, B cells differentiate into either 
antibody-secreting plasma cells or mature B cells which express surface antibody and 
are capable of efficiently presenting antigen to synovial T cells.  Furthermore, B cells 
have also been shown to play a pivotal role in the production of chemokines and 
cytokines that influence further leukocytic infiltration into and retention within the 
RA synovium (Loetscher and Moser 2002). This evidence suggests that B cells have a 
multi-functional role in the pathogenesis of RA and indeed there are several studies 
which highlight the importance of B cells as APC, a role which I shall now discuss. 
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1.4.3 The role of B cells in lymphoid neogenesis and T cell activation 
Interaction between B and T cells within the RA synovium has been extensively 
documented (Young, Adamson et al. 1984; Schroder, Greiner et al. 1996; Weyand, 
Goronzy et al. 2000). Interactions vary from patient to patient, with B and T cells 
forming loosely organized microstructures in some patients or aggregating with 
interdigitating dendritic cells to form germinal centre (GC) like structures (lymphoid 
neogenesis) in other patients (Silverman and Carson 2003). GC are structures 
essential for affinity maturation of B cells and selection by follicular dendritic cells 
(FDC) as well as the development of B cell memory, which relies on specific antigen 
and cognate T cell help (Liu, Joshua et al. 1989; Kosco and Gray 1992). Therefore, 
the presence of lymphoid neogenesis in the synovium indicates a strong immune 
response almost certainly against specific antigens.  Indeed, in patients showing 
lymphoid neogenesis as opposed to loosely organized T and B cell interactions there 
is an increase in the transcription of IgG indicative of antigen-specific B cell 
activation and higher levels of the B cell survival factor APRIL (Seyler, Park et al. 
2005). Antigen-specific B cells are efficient APC able to clonally expand and focus an 
immune response against a particular antigen for presentation to CD4+ T cells 
(Casten and Pierce 1988; Batista and Neuberger 1998; Byersdorfer, Dipaolo et al. 
2004). Furthermore, self-reactive RF specific B cells are able to process different 
antigens complexed with IgG and thus allow effective presentation of various immune 
complexes (Roosnek and Lanzavecchia 1991). Indeed, it is possible that immune 
complexes containing TLR ligands such as chromatin or RNA associated autoantigens 
may be able to break peripheral B cell tolerance by providing their own danger signal 
and overcoming the requirement for T cell help (Christensen, Shupe et al. 2006; 
Herlands, Christensen et al. 2008). In support of this, immune complexes with 
chromatin have been proven to synergistically activate BCR uptake and TLR 
signalling in a MyD88 dependent manner (Leadbetter, Rifkin et al. 2002).  
 
There are many studies using both spontaneous and antigen-induced animal models of 
RA that have demonstrated an essential role for B cells in lymphoid neogenesis and T 
cell activation (Takemura, Klimiuk et al. 2001; O'Neill, Shlomchik et al. 2005; 
Taneja, Krco et al. 2007). An elegant study by Takemura and colleagues 
demonstrated both of these roles impeccably using SCID mice transplanted with 
human RA synovium. T cells identified as having Th1 phenotypes were isolated from 
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the synovial GCs of RA patients and adoptively transferred into the transplanted 
synovium of these SCID mice. Adoptively transferred T cells required both cognate 
HLA DRβ1 alleles with the implanted synovial tissue and B cells in order to become 
activated. The essential role of B cells was demonstrated by the transfer of T cells into 
anti-CD40 mAb B cell depleted synovium or the transfer of synovium containing few 
or no B cells or loosely formed T and B cell aggregates which resulted in abrogated T 
cell activation, IFN  and IL-1  production and GC formation (Takemura, Klimiuk et 
al. 2001).  
 
Germinal centre formation within the synovium is dependent on expression of the 
TNF family member lymphotoxin  (LTβ) by B cells along with other factors 
produced by synovial macrophages and fibroblasts such as CXCL13, CXCL12 and 
CXCL21 involved in lymphoid recruitment and organization (Buckley, Amft et al. 
2000; Takemura, Klimiuk et al. 2001; Weyand and Goronzy 2003). B cells receive 
survival and activation signals from neighbouring DC, fibroblast-like synovial cells 
(FLS) and macrophages in the form of BAFF, APRIL as well as from T cell 
interactions within the germinal centre like structures found in RA synovium (Seyler, 
Park et al. 2005) (Ohata, Zvaifler et al. 2005).   
 
Several antigen-specific mouse models of arthritis including PGIA, CIA and GPI 
induced arthritis have been used to demonstrate the role of B cells as APC in RA 
which suggests that their ability to efficiently present antigen is not restricted to the 
antigen PG or an H-2
d
 BALB/c restricted background.  
 
Early studies by Brennan et al using the PGIA mouse model demonstrated that PG 
specific antibodies were present immediately prior to intense proliferation of 
autoreactive T cells and that B cells isolated from PG immunized mice were able to 
present low concentrations of aggrecan to aggrecan-specific T cells 5/4E8 (Brennan, 
Mikecz et al. 1995). However, this study only established that B cells were able to 
present PG to T cell hybridomas and didn‟t show a specific role for B cells in disease 
onset or progression. In later experiments, the same laboratory performed an elegant 
study demonstrating that B cells were required as both antibody producing cells and 
APC to induce severe PGIA. Importantly, they also demonstrated that the antigen 
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presenting function of the B cells could not be fulfilled by other APC. Using genetic 
manipulation to generate mice with membrane bound heavy chain Ig paired with an 
endogenous hapten specific light chain (mIg) the authors showed that T cells from 
these mice could transfer disease in SCID mice, only if the immunizing PG was 
targeted to antigen-specific B cells. In addition, it was shown that T cells transferred 
from B cell depleted mice failed to transfer disease. To verify the role of antibodies 
they showed that transfer of arthritic serum alone from mice with a normal B cell 
compartment induced only a mild arthritis. The data implies that the onset of severe 
PGIA required both antigen-specific B cells and autoantibodies highlighting the dual 
role of B cells in disease pathogenesis (O'Neill, Shlomchik et al. 2005). Later studies 
by O‟neill et al verified that the antigen presenting function of the B cells was 
dependent on the co-stimulatory molecules CD80/86. Using mixed bone marrow 
chimeras in which CD80/86 expression was absent only on B cells, they showed that 
these mice were resistant to PGIA induction even though PG Ig levels were normal. T 
cells isolated from the PGIA mice were able to transfer disease into SCID recipients. 
However, when T cells isolated from chimeric mice were transferred to SCID 
recipients they developed a much less severe disease that took much longer to 
develop. In vitro stimulation of the T cells with PG and irradiated wt spleen cells, B 
cell depleted spleen cells, B cell CD80/86- or CD80/86- spleen cells verified that B 
cells expressing CD80/86 were required for optimal T cell activation (O'Neill S, Cao 
et al. 2007).  
 
Tanjea et al demonstrated in 2002 that transgenic mice expressing the RA associated- 
allele HLA-DQ8 elicit a vigorous CD4+ response leading to CIA following collagen 
immunisation (Taneja, Taneja et al. 2002). To investigate the role of B cells as APC 
the mice were crossed with μMT mice that lack B cells due to a genetic deletion in the 
IgM gene. Results showed that the DQ8 μMT mice are resistant to CIA implying an 
essential role of B cells in disease pathogenesis. Furthermore, in vitro experiments 
demonstrated that T cells isolated from these mice have abrogated responses to 
collagen unless B cells were used as APC. These data suggests that the role of T cells 
in disease induction is at least partially dependant on the antigen presenting properties 
of B cells (Taneja, Krco et al. 2007). Experiments using the CIA model in rats 
demonstrated that B cells and not DC or macrophages are required as APC for T cell 
recall responses to collagen II in vitro. An interesting finding from this study was that 
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although B cells from immunized rats produced a greater proliferative T cell response, 
B cells from non-immunized rats were still able to function as APC, a suggested 
explanation for this was that alternate cell surface molecules such as B-1 integrins or 
CD26 may enhance collagen II uptake by tight association with the B cell surface 
(Catchpole, Staines et al. 2001).  
 
Cell surface glycoprotein CD44 expressed by B cells binds to hyaluronan (HA) 
fragments and the chondroitin sulphate side chains of aggrecan and ligation with HA 
has been demonstrated to induce B cell proliferation (Rafi, Nagarkatti et al. 1997; 
Fujimoto, Kawashima et al. 2001). Aggrecan is made more freely available by the 
action of degrading proteinases such as aggrecanases and MMPs during the course of 
arthritis (Billington, Clark et al. 1998; Struglics, Larsson et al. 2009; Cawston and 
Young 2010). Therefore, it is possible that binding to CD44 may facilitate aggrecan 
uptake and its presentation to autoreactive T cells. In addition, aggrecan fragments 
containing bound HA may lead to enhanced T cell presentation by co-ligating 
aggrecan-specific BCR with the TLR4 receptor for which HA is a ligand (Tesar, Jiang 
et al. 2006).  
 
The ability of B cells to contribute to ECM degradation via the secretion of MMPs 
has been demonstrated (Di Girolamo, Tedla et al. 1998; Trocme, Gaudin et al. 1998; 
Melamed, Messika et al. 2006). Melamed et al revealed that mature B cells can be 
stimulated to secrete the matrix degrading enzyme MMP-9 by stimulation with LPS, 
concanevalin A and the pro-inflammatory cytokines IL-1, IL-8, TNF- . Secretion of 
MMP-9 can contribute to cartilage degradation and the breakdown of the basement 
membrane aiding transition into the joint tissues (Melamed, Messika et al. 2006; 
Chang, Lin et al. 2008). Di Girolamo et al demonstrated that B cells secrete MMP-3 
as well as MMP-9 in response to pro-inflammatory cytokines or other proteinases and 
when large numbers of B cells aggregate, production of MMP-3 and MMP-9 may 
play a critical role in tissue destruction (Di Girolamo, Tedla et al. 1998). In addition, 
as B cells are competent at secreting these degrading proteinases, they may also be 
capable of degrading cartilage components such as aggrecan, generating self epitopes 
for immune recognition. 
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1.4.4 B cells and cytokines   
B cells within the joint express the cytokines and chemokines IL-1α and or IL-1β, 
TNFα, IL-15, IL-10, IL-6 and LTβ all shown to play a role in the pathogenesis of RA 
(McInnes and Schett 2007). The various cytokines play a role in synovial fibroblast 
activation, FDC organisation and lymphoid neogenesis. However, the amount of these 
cytokines that B cells produce in relation to other synovial cells is not clear. 
 
Besides the pathogenic role proposed for B cells in RA it is possible as with Treg cells 
that there is a dysregulation or dysfunction of IL-10 producing Breg cells in the 
disease state. Indeed treatment of certain autoimmune patients with Rituximab to 
deplete B cells exacerbated disease implying that B cells were conferring a protective 
role (Edwards, Szczepanski et al. 2004; Ardelean, Gonska et al. 2010). There is 
growing evidence that B cells can play a regulatory role in autoimmune disease as 
reviewed in (Fillatreau, Gray et al. 2008; Lampropoulou, Calderon-Gomez et al. 
2010). Splenic B cells isolated during the acute phase of CIA and treated with CD40 
mAb are able to prevent CIA induction when transferred into collagen immunized 
DBA/1 mice (Mauri, Gray et al. 2003). Later experiments identified an in vivo 
transitional 2-marginal zone precursor (T2 MZP) subset of IL-10 producing B cells 
able to confer protection from CIA when transferred from naïve or convalescing mice. 
This regulatory phenotype is dependent on IL-10 as B cells taken from IL-10 deficient 
mice are unable to confer protection (Evans, Chavez-Rueda et al. 2007). It is proposed 
that the mechanisms by which Bregs exert their activity is by regulating a Th1/Th2 
balance (Mauri, Gray et al. 2003). Furthermore, it has been reported that Breg IL-10-
mediated suppression of both pathogenic Th17 and Th1 subsets is critically dependent 
on TLR and MyD88 signalling (Lampropoulou, Hoehlig et al. 2008). Although the 
exact details of these mechanisms are not yet clear, a balance between where B cells 
encounter TLR ligands and the cytokine environment may play a role. For example, a 
recent study has shown a pathogenic role for TLR9 in the activation of bone marrow 
B cells from RA patients. Stimulation of bone marrow B cells with the TLR9 ligand 
bacterial CpG stimulated B cell proliferation, up-regulation of co-stimulatory 
molecules CD86 and CD54 and the production of pro-inflammatory cytokines IL-6 
and TNFα. In addition, a significantly higher level of bacterial DNA was detected in 
bone marrow samples from RA patients compared to osteoarthritis controls 
(Rudnicka, Burakowski et al. 2009). Oedema and the formation of lymphoid 
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neogenesis in subchondral bone can often be seen in patients with RA particularly in 
those patients with early stage RA suggesting that bone marrow may provide a rich 
environment for pathogenic B cell activation (Bugatti, Caporali et al. 2005; Tamai, 
Kawakami et al. 2007).  
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1.5 B cells as antigen presenting cells  
B cells are well documented as APC. However, their exact role in the initiation and 
maintenance of a CD4+ T cell response has remained controversial, due to their 
dependence on help from activated CD4+ T cells, the low frequency of antigen-
specific B cells in the periphery and conflicting evidence from B cell depletion that 
conclude either normal or abrogated T cell responses in their absence (Ron, De 
Baetselier et al. 1981; Janeway, Ron et al. 1987; Epstein, Di Rosa et al. 1995; Liu, Wu 
et al. 1995; Linton, Bautista et al. 2003). Studies using B cell-deficient mice have 
attempted to elucidate the role of B cells in T cell activation in vivo using mice 
depleted of B cells either via the administration of anti-µ antibodies (Janeway, Ron et 
al. 1987), by gene disruption (µMT) (Epstein, Di Rosa et al. 1995; Liu, Wu et al. 
1995; Phillips, Romball et al. 1996) or in which the B cell compartment is deficient in 
MHC class II (Williams, Oxenius et al. 1998; Crawford, Macleod et al. 2006).  
However, the conflicting evidence showing either normal or abrogated T cell 
responses in the absence of B cells has been demonstrated in all the above systems 
and is most likely due to several contributing factors including, variability between 
mouse strains (Rivera, Chen et al. 2001), the effect of B cell depletion on normal 
lymphoid architecture (Linton, Harbertson et al. 2000), the type and form of antigen 
(Constant, Schweitzer et al. 1995) and finally the effect that B cell depletion can have 
on the function of other APC (Macaulay, DeKruyff et al. 1998). Indeed, it has been 
shown that dendritic cells from B cell deficient mice (μMT) mice produce lower 
levels of IL-12 which in turn has an effect on the T cell Th1/Th2 balance, skewing 
production of Th1 cytokines IFNγ and IL-2 and not IL-4 (Moulin, Andris et al. 2000). 
 
B cells play a role in both the humoral and cellular responses by organizing lymphoid 
architecture, producing antibodies and activating T cells. Like the other APC, B cells 
are capable of providing all of the required signals for T cell activation. However, 
unlike dendritic cells and macrophages, B cells are capable of clonal expansion in 
response to antigen. This additional function allows B cells to focus the T cell 
response around small amounts of the antigen-specific to their BCR. Indeed, B cells 
have been implicated as initiators of an adaptive immune response when antigen 
levels are low (Rivera, Chen et al. 2001; Byersdorfer, Dipaolo et al. 2004). 
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1.5.1 Antigen uptake via BCR 
The method of antigen uptake can determine how efficiently peptide MHC class II 
complexes are presented to T cells (Lanzavecchia 1990). Several studies have 
demonstrated that although B cells are capable of taking up antigen via fluid phase 
uptake, this method is inefficient when compared to that of DC (Sallusto and 
Lanzavecchia 1994). However, antigen targeted to the BCR (and other cell surface 
receptors) allows for both efficient processing and presentation of antigens to CD4+ T 
cells (Chesnut, Colon et al. 1982; Lanzavecchia, Abrignani et al. 1988; Carel, Myones 
et al. 1990). Receptor-mediated antigen uptake is carried out most efficiently by the 
BCR. A high affinity BCR allows B cells to effectively compete with other APC for 
antigen capture and presentation and with other B cells for T cell survival signals 
(Rock, Benacerraf et al. 1984; Lanzavecchia 1985). Bias towards receptor-mediated 
antigen uptake, particularly via the highly antigen-specific BCR, highlights B cells as 
a novel group of efficient antigen-specific T cell activators.  
 
1.5.2 The BCR complex  
The B cell receptor complex is a hetero-oligomeric structure consisting of the antigen 
recognition component (BCR) which is a precursor of Ig and additional signalling 
molecules CD79α and CD79β (Hombach, Leclercq et al. 1988). The BCR are 
disulphide linked tetramers of two heavy (H) and two light (L) chains anchored in the 
cell surface (Borst, Brouns et al. 1993). The H chain consists of a single variable 
region and three constant regions and the L chain consists of a single variable and a 
single constant region. The BCR can be separated into two distinct regions the antigen 
recognition region or fragment antigen binding (Fab) and the fragment crystalline 
region (Fc) which provide different effecter functions dependent on the isotype when 
the BCR is secreted as Ig  (Figure 1.3).  
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Figure 1.3 The BCR complex 
Model of the BCR complex including the co-signalling molecules CD79α, CD79β, CD19, CD21 and 
the inhibitory molecule CD22.  The BCR structure comprises of an effecter or fragment crystalline (Fc) 
region and an antigen recognition or Fragment antigen binding (Fab) region. 
 
The BCR undergoes constitutive internalization mediated by the phosphorylation of 
immunoreceptor tyrosine-based activation motifs (ITAM) in the Igα cytoplasmic 
domain (Bonnerot, Lankar et al. 1995). However, upon BCR recognition of 
membrane bound antigen, an increased signalling cascade leads to the formation of an 
immunological synapse. The immunological synapse is surrounded by co-stimulatory 
and adhesion molecules that enable accelerated and efficient uptake, processing and 
presentation of antigen to T cells (Anderson and Siahaan 2003; Carrasco and Batista 
2006). Mutational studies of the BCR have revealed that BCR mediated uptake not 
only ensures efficient uptake of antigen but also drives the accelerated intracellular 
targeting of antigen for loading onto MHC class II (Aluvihare, Khamlichi et al. 1997). 
Peptide loading onto MHC class II molecules is mediated by the non-classical MHC 
class II molecule H2-DM (Ruckrich, Brandenburg et al. 2006). This is itself regulated 
by H2-DO binding to H2-DM at a high pH early in the endosomal pathway, favouring 
high affinity BCR presentation and limiting non-specific uptake via pinocytosis 
(Denzin, Fallas et al. 2005). In addition, as the antigen internalized via the BCR is 
limited to a specific protein on each individual B cell clone, there is little competition 
from other external antigens for processing and peptide generation that will ultimately 
compete for binding to the MHC class II.  
 
The efficiency of BCR mediated uptake has been demonstrated by many laboratories 
using several different model antigens concluding that BCR mediated uptake allows 
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the B cell to present antigen around 10
3
-10
4
 fold more efficiently than non-specific 
uptake via pinocytosis (Chesnut and Grey 1981; Batista and Neuberger 1998). Indeed, 
Lanzavecchia demonstrated that antigen-specific B cells were able to present tetanus 
toxin at concentrations of 10
-11 
M when only a small fraction of BCR are occupied by 
antigen (~0.05%) (Lanzavecchia 1985). Batista and Neuberger demonstrated that the 
affinity of the BCR for its antigen has a direct effect on its ability to present antigen to 
T cells. In studies using lysozyme-specific B cell transfectants and mutated forms of 
lysozyme with differing binding affinities they showed that an antigen/BCR affinity 
of Ka of >10
6
 M
-1
 was required for detectable BCR mediated antigen presentation, 
between a Ka of 10
6
-10
8
 M
-
1 the presentation sensitivity was increased and at Ka 
>10
10
 M
-
1 a threshold was reached and antigen presentation no longer improved 
(Batista and Neuberger 1998). Indeed, differences in affinity have recently been found 
to relate to differences in synapse formation with high affinity BCR interactions 
promoting rapid synapse formation and recruitment of signalling molecules (Liu, 
Meckel et al. 2010).  
 
In addition, B cells may be responsible for promoting the initial T cell responses to 
antigen demonstrated by Crawford et al who showed that T cell activation is impaired 
at early timepoints following immunization with OVA in bone marrow chimeric mice 
where B cells lack MHC class II (Crawford, Macleod et al. 2006).  In support of this, 
other groups have identified the cell surface expression of peptide-MHC class II 
complexes at early timepoints following immunisation, suggesting that B cells 
contribute to the early activation of T cells following antigen encounter (Byersdorfer, 
Dipaolo et al. 2004; Catron, Itano et al. 2004; Yan, Harvey et al. 2006; Pape, Catron 
et al. 2007). 
 
1.5.3 Additional B cell antigen receptors  
B cells are equipped to target specific antigen via the BCR, whilst maintaining the 
ability to adapt the response to opsonised antigen. Indeed, the secreted form of the 
BCR (Ig) can both compete with the BCR for binding to its antigen and also facilitate 
antigen uptake by FcR (Lanzavecchia 1987).  
 
The efficiency of BCR signalling is influenced by CR1 (CD35) and CR2 (CD21) 
complement receptors, CD19 of the Ig superfamily and FcγRII antibody receptors. 
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Antigen targeted to CD19 can upregulate co-stimulatory molecules and efficiently 
activates T cells independently of the BCR (Yan, Wolff et al. 2005). Additionally, 
CD19 and/or CD19-CR2 complexes provide signals to lower the threshold of 
antigenic stimulation through the BCR and augment antigen uptake (Fearon and 
Carroll 2000). Importantly, Rossbacher et al demonstrated that the BCR itself was 
capable of activating complement and providing the CR ligands required for the 
activation of this optimal antigen uptake and presentation (Rossbacher and Shlomchik 
2003). However, in the absence of co-ligation with the BCR, CR2 mediated antigen 
uptake does not upregulate the co-stimulatory molecules required for T cell activation 
and may have a role in initiating T cell anergy (Brown, Barrault et al. 2006).   
 
1.5.4 B cell Tolerance  
The specificity of the BCR is determined firstly during arrangement of the V D and J 
segments of the H and L chains during B cell development in the bone marrow. 
Subsequent B cell receptor editing involving secondary V(D)J recombination occurs 
following BCR recognition of self-antigen to reduce affinity for self (Nemazee 2000).   
 
Naïve B cells that either recognize multivalent membrane bound antigen in the bone 
marrow, are unable to edit their light chains, or fail to encounter their specific-antigen, 
are either eliminated or undergo follicular B cell death due to competition from other 
B cells for antigen-specific survival signals (Nemazee and Burki 1989; Hartley, 
Cooke et al. 1993). Early studies demonstrated that auto-reactive B cells expressing a 
BCR capable of recognising a self antigen were either deleted or made anergic 
(Goodnow, Crosbie et al. 1988). 
 
The mechanisms governing whether autoreactive B cells are deleted, undergo receptor 
editing or become anergic are not clear. However, as with TCR tolerance factors 
affecting the fate of B cells involve affinity of antigen recognition with a weak 
recognition of self antigen resulting in anergy or ignorance and a high affinity 
resulting in deletion. B cells weakly crosslinked by self-antigens in the bone marrow 
may emerge from the follicles as ignorant in the absence of their ligand and/or 
autoreactive T cell help (Nemazee, Russell et al. 1991; Shlomchik, Zharhary et al. 
1993; Hannum, Ni et al. 1996). B cell anergy can occur where as autoreactive antigen 
is not sufficient to trigger apoptosis but is sufficient to prevent follicular entry and the 
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recruitment of T cell help (Shlomchik 2008). In addition, to deletion, editing and 
anergy another  proposed B cell tolerizing mechanisms is the reduction in B cell-
mediated signalling via the sialic binding lectin-SHP-1 tyrosine phosphatase pathway. 
CD22 for example expressed at high levels by mature B cells is a prominent sialic 
binding, Ig domain containing lectin which associates with the BCR and delivers 
inhibitory signals via immunoreceptor tyrosine-based inhibitory motifs (ITIMs) on its 
cytoplasmic tail leading to inhibition of BCR signalling (Pillai, Cariappa et al. 2009).  
 
1.5.5 B cell tolerance breakdown 
Clonally anergic or ignorant B cells are thought to be the source of autoreactivity as 
up to 50% of newly emerging B cells may be anergic (Merrell, Benschop et al. 2006). 
In addition to the deletion of self-reactive B cells, receptor editing can also result in 
rearrangement at the other kappa or lambda loci resulting in a new non self-reactive 
BCR whilst retaining the initial autoreactive BCR (Li, Jiang et al. 2001; Liu, Velez et 
al. 2005). Cells expressing these dual receptors can escape into the periphery as 
potentially autoreactive B cells along with anergic autoreactive B cells or B cells that 
have escaped tolerance mechanisms by some other means such as natural leakiness or 
genetically mediated tolerance failure (Shlomchik 2008). So how do these potentially 
autoreactive B cells become activated? Studies using AM14 BCR Tg mice have 
elucidated AM14 autoreactive RF “IgHa” allotype specific B cells are present in the 
periphery but are clonally anergic. However, when the AM14 BCR Tg mice were 
crossed onto the autoimmune prone MLR.Fas
lpr
 background the anergic B cells 
became activated to produce autoantibodies. This response only occurs in IgH
a
 and 
not IgH
b
 strains in confirming that clonally anergic B cells can be activated in the 
periphery and that this B cell activation is antigen dependent (Wang and Shlomchik 
1999).  Furthermore, subsequent studies have verified that this autoreactive B cell 
activation can occur at extra-follicular sites (William, Euler et al. 2002). Co-ligation 
of the BCR and TLR receptors have been implicated in directing autoreactive extra-
follicular B cell responses possibly in a T independent manner, thus absolving the 
requirement  for autoreactive T cell help (Leadbetter, Rifkin et al. 2002; MacLennan, 
Toellner et al. 2003; Herlands, Christensen et al. 2008; Shlomchik 2008). In addition, 
strong autoreactive T cell help has also been shown to break B cell anergy (Goodnow, 
Brink et al. 1991). Therefore, it is probable that a break in B cell tolerance occurs 
 31 
through a combination of autoreactive B cell precursors, antigen availability and TLR 
stimulation and/or the activation of autoreactive T cell help.   
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1.6 Autoantigen processing and presentation 
 
1.6.1 Candidate autoantigens   
Genetic linkage to HLA alleles and T cell activation markers suggests that rheumatoid 
arthritis is an antigen-driven disease. However, attempts to consistently identify 
autoreactive T cells or disease specific autoantibodies have proven difficult. Studies 
over the years have identified several candidate joint autoantigens as potential targets 
leading to the development of RA, some of which are listed in Table 1.1. The ability 
of certain matrix proteins such as aggrecan and collagen to elicit disease in animals 
and the detection of auto antibodies and autoreactive T cells isolated from RA patients 
make them ideal candidates for further study. However, new proteomics and mass 
spectrometry analysis of RA sera is rapidly detecting novel autoantigens such as 
signalling molecules, citrullinated glycolytic enzymes and molecular chaperones 
(Auger, Balandraud et al. 2009; Goeb, Thomas-L'Otellier et al. 2009). Therefore, it is 
possible that the antigen responsible could vary greatly from patient to patient or 
indeed that several autoreactive antigens may be involved in the same patient. 
Another possibility is that the antigens are post-translationally modified via 
mechanisms such as glycosylation, or citrullination (Axford, Sumar et al. 1992; 
Klareskog, Ronnelid et al. 2008). In addition, as joint cartilage is progressively 
degraded by increased proteinase activity (including  MMP) promoted by pro-
inflammatory cytokines such as IL-1 and TNFα, previously immunopriviledged 
antigens may be uncovered or modified, suggesting that chronic disease progression 
could be a stepwise process involving different antigens at different stages of disease. 
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Antigen                                        Reference                                   Citrullinated 
Aggrecan                          (von Delwig, Locke et al. 2010)                    yes                                                              
Collagen II                       (Burkhardt, Sehnert et al. 2005)                     yes                                                         
Vimentin                          (Vossenaar, Despres et al. 2004)                    yes                                                                   
α-enolase                          (Kinloch, Tatzer et al. 2005)                          yes                                                                        
Fibrin                               (Masson-Bessiere, Sebbag et al. 2001)           yes 
HCgp-39                          (Verheijden, Rijnders et al. 1997) 
Chondrocyte Ag              (Bang, Mollenhauer et al. 1994) 
Human Hsp60                  (van Halm, Slot et al. 2006) 
Fibrinogen                        (Masson-Bessiere, Sebbag et al. 2000)           yes                                                                           
MMPs                              (Sedlacek, Mauch et al. 1998) 
Filagrin                            (Girbal-Neuhauser, Durieux et al. 1999)         yes                                                                                                           
Keratin                            (Chang, Jian et al. 2009)                                   yes 
 
Table 1.1 Table illustrating candidate autoantigens in RA. 
Some of the candidate joint autoantigens identified to date are listed in the above table. If there is 
evidence that the autoantigens can be citrullinated then this is indicated in the right panel.  
 
1.6.2 Antigen uptake by APC 
Methods of antigen uptake (endocytosis) by different APC have been reviewed 
(Lanzavecchia 1996; Mellman 1996). Endocytosis is a process used by all eukaryotic 
cells for cellular homeostasis and recycling of cell surface components. In addition, 
variations of endocytosis are adopted by different APC to internalize exogenous 
antigens for processing and presentation to CD4+ T cells. Phagocytosis by 
macrophages and dendritic cells involves receptor engagement to engulf large 
particles >0.5 μm diameter. Varieties of pattern recognition receptors such as the 
mannose receptor are designed to recognize distinct patterns on bacterial components.  
Uptake is triggered by receptor recognition of pathogen associated molecular patterns 
or antigens opsonised by molecules such as Ig or complement fragments. Receptor 
signalling initiates F actin polymerization and pseudopod extensions that engulf the 
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receptor/ligand complex and form a tight phagosome (Greenberg, Burridge et al. 
1990). Phagosomes rapidly fuse with endosomes and exchange their membrane and 
contents for processing within the endosomal pathway (Kielian and Cohn 1980; 
Unanue 1984). Pinocytosis is a process carried out by macrophages, dendritic cells 
and B cells that typically involves constitutive non-specific fluid phase antigen 
uptake, initiated at clathrin coated pits and resulting in the formation of smaller 
endocytic vesicles <0.2 μm diameter. Macropinocytosis is a clathrin independent 
mechanism of pinocytosis involving the formation of macropinosomes 1-5μm 
diameter (Mellman 1996). Macropinocytosis is performed constitutively by dendritic 
cells and by macrophages following stimulation with MCSF (Racoosin and Swanson 
1989). However, prolonged stimulation of DC with inflammatory stimuli such as 
TNFα, LPS or IL-1 has been shown to dramatically reduce uptake by 
macropinocytosis suggesting that this mechanism of antigen uptake may be shut down 
in mature DC (Sallusto, Cella et al. 1995; West, Wallin et al. 2004). Macropinosomes 
are formed by actin polymerisation and membrane ruffling that form invaginations 
into the cell, that close at the outermost regions to form vesicles. Vesicles are 
subsequently depolymerised and enter the endocytic pathway or are recycled to the 
cell surface (Racoosin and Swanson 1993; Swanson and Watts 1995). Receptor 
mediated endocytosis of soluble antigens is clathrin dependent. Antigen receptors 
such as Fc receptors expressed by macrophages, dendritic cells and B cells or the B 
cell specific BCR complex are clustered within clathrin coated pits and rapidly 
internalize bound antigens delivering them to various endocytic compartments in a 
process dependent on signals relayed via the receptor complex (Aluvihare, Khamlichi 
et al. 1997). The different mechanisms of antigen uptake by B cells, macrophages and 
dendritic cells equips the immune system with a comprehensive set of antigen sifting 
cells to ensure minimal immune evasion by pathogens.  
 
However, depending on which intracellular compartment antigen is endocytosed to, 
different peptide repertoires could be generated from the same antigen influenced by 
factors such as proteinase availability, proteinase activation and pH which differ in 
different intracellular compartments and possibly between different APC (Schneider 
and Sercarz 1997; von Delwig, Bailey et al. 2002).  
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1.6.3 MHC class II assembly and trafficking. 
The majority of peptide epitopes recognised by CD4+ T cells are generated from 
antigens taken up by APC and processed within the endosomal pathway where they 
are loaded onto MHC class II molecules (Robinson and Delvig 2002; Watts 2004).   
Partially folded MHC class II α/β heterodimers are assembled and stabilized with the 
type II transmembrane chaperone protein, known as the invariant chain (li) which is 
found within the endoplasmic reticulum (Cresswell 1996). Signalling via motifs found 
in the li chain cytoplasmic tail facilitates ER egress to the trans Golgi network and 
subsequent transport and retention into the endocytic compartment known as MHC 
class II containing compartment (MIIC) either directly or via the cell surface (Neefjes, 
Stollorz et al. 1990; Pieters, Bakke et al. 1993). A segment of the li chain occupies the 
MHC class II peptide binding groove and prevents premature loading of endogenous 
peptides and partially folded proteins (Roche and Cresswell 1990). Within the MIIC 
most of the li chain is degraded by cysteine and aspartyl proteinases including the 
cysteine proteinases cathepsins S and L which leave behind a small peptide remnant 
known as the class II-associated invariant chain peptide (CLIP) (Nakagawa, Roth et 
al. 1998; Riese and Chapman 2000). Removal of CLIP is catalyzed by the MHC class 
II like molecule, human leukocyte antigen-DM (HLA-DM) in exchange for antigenic 
peptides of  ~15 amino acids either within in the endosomal compartment or at the 
cell surface (Denzin and Cresswell 1995). The molecular mechanisms governing 
MHC class II transport within the endosomal pathway and to the plasma membrane 
involve the ubiquitination of peptide loaded MHC class II which acts as a transport 
signal for MHC class II internalization from the plasma membrane and its sorting to 
lysosomes. Indeed, ubiquitination of MHC class II is downregulated in activated 
compared with immature dendritic cells by the differential expression of the ubiquitin 
ligase MARCH 1 resulting in an increase MHC class II cell surface expression (van 
Niel, Wubbolts et al. 2008). However, MARCH-1 is highly expressed in B cells and is 
involved in the regulation of MHC class II degradation via ubiquitination, indicating 
that this mechanism is central to the turnover of functional MHC class II at the cell 
surface. (Matsuki, Ohmura-Hoshino et al. 2007). 
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1.6.4 Antigenic peptide generation and loading of MHC class II molecules 
The majority of antigen processing is thought to take place in the same endosomal 
compartments as li processing (Watts 1997).  MHC class II molecules can be found in 
several different endocytic compartments with distinct alterations in morphology from 
early to late endosomes (Rocha and Neefjes 2008). Evidence suggests that MHC class 
II can capture antigen at various points along the pathway (Hiltbold and Roche 2002). 
Factors affecting peptide processing include:  
 
1.6.4.1 Proteolysis 
 The requirement for antigen to be degraded into peptides prior to loading of MHC 
class II molecules was described by Shimonkevitz in 1983 using fixed APC and 
proteinase degraded ovalbumin. Additional observations from this study were that 
different proteinases could either preserve or destroy different antigenic epitopes 
(Shimonkevitz, Kappler et al. 1983). Cysteine, serine, aspartyl and metalloproteinases 
have all been linked to the processing of different protein antigens into peptide 
fragments and are capable of generating or destroying immunogenic self-peptides 
involved in autoimmunity (Bryant, Lennon-Dumenil et al. 2002; Honey and 
Rudensky 2003). See Table 1.2 for list of enzymes implicated in antigen processing. 
Examples include the processing of Goodpastures autoantigen (collagen 
alpha3(IV)NC1). Cathepsin D diminishes responses in T cells taken from 
Goodpastures patients and this degradatitve processing could be blocked by the 
cathepsin D/E inhibitor Pepstatin A (Zou, Hannier et al. 2008).   
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Cysteine proteinases 
Cathepsins 
C,B,F,H,K,L,S,N,T,U,V,W,Z 
and AEP 
 
(Honey and Rudensky 2003) 
Aspartyl proteinases Cathepsins D and E 
 
(Villadangos, Bryant et al. 
1999) 
Serine proteinases Cathepsin G, elastase, plasmin 
(Burster, Macmillan et al.) 
(Honey and Rudensky 2003) 
Other enzymes 
involved in antigen 
processing 
GILT 
(Phan, Arunachalam et al. 
2000) 
Endogenous 
proteinase 
inhibitors 
Cystatins, high pH, proteinase 
pro-domains and p41. 
(Kopitar-Jerala 2006) 
(Fineschi, Sakaguchi et al. 
1996) 
 
Table 1.2 Proteinases involved in the antigen processing pathway.  
Listed above are the major families of proteinases involved in antigen processing including some of the 
endogenous inhibitors known to control their activation. 
 
Extracellular proteolysis of joint components is one of the earliest observations in 
rheumatoid arthritis. Endopeptidases and exopeptidases have been implicated in the 
cleavage of carboxyl termini of naturally occurring peptides that are loaded onto 
MHC class II molecules (Chicz, Urban et al. 1992). Studies have shown that cathepsin 
B has both exopeptidase and endopeptidase activity and is involved in the 
extracellular processing of the joint matrix component aggrecan. Cleavage with 
cathepsin B or matrix metalloproteinases in the IGD domain of aggrecan produces the 
small G1 fragment of aggrecan containing the neoepitope site „VDIPEN‟ (Mort, 
Magny et al. 1998). However, the effects of this extracellular aggrecan processing on 
T cell recognition are not known.  
 
Experiments using mice lacking in one of the enzymes involved in degrading the li 
chain, cathepsin S (CatS) revealed that the CatS
-
 mice were resistant to CIA 
(Nakagawa, Brissette et al. 1999). Observations by Nakagawa et al revealed CD4+ T 
cells from CatS
-
 mice showed abrogated responses to collagen II but normal responses 
to several other protein antigens. This implies a dual role for CatS in li degradation 
and collagen II processing. These data highlight that certain proteinases such as CatS 
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may be involved in generating arthritogenic peptide repertoire from joint autoantigens 
such as collagen II but not other antigens and therefore different proteinases must be 
involved in the processing of different autoantigens.  
 
 Other enzymes involved in the processing of protein antigens include the γ-interferon 
induced lysosomal thiol reductase GILT which reduces disulfide bonds to facilitate 
unfolding of proteins (Phan, Arunachalam et al. 2000) and the cysteine proteinase 
asparagine endopeptidase (AEP) implicated as the enzyme involved in the initial steps 
of li degradation and the dominant enzyme involved in processing the c terminal 
fragment of tetanus toxin by B cells (Manoury, Hewitt et al. 1998; Manoury, Mazzeo 
et al. 2003).  
 
Further complexity exists as proteinases themselves can be regulated by endogenous 
inhibitors such as cystatins. Cystatin C for example, which is expressed by dendritic 
cells and macrophages, is an endogenous inhibitor of cathepsin S regulated by 
inflammatory stimuli such as TNFα and IFNγ (Barrett 1986; Pierre and Mellman 
1998; Frendeus, Wallin et al. 2009). Furthermore, studies have demonstrated that the 
pro-inflammatory cytokines TNFα and IL-1β present at high levels in the synovium 
increase activity of the antigen degrading proteinases cathepsins S and B and increase 
antigen presentation efficiency, possibly due to indirect effects on cystatins (Fiebiger, 
Meraner et al. 2001). Proteinase activity within APC is also regulated by levels of 
proteinase chaperones such as the AEP chaperone p41 li, comparative levels of other 
proteinases required for the activation of proteinase precursors or chaperone 
degradation and intra-cellular pH (Watts 2004).  
 
 Whilst enhanced lysosomal proteolysis can increase the efficiency of antigen 
presentation to T cells, degradatitve proteolysis has also been demonstrated to result 
in less efficient antigen presentation both in vitro and in vivo (Vidard, Rock et al. 
1991; Delamarre, Couture et al. 2006). Therefore, the conditions required for efficient 
processing and presentation of T cell epitopes will almost certainly vary depending on 
the stability of the antigen and access of proteinases-specific cleavage sites. In 
addition the repertoire of proteinases and their endogenous inhibitors (e.g. cystatins, 
p41) will vary dependent on APC type and activation of proteinases such as 
cathepsins B, D, E and L which require acidic pH will favour antigens processed in 
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late acidic compartments rather than early in the endosomal pathway (Goettlich-
Riemann, Young et al. 1971).  
 
1.6.4.2 Intracellular pH  
Early experiments performed by Ziegler and Unanue, using ammonia and chloroquine 
to neutralize the pH of endocytic compartments, demonstrated the requirement of an 
acidic environment for efficient processing of 
125
I-labelled listeria by macrophages 
(Ziegler and Unanue 1982). Endosomal compartments become progressively more 
acidic as they move into the cell due to vacuolar ATPase activity (Mellman, Fuchs et 
al. 1986). Since those early experiments by Ziegler and Unanue many studies have 
dissected the importance of endosomal pH and have demonstrated how the 
intracellular environment modulates proteinase activity, peptide generation and 
loading onto MHC class II molecules. Low pH has been shown to initiate the initial 
unfolding of antigens aiding processing for MHC class II presentation (Jensen 1993). 
Inflammatory triggers such as LPS can also increase the efficiency of antigen 
processing by increasing ATPase activity in endosomal compartments which in turn 
lowers the endosomal pH enhancing antigen processing and presentation(Trombetta, 
Ebersold et al. 2003). An acidic environment is required for the activation of 
proteinase precursors such as cathepsins L and B (Mason, Gal et al. 1987; Rowan, 
Mason et al. 1992) and for the activity of the protein reducing enzyme GILT (Phan, 
Arunachalam et al. 2000).   
 
APC have an extra mechanism for regulating peptide editing in the form of the MHC 
class II α/β heterodimer HLA-DO. HLA-DO molecules function as HLA-DM 
regulators thought to be controlled by the pH of the endosomal compartments 
skewing peptide loading of MHC class II molecules in favour of the more acidic late 
endosomes (Denzin, Fallas et al. 2005). Interestingly, BCR-mediated uptake triggers 
rapid transport of antigen/BCR complexes to the late endosomal compartment 
implying that HLA-DO-HLA-DM regulation is in place so that B cells preferentially 
present specific antigen taken up via the BCR.   
Fine tuning of intracellular pH to prevent destruction of T cell epitopes in early 
endosomal compartments has also been demonstrated by Savina et al in DC. The 
group demonstrated that NADPH oxidase mediates production of reactive oxygen 
species which causes sustained alkalization of phagosomes promoting enhanced 
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antigen presentation (Savina, Jancic et al. 2006). However, its relevance to antigen 
presentation by other APC is not yet known. 
 
1.6.4.3 The antigen structure  
The extent of antigen processing required to generate peptide fragments able to bind 
MHC class II molecules can differ greatly depending on the antigen structure as 
reviewed in (Robinson and Delvig 2002). GILT and a low pH may be required to 
initially reduce disulphide bonds and unfold certain antigens allowing access to the 
peptide by endosomal proteinases. 
 
Partially degraded or denatured proteins may also bind directly to MHC class II 
without the need for further intracellular processing such as the candidate joint 
autoantigen fibrinogen epitope Aα551-578 and the model antigen HEL (Lee, Matsueda 
et al. 1988; Castellino, Zappacosta et al. 1998). However, whether this minimal 
processing event is sufficient to enable binding of all protein antigens is not known.  
 
Differences in the extent of processing required by the antigen can have a major effect 
on the survival of certain epitopes. Proteins are increasingly degraded as they travel 
through the endosomal pathway and some epitopes will be destroyed (termed 
„degradatitve processing‟). Other epitopes that require minimal processing may be 
generated extracellulary or within the less proteolytic early endosomes and hence will 
be available for MHC class II binding (Watts 1997; Delamarre, Couture et al. 2006). 
MHC class II molecules that recycle from the APC cell surface are the most likely 
source of MHC class II for binding these minimally processed epitopes as Peptide 
loading of recycling MHC class II molecules occurs within the mildly acidic 
environment of the early endosomes (Salamero, Humbert et al. 1990; Griffin, Chu et 
al. 1997; Accapezzato, Nisini et al. 1998; Pathak and Blum 2000). In addition, there is 
also evidence of exogenously processed peptides such as those derived from the MS 
autoantigen myelin basic protein (MBP), binding directly to MHC class II molecules 
present on the cell surface of APC mediated by cell surface levels of HLA-DM on 
dendritic cells and B cells (Arndt, Vogt et al. 2000).   
 
 Avoiding the degradatitve environment of the late endosomes will alter the peptide 
repertoire available for class II loading on MHC class II possibly uncovering cryptic 
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epitopes usually destroyed and therefore not encountered by CD4+ T cells during 
their development. Another possibility for the generation of an alternate peptide 
repertoire exists following uptake of sequestered or opsonised antigens by receptors 
such as the BCR, FcR or complement receptors (CR). Jacquier-Sarlin et al have 
shown that fluid phase uptake of tetanus toxin is improved when C3b has bound to it. 
Using C3b bound tetanus toxin the group showed that the improved processing and 
presentation was due to the bound C3b preventing proteolysis by cathepsin D 
(Jacquier-Sarlin, Gabert et al. 1995). Additionally immune complexes containing C3d 
can augment the signal through BCR ligation via CR2 thus improving presentation 
(Edwards, Cambridge et al. 1999; Barrault and Knight 2004). Antigen-capture via the 
BCR, Ig or CR results in the entire internalized BCR/Ig/complement-antigen complex 
becoming the substrate for endosomal processing (West, Lucocq et al. 1994; Jacquier-
Sarlin, Gabert et al. 1995)}. The consequences of this are that antigenic epitopes 
masked by the BCR/Ig/complement will either be suppressed due to the physical 
masking of proteinase cleavage sites or enhanced due to their increased survival 
during transit to the MHC class II compartment (Watts and Lanzavecchia 1993; 
Jacquier-Sarlin, Gabert et al. 1995; Simitsek, Campbell et al. 1995). In addition, 
minimally processed antigen bound to the BCR can be captured by neighbouring 
membrane-bound MHC class II molecules in a sort of hand-over manner. The 
relevance of this finding is that early capture of minimally processed antigen could 
improve the survival of certain T cell epitopes that would normally be destroyed 
within the degradatitve environment of late endosomes (Moss, Tree et al. 2007). 
 
An additional outcome of this minimal processing  is that suppression of  dominant 
MHC class II epitopes that require the proteolytic environment of  late endosomes 
may result in the enhanced MHC class II loading and subsequent presentation of sub-
dominant epitopes that would be otherwise invisible to the immune system (Dai, 
Carayanniotis et al. 2005). The efficiency of BCR mediated uptake and presentation is 
clearly influenced by the stability of the BCR-antigen complex. Rapid transit of the 
BCR/antigen complex may be necessary to retain antigen on the BCR long enough for 
delivery to the MHC class II (Aluvihare, Khamlichi et al. 1997) whereas in the 
absence of a high affinity interaction certain epitopes have been shown to be 
preferentially processed earlier in the endosomal pathway where they can be 
presented by recycling MHC class II molecules (Brooks and Knight 2004). The 
 42 
resulting consequences of this tight affinity are the destruction of certain T cell 
epitopes by delivery into a more degradatitve acidic compartment or conversely 
protection of certain T cell epitopes from degradation by the sequestering nature of 
the BCR (Davidson and Watts 1989).   
 
Post-translational modification of proteins by phosphorylation, glycosylation, 
methylation and citrullination leads to subtle differences in the way that antigens are 
processed by APC generating neoepitopes with enhanced affinity for TCR, BCR or 
MHC (Anderton 2004). Evidence indicates that certain T cell epitopes require specific 
methods of proteolysis to avoid/promote their degradation. Therefore it is possible 
that a particular combination of antigen modification, uptake, enzyme degradation and 
APC type could result in the generation and subsequent presentation of cryptic 
epitopes that were not previously generated by APC involved in T cell tolerance 
induction mechanisms (Goodman and Sercarz 1983). 
 
1.6.5 Inhibition of the antigen processing and presentation pathway. 
As detailed above differences in antigen structure will affect the extent of proteolysis 
required, the pH environment required for initial antigen unfolding and access to 
proteinase cleavage sites and which APC type is most equip to efficiently process the 
antigen. Over the years many studies with a variety of chemical inhibitors of various 
components of the antigen processing pathway have been utilised to dissect the 
requirement for a particular proteinase, pH, and protein synthesis. This inhibitor 
system can be used to uncover the processing requirements of different antigens 
involved in infection, cancer and autoimmunity possibly leading to the discovery of 
antigen-specific targeting for autoimmune or cancer therapy or improved delivery 
systems for targeting vaccines.  
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1.6.5.1 Cycloheximide and Brefeldin A  
Cycloheximide is an inhibitor of protein synthesis that acts by binding to ribosomes 
and preventing eEF2-mediated translocation which depletes newly synthesised MHC 
class II molecules (Schneider-Poetsch, Ju et al.; Kerridge 1958). 
 
Brefeldin A is an inhibitor of ER/Golgi transport that disrupts the delivery of newly 
synthesised proteins (including MHC class I and II molecules) to the cell surface or 
endosomal pathway. The effects of Brefeldin A are tubulation of the 
Golgi/ER/endosomal pathway that result in attenuated Golgi/ER transport but normal 
cell surface recycling of previously generated MHC class II. Newly synthesised 
proteins are retained in the ER of Brefeldin A treated cells and become processed by 
Golgi enzymes (Orci, Tagaya et al. 1991; Klausner, Donaldson et al. 1992).  
 
Therefore, both inhibitors can be used to determine whether epitopes are presented via 
the classical pathway of antigen presentation on newly synthesised MHC class II 
molecules or via the recycling pathway loaded in the mildly acidic early endosomes 
on recycling class II molecules, independently of newly synthesised MHC class II and  
the li chain (St-Pierre and Watts 1990). Indeed, Brefeldin A and cycloheximide has 
been used to verify the processing pathway of several antigens including the M5 
protein of Streptococcus pyogenes, capsular Caf1 antigen of Yersinia pestis and 
influenza hemaglutinin protein. Results from these experiments have revealed that 
whilst some antigenic epitopes require minimal processing and are presented by 
recycling MHC class II other epitopes from the same antigens require presentation via 
the classical pathway on newly synthesised MHC class II  (Delvig and Robinson 
1998; Sinnathamby and Eisenlohr 2003; Musson, Morton et al. 2006). Antigens 
presented via the recycling pathway require minimal processing and may be partially 
degraded by extracellular enzymes such as MMPs upregulated during inflammatory 
conditions (Accapezzato, Nisini et al. 1998; Santambrogio, Sato et al. 1999). The 
recycling pathway is independent of the li chain and subsequently the requirement for 
H-2 DM editing. Therefore, it is possible that this less stringent peptide loading and 
extracellular degradation may result in the presentation of immunogenic epitopes that 
have not been encountered during T cell development and are subsequently not 
tolerized against. Therefore, uncovering the presentation pathway of 
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immunodominant epitopes from candidate joint autoantigens such as aggrecan may 
help to elucidate their role in arthritic diseases such as RA 
 
1.6.5.2 Ammonium chloride 
 Ammonium chloride is a weak base agent that can be used to raise the endosomal pH 
to pH 6.5 or above (Poole and Ohkuma 1981). Endosomal pH plays an important role 
in the activation of proteolytic enzymes, the initial unfolding of antigens and peptide 
loading of MHC class II (Jensen 1993; Riese and Chapman 2000; Denzin, Fallas et al. 
2005).  Most endosomal aspartyl and cysteine proteinases function optimally at acidic 
pH (aspartic proteinases pH 2.8-4, cysteine proteinases pH 5-6) with the exception of 
cathepsin S that remains functional within the pH range of most endosomal 
compartments (Fineschi and Miller 1997). The serine and metalloproteinases are 
functional closer to neutral pH and are thought to be involved in the extracellular 
processing of antigens (Bond and Butler 1987).  
 
Due to the differences in the requirements of endosomal proteinases for a pH 
optimum, the effects of pH change on the processing of specific antigens can be 
determined by the use of ammonium chloride or other pH affecting agents such as 
chloroquine (Yoshikawa, Watanabe et al. 1987; Musson, Walker et al. 2003). In 
addition, the use of pH altering agents not only clarifies the requirement for a 
particular pH environment for proteinase activity, but it can also indicate whether an 
antigen is processed within early endosomal compartments implying the involvement 
of the recycling pathway or in late endosomes indicating presentation via the classical 
pathway.  
 
1.6.5.3 Proteinase inhibitors  
As described in Section 1.6.4.1 proteinases are involved in both the removal of the li 
chain from MHC class II and in generating peptide fragments to fit into the MHC 
class II binding groove. However, the generation of some epitopes appear to be reliant 
on one or more of these proteinases, whereas others may not be reliant on any. 
Examples of this are described above in Section 1.6.4.3. Therefore the requirement of 
a specific proteinase for the generation of a particular antigenic epitope can be 
determined by the use of proteinase or proteinase family specific inhibitors.  
However, results must be interpreted with caution due to the possibility of redundancy 
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between proteinase families. Indeed, AEP has been implicated as playing an 
important role in the initial degradation of the li chain (Manoury, Mazzeo et al. 2003; 
Watts, Mazzeo et al. 2003). However, results from experiments using AEP deficient 
mice have shown that AEP is not essential for li degradation implying that other 
proteinases are capable of mediating this step in the absence of AEP (Maehr, Hang et 
al. 2005).  
 
Pepstatin A is an aspartyl proteinase inhibitor shown to inhibit cathepsin D and E and 
previously used to show the involvement of aspartyl proteinases in early li 
degradation whilst having no effect on the peptide generation from OVA antigen 
(Zhang, Maekawa et al. 2000). In contrast, pepstatin A has been shown to augment 
responses to epitope 274-286 found in the diabetes autoantigen GAD65 (Reijonen, 
Elliott et al. 1999). However, using the same autoantigen Reijonen et al showed that 
the cysteine and serine inhibitor leupeptin inhibited T cell responses (Reijonen, Elliott 
et al. 1999). These data clarify that different antigens/antigenic epitopes are processed 
by different proteolytic enzymes and the processing requirements of autoantigens 
such as those implicated as playing a role in autoimmunity can be determined using 
proteinase inhibitors. 
   
However, problems with inhibitors such as pepstatin A are that they are poorly 
soluble and inefficiently transported across the cell membrane. Therefore new studies 
into improving their delivery via linking to BSA or mannose and the generation of 
new cell permeable alternatives have been described (Mohamadzadeh, 
Mohamadzadeh et al. 2004; Free, Hurley et al. 2006; Zaidi, Burster et al. 2007). 
Indeed, cell permeable alternatives of pepstatin A demonstrate the role of aspartic 
proteinases in the generation of peptide fragments from tetanus toxoid and protein 
purified derivative by different APC.  
 
Leupeptin is a cysteine and serine inhibitor shown to inhibit the proteinase cathepsin 
B. Earlier studies elucidated a role for cysteine and serine proteinases in the 
generation of some but not all antigenic fragments derived from hen egg lysozyme 
(Puri, Lonai et al. 1986) and keyhole limpet hemocyanin (Yoshikawa, Watanabe et al. 
1987). However, as described above cysteine proteinases may also have a destructive 
role in the processing of certain antigenic epitopes as mentioned above where 
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leupeptin abrogated T cell responses to certain epitopes derived from the autoantigen 
GAD65 (Reijonen, Elliott et al. 1999). This has also been shown for the certain 
epitopes from the model antigen OVA, OVA
322-336 
presentation is augmented in the 
presence of leupeptin and destroyed if digested in vitro with the cathepsins B and L 
(Rodriguez and Diment 1995). (2S,3S).trans.epoxysuccinyl-L-leucylamide-3-
methylbutaneethylester (E64-d) is a broad spectrum membrane permeable cysteine 
proteinase inhibitor that irreversibly inhibits cathepsins S, L and B (Bond and Butler 
1987). E64-d has been shown to affect the generation and presentation of some but 
not all epitopes derived from the recombinant protective antigen (PA) of Bacillus 
Anthracis and showed a profound negative effect on presentation of  3 epitopes 
derived from the V antigen from Yersinia pestis (Musson, Walker et al. 2003; Shim, 
Musson et al. 2006). Interestingly, the finding that leupeptin and E64-d do not affect 
the presentation of all epitopes investigated implies that cysteine proteinases are 
playing a role in the generation of antigenic epitopes and not in li degradation that 
would abrogate all peptide loading of MHC class II. 
3,4-dichloroisocoumarin (DCI) is a broad spectrum serine proteinase inhibitor and 
Phenanthroline is a broad spectrum inhibitor of metalloproteinases. Serine and 
metalloproteinases are considered as extracellular non endosomal enzymes involved 
in antigen processing at the cell surface or in the extracellular space at neutral pH, 
examples include trypsin (Accapezzato, Nisini et al. 1998) the metalloproteinase 
(aminopeptidase N) involved in trimming of peptides bound to MHC class II 
(Amoscato, Prenovitz et al. 1998) and various members of the matrix 
metalloproteinase family involved in degrading extracellular matrix components 
detailed in section 1.7.2 (Cawston and Young 2010).   
 
Studies using DCI and phenanthroline have implicated a crucial role for serine 
proteinases but not metalloproteinases in the generation of PA epitopes (Musson, 
Walker et al. 2003)  and the crucial role for metalloproteinase MMP-9 in the 
generation of epitopes derived from the candidate autoantigen collagen II (Van den 
Steen, Proost et al. 2002).  B cell, macrophage and dendritic cell expression of MMP-
9 has been reported therefore it is possible that these APC are involved in the 
extracellular processing of joint autoantigens (Di Girolamo, Tedla et al. 1998; 
Trocme, Gaudin et al. 1998; Bartholome, Van Aelst et al. 2001; Gough, Gomez et al. 
2006).   
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Therapeutic benefits of targeting various cathepsins are now coming to light. 
Uncovering the role of cathepsin S has lead to the development of potential 
therapeutics for targeting immune diseases such as Rheumatoid Arthritis the efficacy 
of which is currently under investigation (Gupta, Singh et al. 2008). In addition, the 
role of MMPs in cartilage degradation during rheumatoid arthritis progression is well 
established. However, their role in the generation of immunogenic epitopes from 
candidate joint autoantigens remains to be clarified. Further understanding of how 
immunogenic epitopes are generated from candidate autoantigens and their effects on 
breaking T cell tolerance will give us a greater insight into the initiation/chronicity of 
potentially antigen-driven autoimmune diseases such as RA.  
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1.7 Proteoglycan aggrecan as a candidate joint autoantigen 
MHC class II association and the presence of autoreactive T cells and antibodies in 
patients with RA suggest the involvement of joint autoantigens in disease 
pathogenesis. However, the autoantigen responsible for the onset or perpetuation of 
the disease remains to be elucidated. One possible candidate autoantigen is aggrecan, 
the large aggregating proteoglycan found in the articular cartilage, brain, meniscus, 
tendons and muscle. 
 
1.7.1 Aggrecan structure and function 
Aggrecan is the major proteoglycan found in articular cartilage.  Articular cartilage is 
predominantly made up of ECM produced and maintained by resident cartilage cells 
(chondrocytes). ECM consists of type II collagen, proteoglycans including aggrecan, 
decorin, fibromodulin and biglycan, hyaluronan and various other matrix proteins and 
elastic fibres (Kiani, Chen et al. 2002; Poole, Kobayashi et al. 2002). Aggrecan 
structure and function has been reviewed and is summarized below (Hardingham, 
Fosang et al. 1994; Kiani, Chen et al. 2002; Dudhia 2005).    
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Schematic representation of the structure of aggrecan.  
 Aggrecan contains 3 globular domains G1, G2, G3 separated by two inter-globular domains (IGD). 
The IGD that separates domains G1 and G2. There are 2 chondroitin sulphate regions (CS1 and CS2) 
and 1 keratan sulphate region (KS-rich). The G2 region consists of a proteoglycan tandem repeat 
(PTR). The G3 region contains 4 different motifs, the complement regulatory protein motif (CRP), 2 
epidermal growth factor regions (EGF) and a C-type lectin motif (Lectin). The structure of the link 
protein is very similar to that of the G1 region of aggrecan, as both regions contain an 
immunoglobulin fold (Ig fold) and 2 PTR. (Hardingham,T.E et al Eur J Clin Chem Clin Biochem, 
1994) 
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The structure of aggrecan consists of a protein core of around 250 kDa containing 3 
highly conserved globular (G) domains (G1, G2, and G3), an inter-globular domain 
(IGD) and a GAG attachment region consisting of keratan sulphate (KS) and 
chondrotin sulphate (CS) sidechains. The N terminal G1 domain contains an 
immunoglobulin fold (Ig fold) region of around 100 amino acids that forms 2 β sheets 
stabilised by a disulphide bond. The Ig fold promotes the interaction with the G1-like 
link protein responsible for stabilising aggrecan interactions with hyaluronan within 
the matrix (Grover and Roughley 1994).  The G1 domain also contains 2 copies of a 
motif known as proteoglycan tandem repeat (PTR) which form 2 disulphide bonds per 
tandem responsible for aggrecan binding to HA (Watanabe, Yamada et al. 1998). The 
interaction with HA is also stabilised by an o-linked oligosaccharide side chain 
(Hascall and Heinegard 1974).  
 
The G2 domain contains 2 PTR motifs and is functionally linked to aggrecan 
secretion (Kiani, Lee et al. 2001). The KS domain is the major site of KS attachment. 
Approximately 30 KS chains are attached to one aggrecan molecule predominantly at 
the KS domain, but also at the IGD, G1 and G2 regions (Fosang and Hardingham 
1991; Barry, Neame et al. 1994). The KS attachment sequence is a repeating region of 
proline-serine and proline threonines found in both human and bovine aggrecan 
(Antonsson, Heinegard et al. 1989; Doege, Sasaki et al. 1991). The CS domain is the 
largest aggrecan domain and contains approximately 100 CS chains. The CS 
attachment sequence is proposed to be a series of ser-gly dipeptide repeats separated 
by an acidic residue (Bourdon, Krusius et al. 1987).   
 
The G3 domain contains 2 epidermal growth factor like domains (EGF), a 
carbohydrate recognition domain (CRD) and a complement regulatory protein B 
domain (CRB). The function of the G3 domain is thought to be involved in mediating 
aggrecan secretion and in post translational modifications such as glycosylation 
(Kiani, Lee et al. 2001). 
 
Aggrecan is immobilised within the extracellular matrix via its association with 
hyaluronan. This association aided by a 41-48 kDa link protein can produce 
aggregates containing over 100 aggrecan/link proteins aggregated with 1 hyaluronan 
chain (Dudhia 2005). Aggregates with molecular masses of up to 10
9
 Da are highly 
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anionic due to the fixed negative charge of the glycosaminoglycan side chains; 
providing hydration of the cartilage, nutrient and solute transport and weight bearing 
resistance during joint loading (Maroudas, Muir et al. 1969; Dudhia 2005). Loss of 
aggrecan aggregates leads to a loss in its functionality and eventual cartilage 
destruction. 
 
1.7.2 Aggrecan breakdown and turnover in disease:  the role of Metalloproteinases. 
Both of the major components of the extracellular matrix collagen II and aggrecan are 
relatively long lived and undergo considerable modification during the normal ageing 
process (Dudhia 2005). However, in rheumatoid arthritis one of the earliest observed 
changes is the depletion of cartilage aggrecan (Rousseau, Sumer et al. 2008). 
Aggrecan is degraded at distinct cleavage sites during the course of arthritis by the 
action of degrading proteinases such as a disintegrin and metalloproteinase domain 
(ADAMTS) 1,4,5,8,9 and MMPs 1,2,3,7,8,9,13,14,19,20, cathepsins G and B, calpain 
and elastase (Figure 1.5) (Billington, Clark et al. 1998; Struglics, Larsson et al. 2009; 
Cawston and Young 2010; Struglics and Hansson 2010).. In addition, aggrecan 
degradation is thought to occur because of the differential expression and hence loss 
of balance between aggrecan degrading enzymes such as MMPs and their endogenous 
inhibitors tissue inhibitors of metalloproteinases (TIMPS) (Tetlow and Woolley 1999; 
Ishiguro, Ito et al. 2001).  
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Figure 1.5 Aggrecan cleavage by extracellular proteinases. 
Aggrecan cleaved by extracellular proteinases. Aggrecan core protein contains 3 globular domains 
G1, G2 and G3. Cleavage of aggrecan occurs most prominently within the G1 and G2 regions by 
matrixmetalloproteinases (MMP) or a disintegrin and metalloproteinase with thrombospondin motifs 
(ADAMTS). Proteinases and their corresponding cleavage sites are depicted above. 
 
 
MMPs play a major role in the removal of ECM during tissue resorption and are 
involved in many physiological functions including normal joint turnover, wound 
healing, bone remodelling and angiogenesis as well as pathogenesis of diseases such 
as RA (Nagase and Woessner 1999). During RA pathogenesis MMPs are produced by 
activated fibroblast-like synoviocytes, infiltrating immune cells such as neutrophils 
and macrophages, osteoclasts and chondrocytes (Yoshihara, Nakamura et al. 2000; 
Zeisel, Druet et al. 2005; Takaishi, Kimura et al. 2008). However, their expression has 
also been reported by B cells and dendritic cells (Kouwenhoven, Ozenci et al. 2002; 
Melamed, Messika et al. 2006). MMPs are synthesised as inactive zymogens and the 
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difference between normal joint turnover and joint disease requires a careful balance 
between their activation mediated by autocatalysis, other MMPs and serine 
proteinases and their inhibition by TIMPs, a disruption of this balance can lead to the 
unwanted destruction of cartilage components including aggrecan and collagen II (Ra 
and Parks 2007). 
  
Neoepitope-specific monoclonal antibodies have been developed that recognise the N 
and C terminus of aggrecan cleavage products and not intact aggrecan and have been 
useful tools in determining cartilage degradation during arthritic diseases such as RA 
(Fosang, Last et al. 2010). Two main cleavage sites result in the generation of 
aggrecan neoepitopes, C terminus VDIPEN-341 ↓ N terminus 342-FFGVGGE and 
NITEGE-373 ↓  374-ARGSV (Singer, Kawka et al. 1995; Fosang, Last et al. 1996; 
Lark, Bayne et al. 1997).   
 
The increased expression of MMPs and ADAMTS is thought to be predominantly 
mediated by the pro inflammatory environment of the inflamed synovium. Studies 
using bovine cartilage explants stimulated with pro-inflammatory cytokines such as 
IL-1 and TNFα have revealed an increased production of ARGSV neoepitopes 
detectable by the neoeptiope-specific monoclonal antibody BC-3 (Hughes, Caterson 
et al. 1995). More importantly, IL-1 and TNFα have been demonstrated to upregulate 
levels of MMPs and the G1 neoepitope fragments VDIPEN-341 and NITEGE-373 in 
cartilage and synovial fluid from rheumatoid patients (Lark, Bayne et al. 1997; 
Sondergaard, Henriksen et al. 2006; Larsson, Lohmander et al. 2009). The 
significance of this is that aggrecan cleavage by MMPs in the IGD domain results in 
the ARGSV and NITEGE fragments, a total loss of glycosaminoglycan sidechains 
from aggrecan and hence a loss of aggrecan functions. Furthermore, additional 
cleavage sites within the link protein which can result in the release of the entire 
aggrecan molecule from the cartilage, although cleavage in this domain is not as 
significant as that within the IGD (Wells, Davidson et al. 2003). 
 
However, as illustrated in Figure 1.5, the IGD is not the only aggrecan cleavage site 
targeted by MMPs the G3 domain is very susceptible to proteolysis and loss of G3 
can occur shortly after its secretion (Lee, Chen et al. 2002). Indeed, the heterogeneity 
of aggrecan fragments isolated from cartilage is partly due to the loss of the G3 
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domain and some of the CS region (Hardingham, Fosang et al. 1990) probably due to 
proteolytic attack. The IgM antibody 846 recognises chondroitin sulphate sidechains 
attached to amino acid 846 present within the G3 domain of aggrecan and has been 
utilised to detect the presence of newly synthesised aggrecan that has not yet been 
incorporated into the ECM (Mansson, Carey et al. 1995). The presence of 846 
epitopes is barely detectable in healthy joints yet increased in synovial fluid of 
diseased joints of RA patients indicative of the degradation of newly synthesised 
aggrecan (Poole and Dieppe 1994; Mansson, Carey et al. 1995). In addition, as 
cleavage within the IGD domain of aggrecan results in a G1 fragment remaining 
bound to hyaluronan within the cartilage, this may act as a competitor for the 
incorporation of newly synthesised aggrecan molecules.    
 
The increase in the concentration of aggrecan fragments found in serum and synovial 
fluid may trigger or potentiate the immune response within the joint.  In addition, loss 
of the CS region as well as a loss of CS side chains from aggrecan has been reported 
in RA synovial fluid (Ortutay, Polgar et al. 2003). Therefore, differentially modified 
aggrecan fragments could result in altered processing requirements by APC, the 
generation and presentation of cryptic epitopes and a break in T cell tolerance. In 
addition the number of aggrecan molecules with intact G3 declines with age as does 
the incidence of RA indicating that as extracellular processing of aggrecan increases 
more antigen is available to break any tolerance mechanisms in place to prevent T or 
B cell autoreactivity (Dudhia, Davidson et al. 1996).  
 
1.7.3 Proteoglycan induced arthritis 
Animal models that mimic clinical, pathological and histological features of RA such 
as collagen induced arthritis (CIA) and proteoglycan induced arthritis (PGIA) allow 
preliminary studies of a genetically identical population of diseased animals without 
the complication of disease heterogeneity that hinders human RA studies. Additional 
benefits of mouse models of RA are that the “Day 0” of disease onset is 
experimentally induced and the subsequent steps in disease pathology can be followed 
which is not possible with human studies (Kannan, Ortmann et al. 2005).  
 
PGIA is a murine model of RA in which disease can be induced in either, BALB/c 
(H-2
d
)  or  HLA-DR4 or HLA-DQ8 humanized transgenic mice and also in some C3H 
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(H-2
k
) strains, by the immunization with deglycosylated aggrecan in  adjuvant (Glant, 
Bardos et al. 2001; Szanto, Bardos et al. 2004).  
 
PGIA is a Th1 mediated disease and Th17 cells are not required either for its onset or 
severity (Hollo, Glant et al. 2000; Doodes, Cao et al. 2008). However, IL-17 is able to 
mediate disease in the absence of IFNγ (Doodes, Cao et al. 2010).  In addition, IL-27 
expressed within the joints and spleen of arthritic PGIA mice is important in 
mediating Th1 differentiation required for the induction of disease (Cao, Doodes et al. 
2008).  
 
The requirement for MHC class II restriction implies that predisposition to disease is 
governed by the polymorphic MHC class II molecules able to present autoantigenic 
peptides to T cells (Abraham and David 2000). Human, canine, porcine, sheep or 
bovine aggrecan are all capable of inducing PGIA providing both the CS and KS side 
chains are removed. Disease requires 2-4 intraperitoneal injections of deglycosylated 
aggrecan and peak of onset is around 50-70 days (Glant and Mikecz 2004).  
 
Studies have identified that the predominant immunogenic epitopes of aggrecan are 
found in the G1 domain (Leroux, Guerassimov et al. 1996; Zhang, Guerassimov et al. 
1998). However, the immunogenic properties of aggrecan or G1 are reliant on the 
removal of the CS and KS chains or KS only in the case of G1 by chondroitinase and 
keratanase. This observation implied that glycosylation may influence the immune 
responses of aggrecan-specific T cells. Indeed, in vitro experiments clarified that 
removal of the KS chains from G1 domain improves presentation of aggrecan to 
cloned aggrecan-specific T cell hybridomas and identified the predominant T cell 
epitope 70-84 located in the A loop of G1 (Zhang, Guerassimov et al. 1998). [Note: - 
Epitope 70-84 is defined as 84-103 in this thesis when including the aggrecan 
signal sequence of 19 amino acids]. Peptide mapping studies have uncovered 3 other 
epitopes identified as arthritogenic 49-63 located in the A loop of G1, 155-169 located 
in the B loop of G1 and 2373-2387 located in the G3 domain designated peptide 
p135H (Hanyecz, Bardos et al. 2003; Buzas, Vegvari et al. 2005). Indeed, this G3 
epitope 
2373
TTYKRRLQKRSSRHP
2387
 contains a highly homologous sequence motif 
(underlined) to that of the arthritis susceptibility shared epitope found in HLA-DR4 
molecules. The arthritogenic properties of the G3 p135H were demonstrated when 
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SCID mice hyper-immunized with p135H developed arthritis following one 
subsequent immunisation with human deglycosylated aggrecan in incomplete Freunds 
adjuvant (Hanyecz, Bardos et al. 2003).  
 
Disease onset is preceded by a humoral Ig response and requires both T and B cells as 
both are required to transfer disease to synergic irradiated BALB/c mice (Mikecz, 
Glant et al. 1990). T cells are required to act as „help‟ in supporting autoantibody 
production (Angyal, Egelston et al. 2010). However, transfer of antibodies alone is 
not sufficient to transfer disease (Mikecz, Glant et al. 1990).  
 
Later studies by Brennan et al implicated B cells as being capable of presenting 
immunodominant epitopes from the G1 domain to the  aggrecan  specific T cell 
hybridoma 5/4E8 (Brennan, Negroiu et al. 1995). The 5/4E8 clone was later shown to 
induce PGIA upon adoptive transfer into naïve BALB/c mice (Buzas, Brennan et al. 
1995). The immunogenic epitope recognised by 5/4E8 was later confirmed to be G1 
84
ATEGQVRVNSIYQDK
103
 (Buzas, Hanyecz et al. 2003). This epitope was shown 
to be the dominant epitope in BALB/c, HLA DR4 and DQ8 mice (Buzas, Vegvari et 
al. 2005). To further analyze the role of 84-103-specific T cells 5/4E8 in PGIA a 
transgenic mouse was generated expressing the 5/4E8 Va1.1 and Vβ4 TCR. Mice 
were generated in a CBA X C57BL/6 background and backcrossed into a BALB/c 
background. Studies using the TCR-5/4E8 transgenic mice have shown that transfer 
of TCR-5/4E8 spleen cells along with human aggrecan into synergic BALB/c RAG2-
/- mice induced PGIA. TCR-5/4E8 transgenic mice display increased arthritis 
susceptibility and developed an aggressive form of the disease upon immunisation 
with deglycosylated human cartilage proteoglycan (Berlo, van Kooten et al. 2005; 
Berlo, Guichelaar et al. 2006).  
 
PGIA resembles the clinical features of human RA and data generated from this 
model uncovers the generation of aggrecan-specific antibodies and T cell mediated 
disease progression similar to that seen in RA patients. Using this model O‟Neill et al 
demonstrated the essential role for B cells in disease pathogenesis. Importantly, they 
also showed that B cells were required to act both as APC as well as secreting 
antibodies against aggrecan (O'Neill, Shlomchik et al. 2005).  
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Indeed as discussed in Section 1.4.3, O‟Neill and colleagues later demonstrated that 
expression of the co-stimulatory molecules CD80/86 on B cells is required for optimal 
activation of T cells required for T cell mediated transfer of arthritis from WT into 
SCID mice. (O'Neill S, Cao et al. 2007). In support of this finding another study 
investigating PGIA development demonstrated that there was a reduction in disease, 
an inability of T cells to transfer disease into SCID mice and a significant reduction in 
T cell recall to aggrecan following B cell depletion (Hamel, Doodes et al. 2008).  
 
Studies using humanized mice expressing HLA DR4 and HLA DQ8 enabled peptide 
mapping of aggrecan epitopes without the genetic variation associated with human 
studies. Data from these experiments identified that 24 out of 31 HLA positive 
immunogenic human aggrecan peptides presented on relevant RA susceptibility HLA 
alleles were located in the G1 domain. Importantly, GRVRVNSAY located within the 
70-84 (84-103) region was identified as 1 of 2 G1 peptides identified as 
dominant/arthritogenic in BALB/c mice and DR4. Ab
0 
(Szanto, Bardos et al. 2004).  
 
1.7.4 Humoral and cellular responses to aggrecan in RA patients.  
            A case for the role of T and B cells in the pathogenesis of RA has been demonstrated 
by the observations discussed in previous sections of this thesis. Aggrecan destruction 
during disease and its role in generating an RA like disease in animal models has also 
been discussed. However, both cellular and humoral immune responses to aggrecan 
have been detected in patients with several rheumatic diseases such as rheumatoid 
arthritis but also osteoarthritis, ankylosing spondylitis and juvenile idiopathic arthritis 
(Golds, Stephen et al. 1983; Sigal, Johnston et al. 1988; Kamphuis, Hrafnkelsdottir et 
al. 2006; de Jong, Berlo et al. 2010).  Cellular responses to deglycosylated aggrecan, 
specifically epitopes within the G1 domain, have been described above.  
             
            To demonstrate T cell reactivity to G1 domain in patients suffering from RA Li et al 
generated and characterised 15 G1 specific T cell lines from rheumatoid arthritis 
patients and data from this study showed that 14 out of 15 patients expressed a Th1 
profile. G1-specific T cells were detectable at 4.97 per 10
-6 
in peripheral blood 
lymphocytes and 9.85 per 10
-6 
in synovial fluid (Li, Zhang et al. 2000). Furthermore, 
later studies by Zou et al identified G1 responses in RA and AS patients and went on 
to define the immunodominant peptides within the G1 region as 116-133, 148-165, 
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252-269 and 292-309 in AS and 116-133, 148-165, 252-269 and 292-309 in RA (Zou, 
Zhang et al. 2003). This group tested peptide responses to G1 previously 
demonstrated in HLA transgenic mice and identified peptides 16-39 and 263-282 as 
the peptides  responded to most frequently in RA patients (SI >1.8 in over 50% 
patients). Interestingly, the aggrecan epitope 263-282 has a high sequence homology 
with Yersinia Yop protein and RA patients responding to Yersinia Yop also 
responded to 263-282, responses to Yop were not detected in healthy controls (de 
Jong, Berlo et al. 2010). These data suggest a possible role for “molecular mimicry” 
of infectious components in the breaking of T cell tolerance in susceptible patients. 
This phenomenon of microbial peptides cross reacting with self-antigens has been 
previously described and implicated in driving RA following immunization with 
hepatitis B surface antigen (Pope, Stevens et al. 1998; Hill, Wang et al. 2003). 
 
            Finally, responses to modified aggrecan p84-103 have been reported recently, >60% 
of RA patients (total number 28 and none of the 18 healthy controls) responded to in 
vitro citrullinated but not un-citrullinated aggrecan p84-103. Interestingly, the PBMCs 
responding to citrullinated aggrecan p84-103 produced high levels of IL-17 in 
response to stimulation, this is in contrast to animal models of PGIA that are found to 
be independent of Th17 (Doodes, Cao et al. 2008; von Delwig, Locke et al. 2010). 
Indeed, increased levels of IL-17 have been reported in patients suffering from RA 
(Ziolkowska, Koc et al. 2000; Miossec 2004). However, contrasting data from 
different animal models indicate that the requirement for IL-17 is probably regulated 
by a balance of other mediators such as IFNγ, IL-15 and IL-27 and possibly differs 
dependent on the autoantigen or indeed the post translational modifications of 
autoantigen involved (Ziolkowska, Koc et al. 2000; Nakae, Nambu et al. 2003; Cao, 
Doodes et al. 2008; Doodes, Cao et al. 2008). 
. 
            In addition to the cellular responses to aggrecan observed in RA patients, increased 
levels of autoantibodies have also been reported in synovial fluids and sera from 
rheumatoid arthritis patients compared to healthy controls, particularly to the G1 
domain (Karopoulos, Rowley et al. 1996; Vynios, Tsagaraki et al. 2006). This data 
implies that there is a localised immune response to aggrecan possibly as a result of 
the germinal centre like structures observed in the synovium of many RA patients.  
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1.8 Aims of the project 
The aims of this project were to develop a system for studying aggrecan processing 
and presentation by aggrecan-specific B cells and to compare aggrecan processing 
and presentation by B cells to that seen with other APC. Specific targets were: 
 
 To isolate the model antigen (proteoglycan aggrecan). 
 To generate aggrecan-specific B cells  
 To investigate the kinetics of aggrecan processing and presentation by 
aggrecan-specific B cells in comparison to that of dendritic cells and 
macrophages. 
 To investigate the intracellular and extracellular enzymes involved in 
aggrecan processing by the different APC. 
 To determine the pathway involved in the presentation of the 
immunodominant G1 epitope 84-103 by the different APC. 
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2. Materials and Methods 
 
2.1. Antigens 
 
2.1.1 Bovine Aggrecan Preparation 
Aggrecan was prepared as previously described (Billington, Clark et al. 1998).  
 
2.1.1.2. Dissection 
Bovine nasal sections were supplied by Coast and County Meat Supply Co.Ltd, 
(Gateshead, Tyne & Wear) and dissected as follows: Noses were cut half way down 
the septum behind the nostrils, then along the top of the nostrils to give a T shaped 
segment, then cut along the bottom to release the septum. All soft tissue was removed 
and the septa were scraped until white. Septa were weighed, washed in Dulbeccos 
phosphate buffered saline (PBS) (Biowhittaker) and cut into approx 2x2x2 mm 
pieces. The pieces of nasal septum were placed in extraction buffer at 10ml/g (50 mM 
Na Acetate pH 6.0, 0.4 M GuHCL and 10 mM sodium salt of EDTA). 2 mM 
Phenylmethanesulfonyl fluoride (PMSF) in 100% ethanol, 5 mM benzamidine in 50 
mM Na acetate buffer pH 6.0 and 0.1 mM 6-aminohexanoic (caproic) acid in 50 mM 
Na acetate buffer pH 6.0 were added to extraction buffer immediately prior to use. 
The septum fragments were homogenised thoroughly using an Ultra-Turrax T25 
(IKA-Labortechnik, Loughborough, UK) and left stirring in the extraction mixture at 
4
o
C for 60 h. 
 
2.1.1.3. Proteoglycan separation by caesium chloride gradient 
Extraction supernatant was decanted into Oak ridge tubes (35ml/tube) (Sorvall) and 
centrifuged at 16,500G for 23 min (Sorvall RC5 Plus). Supernatants were carefully 
removed and pooled. Caesium chloride was added to give a final concentration of 609 
mg/ml.  The resultant solution was transferred to 35 ml Sorvall Ultracentrifuge tubes, 
sealed and centrifuged at 36,300G (rotor TFT 70.38 and TFT 65.38 Sorvall 
Ultracentrifuge) at 10
o
C for 24 h. Following centrifugation, tubes were snap-frozen in 
a CO2/methanol bath and stored at -80
o
C. The bottom 25% of each tube was removed 
using a sterile hacksaw, thawed and dialysed at 4
o
C in size 3 dialysis tubing (Sigma) 
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against 2 L of 50 mM Tris acetate pH 7.4, 10 mM EDTA. Dialysis buffer was 
changed 4 times over 48 h. 
 
2.1.1.4. Deglycosylation 
The chondroitin sulphate content of both glycosylated and deglycosylated aggrecan 
was measured using the Dimethyl-methylene blue (DMB) assay (Farndale, Sayers et 
al. 1982). 250 l DMB solution (containing 0.32% DMB in ethanol, 0.2% formic 
acid, 0.2% sodium formate per 1 L and stored in dark at 4
o
C) was added to 40 l of 
aggrecan preparation (before and after enzyme treatment) along with a standard curve 
prepared from a 1 mg/ml (phosphate buffer) chondroitin sulphate stock in a 96 well 
flat-bottomed plate incubated for 30 min.  Absorbance was measured at 530 nm.   
 
Keratanase and Chondroitinase ABC (Sigma) were added to the glycosylated 
aggrecan preparation at 25 mU/mg and 1.25mU/mg of chondroitin sulphate content 
respectively. Both enzymes were dissolved in 50 mM Tris HCL pH 7.4, added to the 
glycosylated aggrecan simultaneously and incubated for 5 h at 37
o
C. The 
deglycosylated aggrecan was then dialysed into Tris HCL pH 7.4 for 24 h with 4 
buffer changes.  
 
2.1.51. Quantification 
Protein concentration of aggrecan was determined using a bicinchoninic acid (BCA) 
assay kit (Pierce), both before and after deglycosylation. Typical yield = 37 mg/ per 
septum. 
 
2.1.1.6. SDS –polyacrylamide gel electrophoresis 
Various dilutions of aggrecan were incubated for 5 min at 95
o
C in laemelli loading 
buffer (4% SDS, 20% glycerol, 10% 2-Mercaptoethanol, 0.004% bromphenol blue 
and 0.125 M Tris HCL pH 6.8) containing 100 mM dithiothreitol (DTT) (Sigma), 
(along with molecular weight markers (Amersham)). Proteins were separated on a 7% 
polyacrylamide gel at 100 volts and visualised with 0.16% PhastGel Blue R-350 (GE 
Healthcare) (10% acetic acid, 10% methanol) following destaining (10% acetic acid, 
10% methanol). 
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2.1.1.7. Viscometry 
The Viscosity of the aggrecan preparation was measured using a Contraves Low 
Shear 30 viscometer at 37
o
C. Viscosity was measured for both deglycosylated and 
glycosylated aggrecan under the following conditions:  a) aggrecan alone b) aggrecan 
pre-treated with 10 mM DTT and 5 mM iodoacetamide to reduce disulphide bonds 
then incubated with Hyaluronan for 24 h at 4
o
C c) aggrecan after incubation with 
Hyaluronan for 24 h and again following 15 h incubation 4
o
C with 50 mM DTT and 5 
mM iodoacetamide. Glycosylated aggrecan was measured at concentrations 0.405 
mg/ml; 0.27 mg/ml, 0.135 mg/ml and deglycosylated aggrecan was measured at 1.62 
mg/ml, 0.81mg/ml and 0.405 mg/ml.  
 
2.1.1.8. ELISA  
Anti-aggrecan antibody secreting cells (see section 3.4) were cultured for several days 
and supernatant was removed. Cells and debris were removed from the supernatant by 
centrifugation at 400G for 10 min. 96 well Immunosorb plates (NUNC) were coated 
with 50 μl coating buffer (150 mM NA2CO3, 350 mM NaHCO3) or coating buffer 
containing 2 μg/ml of deglycosylated aggrecan. Plates were wrapped in parafilm and 
incubated at 4
o
C overnight and then washed 3 times with PBS containing 0.1% Tween 
to remove any unbound material. To prevent non-specific binding of antibodies the 
plates were blocked by the addition of 200 μl 2% milk powder in PBS to each well 
and incubated for 1 h at 37
o
C. Plates were washed 3 times and doubling dilutions of 
cell supernatants were added to the plate and incubated for 1 h at 37
o
C. Plates were 
washed 3 times and 100 μl horseradish peroxidase (HRP)-conjugated goat anti-mouse 
(BD Pharmingen) (concentration 1; 2000) was added to all wells. Plates were 
incubated for 1 h at 37
o
C and washed 6 times. Substrate 3,3‟,5,5‟-
Tetramethylbenzidine (TMB) (Sigma) 1% was subsequently added along with 0.3 
μl/ml hydrogen peroxide in phosphate citrate buffer (0.2 M NA2HPO4, 0.1 M citrate) 
for 4 min, the reaction was stopped using 2 M H2SO4 and absorbance was read using 
a spectraMax 190 microplatereader (Molecular devices)  at 450 nm. Controls included 
a positive control where mouse (IgG1) anti-aggrecan antibody (Serotec) was added to 
wells coated with aggrecan and negative controls where media only was added to 
wells coated with aggrecan and anti-aggrecan antibody or neat supernatant was added 
to wells coated in coating buffer only. 
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2.1.1.9. Biotinylation 
Aggrecan (in PBS) was biotinylated according to manufacturer‟s instructions (Pierce 
EZ-Link Sulfo-NHS-LC-Biotin) at 3 different biotin/protein ratios (40-fold, 20-fold 
and 10-fold molar excess). Reactions were incubated for 30 min at room temperature 
and then dialysed overnight in PBS to remove any non-reacted and hydrolyzed biotin 
from the solution. 
Biotinylation was determined using ELISA. 2 g/ml of biotinylated aggrecan was 
adsorbed onto plates and detected either by anti- aggrecan antibody (Serotec) or 
supernatant from anti-aggrecan secreting hybridomas (F1.11) generated by Dr A 
Knight and John Robinson, followed by appropriately labelled secondary antibodies 
or directly using streptavidin HRP.  
 
2.1.1.10 Reduction and alkylation of aggrecan. 
An aliquot of 5 ml (1.6 mg/ml) deglycosylated aggrecan was incubated for 5 h at 37
o
C 
with 10 mM DTT. The reduced aggrecan was subsequently alkylated by incubation 
with 30 mM iodoacetamide overnight at room temperature in the dark. Reduction and 
alkylation was determined using ELISA. 2 g/ml of reduced and alkylated aggrecan 
was adsorbed onto plates and detected by anti-aggrecan antibody (1-C-6) that 
recognises a reduced and alkylated form of aggrecan (Stevens, Oike et al. 1984) 
followed by HRP labelled anti-mouse secondary antibodies.  
 
2.1.2. Recombinant tetanus toxin C fragment (TTCF). 
TTCF was provided by Dr A Knight and was used as a positive control antigen in 
several experiments. TTCF was expressed as a histidine tagged protein in E.coli as 
described in (Hewitt, Treumann et al. 1997).  
 
2.1.3. Peptides 
All peptides were purchased from Genscript and described in (Buzas, Vegvari et al. 
2005). Synthetic peptide 84-103 is a 20mer peptide containing an epitope from the G1 
domain of aggrecan with the sequence   
84
VVLLVATEGRVRVNSAYQDK103. 
Synthetic peptides p2373-2387 
2373
TTYKRRLQKRSSRHP2387 classified as 
dominant/arthritogenic/cryptic and p2363–2378 2363EEPRITCTDPTTYKRR2378 
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classified as conditionally immunogenic (“super-cryptic”) are epitopes from the G3 
domain of aggrecan.  
 
2.2. Cell lines and culture 
A20-1 is a murine B cell lymphoma, (BALB/c haplotype H-2
d,
 IgG2a
+ 
; (Kim, 
Kanellopoulos-Langevin et al. 1979)). A20 8AGR clone 4G11 (A20-1 HS) are 
modified A20-1 cells, Hypoxanthine 5 mM, aminopterin, 20 mM, Thymidine 0.8 mM 
(HAT) sensitive (HS). A20-1 cells were grown in the presence of 8-azaguanine (8-
AG); 8AGR resistant colonies were tested for aminopterin sensitivity. Anti-aggrecan 
antibody secreting hybridomas (F1.11) were generated by A Knight and John 
Robinson. (H-2A
d
 restricted) murine T cell hybridoma 192, which recognise p83-104 
from aggrecan as generated by Katie Lowes and provided by John Robinson. 
BW5147 lymphoma cells (TCRα-/β-) were provided by Dr P. Marrack, Denver. All 
cells unless stated otherwise were grown at 37
o
C in a 5% CO2 atmosphere in RPMI 
1640 (Invitrogen), supplemented with 100 g/ml kanamycin, 2 mM glutamine, 1 mM 
sodium pyruvate, 1 mM non-essential amino acids (Invitrogen), 50 M -
mercaptoethanol (Sigma) and containing 10% foetal bovine serum (FBS) (First link 
Ltd) (cRPMI).  
 
A20-3A5 TTCF-specific B cells were provided by A Knight (Knight, Lucocq et al. 
1997) and were grown in cRPMI containing 0.5 mg/ml G418 and 0.75 mg/ml 
hygromycin B. The IL-2 dependent mouse T cell lymphoma HT-2 and CTLL-2 were 
cultured in cRPMI supplemented with 1.5 ng/ml recombinant IL-2.   
 
Mouse fibroblasts (L cells) transfected with CD40L DNA (L47) and control 
untransfected fibroblasts (L5) were a kind gift from Dr Tom Barr, University of 
Edinburgh (Wohlleben, Gray et al. 1996). L cells were cultured in IMDM (Invitrogen) 
supplemented with 1 mg/ml G418, 5% FBS, 100 g/ml kanamycin, 2 mM glutamine, 
1 mM sodium pyruvate, 1 mM non-essential amino acids, 50 M -mercaptoethanol. 
HeLa cells were cultured in DMEM (Invitrogen) supplemented with 100 g/ml 
kanamycin, 2 mM glutamine, 1 mM sodium pyruvate, 1 mM non-essential amino 
acids, 50 M -mercaptoethanol and containing 10% FBS.  
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2.3   Cryopreservation of cells. 
In order to maintain consistency in both the genotype and phenotype of the generated 
T and B cell hybridomas, aliquots of cultured cells were frozen at the earliest 
opportunity.   
 
2.3.1 Freezing cells 
Cells were grown to mid-log phase in either 24 well plates (T cell hybridomas) or T25 
tissue culture flasks (B cell hybridomas) and counted. Cells were pelleted in 15 ml 
sterile falcon tubes by centrifugation at 400G for 5 min. The supernatant was removed 
and cells slowly resuspended in ice cold freezing media (FBS containing 10% 
DMSO) to a final cell concentration of 1-2 x 10
6
 cells/ml. The cell suspension was 
transferred to cold cryovials (1 ml/vial) and stored at -80
o
C overnight. After 24 h, cell 
aliquots were transferred to liquid nitrogen for long-term storage. 
 
2.3.2 Thawing cells 
Cell aliquots were removed from liquid nitrogen and directly thawed in a 37
o
C 
waterbath and transferred to a 15 ml tube. RF-2 was added slowly to the tube and 
cells were pelleted by centrifugation at 400G for 5 min. Cells were resuspended in 
cRPMI and transferred to either 24 well plates at various cell dilutions (T cell 
hybridomas) or T25 flasks (B cell hybridomas) at a 1:5 dilution. 24 h later cells are 
observed using an inverted microscope and re-seeded if necessary. 
 
2.4 Single cell cloning 
Cells were washed in RF-2 and resuspended at 3, 5 and 10 cells/ml in cRPMI. 100 l 
of cell suspension was plated out onto 5 x 96 well flat bottom plates to give a final 
concentration of 0.3, 0.5 and 1 cell/well. Plates were incubated at 37
o
C in a 5% CO2 
atmosphere until colonies were visible by eye. Colonies were transferred to 24 well 
plates and expanded accordingly. 
 
 
 
 
 
 65 
2.5 Preparation of bone marrow derived dendritic cells for use as APC 
Male BALB/c approx 6-8 weeks old were sacrificed by cervical dislocation. Femurs 
were removed into cRPMI and cleaned of all excess tissue. Each end of the femur was 
cut off and the marrow cavity was flushed with cRPMI using a 5 ml syringe and a 25 
gauge needle. Washing continued until all of the bone marrow contents were 
removed. Bone marrow cells were washed in cRPMI by centrifugation at 400G for 5 
min. Cells were resuspended in 10 ml cRPMI containing 20 ng/ml of recombinant 
murine granulocyte monocytes colony stimulating factor (GM-CSF) (Peprotech). 
Approximately 2 x 10
6
 cells were seeded per sterile 100 mm petri dish and incubated 
at 37
o
C in a 5% CO2 atmosphere. Bone marrow cells were fed at day 3 by adding 10 
ml of fresh cRPMI containing 10 ng/ml GM-CSF to each dish and again at days 6 and 
8 by removing 10 ml of culture medium from each dish and replacing it with 10 ml of 
fresh cRPMI containing 20 ng/ml GM-CSF. 10 days after culture, dendritic cells were 
screened by flow cytometry for the surface marker CD11c and MHC class II and were 
used as APC in antigen presentation assays.  
 
On the day of the experiment bone marrow dendritic cells were carefully harvested 
using a cell lifter. The cells were pelleted by centrifugation at 400G for 5 min, 
resuspended in RPMI 1640 containing 2% FBS (RF-2) and centrifuged again to wash. 
Cells were resuspended in cRPMI, counted and adjusted to 1 x 10
4
/well for unfixed 
antigen presentation assays and 3 x 10
5
/well for fixed antigen presentation assays to 
allow for cell loss during the fixation and washing process.  
 
2.6 Preparation of bone marrow derived macrophages for use as APC 
Bone marrow cells were isolated as described in section 2.5. To differentiate cells 
into bone marrow derived macrophages, cells were cultured in bone marrow 
macrophage medium (BMM) (cRPMI supplemented with 5% horse serum (Sigma) 
and 10% culture supernatant from L929 cells as a source of macrophage colony 
stimulating factor (M-CSF). Cells were seeded in sterile 100 mm petri dishes at 
approximately 4 x 10
6
 per dish and incubated at 37
o
C in a 5% CO2 atmosphere.  
Macrophages were fed at day 3 by adding 5 ml of fresh BMM to each dish. 7 days 
after culture, bone marrow cells were used as APC in antigen presentation assays or 
can be maintained for an extended period by re-seeding the cells into new petri dishes 
with fresh BMM.   
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24 h prior to their use in antigen presentation experiments, bone marrow macrophages 
were activated by adding 100 ng/ml of recombinant murine interferon γ (IFN-γ) 
(R&D Systems) to each petri dish.  On the day of the experiment the supernatant was 
removed, RF-2 was added to each petri dish and the bone marrow macrophages were 
harvested using a cell scraper. The cells were pelleted by centrifugation at 400G for 5 
min, resuspended in RF-2 and centrifuged again to remove all residual IFN-γ. Cells 
were resuspended in cRPMI and screened by flow cytometry for cell surface markers 
F4/80 and MHC class II. 1 x 10
4
/well bone marrow macrophages were seeded for 
unfixed antigen presentation assays and 3 x 10
5
/well for fixed antigen presentation 
assays to allow for cell loss during the fixation and washing process.   
 
2.7 Animals 
BALB/c (H-2
d
) mice were purchased from Harlan Olac 1975 Ltd, Cirencester, UK 
and maintained under pathogen free conditions in the Comparative Biology Centre 
(CBC) at Newcastle University.  Tissues from female mice were used for in vitro 
studies. TCR transgenic mice (TCR-5/4E8-tg) expressing the T cell receptor Vα1.1 
and Vβ4 chains specific for the dominant arthritogenic 84-103 epitope of human 
proteoglycan aggrecan designated (5/4E8), backcrossed into the BALB/c (H-2
d
) strain 
were a kind gift from Willem van Eden, Institute of infectious Diseases and 
Immunology, Division of Immunology, Utrecht University, Utrecht, The Netherlands 
(Berlo, van Kooten et al. 2005; Berlo, Guichelaar et al. 2006). All experiments were 
carried out under the project licence of John Robinson in accordance with Home 
Office and Newcastle University regulations.  
 
2.8 Immunisations 
All subcutaneous or intra-peritoneal immunisations were performed by either Dr A.M. 
Knight or R. Stewart within the Comparative Biology Centre. Mice were immunised 
with an emulsion of either aggrecan or peptide in Titermax (subcutaneous) or 
potassium aluminium hydroxide (alum) intra-peritoneally. 
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2.9 Generation of immortalized aggrecan-specific B cells by fusion with A20-1 
HS lymphoma cells. 
 
2.9.1 Fusion 1 immunisation 
166 g deglycosylated aggrecan was emulsified vol/vol with 9% potassium 
aluminium hydroxide (alum) and adjusted to pH 7 by the addition of NaOH.  The 
aggrecan/alum emulsion was washed and resuspended in PBS, and a final volume of 
250 l was administered per immunization. A group of 4 female BALB/c mice aged 
6-8 weeks received intraperitoneal immunizations at day 1 and day 21. Two of the 
immunized mice were given a final boost at day 42 and spleens removed at day 47 
(day 5 mice) and 2 mice were boosted at day 45 and spleens removed at day 47 (day 2 
mice). Mice were bled both pre- and 10 days post-immunization and a final terminal 
bleed was taken under anesthetic. Antibody responses to deglycosylated aggrecan are 
routinely tested by ELISA and cells were used for fusion with A20-1 HS lymphoma 
cells.   
 
2.9.2 Fusion 2 immunization 
A group of 4 female BALB/c mice aged 6-8 weeks received a subcutaneous 
immunization at day 1 with a full dose of aggrecan (166 µg) emulsified vol/vol with 
Titermax, followed by two subsequent subcutaneous immunizations at days 21 and 42 
with a 10-fold reduced dose of the aggrecan–Titermax emulsion. The mice received a 
final intra-peritoneal boost containing 166 µg aggrecan emulsified with alum at day 
63 and spleens were removed at day 68.  Mice were bled prior to immunisation and at 
days 10 and 31 post-immunisation and a final bleed was taken under terminal 
anaesthetic. Antibody responses to deglycosylated aggrecan were routinely tested by 
ELISA. Splenocytes were isolated and cultured with 50 µg LPS and 50 µg 
deglycosylated aggrecan for 48 h before fusing to A20-1HS cells. 
 
2.9.3  Splenocyte/A20-1 HS fusion  
Mice were sacrificed and splenocytes were isolated and formed into a single cell 
suspension via passage through sterile nylon gauze. Cells were centrifuged and red 
blood cells were lysed by adding 2 ml cell lysis buffer (Sigma) /spleen for 4 min at 
room temperature. Splenocytes and the HAT sensitive fusion partner A20-1HS were 
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washed and resuspended in serum free Hanks balanced salt solution (HBSS) (Sigma). 
2.5 x 10
7 
A20-1HS cells were mixed with 5 x 10
7 
splenocytes and the cells were 
centrifuged at 400G for 5 min. Supernatant was removed by aspiration leaving the 
pellet dry. 25 l serum free HBSS was added and the cells were resuspended by 
gentle pipetting; 0.5 ml of 37
o
C polyethylene glycol/ Dimethyl sulfoxide 
(PEG/DMSO) (Sigma) was added dropwise to the cell suspension and mixed for 2 
min in a 37
o
C waterbath. The suspension was subsequently diluted with serum-free 
RPMI 1640 at 37
o
C and cells were centrifuged at 400G for 5 min. The cells were 
resuspended in 50 ml 37
o
C cRPMI,  plated out into 24 well plates 500 l/well and 
incubated at 37
o
C in a 5% CO2 atmosphere for 24 h before adding (500 l/well) 2x 
HAT (Sigma) in cRPMI.  HAT resistant colonies were usually identified at day 10 
and expanded accordingly. Hybridomas were subsequently cultured in cRPMI 
containing 1x hypoxanthine-Thymidine (HT) and finally into cRPMI.  
 
2.9.4 The use of CD40L transfectants to expand splenic B cells prior to fusion. 
Splenocytes were isolated from aggrecan-immunized mice (using the immunisation 
protocol described in section 2.9.1) and co-cultured with monolayers of murine 
CD40L transfected L cells. (CD40L expression was regularly tested and compared to 
control L cells by flow cytometry using FITC-conjugated anti-CD40L, a kind gift 
from Dr Tom Barr, University of Edinburgh). CD40L transfectants were irradiated 
(3000 rad) and seeded in 6 well plates (4 x 10
4
/well) in cRPMI and incubated 
overnight at 37
o
C in 5% CO2 to establish monolayers. Supernatant was removed from 
the monolayers and 2.5 x 10
5
 splenocytes were added to each well in cRPMI 
containing 10 ng/ml murine rIL-4 (Peprotech).  5.5 x 10
-7 
M
 
cyclosporine A (Sigma) 
was added to each well to prevent outgrowth of T cells. Cells were passaged and 
transferred to fresh irradiated monolayers every 4 days. To determine the percentage 
and viability of the isolated B cells, cells were screened by flow cytometry at days 0, 
4, 8 and 12 both unstained and stained with FITC conjugated anti-TCR and PerCP 
conjugated B220. Controls for this experiment included cells co-cultured with, 
CD40L transfectants/ untransfected L cells only, CD40L/L cells + IL-4 only and 
CD40L/L cells + cyclosporine A only.  
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2.10. Fusion screening 
 
2.10.1. Flow cytometry 
All staining was carried out in 96 well round bottom plates at 4
o
C in the dark in the 
presence of 2.4G2 Fc block (previously determined to block the binding of FITC 
conjugated 2.4G2 antibodies) to ensure that staining was not due to antibodies binding 
Fc receptors expressed on the cells. For each sample 2.5 x 10
5
 cells were washed in 
PBS containing 2% FBS (FACS buffer), pelleted at 1400rpm at 4
o
C and resuspended 
in FACS buffer. 2.4G2 Fc block was added to appropriate wells and incubated for 60 
min. Primary antibodies were added and incubated for a further 60 min. Cells were 
then washed 4 times and resuspended in PBS 2% FBS. Secondary antibodies were 
added to appropriate wells and incubated for a further 60 min; cells were subsequently 
washed 4 times and resuspended in 400 l PBS 2% FBS. 10,000 events were 
collected for each sample using a FACScan flow cytometer (BD Biosciences) and 
data analysed with Flowjo software (Treestar
TM
) (see Table 2.1 for antibodies used 
and concentrations). 
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Table 2.1 Antibodies used for flow cytometry analysis. Listed are all antibodies used for 
flow cytometry experiments. 
Antibody Concentration Isotype Supplier 
Rat anti-mouse IgG1 FITC 1:100 IgG1, κ BD Pharmingen 
Rat anti-mouse IgG2a FITC 1:100 IgG1, κ BD Pharmingen 
Rat anti mouse IgG2b FITC 1:100 IgG2a, κ BD Pharmingen 
Rat anti mouse IgG3 FITC 1:100 IgG2a, κ BD Pharmingen 
Rat anti-mouse IgM FITC 1:100 IgG2a, κ BD Pharmingen 
Hamster anti-mouse B7.1 PE 1:100 IgG2, κ BD Pharmingen 
Rat anti mouse B7.2 PE 1:100 IgG2a, κ BD Pharmingen 
Rat anti-mouse class II I-A, I-E PE 1:1000 IgG2b, κ BD Pharmingen 
Rat anti-mouse class II I-A, I-E FITC 1:1000  BD Pharmingen 
Rat anti-mouse kappa light chain PE 1:100 IgG1, κ BD Pharmingen 
Rat anti-mouse lambda light chain FITC 1:100 IgG2a, κ BD Pharmingen 
Rat anti-mouse CD16/CD32 (Fcγ III/II 
receptor) FITC 
1:100 IgG2b, κ BD Pharmingen 
Streptavidin FITC/ Streptavidin APC 1:1000  BD Pharmingen 
Rat anti-mouse F4/80 FITC 1:100 IgG2b, κ BD Pharmingen 
Rat anti-mouse CD11c PE 1:100 IgG2, κ BD Pharmingen 
Aggrecan-bio 50 g/ml  See Materials and 
Methods 
Rat anti-mouse CD16/CD32 (Fcγ III/II 
receptor) 2.4G2 block and 2.4G2 bio. 
75 g/ml IgG2b, κ (in house) 
Rat anti- mouse Vβ4 PE 1:100 IgG2b, κ BD Pharmingen 
Rat anti-B220 PerCP 1:100 IgG2a, κ BD Pharmingen 
Rat anti-CD40/ Rat anti-CD40L   
Dr Tom Barr 
(Wohlleben, Gray 
et al. 1996) 
Rat anti-CD4 perCP 1:100 IgG2a,  κ BD Pharmingen 
 
Rat anti-TCR FITC/PE 
 
1:100 
 
IgG2b, κ BD Pharmingen 
 
Rabbit anti-human IgG H + L biotin Fab2  
 
1:100  Southern Biotech. 
Assoc. 
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2.10.2 Antigen presentation assay 
 Antigen was added at graded doses to duplicate wells in a 96 well flat bottomed plate 
together with antigen presenting cells and T cells in a total volume of 200 μl.  Antigen 
presenting cells and T cells were added into each well at the following concentrations: 
5x10
4
 T cells, 5x10
4
 non-specific B cells, 1x10
4
 aggrecan-specific B cells, 1x10
4
 bone 
marrow derived dendritic cells or 1x10
4
 bone marrow derived macrophages.  Negative 
controls were medium or antigen only, medium or antigen together with T cells and 
medium and antigen together with antigen presenting cells. Assays were incubated at 
37
o
C in 5% CO2 for 24 h and then frozen to lyse all of the cells. T cell stimulation was 
measured by the amount of IL-2 released into the culture supernatant. IL-2 was 
detected by the proliferation of IL-2 dependent T cell lines (HT-2 or CTLL-2).   
 
2.10.3 IL-2 bioassay 
HT-2 cells were used to quantify IL-2 in fusion assay supernatants. However, CTLL-2 
cells were later found to be a more efficient cell line and were used to detect IL-2 
levels in all subsequent experiments including all of the transfectant assays. 
 
24 h prior to use CTLL-2 were starved of IL-2 by washing in RF-2 to remove IL-2 
and resuspended in cRPMI. HT-2 cells were washed 4 times in RF-2 immediately 
prior to use. 50 μl of the culture supernatant was transferred to wells of a new 96 well 
flat bottomed plate and incubated for 24 h with 50 μl of either pre-starved 3x104 
CTLL-2 or HT-2. Positive and negative controls were performed for HT-2/CTLL-2 
proliferation where either 50 μl cRPMI containing no IL-2 or 50 μl of rIL-2 at graded 
doses were added to duplicate wells along with 50 μl of 3x104 HT-2 or CTLL-2. To 
quantify cell proliferation, 18.5 kBq 
3
H thymidine (Amersham) was added per well 
for the last 18 h of culture. The assay was harvested onto printed glass filter mats 
(Wallac) using a cell harvester (Packard Micromate 196, Canberra Harwell, Didcot, 
UK) and counted using a liquid scintillation β-counter (1450 LSC and Luminescence 
Counter, Perkin Elmer MicroBeta Trilux; CT, USA ). 
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2.11 Antigen presentation assay (fixed APC system)  
The fixed APC system can be divided into two sub-sections 
 The first describes how cells are pre-fixed and then used to detect pre-
processed antigen in the form of peptides.  
 The second system describes how cells are initially incubated with antigen +/- 
inhibitors of antigen processing, washed and then post-fixed to study the 
pathways and enzymes involved in antigen processing  
  
2.11.1 Pre-fixation of APC 
Bone marrow macrophages, dendritic cells and aggrecan-specific B cells (see section 
2.16) were harvested, washed and 3x10
5  
cells/well were seeded in 96 well v bottomed 
plates. Cells were pelleted by centrifugation at 400G for 5 min, resuspended in 100 μl 
of ice cold 1% paraformaldehyde solution and incubated at room temperature for 5 
min. 100 μl of ice cold 0.05% Gly-Gly solution was added to each well and cells were 
pelleted by centrifugation at 400G for 5 min.  The cells were then washed 3 times and 
resuspended in cRPMI. 1x10
4
 cells were seeded in triplicate wells of  a new 96 well 
flat bottomed plate in 200 μl  of  cRPMI containing  5x104 T cell hybridoma (192) 
and either 10 nM p84-103 or 200nM of aggrecan.  Assays were incubated at 37
o
C in 
5% CO2 for 24 h and following freezing, 50 μl of supernatant was harvested and IL-2 
levels detected by CTLL-2 proliferation as described in section 2.10.3. 
 
2.11.2  Post-fixation of APC 
Bone marrow macrophages, dendritic cells and aggrecan-specific B cells (see section 
2.11) (5x10
4
/ well) were seeded in a 96 well v bottomed plate in 200 μl cRPMI 
containing either 10 nM p84-103, 200nM aggrecan or medium only and incubated at 
37
o
C in 5% CO2 for 6 h.  
For inhibitor studies cells were pre-treated with inhibitors (or inhibitor solvent only,) 
before the addition of antigen. All of the inhibitors used and pre-treatment incubation 
times are shown in Table 2.2.  
Following 6 h incubation with antigen, APC were pelleted by centrifugation at 400G 
for 5 min and washed 3 times in HBSS. The cells were then fixed as described above 
(Section 2.11) and 1x10
4
 fixed cells were seeded in triplicate wells of a new 96 well 
flat bottomed plate in 200 μl  of  cRPMI containing  5x104 T cell hybridomas (192) 
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and either 10 nM of p84-103 or 200 nM of aggrecan. Assays were incubated at 37
o
C 
in 5% CO2 for 24 h and then frozen to lyse all of the cells. The supernatant was 
harvested and IL-2 levels detected by CTLL-2 proliferation as described previously 
(section 2.10.3). Control wells included live cells incubated with the above antigen 
concentrations and pre-fixed cells (section 2.20) subsequently incubated with the 
antigen.  
 
2.12 Inhibitors of antigen processing 
Details of all of the inhibitors used in the post fixation experiments are shown in 
Table 2.2 All inhibitors were purchased from Sigma. 
 
Inhibitor Solvent Dose range 
Pre-treatment 
time 
References 
Ammonium chloride H2O 50-400 mM 3 h 
(Conte, Petrone et al. 
1996) 
Brefeldin A ethanol 0.125-2 μg/ml 3 h 
(Orci, Tagaya et al. 
1991) 
Cycloheximide DMSO 10-80 μM 3 h 
(St-Pierre and Watts 
1990) 
DCI DMSO 10-80 μM 1 h 
(Harper, Hemmi et al. 
1985) 
E-64d DMSO 10-100 μM 1 h 
(Tamai, Matsumoto 
et al. 1986) 
Pepstatin A DMSO 0.5- 4 mM 1 h 
(Puri and Factorovich 
1988) 
Leupeptin DMSO 2.5-20 μM 1 h 
(Aoyagi, Takeuchi et 
al. 1969) 
1, 10 Phenanthroline DMSO 200-1600 μM 1 h 
(Takahashi, Cease et 
al. 1989) 
 
Table 2.2 Inhibitors of antigen processing and presentation used in this study. 
3, 4-dichloroisocoumarin (DCI), (2S, 3S)-trans-epoxylsuccinyl-L-leucylamino-3-methylbutane ethyl 
ester (E-64d), dimethyl sulfoxide (DMSO 
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2.13  Construction of plasmids encoding aggrecan-specific BCR. 
 
2.13.1 Cell lines and plasmids 
The B cell hybridoma F1.11 that produces an Ig against bovine aggrecan was 
generated by Dr A Knight and Prof J Robinson by fusing splenocytes from aggrecan-
immunized mice with the Ig 
–ve
 B cell hybridoma NSO. I subsequently cloned the 
F1.11 hybridoma by limiting dilution as described in section 2.4. Resultant clones 
were screened by ELISA for aggrecan-specificity and to determine the antibody 
isotype and light chain usage (see section 2.13.2). The representative aggrecan-
specific B cell hybridoma clone C71 (IgG1
+
, ) was chosen for further experiments. 
The B cell hybridoma 1-C-6 (IgG1
+
, ) was kindly donated by Prof B Caterson, 
Connective Tissue Biology, Cardiff School of Biosciences, Cardiff University 
(Caterson 1987). 1-C-6 mAb recognises repeated epitopes present in both the G1 and 
G2 domains of aggrecan and requires reduction and alkylation of aggrecan for the 
best exposure of the amino acid sequence QAAY that form the basis of recognition 
(Stevens, Oike et al. 1984; Caterson 1987).   
 
2.13.2 Characterisation of the C71 and 1-C-6 antibodies by ELISA 
ELISA was used to verify the antigen-specificity, heavy chain isotype and light chain 
usage of C71 antibodies (previously described for 1-C-6 in (Caterson 1987).  C71 
hybridomas were cultured for several days to allow cells to exceed optimal density 
and supernatant was removed. Cells and debris were removed from the supernatant by 
centrifugation at 400G for 10 min. ELISA was carried out as described previously in 
section 2.1.1.8 using 96 well ELISA plates coated with 2 μg/ml of deglycosylated 
aggrecan, reduced/alkylated aggrecan, anti-IgG1, anti-IgG2a, anti-IgG3 or anti-IgM, 
anti-kappa light chain and anti-lambda light chain. C71/1-C-6 cell supernatant was 
titrated using doubling dilutions, added to the plate and incubated for 1 h at 37
o
C. 
Bound C71/1-C-6 antibodies were detected following the addition of HRP-conjugated 
goat anti-mouse (1:2000) and substrate TMB with hydrogen peroxide in phosphate 
citrate buffer, optical density was read at 450 nm. Controls for these experiments 
included a positive control where anti-aggrecan antibody (Serotec) was added to wells 
coated with aggrecan and negative controls where media only was added to wells 
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coated with aggrecan and anti-aggrecan antibody or neat supernatant was added to 
wells coated in coating buffer only.  
 
2.13.3 RNA extraction 
Total RNA was isolated from 1x10
7 
A20-1 HS, C71 and I-C-6 cells using RNeasy 
RNA isolation kit according to the manufacturer‟s instructions (Qiagen).  RNA was 
eluted into 50 μl of RNase free water.  All work with RNA was carried out using 
RNase free eppendorfs, reagents and tips and gloves were worn at all times to prevent 
RNase contamination. RNA purity and concentration was determined using a 
NanoDrop ND1000 (Labtech International). In addition, 1 μg of RNA was separated 
on a 1.5% agarose gel along with molecular weight markers (Amersham) at 100 volts 
for 20 min and visualised using an AlphaImager (Alpha Innotech Corporation, GRI 
Ltd) at (365-nm) UV to verify integrity and purity.  Total RNA was stored at -80
o
C. 
 
2.13.4 Rapid amplification of cDNA ends 
Doenecke et al successfully amplified unknown sequences from the 5‟ end of cDNA 
using rapid amplification of cDNA ends (RACE) (Figure 2.1). To verify that this 
procedure was reproducible, I repeated their experiment to isolate VH cDNA from 
A20-1 cells and confirmed that the amplified VH sequence was identical to their 
already published data (Doenecke, Winnacker et al. 1997; Wang, Chen et al. 2006). 
Subsequently cDNAs encoding the VH and VL regions from the two aggrecan-
specific monoclonal antibodies (C71 and 1-C-6) were successfully isolated using this 
method. 5‟ RACE was carried out according to the manufacturer‟s instructions. In 
brief, gene-specific primers (H chain GSP1, H chain GSP2, L chain GSP1 and L 
chain GSP2) for both the IgG1 H chain and kappa L chain of murine immunoglobulin 
were designed based on published sequences (Doenecke, Winnacker et al. 1997). First 
strand cDNA was synthesized from A20-1HS, C71 and 1-C-6 total RNA using H or L 
chain GSP1 and Superscript II reverse transcriptase (Superscript II RT). 2.5 pmoles of 
H or L chain GSP1, 1 μg of sample RNA and deionized, diethylpyrocarbonate 
(DEPC) treated water (Invitrogen) were added to a thin walled PCR tube to a final 
volume of 15.5 μl and RNA was denatured by heating the tube to 70oC for 10 min. 
The tube was chilled on ice for 1 min before the addition of 2.5 μl 10x PCR buffer, 25 
mM MgCl2, 10 mM dNTP mix and 0.1 M DTT. The contents were mixed gently and 
incubated for 1 min at 42
oC before the addition of 1 μl Superscript II RT. The 
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contents were mixed and incubated for 50 min at 42
o
C to synthesize the cDNA. The 
temperature was adjusted to 70
o
C for 15 min to terminate the reaction and the tube 
was centrifuged for 10 seconds to collect the contents and placed at 37
oC. 1 μl of 
RNase mix was added and incubated at 37
o
C for 30 min to degrade the RNA. cDNA 
was purified using a simple nucleic acid prep (S.N.A.P) column procedure to remove 
excess nucleotides and H or L chain GSP1 before terminal deoxynucleotidyl 
transferase (TdT) tailing of the cDNA. 10 μl of the S.N.A.P. purified cDNA was 
transferred to a new tube with 6.5μl DEPC water, 5μl 5x tailing buffer and 2 mM 
dCTP and incubated for 3 min at 94
oC before being placed on ice. 1 μl of TdT was 
added to the tube mixed gently and incubated for 10 min at 37
o
C. TdT was heat 
inactivated by incubation at 65
o
C for 10 min before being placed on ice prior to PCR 
of dc-tailed cDNA. Tailed cDNA was amplified by PCR using the H or L chain GSP2 
nested primer listed in Table 2.3. 5 μl of dC-tailed cDNA was transferred to a thin 
walled PCR tube along with 31.5 μl sterilized distilled water, 5 μl 10x PCR buffer, 25 
mM MgCl2, 10 mM dNTP mix, 2 μl of 10 μM H or L chain GSP2 solution and 2 μl of 
10 μM abridged anchor primer solution. 0.5 μl of Taq DNA polymerase was added to 
the tube, contents was mixed and transferred to the pre-heated PCR machine (94
o
C).  
PCR programme for 35 cycles was denaturation at 94
o
C for 1 min, annealing of 
primers 55
o
C for 1 min and primer extension 72
o
C for 1 min, followed by a final 
extension at 72
o
C for 5 min. PCR products were analyzed by 1% agarose gel 
electrophoresis, using molecular weight standards, followed by visualization using at 
(365-nm) UV. 
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Figure 2.1 Rapid amplification of cDNA ends to amplify unknown VH and VL 
regions.  First strand cDNA is synthesized using a gene specific primer (GSP1). The RNA template is 
removed by the addition of RNAse. A homopolymeric tail is added to the 3’ of the amplified cDNA 
using TdT and dCTP.  PCR amplification of the unknown cDNA sequence is achieved using a nested 
GSP2 primer that anneals to the known sequence encoding the Ig C domain and an abridged anchor 
primer that recognizes the homopolymeric 5’tail.   Extracted from (Invitrogen 2002) 
 
 
2.13.5 Cloning 
Subsequent to RACE performed on RNA isolated from C71 and 1-C-6 the final PCR 
products were cloned into pCR
®
 2.1 plasmid vectors using TOPO
 
TA Cloning
®
 kit 
(Invitrogen) according to manufacturers instructions. In brief, 4 μl of PCR product 
was transferred to an eppendorf tube along with 1 μl of salt solution and 1 μl of the 
TOPO vector, the contents was mixed and incubated for 5 min at room temperature 
before being placed on ice.  Top 10 competent E.coli (Invitrogen) were transformed 
with the ligation mixture and plated overnight onto pre-warmed selective LB agar 
plates containing 50 μg/ml ampicillin. (Negative controls for this step were Top 10 
competent E.coli only plated onto ampicillin selection plates). The following day 
single colonies were picked for overnight culture and plasmid preparation.  
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Name Sequence 
 
Heavy chain 
GSP1 
5'-ATTTTGTCGACCKYGGTSYTGCTGGCYGGGTG-3'    
 
Heavy chain 
GSP2 
5'-GCACACYRCTGGACAGGGATCCAGAGTTCC-3'  
Light chain GSP1 5'-TTTGGGGTAGAAGTTGTT-3'  
Light chain GSP2 5'-TAACTGCTCACTGGATGGTGGGAAGATGGA-3'    
Abridged anchor 
primer (AAP) 
5'-GGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG-3'    
 
Heavy chain 3‟ 
primer including 
restriction site for 
Apa1 
 
5'-GGGCCCTTGGTGGAGGCAGCAGAGACAGTGACCA 
GAGT-3'     
 
Heavy chain 5‟ 
primer including 
restriction site for 
Xho1 
5'- CTCGAGCCATGGCTGTCCTGGTGCTGTTC-3'    
 
 1-C-6 Light 
chain 3‟primer 
including 
restriction site for 
Bbs1 
5'-ATGAAGACAGATGGTGCAGCCACAGTTTTGATTTC 
CAGCTTGGTGCC-3'    
C71 Light chain 
3‟primer 
including 
restriction site for 
Bbs1 
 
5'-
ATGAAGACAGATGGTGCAGCCACAGTTTTTATTTCCA 
GCTTGGTCCC-3'    
 1-C-6 Light 
chain 5‟primer 
including 
restriction site for 
Xba1 
 
 
5'-TCTAGAATGAAGTTGCCTGTTAGGCTG-3'   
C71 Light chain 
5‟primer 
including 
restriction site for 
Xba1 
5'-TCTAGAATGGATTTTCATGTGCAGATT-3'    
 
 
 
 
 
M13 F 5´-GTAAAACGACGGCCAG-3´ 
 
M13 R 5´-CAGGAAACAGCTATGAC-3´ 
 
 
Table 2.3 Primers purchased for the generation of aggrecan-specific BCR heavy 
and light chains. Primers all purchased from Eurofins, MWG, Operon.  
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2.13.6 Plasmid DNA isolation 
Plasmid DNA was prepared from overnight bacterial cultures using a QIAprep spin 
miniprep kit (Qiagen) according to manufacturer‟s instructions. In brief, bacterial 
colonies were grown in selective 2 ml LB broth overnight at 37
o
C in a shaking 
incubator.  The bacterial cells were harvested by centrifugation at 6800G for 3 min 
and plasmid DNA was isolated and bound to the Qiagen miniprep column. To elute 
the DNA, the column was placed in a clean eppendorf tube, 50 μl of water was added 
to the centre of the column membrane, left at room temperature for 1 min and then 
centrifuged at full speed for 1 min. Plasmid DNA was quantified using the NanoDrop 
ND1000 (A260/A280). 
 
2.13.7 DNA sequencing 
Several different preparations of mini prep and maxi prep pCR2.1 C71 and I-C-6 
DNA were bidirectionally sequenced (Cogenics) using the M13F and M13R forward 
and reverse primers described in Table 2.3. 
 
Sequencing ensured that multiple clones contained identical sequences. Subsequently, 
sequences were aligned with those previously described for other immunoglobulin H 
and L chain variable regions (Gilliland, Norris et al. 1996; Kwak, Lee et al. 1996; 
Karlstrom, Zhong et al. 2000; Park, Jin et al. 2000; Cauerhff, Goldbaum et al. 2004) 
using Entrez Nucleotide, NCBI sequence viewer v2.0.  
 
2.13.8 Maxi preps 
Following DNA sequencing to verify the quality and correct sequence of the plasmid 
DNA, maxi preps were carried out to amplify the amount of plasmid DNA available.  
Maxi preps were prepared from 250 ml overnight bacterial cultures using Qiagen 
maxi plasmid kit (Qiagen) according to manufacturer‟s instructions. Following this, 
maxi prep DNA was quantified by nanodrop and used for further cloning steps, cell 
transfection and long term storage stocks at -80
o
C.   
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2.13.9 Restriction digests. 
Restriction digests were performed to remove plasmid inserts:-  
 To verify that the correct sized insert has ligated with the plasmid. To do this 
the restriction digest is subsequently separated on a 1% agarose gel and 
visualized at (365-nm) UV.  
or  
 To remove the insert and subsequently ligate it with a different plasmid. To 
do this the restriction digest was separated on a 1% agarose gel, visualized at 
(365-nm) UV and the insert excised from the gel using a scalpel. The DNA 
was extracted from the gel and ligated to either an empty plasmid, or a 
plasmid vector already containing an insert. In the case of the latter, the 
unwanted insert was excised by restriction digest, separated by agarose gel 
electrophoresis and the linearized plasmid vector DNA isolated. In brief these 
procedures are detailed below. 
 
Restriction enzymes used for cloning were; Xho1, Not1, Kpn1, Sac1, Apa-1, Bbs-1, 
Xba1, BsshII (New England Biolabs). A typical restriction digest consisted of; 10 U 
of restriction enzyme per 1 μg of DNA incubated for 1 h at the appropriate reaction 
temperature. In a total reaction volume of 50 μl, 5 μl 10x appropriate buffer was 
added +/- BSA and the incubation temperature of the reaction is dependent on the 
enzyme. Calf intestinal phosphate (CIP) (NEB) was added to remove 5‟ phosphatase 
groups when digesting vectors thus preventing linearized vectors from self re- 
ligation. 5 μl of CIP was added to 40 μl of digestion reaction along with 5μl NEB 
buffer 3 and incubated at 37
o
C for 1 h. 
 
De-phosphorylated DNA fragments were separated from CIP and other DNA 
fragments on a 1% agarose gel and visualized at (365-nm) UV, followed by the gel 
purification/extraction step to extract and purify the vector/insert DNA. 
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2.13.10 Gel extraction/purification 
DNA was extracted from agarose gels using a QIAEX II gel extraction kit (Qiagen) 
according to manufacturer‟s instructions. DNA was eluted in 20 μl of H2O and 1 μl 
was separated on a 1% agarose gel for 30 min at 100 volts and visualized at (365-nm) 
UV. 
 
2.13.11 DNA ligation 
DNA ligation was used to clone restriction fragments and generate new plasmid 
constructs. Ligations were performed using the enzyme T4 ligase (NEB). Typical 
ligation reactions included 100 ng vector and 500 ng insert, 1 μl 10x T4 DNA ligase 
buffer, 1 μl T4 DNA ligase made up to a total volume of 10 μl. The reaction was 
mixed and incubated overnight at 4
o
C overnight. 
 
2.13.12 PCR to introduce restriction sites required for subsequent cloning steps. 
Initial clones were used to identify the sequences of the 1-C-6 and C71 V regions. 
Primers were then designed to amplify the H and L chain aggrecan-specific C71 and 
1-C-6 V regions and to incorporate the restriction site sequences (Xba1 /BbS1 L 
chain) and (Xho1/Not1 H chain) and sequences encoding the first few amino acids of 
the H and L chain constant regions from the anti-human tetanus toxin C fragment 
BCR (TTCF) (Knight, Lucocq et al. 1997). 50 μl PCR reactions consisted of 1 μl of 
Qiagen mini prep DNA template, 2 μl of the 5‟ and 3‟ primers (10 pmol/μl stock), 5 
μl 10x PCR buffer, 3 μl 25 mM Mg2+, 1 μl deoxyribonucleotide triphosphates 
(dNTPs), 35.5 μl H2O and 0.5 μl Taq polymerase. PCR programme for 35 cycles was 
denaturation at 94
o
C for 1 min, annealing of primers 55
o
C for 1 min and primer 
extension 72
o
C for 1 min, followed by a final extension at 72
o
C for 5 min. Following 
amplification PCR products were gel purified and re-cloned into pCR2.1.  
 
Subsequently, the variable regions from TTCF H and L were removed using the 
restriction enzymes (Xba1/BbS1 L chain and Xho1/Not1 H chain). C71/1-C-6 
aggrecan-specific V regions now including compatible restriction sites and sequences 
encoding 12 amino acids present in the TTCF H chain C region or 20 amino acids 
from the TTCF L chain C region were ligated with digested C regions from the TTCF 
H and L to generate human/mouse chimeric aggrecan-specific H and L chains. The 
chimeric H and L chains were then digested from pCR2.1 and sub-cloned via several 
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plasmids into the final lymphocyte expression vectors pMCFR as illustrated in 
Chapter 4 (Figures 4.9 and 4.11). 
 
 
 
                                                                                                                                                                                                      
Stratagene   www.Stratagene.com                      Invitrogen www.invitrogen.com                                                                            
                                                                                                                                                                                                                                                                              
Invitrogen www.invitrogen.com                            Pharmacia Biotech www.lablife.org 
pMCFR/hyg/NI Peter Cresswell No map available 
 
Table 2.4 Plasmids used for BCR H and L chain cloning. Listed are all of the plasmids 
used during the generation of the H and L chains of the aggrecan-specific BCRs.  
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2.14 Transfection with the aggrecan-specific BCR plasmids 
Following several rounds of cloning the final 4 pMCFR constructs containing 1-C-6 
H chain (pMCFR  1C6H), 1-C-6 kappa L chain (pMCFR 1C6L), C71 H chain 
(pMCFR C71H) and C71 kappa light chain (pMCFR C71L) were ready for 
transfection into cells. To verify that the constructs were assembled correctly and 
expressed they were firstly transfected into HeLa cells using Lipofectamine 
(Invitrogen). Following successful transfection into HeLa cells the construct were 
transfected into the A20-1 HS B lymphoma cell line by electroporation using a 
Nucleofector AAD-1001 (Amaxa).  
 
2.14.1 Transient transfection of plasmids containing C71/ 1-C-6 BCR into HeLa 
cells. 
Lipofectamine
TM
 2000 was used to transiently transfect the final pMCFR 1C6H, 
pMCFR 1C6L, pMCFR C71H and pMCFR C71L plasmid constructs into HeLa cells. 
In brief, 24 h prior to transfection 8x10
5
 HeLa cells were seeded onto glass coverslips 
in 24 well plates so that cells were 90-95% confluent the following day. 
Approximately 1 μg of each plasmid was diluted in 50 μl Opti-MEM I reduced serum 
medium (Invitrogen) and mixed. 2 μl of Lipofectamine reagent was diluted in 50 μl of 
Opti-MEM I and incubated at room temperature for 5 min. The diluted DNA and the 
diluted Lipofectamine reagent were mixed together and incubated at room 
temperature for a further 20 min. The DNA complexes were added to the wells 
containing the adhered HeLa cells (100 μl/ well) and incubated at 37oC in 5% CO2 for 
24 h before testing for transgene expression by Immunofluorescence using a Leica 
DM LB2 fluorescence microscope (Leica). 
 
2.14.2 Amaxa electroporation 
A20-1 HS cells were transfected using a Nucleofector AAD-1001 and the cell line 
nucleofector kit L (Amaxa Biosystems).  In brief, A20-1 HS cells were washed once 
in PBS and then approximately 2x10
6
 cells were resuspended in 100 μl buffer L. 2 μg 
of plasmid DNA (detailed in Table 5) was added, mixed well and the cell/DNA 
suspension was transferred to nucleofector cuvettes. Following nucleofection using 
programme L-13 (optimized by Amaxa Biosystems for A20-1 transfection cells were 
immediately removed from the nucleofector cuvettes and transferred to 6 well plates 
containing 3 ml cRPMI and incubated at 37
o
C in 5% CO2 for 24 h. Typically 1 ml of 
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the cell suspension was then removed for screening by flow cytometric analysis. In 
addition, 1 ml was also removed for screening by antigen presentation assay and the 
remaining 1 ml was expanded for the generation of stable cell lines (see Section 2.15) 
 
2.15 A20-1 HS generation of stable cell transfectants.  
To generate A20-1 HS stable cell lines expressing the C71 or 1-C-6 aggrecan-specific 
BCR, cells were transfected with the C71/1-C-6 H and L chain plasmids, generated in 
section 2.13. 48 h later cells were washed in RF-2 by centrifugation at 400G for 5 
min. Cells were resuspended in 50 ml cRPMI containing selection antibiotics at 50% 
the dose previously established to kill untransfected A20-1 HS cells (0.25 mg/ml 
G418 and 0.375 mg/ml hygromycin B) and plated out 500 μl/well into 4 x 24 well 
plates/transfection. 10 days later 500μl of cRPMI containing 2x G418 (1mg/ml) and 
2x hygromycin B (1.5 mg/ml) was added to the wells. Colonies were visible by day 
21, expanded accordingly in 0.5 mg/ml G418/0.75 mg/ml hygromycin B and screened 
using flow cytometry and antigen presentation assays. Positive colonies were later 
cloned using the single cell cloning method described in Section 2.4. 
 
 
TRANSFECTION CONDITIONS 
C71 heavy chain only 
C71 light chain only 
C71 heavy and light chain 
 1-C-6 heavy chain only 
 1-C-6 light chain only 
 1-C-6 heavy and light chain 
No DNA negative control 
TTCF heavy chain only positive control 
TTCF light chain only positive control 
TTCF heavy and light chain only positive control 
pmaxGFP
TM
 positive control (AMAXA) 
 
Table 2.5 Plasmids used to transfect cells by electroporation or lipofection.  
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2.16 Transfectant analysis 
 
2.16.1 HeLa transfectant Immunofluorescence 
Medium was removed from transfected HeLa cells and cells were washed 3 times in 
PBSA (PBS containing 0.01% MgCl2, 0.01% CaCl2). PBSA wash was removed and 
500 μl of 3% paraformaldehyde (PFA)/PBS solution was added to each well and 
incubated at room temperature for 20 min. Cells were washed 3 times in PBSA. 50 
mM NH4Cl was added to each well and incubated for 10 min at room temperature to 
quench the PFA and cells were washed 3 times in PBSA. To permeabilize the cells, 
500 μl of Triton x-100 0.2% (Sigma) was added to each well and incubated at room 
temperature for 4 min. The cells were washed 3 times in PBSA. Primary antibodies, 
rabbit anti-human IgG H + L biotin Fab
2
 (Southern Biotech. Assoc. Inc.) and rabbit 
anti-human kappa light chain bio (Serotec), were diluted (1:100) in PBSA 2% FBS 
and added as droplets onto a sheet of parafilm. The glass coverslips containing the 
permeabilized HeLa cells were placed onto the primary antibody droplet and 
incubated for 1 h in the dark in a dampened container. The slides were returned to a 
24 well plate and washed 3 times in PBSA FBS 2%.  Streptavidin FITC was diluted 
1:1000 in PBSA and added in droplet form to a sheet of parafilm. The glass coverslips 
were placed onto the diluted streptavidin FITC and incubated for 30 min in the dark in 
a dampened container. Slides were returned to a 24 well plate, washed 4 times in 
PBSA and then washed thoroughly in a glass beaker containing H2O to remove all 
traces of PBS. Coverslips were dried and mounted (Citifluor, Agar Scientific) onto a 
microscope slide for visualization by immunofluorescence.  
 
2.16.2 A20-1 HS transfectant screening (Flow cytometry). 
A20-1 HS cells were screened for the expression of a new aggrecan-specific BCR 
containing a human H chain C region, both 24 h post transfection and following the 
generation of stable transfectants. Cells were prepared for flow cytometry as 
described in section 2.12.1. In brief, cells were washed in FACS buffer and incubated 
for 1 h on ice in FACS buffer containing either primary antibody rabbit anti-human 
IgG H + L biotin Fab
2
 (1:100) or biotinylated aggrecan 50 μg/ml. Cells were washed 
3 times in FACS buffer. Cells were mixed with streptavidin FITC, diluted 1:100 and 
incubated for 1 h on ice, in the dark. Cells were washed 6 times and resuspended in 
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200 μl FACS buffer. 10,000 events were collected for each sample using a FACScan 
flow cytometer and data analysed using Flowjo software.  
 
2.16.3 A20-1 HS transfectant screening (Antigen presentation). 
A20-1 HS transiently transfected cells (C71 and  1-C-6) were screened (using the 
antigen presentation assay described in section 2.10.2) 24 h post transfection using 
graded doses of deglycosylated aggrecan, p84-103 and the p84-103-specific T cell 
hybridoma 192. Antigen presentation by C71 and  1-C-6 stable transfectants were 
compared with dendritic cells and macrophages using deglycosylated aggrecan, 
glycosylated aggrecan, TTCF, p84-103, p2373-2387, p2363–2378 and the p84-103-
specific T cell hybridoma (192), the  p2373-2387 specific T cell hybridoma (D9),  the 
p2363–2378-specific T cell hybridoma (D11) and the TTCF 1120-1137-specific T cell 
hybridoma MC52 (Marzena Ciechomska unpublished). 
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2.17 Generation of aggrecan-specific T cell hybridomas 
2.17.1 Immunisation, cell isolation and in vitro re-stimulation. 
6-8 week female BALB/c mice were immunized subcutaneously in a single footpad 
with either 25 µl of aggrecan (27 µg) or synthetic peptides p2363-2378 or p2373-
2387 (100 µg) emulsified in Titermax and popliteal lymph nodes were removed 7 
days later.  
 
Day 0: Popliteal lymph node cells were passed through a cell strainer and washed in 
RF-2 by centrifugation at 400G for 5 min. The cells were then resuspended in cRPMI, 
seeded at 3x10
6
/well in a total volume of 200 µl with either 50 µg/ml of aggrecan or 
100 µg/ml of either peptide p2363-2378 or p2373-2387 (Table 2.6) and incubated at 
37
o
C in 5% CO2 for 3 days.   
 
Day 3:  T cell lines were pooled from several wells and viable cells were separated by 
density gradient centrifugation. The cells were washed in RF-2 by centrifugation at 
400G for 5 min and resuspended in 5 ml of cRPMI.  5 ml of Lymphoprep density 
separation medium of 1.077 g/ml (Axis Shield PoC AS) was loaded into a 15 ml 
falcon tube, the cell suspension was carefully layered on top and centrifuged at 700G 
for 10 min.  Viable cells were recovered from the interface and washed in RF-2 by 
centrifugation at 400G for 5 min and resuspended in cRPMI and seeded at 6x10
5
/well 
in 2 ml cRPMI containing 5 ng/ml rIL-2. 
 
Day 7:  1 ml of medium was removed and replenished with 1 ml cRPMI containing 
0.1 ng/ml rIL-2. 
 
Day 14: Resting T cells were re-stimulated with antigen (see Table 2.6).  1 ml of 
medium was removed from wells and replaced with l ml cRPMI containing irradiated 
splenocytes (20 grays/5 min) as a source of antigen presenting cells and either 100 
μg/ml of peptide (p2363-2378 or p2373-2387) or 50 μg/ml of aggrecan.  
 
This 14 day cycle was repeated 3 times before the T cell lines were tested for antigen-
specificity using a proliferation assay and then fused to the T cell lymphoma cell line 
BW5147 3 days post re-stimulation 
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2.16.2 T cell fusion 
BW5147 cells and T cell blasts were washed twice in serum free HBSS by 
centrifugation at 400G. Cells were then mixed at a 1:1 ratio (2x10
6
 of each) and 
washed in HBBS. All of the supernatant was carefully removed and the pellet was 
resuspended in 0.7 ml of PEG (Sigma) added a dropwise. Cells were washed by 
centrifugation at 200G for 5 min in 14 ml of pre-warmed (37
o
C) HBSS (added slowly 
to the cell suspension) and resuspended in pre-warmed (37
o
C) cRPMI.  The fused 
cells were seeded at various dilutions; 1:1, 1:3 and 1:9 in flat bottomed 96 well plates 
100 μl/well and incubated at 37oC in 5% CO2 for 24 h before adding (100 l/well) of 
2x HAT. HAT resistant colonies were observed by day 10 and expanded accordingly. 
 
 
 
Table 2.6   Antigens used for animal immunisation and re-stimulation of T cells. 
 
 
 
 
 
 
 
 
 
 
 
Immunizing antigen        Re-stimulating 
antigen 
Aggrecan Aggrecan 
Aggrecan p2373-2387 
Aggrecan p2363-2378 
p2373-2387 p2373-2387 
p2363-2378 p2363-2378 
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2.17 Cytokine analysis of CD4+ T cells from TCR-5/4E8-tg mice. 
 
2.17.1 CD4
+
 T cell isolation 
Four TCR-5/4E8-tg mice were sacrificed and cells were isolated from the spleens. 
Cells were pooled and passed through a 100 μm cell strainer (BD Biosciences) to 
form a single cell suspension. Cells were transferred to a 15 ml falcon tube, 
centrifuged and red blood cells lysed by adding 2 ml of red blood cell lysis buffer per 
spleen (Sigma) for 4 min at room temperature. Cells were washed in RF-2 by 
centrifugation at 400G for 5 min and resuspended in cRPMI.  Cells were pelleted at 
400G for 10 min and all of the supernatant removed. Cells were resuspended in ice 
cold MACS buffer (PBS, 0.5%BSA, 2 mM EDTA, 90 μl/107 cells).  10 μl of CD4 
(L3T4) Microbeads (Miltenyi Biotech) were added per 10
7
 cells, mixed and incubated 
for 15 min on ice. During the incubation period an LS separation column (Miltenyi 
Biotech) was prepared by placing it in the magnetic field of a VarioMacs separator 
(Miltenyi Biotech) and rinsing the column with 3 ml of ice cold MACS buffer. 
Following the 15 min incubation cells were washed by adding 2 ml of ice cold MACS 
buffer per 10
7
 cells and centrifuged at 400G for 10 min. The supernatant was removed 
and cells were resuspended in 500 μl of ice cold MACS buffer/108 cells ready for 
magnetic separation. The cell suspension was applied onto the column and the 
unlabelled cells that passed through were collected in a 15 ml falcon tube. The 
column was washed 3 times in 3 ml MACS buffer and the total eluent was collected 
(unlabelled fraction). To isolate the magnetically labelled CD4
+
 fraction the column 
was removed from the separator and placed on a 15 ml falcon tube. 5 ml of MACS 
buffer was added to the column and the labelled fraction was removed by applying a 
plunger to the column once to flush out the bound cells. The cells were washed in RF-
2 by centrifugation at 400G for 5 min, resuspended in cRPMI and counted.  
 
2.17.2 Flow cytometry to determine purity and TCR Vβ4 usage of the isolated CD4+ 
T cells. 
p84-103-specific T cells express Vα1.1+/Vβ4+ TCR (Berlo, van Kooten et al. 2005). 
Isolated cells were incubated with anti-CD4 PerCP, anti-TCRαβ PE and anti-vβ4 PE 
to detect the total CD4+ and TCRαβ + population and the proportion of Vβ4 + T cells. 
Cells were transferred to FACS tubes at approximately
 
2.5x10
5
/tube, pelleted by 
centrifugation at 400G for 5 min and washed in FACS buffer. The supernatant was 
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removed and the cells were resuspended in the appropriately diluted primary antibody 
(Table 2.1) and incubated at 4
o
C for 1 h in the dark.  Cells were washed 3 times in 
ice-cold FACS buffer at 400G for 5 min, resuspended in 200 μl of ice cold FACS 
buffer and placed on ice until analysis using a FACScan flow cytometer (BD 
Biosciences) and data analysed with Flowjo software (Treestar
TM
). All staining was 
carried out in 96 well round bottom plates at 4
o
C in the dark in the presence of 2.4G2 
Fc block. 
 
2.17.3 Cytokine analysis 
Antigen presentation assays (described previously in section 2.10.2) were used to 
determine the cytokines produced by CD4+ TCR-5/4E8 T cells in response to p84-
103 or aggrecan.  CD4+ TCR-5/4E8 T cells (5x10
4 
/well) were incubated for 72 h 
with 1x10
4
 dendritic cells, macrophages, aggrecan-specific B cells (C71-4C5 and C71 
-5F10) or 5x10
4
 A20-1 HS B cell hybridomas and graded doses of either p84-103 or 
aggrecan. Controls included each of the APC or T cells only incubated with medium, 
aggrecan or p84-103 and medium or antigen without any cells. The assay was frozen 
after 72 h to lyse the cells. 50 μl of supernatant was removed from each well to detect 
IL-2 by CTLL-2 proliferation, 50 μl was used to detect IL-10 and 50 μl was used to 
detect IFNγ levels by ELISA.  
 
 96 well ELISA plates were coated with 50 μl coating buffer containing 2 μg/ml of 
either anti-IL-10 or anti-IFNγ capture antibody (BD Biosciences). Plates were 
wrapped in parafilm and incubated at 4
o
C overnight. Following the overnight 
incubation plates were washed with PBS containing 0.1% Tween to remove the 
unbound antibody and blocked by adding 200 μl 2% milk powder/PBS to each well 
and incubating for 1 h at 37
o
C. A standard curve was determined for each plate by 
adding graded doses of rIL-10 or rIFNγ beginning with a top dose of 100 ng/ml to 
each plate containing the relevant capture antibody. 50 μl of supernatant from the 
antigen presentation assay was transferred to each plate containing either anti-IL-10 
or anti-IFNγ and the relevant recombinant cytokine standards and incubated at room 
temperature for 2 h. Plates were washed 4 times with PBS containing 0.1% Tween. 
100 μl of biotinylated detection antibody (0.5 μg/ml, anti-IL-10 or anti-IFNγ) (BD 
Biosciences) was added to each well and incubated for 1 h at room temperature. 
Plates were washed 6 times with PBS containing 0.1% Tween. 100 μl of extra-avidin 
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peroxidase diluted 1/1000 in 2% milk powder/PBS was added to each well and 
incubated at room temperature for 30 min. Plates were washed 6 times with PBS 
containing 0.1% Tween. Substrate (TMB) was subsequently added along with 
hydrogen peroxide in phosphate citrate buffer for 4 min, the reaction was stopped 
using 2 M H2SO4 and absorbance was read at 450 nm. Controls for this experiment 
included blank wells coated with capture antibody and subsequently incubated with 
media only. 
 
2.18 Statistical analysis 
Significant differences between groups of 3 or more was determined by one-way 
ANOVA using a 95% confidence interval followed by Tukeys test for multiple 
differences between experimental means. Experiments in which 2 groups were 
compared, significant differences were determined using students T test (Graphpad 
Prism 5.0 statistical and graphing software). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 92 
3. Generation of immortalized aggrecan-specific B cells by fusion 
with A20-1 HS lymphoma cells. 
 
3.1 Introduction 
            B cells play a multifaceted role in the pathology of RA by the secretion of 
autoantibodies (Duskin and Eisenberg) and pro-inflammatory cytokines (Lund, Garvy 
et al. 2005) (Dorner and Burmester 2003). In addition, antigen-specific B cells are 
very efficient antigen presenting cells (APC) and contribute to T cell activation 
(Weyand, Seyler et al. 2005).  Proteoglycan induced arthritis (PGIA) is a mouse 
model of RA, in which mice immunized with aggrecan in adjuvant develop a disease 
very similar to human RA. Using this model Shlomchik et al revealed that B cells 
were essential not only in providing autoantibodies but also as aggrecan-specific APC 
(O'Neill, Shlomchik et al. 2005). 
 
            Studies in the past few years have identified elevated levels of aggrecan cleavage 
products, aggrecan-specific antibodies and aggrecan-specific T cells in RA patients 
(Poole and Dieppe 1994) (Vynios, Tsagaraki et al. 2006) (Zou, Zhang et al. 2003). In 
addition, germinal centre like structures, containing proliferating B and T cells have 
been found in many RA patients (Weyand, Goronzy et al. 2000). Rituximab is an anti-
CD20 monoclonal antibody therapy used to deplete both pre and mature B cells which 
has been used to successfully treat RA patients for whom other therapies have failed 
(Edwards and Cambridge 2006). 
 
            Taken together these data imply a role for both aggrecan and aggrecan-specific T and 
B cells in the induction and perpetuation of disease pathogenesis. However, these 
studies fail to identify the mechanisms by which B cells act as essential APC.  
 
            In the previous chapter, I described how I have isolated and modified aggrecan from 
bovine nasal cartilage. In this chapter I have established an antigen presentation 
system that could be used to compare aggrecan presentation by A20-1 HS B cells, 
dendritic cells and macrophages. My findings concur with previous studies that 
demonstrate B cells are poor at non-specific antigen uptake and presentation 
(Kakiuchi, Chesnut et al. 1983; Rock, Benacerraf et al. 1984). However, it has been 
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well documented that B cells are highly efficient at presenting antigen to T cells when 
they express an antigen-specific BCR (Lanzavecchia 1985; Casten, Kaumaya et al. 
1988; Batista and Neuberger 1998). Therefore, in order to study the effective uptake 
and presentation of aggrecan by B cells I needed to generate B cells with an aggrecan-
specific BCR. Methods used to isolate antigen-specific B cells involve immunization 
with antigen to increase the usually low numbers of specific B cells followed by 
isolation using a capture antigen adsorbed on a solid surface, rosetting on antigen 
coated particles or isolation by staining with fluorescent antigen followed by flow 
cytometric cell sorting (Kodituwakku, Jessup et al. 2003; Newman, Rice et al. 2003). 
However, these methods have had limited success and produced low yields. 
Therefore, my first approach was novel and based on the widely used monoclonal 
antibody production protocol first described by Kohler and Milstein used to boost a 
population of antigen-specific B cells that are usually present at a very low frequency 
<1% (Kohler and Milstein 1975; Oshiba, Renz et al. 1994). According to this method, 
it is important to give animals several immunizations with antigen in adjuvant. The 
resulting antigen-specific cells are then isolated from the animal and immortalised by 
fusion with an immunoglobulin negative tumour B cell such as the NSO mouse 
myeloma cell line. NSO cells lack the enzyme hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT) and are resistant to azaguanine and the “salvage 
pathway” of DNA synthesis. The addition of aminopterin to culture media blocks 
DNA de novo synthesis and therefore, unless NSO cells are fused with a HGPRT+ 
cell such as an ex-vivo B cell they will die in medium containing Hypoxanthine (5 
mM), Aminopterin (20 mM), Thymidine (0.8 mM) (HAT). To identify successfully 
fused cells the NSO/splenic B cell fusion population are grown in HAT selection 
medium and resultant fusion colonies are screened for the production of antigen-
specific Ig by ELISA.   
 
            Immunizing mice with antigen in adjuvant stimulates their adaptive immune system 
to produce both plasma cells that secrete antigen-specific Ig and memory B cells that 
express a surface Ig specific for aggrecan (BCR). Therefore, in principle this method 
could be used to expand and immortalize memory B cells expressing an aggrecan-
specific BCR (illustrated in Figure 3.1) and the aggrecan-specific B cells could be 
used to understand the mechanisms by which B cells process and present the 
candidate rheumatoid arthritis antigen, aggrecan to aggrecan-specific CD4
+
 T cells.  
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For the purpose of this study the B cell lymphoma cell line A20-1 HS was used as a 
fusion partner to ensure that the aggrecan-specific Ig would be expressed on the cell 
surface (BCR) rather than secreted as antibody (discussed in section 3.2.1).  
 
 
 
 
 
 
 
             
 
 
3.1.2 The aim of this chapter:  
 To immortalize B cells isolated from aggrecan-immunized mice. 
 To screen resultant colonies for B cells expressing an aggrecan-specific BCR.  
 To assess their potential as antigen presenting cells. 
 
 
Figure 3.1 Splenocyte fusion protocol to generate aggrecan-specific B 
cell hybridomas. Mice were immunised on 4 separate occasions at 3 week intervals 
with deglycosylated aggrecan to boost a population of aggrecan-specific B cells (shown 
in red). The mice were sacrificed and splenocytes removed. Splenocytes were mixed at a 
2:1 ratio with A20-1 HS B lymphoma cells pelleted by centrifugation and fused with 
polyethylene glycol (PEG). The cells were plated out in selection media containing 
HAT. Cells that were not successfully fused die in the selection media and fused cell 
populations are expanded and screened by flow cytometry and antigen presentation 
assays to identify those cells that are fused with aggrecan-specific B cells.  
 95 
3.2 Results  
            3.2.1 Immunisation and cell fusion.  
Primary immunisation with antigen produces early response, low affinity Ig (Kohler 
and Milstein 1975). However, this first encounter with antigen allows the subsequent 
clonal expansion of antigen-specific T cell and B cells which are now „primed‟ upon 
additional encounter with the same antigen. B cells with antigen-specific BCR appear 
at around 5-6 days post immunisation and circulating Ig appears at around day 7 
peaking at day 10 (Kohler and Milstein 1975). Subsequent immunisations promote a 
stronger and more rapid immune response designed to allow primed lymphocytes to 
eliminate pathogens before they cause disease. Therefore, following a second boost, 
antigen-specific B cells are detectable at days 3-4 and circulating Ig at around the 
same time, peaking at around days 10-14, which persists for around 2-4 weeks 
(Kohler and Milstein 1975). Further immunisations with antigen in adjuvant will 
boost the affinity of Ig due to somatic mutations that occur within the variable regions 
of the BCR heavy and light chains during antigen induced expansion and activation 
(Kim, Davis et al. 1981). Somatic mutations can produce a higher affinity BCR that 
will bind to the antigen and induce the expansion of high affinity B cells.  
 
Based on this strategy, groups of mice were either given 3 immunisations (fusion 1) 
or 4 immunisations (fusion 2). A gap of approximately 3 weeks was left between 
immunisations to ensure that circulating antigen-specific Ig was cleared, and the 
immunising antigen was not rapidly complexed with the Ig and removed from the 
circulation (Harlow 1988). To test the anti-aggrecan responses in the immunized 
mice, serum was obtained and tested for Ig levels prior to immunisation and 5 days 
post initial immunisation and following each subsequent boost. Results in Figure 3.2 
show that the collected serum contains no aggrecan-specific Ig prior to immunisation. 
However, following an initial immunisation with aggrecan, aggrecan-specific Ig was 
detected, with Ig levels increasing with each subsequent boost. For both fusion 
immunisation protocols the final aggrecan immunisations in alum were introduced 
intra-peritonealy to allow antigen-specific B cells to accumulate in the spleen. Cells 
were recovered from the spleen either 5 or 10 days post final immunisation and fused 
with a B lymphoma cell.  Initial attempts by Dr Knight and Prof Robinson to fuse 
memory B cells with the B cell lymphoma NSO proved unsuccessful. We 
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hypothesised that NSO cells may not be a good candidate for fusion as this cell line is 
a non-Ig secreting, (-ve for both H and L chain) cell that may not support the cell 
surface expression of a BCR (Galfre and Milstein 1981). The HAT sensitive 
lymphoma cell line A20-1 HS expresses surface Ig, is able to present high doses of 
antigen to CD4+ T cells and may be a more suitable candidate for this protocol. 
Therefore, following a final immunisation, cells were isolated from the spleen and 
fused to the A20-1 HS cells to generate immortalized hybridoma cells. 
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Figure 3.2 The reactivity of pre-bleed, post-bleed and terminal 
bleed with aggrecan detected by ELISA. Each point represents serum 
pooled from 4 mice and shows anti-aggrecan antibody titres either prior to 
immunisation (pre-bleed), 10 days post 1st immunisation with aggrecan (bleed 1), 10 
days post 2
nd
 immunisation with aggrecan (bleed 2) and 5 days post the 3
rd
  and final 
immunisation with aggrecan (terminal bleed).  
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3.2.2 Characterisation of fusion cells by flow cytometry and antigen presentation.   
 
3.2.2.1 Flow cytometry 
Initial fusion of splenocytes isolated from mice immunized under the 2 described 
protocols (section 2.9.1) with A20-1 HS generated a total of 53 HAT resistant 
colonies. These fusions were initially screened by flow cytometry for BCR heavy 
chain isotype and light chain usage (Representative fusions shown in Figure 3.3). As 
expected all of the fusions expressed an IgG2a 
+/κ light chain+ BCR at comparable 
levels to that seen on the fusion partner A20-1 HS.  However, 7 fusions including 
representative fusions 13 and 24 also expressed an additional BCR H chain isotype. 
Subsequently, A20-1HS and all of the fusions were examined for the expression of 
cell surface molecules involved in antigen presentation, MHC class II and the co-
stimulatory molecules B7.1 and B7.2 (Figure 3.4). Results show that fusion 53 
expressed surface MHC class II at levels comparable to that seen on the A20-1 HS 
fusion partner. However, both fusions 13 and 24 express higher levels of MHC class 
II. Fusion 13 expresses comparable levels of the co-stimulatory molecules B7.1 and 
slightly higher levels of B7.2 than the A20-1 HS fusion partner. Fusions 24 and 53 
express higher levels of both B7.1 and B7.2 when compared to A20-1 HS cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 99 
                  
 
 
                           
  
 
                   
 
 
                           
 
 
                                                
 
 
Figure 3.3 Characterisation of BCR phenotype by flow cytometry 
Staining of gated A20-1HS cells and 3 representative fusion populations for various BCR isotype 
markers. Red histograms represent unstained cells and the blue histograms represent cells stained for 
the various markers. Antibodies were either FITC, PE or biotin conjugated, in the latter case 
streptavidin FITC was used as a secondary reagent. All experiments were carried out at 4
o
C in the 
presence of Fc block. Mean fluorescence intensity values are shown below each histogram. Data is 
representative of 3 independent experiments. 
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Figure 3.4 Expression of molecules involved in antigen presentation verified by 
flow cytometry Staining of gated A20-1HS cells and 3 representative fusion populations for 
various cell surface markers involved in antigen presentation to CD4
+
 T cells. Red histograms 
represent unstained cells and the blue histograms represent cells stained for the various markers. 
Antibodies were PE conjugated. All experiments were carried out at 4
o
C in the presence of Fc block. 
Mean fluorescence intensity values are shown below each histogram. Data is representative of 3 
independent experiments. 
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3.2.2.2 Antigen presentation assay. 
As described in Chapter 1, B cells would be expected to be more efficient at 
aggrecan presentation when they express an aggrecan-specific BCR. Therefore, if the 
fusions shown in Figure 3.3 have resulted from a fusion with an aggrecan-specific 
memory B cell, then aggrecan presentation to T cells should be more efficient than 
that seen with the fusion partner A20-1 HS.   
 
The extent of aggrecan presentation to the BALB/c (H-2
d
) aggrecan84-103 -specific T 
cell hybridoma 192 was determined using antigen presentation assays as illustrated in 
(Figure 3.5).  A20-1 HS or fusion cells were cultured with the T cell hybridomas 192 
for 24 h in the presence of graded doses of aggrecan. Initially, T cell hybridoma 
activation was measured by IL-2 production using the IL-2 dependent cell line HT-2. 
However, subsequently I found the IL-2 dependent cell line CTLL-2 to be more 
sensitive for detecting IL-2 production (data showing comparison in Figure 3.6).  
Therefore, following the screening of cells from fusion number 1, supernatants from 
all subsequent experiments were screened using CTLL-2. HT-2 or CTLL-2 cells were 
cultured with assay supernatant and proliferation in response to IL-2 was measured by 
the incorporation of tritiated thymidine. The efficiency of antigen presentation can 
then be determined by noting the minimum dose of aggrecan required to obtain an IL-
2 response.  
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Figure 3.5 Antigen presentation assay.  
A20 B lymphoma cells or other APC and T cells (T) are incubated for 24 h in a 96 well plate in the 
presence of graded doses of antigen (aggrecan or p84-103).T cell stimulation is measured by resultant 
IL-2 production. In order to quantitate IL-2 production following a single cycle of freeze/thawing 
supernatants were transferred to new plates and cultured with IL-2 dependent cell lines (HT-2 or 
CTLL-2) and 
3
H thymidine.  HT-2 or CTLL-2 proliferation in response to IL-2 can then be measured 
by 
3
H thymidine incorporation. 
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Figure 3.6 HT-2/CTLL-2 dose response curves to IL-2 
.Initial antigen presentation assays with fusions were carried out using IL-2 
dependent cell line HT-2 to quantitate the amount of IL-2 present in T cell assay 
supernatants. All data generated from fusion 2 shows IL-2 detection by the IL-2 
dependent cell line CTLL-2.  HT-2 and CTLL-2 were incubated with graded doses of 
recombinant IL-2 for 24 hours. 
3
H thymidine was added for 18 hours, cells were then 
harvested onto glass fibre filters and 
3
H thymidine incorporation was quantified and 
displayed as 
3
H thymidine cpm. Results represent the mean cpm + S.D. of duplicate 
wells.  
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Data from flow cytometry analysis and antigen presentation assays reveals distinct 
patterns by the fusion cells. Either, fusions did not present aggrecan more efficiently 
than the A20-1 HS fusion partner and were negative for the expression of a new 
isotype BCR (not shown) and were excluded from further studies, or they fell into the 
following categories and representative colonies were used for further examination of 
their potential as representative aggrecan-specific antigen presenting B cells (data 
shown in Figure 3.7). 
 
Pattern a, 7 fusions were positive for the expression of a new BCR yet did not 
present aggrecan more efficiently than A20-1 HS.  
Pattern b, 1 fusion (fusion 24) was positive for the expression of a new BCR and 
presented aggrecan more efficiently than A20-1 HS.  
Pattern c, 10 fusions (including fusion 53) were negative for the expression of a new 
isotype BCR yet presented aggrecan more efficiently than A20-1 HS.  
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Figure 3.7 Antigen presentation by fusions generated from immunisation 
protocol 1. Pattern a shows a representative fusion that expressed a new isotype BCR yet did 
not present aggrecan more efficiently than A20-1 HS. Pattern b shows a representative fusion that 
expressed a new BCR and presented aggrecan more efficiently than A20-1 HS. Pattern c shows  a 
representative fusion that did not express a new isotype BCR and yet presented aggrecan more 
efficiently than A20-1 HS. A20-1 HS, or  fusion cells (5x10
4
) expressing either IgG2a and a new 
isotype BCR or IgG2a+ only were cultured with aggrecan84-103-specific T cell hybridomas 192 
(5x10
4
) in the presence of graded doses of aggrecan for 24 h. Cells were killed by freezing at -
80
o
C and supernatant was removed for bioassay with CTLL-2 cells.
 3
H thymidine was added for 
18 h and T cell responses were determined and displayed as 
3
H thymidine cpm +/- SEM. Data are 
representative of three experiments.  
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I generated several populations of cells, which from my initial analysis, appeared to 
be good candidates for the expression of an aggrecan-specific BCR (patterns b and c). 
However, following prolonged periods of time in culture the fusions began to lose 
their efficiency at presenting aggrecan to the T cell hybridoma 192. I hypothesised 
that as the fusion cell populations were not yet clonal that this decline in antigen 
presentation efficiency could be due to an outgrowth of non-specific cells from a 
heterogeneous population. Therefore, to further investigate the candidate aggrecan-
specific B cells, 44 single cell clones were generated from representative fusions 24 
(pattern b) and 53 (pattern c) (Figure 3.7). Clones were re-screened for BCR heavy 
chain isotype to verify that they had retained that of the original fusion population and 
then examined for their ability to present aggrecan using the antigen presentation 
assay described. Flow cytometry confirmed that a representative clone of fusion 24 
(24.14) retained the parental phenotype (BCR IgG2a
+
 / IgM
+
) and a representative 
clone of fusion 53 (53.28) retained the parental phenotype (BCR IgG2a
+
) (data not 
shown).  
 
Figure 3.8a, demonstrates that both clones 24.14 and 53.28 have retained their ability 
to show enhanced aggrecan presentation to the T cell hybridomas 192 in comparison 
to A20-1 HS efficiently presenting aggrecan from doses of 10nM (p<0.01). In all 
antigen presentation experiments thus far, cells had been incubated with graded doses 
of deglycosylated aggrecan. Figure 3.8b shows that A20-1 HS were unable to present 
aggrecan in its glycosylated form to the T cell hybridoma 192 even when incubated at 
high doses (200 nM). However, both fusions 24.14 (BCR IgG2a
+
 / IgM
+
) and 53.28 
(BCR IgG2a
+
) were able to efficiently present glycosylated aggrecan at doses of 50 
nM (p<0.001).   
 
It is possible that the enhanced presentation seen by the fusions when compared to 
that of A20-1 HS is not due to aggrecan uptake and processing but may reflect an 
overall improvement in T cell stimulation capacity due to surface presentation of the 
epitope 84-103 on H-2
d 
for example. Therefore, I repeated the antigen presentation 
assay using graded doses of the synthetic peptide p84-103 as a pre-processed form of 
aggrecan. Data from Figure 3.8c shows that fusion 24.14 could present p84-103 
approximately 10-fold more efficiently than A20-1 HS at doses of 0.003Nm 
(p<0.001) which correlates with the 10-fold improvement of deglycosylated aggrecan 
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seen in Figure 3.8a. This result may be explained by the data in Figure 3.4 that 
shows relatively increased expression of MHC class II and the co-stimulatory 
molecules B7.1 and B7.2 by fusion 24.14 compared to 53.28 and A20-1 HS. 
However, fusion 53.28 did not present p84-103 more efficiently than A20-1 HS 
indicating that the improved presentation of both deglycosylated and glycosylated 
aggrecan may be due to more efficient uptake and/or processing by the 53.28 cells. 
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3.2.2 Verification of the expression of an aggrecan-specific BCR. 
* 
Figure 3.8 Antigen presentation by clones generated from fusions 24 and 53 
generated from immunisation protocol 1. A20-1 HS, or the fusion cells 24.14 and 53.28 
(5x10
4
) were cul ur d with aggrecan84-103-specifi  T cell hybridomas 192 (5x10
4
) in the presence 
of graded doses of a) deglycosylated aggrecan, b) glycosylated aggrecan and c) p84-103 for 24 h. 
Cells were killed by freezing at -80
o
C and supernatant was removed for bioassay with CTLL-2 
cells. 
3
H thymidine was added for 18 h and T cell responses were determined and displayed as 
3
H 
thymidine cpm +/- SEM. Data are representative of three experiments. The asterix represents 
statistical significance determined by one-way ANOVA where p<0.05. 
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Data thus far was consistent with the expression of an aggrecan-specific BCR by 
fusions 24.14 and 53.28. Therefore, several attempts were made to verify this, before 
attempting more complex molecular processing studies.     
 
3.2.2.3 Detection of aggrecan binding to fusions by flow cytometry.  
The cloned fusions were screened for their ability to bind aggrecan. In order to 
achieve this, aggrecan was biotinylated using several different molar ratios of 
aggrecan/biotin. Following removal of excess biotin, the modified aggrecan was then 
tested by ELISA to verify a) that the biotinylated aggrecan was still recognisable by 
aggrecan-specific Ig and b) that the modified aggrecan contained sufficient biotin 
molecules to allow detection with streptavidin-HRP (Figure 3.9). 
 
If the fusion clones express an aggrecan-specific BCR then I hypothesised that bound 
biotinylated aggrecan should be detected by flow cytometry following the addition of 
streptavidin-FITC. Fusion clones were incubated with 200 nM aggrecan (biotinylated 
at different molar concentrations) for 1 h followed by several washes and a 1 h 
incubation with streptavidin-FITC. Cells were kept on ice for the entire experiment to 
reduce internalization of the BCR and aggrecan. Data in Figure 3.10 shows that 
binding of the biotinylated aggrecan by the B cell fusion clones was not detectable by 
flow cytometry. In addition, following incubation with up to 400 nM of the 
biotinylated aggrecan, fusion cells were still not able to retain the aggrecan at the cell 
surface for detection by flow cytometry (not shown). 
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                a) 
 
 
 
 
 
 
                 b) 
 
 
 
 
 
 
 
Figure 3.9 ELISA to determine the biotinylation of aggrecan and to confirm that 
biotinylation does not prevent recognition by aggrecan-specific antibodies.  
Aggrecan was biotinylated at various molar ratios of biotin to aggrecan: 10 times biotin excess (10x), 
20 times excess (20x) or 40 times excess (40x).  Following dialysis, biotinylated aggrecan was bound to 
ELISA plates and detected by serial dilutions of either a) anti-aggrecan Ig (Serotec) followed by 
detection reagent HRP-conjugated anti-mouse or b) HRP-conjugated streptavidin. Data is 
representative of triplicate wells and 2 independent experiments. 
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Figure 3.10 Aggrecan was not detected bound to the surface of candidate 
aggrecan-specific fusion clones by flow cytometry. Staining of gated A20-1 HS cells 
and fusion clones 24.14 and 53.28 for surface bound aggrecan. Red histograms represent 
unstained cells and the blue histograms represent cells stained for the various markers. Aggrecan 
was biotin conjugated at either 10x, 20x or 40x molar excess and incubated with the cells for 1 h 
at a concentration of 200 nM. Cells were washed and then incubated with the secondary reagent 
streptavidin FITC for 1 h.  All experiments were carried out at 4
o
C. Data is representative of 3 
independent experiments.  
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3.2.2.4 Presentation of p84-103 and deglycosylated aggrecan to T cell hybridomas 
192 by fusion clones 53.28 and 24.14 in the presence of anti-Ig, anti-class II or 
anti-Fc to block presentation.  
Can presentation via BCR mediated uptake be blocked by antibodies to the BCR?  
 
Fusion clones were incubated with aggrecan and T cell hybridoma 192 in the presence 
of polyclonal anti-mouse IgG Fab
2
, polyclonal anti-mouse IgM Fab
2
, anti-mouse 
MHC class II or anti-mouse anti-FcRγII/III receptor antibodies (2.4G2) for 24 h (data 
shown in Figure 3.11.) If the observed improvement in presentation is BCR 
mediated, the addition of anti-Ig should have an inhibitory effect. However, I did not 
observe any inhibition by the addition of anti-Ig antibodies to the antigen presentation 
assay containing fusion clones. Furthermore, anti-Fc Ig was added to the antigen 
presentation assay to confirm whether Ig secreted by the fusion cells was aiding 
aggrecan uptake and presentation. The addition of 2.4G2 anti-Fc receptor antibodies 
had no effect on aggrecan presentation by the fusion cells. Anti-MHC II antibodies 
were used as a positive control and as expected the addition of the latter antibody had 
a profound inhibitory effect by preventing presentation of aggrecan peptide/MHC II 
complexes to the T cell hybridomas 192. Interestingly, the addition of increasing 
doses of both anti-IgM and anti-Fc antibodies blocked presentation of aggrecan by the 
A20-HS. A possible explanation for this is that the anti-IgM and anti-Fc antibodies 
are having a slightly toxic effect on these cells which is enough to effect antigen 
uptake such as that required for aggrecan presentation, but not sufficient to effect 
surface presentation of p84-103 that does not require uptake. 
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Figure 3.11 Antigen presentation by A20-1HS and fusion cells 53.28 and 24.14 
in the presence of anti-Ig, Fc and MHCII antibodies. A20-1 HS, or the fusion cells 
53.28 and 24.14 were cultured with aggrecan84-103-specific T cell hybridomas 192 and 200 nM 
deglycosylated aggrecan or 10 nM p84-103 in the presence of graded doses of a) anti-IgG, b) anti-
IgM, c) anti-FcγRII/III or d) anti-MHCII antibodies for 24 h. Cells were killed by freezing at -80oC 
and supernatant was removed for bioassay with CTLL-2 cells.  
3
H thymidine was added for 18 h and 
T cell responses were determined and displayed as 
3
H thymidine cpm +/- SEM. Data are 
representative of triplicate wells and 2 independent experiments. 
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3.2.2.5 Ig characterisation by ELISA. 
Do the fusions secrete aggrecan-specific Ig? 
 
To further test the antigen-specificity of the BCR expressed by the B cell fusions 
53.28 and 24.14, Ig secreted by the fusions into culture supernatant was examined by 
ELISA. Cells were cultured for several days to ensure a high cell density, pelleted by 
centrifugation and the supernatant collected. Initial experiments verified that Ig were 
present in the culture supernatant and detectable by ELISA. However, the Ig detected 
was not able to bind to aggrecan that had been bound to ELISA plates (data not 
shown).  I hypothesised that the Ig detected in the culture supernatant may have a low 
affinity for aggrecan. To overcome this potential problem the Ig present in the 
supernatant was concentrated using vivaspin sample concentrator columns (GE 
Healthcare) and then tested for its ability to bind to aggrecan via ELISA (data shown 
in Figure 3.12.) Results shown in Figure 3.12a confirmed that IgG2a concentrated 
from 24.14 and 53.28 supernatant were detectable on the ELISA plates at higher 
levels than the control (Ig isolated from the anti–aggrecan secreting F1.11 hybridoma 
clone C10.3). However, 24.14 also expresses surface IgM and this was not detected in 
the concentrated supernatant (Figure 3.12 b). Data in Figure 3.12c shows the Ig 
collected from fusion clones did not bind to aggrecan using ELISA (despite their 
concentration in the supernatant being higher than that of the aggrecan-specific hybrid 
C10.3 (Figure 3.12a). Thus, this data demonstrates that the Ig secreted by both fusion 
clones 24.14 and 53.28 is not aggrecan-specific.   
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Figure 3.12 ELISA to determine the antigen-specificity of the 53.28 and 
24.14 secreted Ig. Fusions 24.14 and 53.28 were grown for several days in culture until 
the cells were above optimal density. A20-1 HS supernatant was used as a negative control 
that does not secrete aggrecan-specific Ig. C10.3 anti-aggrecan Ig was used as a positive 
control.  Supernatant was then concentrated by vivaspin sample concentrators and used un-
diluted on ELISA plates coated with either a) 2 μg/ml anti-IgG2a, b) 2 μg/ml anti-IgM or c) 
graded doses of aggrecan. Data is representative of triplicate wells and 2 independent 
experiments. 
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3.2.2.6. Is aggrecan presentation improved due to the extracellular proteinases? 
 Do the fusions secrete proteinases that aid the presentation of aggrecan?  
 
I wanted to investigate whether the observed improvement in aggrecan presentation 
by the fusions was due to the production and secretion of proteinases such as MMPs 
or ADAMTs demonstrated to aid extracellular processing of aggrecan (Cawston and 
Young 2010) (Figure 3.13). To examine this, the fusions were incubated for 24 h 
with a dose of aggrecan (12.5 nM) that is only presented by fusions and not by the 
A20-1 HS cells; supernatant was removed and transferred to wells containing either 
live or paraformaldehyde fixed A20-1 HS cells and T cell hybrids 192. If the fusions 
were processing aggrecan extracellularly then one would expect that after 24 h they 
would have processed the aggrecan sufficiently, so that it could now be presented by 
the A20-1 HS cells without the requirement for further processing. However, to 
ensure that sufficient aggrecan was available for presentation by the A20-1 HS cells, 
following any extracellular proteolysis and uptake by the fusion cells, an additional 
12.5 nM aggrecan was added to wells along with the transferred supernatant. Controls 
included live and fixed A20-1 HS cells incubated with graded doses of aggrecan or 
p84-103 and live A20-1 HS cells incubated with graded doses of supernatant and 25 
nM aggrecan. Data in Figure 3.14 shows that there was nothing in the supernatant 
that could pre-process aggrecan sufficiently to allow presentation by fixed cells. Also, 
there was nothing present in the supernatant such as proteinases or cytokines that 
were able to improve the presentation of a low dose of aggrecan (12.5 nM) by live 
A20-1 HS cells. Positive controls A20-1 HS, live + p84-103, live + aggrecan and 
fixed + aggrecan showed normal dose responses similar to those observed in previous 
experiments. 
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Figure 3.13 Illustration depicting the extracellular processing of aggrecan. 
Aggrecan is processed in vivo by various proteinases such as matrix metalloproteinases (MMP) and A 
disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) (Cawston and Young 2010). 
The cells in grey represent B cells that may secrete proteinases capable of the extracellular processing 
of aggrecan.  
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Figure 3.14 The improvement in presentation by the fusion cells is not due to the 
extracellular processing of aggrecan.  Fusion cells 53.28 were incubated with a low dose of 
aggrecan (12.5 nM) for 24 h. 12.5 nM of aggrecan is efficiently presented by the fusion cells but not A20-
1 HS. Following the 24 h incubation period fusion cells were pelleted and the supernatant was removed. 
Fixed and live A20-1HS cells were incubated with either fusion supernatant (SUP) and an additional 
12.5 nM aggrecan, graded doses of aggrecan or graded doses of peptide p84-103 for 24 h. Cells were 
killed by freezing at -80
o
C and supernatant was removed for bioassay with CTLL-2 cells.  Tritiated 
thymidine was added for 18 h and T cell responses were determined and thymidine cpm displayed as 
3
H 
+/- SEM.  Data is representative of triplicate wells and a single experiment.  
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3.2.2.7 Aggrecan presentation to T cell hybridomas specific for epitopes within the 
G3 domain.  
Do the fusions present an alternative aggrecan epitope more efficiently? 
 
All of the antigen presentation assays thus far were carried out using a previously 
generated (John Robinson) T cell hybridoma 192 that recognises the 
immunodominant T cell epitope 84-103 from the G1 domain of aggrecan. Previous 
studies have demonstrated that BCR mediated uptake can either improve, or impede, 
the presentation of certain T cell epitopes by masking the epitope and preventing 
either its degradation or generation by endosomal proteinases (Simitsek, Campbell et 
al. 1995). I hypothesised that if the BCR of the recently generated B cell fusions were 
also specific for the immunodominant G1 domain, this may impede optimal 
presentation to the 192 T cells due to steric hindrance by the BCR illustrated in 
Figure 3.15. 
Therefore, I aimed to generate aggrecan-specific T cell hybridomas that recognised 
epitopes derived from a region distinct from G1. BALB/c mice were immunized with 
aggrecan and Titremax in the footpad; 10 days later popliteal lymph node cells were 
isolated and re-stimulated in culture with the synthetic peptides spanning either amino 
acids 2373-2387 or 2363-2378 (previously shown to induce T cell responses in mice 
(Buzas, Vegvari et al. 2005). These cells were fused with BW5147 TCR 
/ - 
lymphoma cells and HAT resistant T cell fusions were tested for their ability to 
recognize both aggrecan and the two G3 peptides. 35 positive HAT resistant fusions 
were incubated with APC (J774 macrophages or 53.28/24.14 fusion cells) and graded 
doses of either aggrecan, G3 peptides or p84-103 and T cell activation was measured 
by IL-2 production (not shown). Results showed that when mice were immunized 
with aggrecan all of the resultant T cell population were specific for the dominant 
peptide 84-103 epitope from the G1 region, despite in vitro stimulation with G3 
peptides p2373-2387 or p2363-2378.  
 
Alternately, I took another approach in an attempt to maximize the chances of 
generating T cell hybridomas that recognize epitopes from the G3 region. Mice were 
immunized with the G3 peptides p2373-2387 or p2363-2378 and then re-stimulated in 
vitro with the corresponding peptide. Using this method I generated T cell 
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hybridomas D9
2373-2387 
and D11
2363-2378 
that respond to both of these epitopes (data 
shown in Figure 3.16a.) However, these G3 specific T cell hybridomas do not 
recognize whole aggrecan (Figure 3.16b), implying that either the G3 epitopes are 
cryptic and are not generated by the APC, or that the T cells will only respond when 
the aggrecan is given in its pre-processed form as peptide. Indeed, previous studies 
have shown that a subset of T cells known as type B T cells will only recognise 
antigen in a peptide form that is subsequently loaded onto MHC class II molecules in 
a different conformation to that of antigens processed within the endosomal 
compartments of the APC (Pu, Lovitch et al. 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 Aggrecan structure masked by an aggrecan G1 specific BCR. 
Aggrecan G1 specific BCR represented in grey, bound to the G1 domain of aggrecan may impede 
processing and presentation of G1 derived peptides by physically preventing the access of endosomal 
proteinases to the G1 domain figure modified from  (Hardingham, Fosang et al. 1994). 
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Figure 3.16 G3 specific T cell hybridomas fail to recognize APC processed 
aggrecan. A20-1 HS, or the fusion cells 24.14 and 53.28 (5x104) were cultured with aggrecan2373-2387 
(D11) or 2363-2378 (D9) specific T cell hybridomas (5x10
4
)  in the presence of graded doses of a) peptides 
p2373-2387 or p2363-2378 or (b) aggrecan for 24 h. Cells were killed by freezing at -80
o
C and 
supernatant was removed for bioassay with CTLL-2 cells. Tritiated thymidine was added for 18 h and 
T cell responses were determined and displayed as 
3
H thymidine cpm +/- SEM. Data are 
representative of three experiments.   
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3.2.3 Alternate immunisation and fusion protocols. 
 
3.2.3.1 CD40L transfectants to improve B cell isolation prior to fusion. 
Human CD40L- activated B cells can be successfully expanded for long periods of 
time in vitro (Schultze, Michalak et al. 1997; Coughlin, Vance et al. 2004). In 
addition, it was documented in 2008 that ex vivo murine antigen-specific B cells could 
be generated by hyper-immunising mice with NP-BSA then expanded in vitro by co-
culture with CD40L transfectants and recombinant IL-4 (rIL-4) in the presence of 
cyclosporine A (CsA) to eliminate the T cell population (Ahmadi, Flies et al. 2008).  
 
I attempted to repeat this finding in order to expand and improve the viability of B 
cells from aggrecan-immunized mice prior to fusion. To do this murine CD40L 
transfected L cells were grown in monolayers and cultured with splenocytes in the 
presence of rIL4 and CsA. Cells were harvested at various timepoints, tested for 
viability using trypan blue exclusion and the percentage of B220
+
 B cells was 
determined by flow cytometry. Controls for this experiment included splenocytes co-
cultured with CD40L expressing monolayers only, monolayers with IL-4 only and 
monolayers with CsA only. In addition, the same conditions were repeated using 
untransfected L cells (data is shown in Figure 3.17). Results from two independent 
experiments revealed an initial increase in the % of B cells after 4 days when co-
cultured with CD40L monolayers, CsA and IL-4 (Figure 3.17a). However, following 
this period the B cell population began to steadily decline and after 12 days in culture 
the isolated B cell population had completely lost viability. B cells co-cultured with L 
cells only, either in the presence or absence of CsA and IL-4 began to steadily decline 
after day 1 in culture (Figure 3.17b). Observations from the trypan blue exclusion 
confirmed that the entire isolated splenocyte population became decreasingly viable in 
the days following isolation in line with the decreasing B cell population.  
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Figure 3.17 Splenic B cells could not be expanded in vitro by activation 
with CD40L and rIL-4. Splenocytes were co-cultured in duplicate wells for 12 days 
with either irradiated a) CD40L-transfected L cells or b) untransfected L cells as a 
negative control. Cyclosporine A was added to eliminate the T cell population. Duplicate 
wells were harvested at days 4, 8 and 12 and percentage of B220
+
 cells was determined 
by flow cytometry. Data represents the total percentage of B220
+
 B cells in culture at 
various timepoints. Data is representative of  2 independent experiments. 
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3.2.3.2 An alternate set of parameters for B cell fusion were carried out with slight 
adjustments made to the immunisation protocol 
 In a separate attempt to improve the aggrecan-specific population of B cells prior to 
fusion, three changes were made to the immunisation protocol. 
 
1. An alternative immunogenic adjuvant was used. In the previous immunisation 
protocol the adjuvant used was alum (aluminium hydroxide). Alum is used to 
deposit the antigen when injected and prevent its rapid catabolism and is a safe 
choice for the intraperitoneal injections required for the final antigen boost to 
localise the reaction to the spleen. However, it may not be sufficiently 
immunogenic for this antigen. Therefore, for this protocol the adjuvant used 
for initial immunisations into the flank was Titermax which is a water-in-oil 
adjuvant that consists of squalene, an emulsifier, a patented block copolymer 
and microparticulate silica. Titermax is reported to be less toxic than the 
immunogenic adjuvant freunds complete adjuvant and yet stimulates an equal 
or greater antibody response (Stills 2005). As adjuvants can control Ig isotype 
and efficiency of antigen-specific response (Stills 2005), I thought it important 
to adapt the immunisation protocol and test a different routinely used 
immunogenic adjuvant. However, the final intra-peritoneal immunisation had 
to be given in alum as the mice became ill after intra-peritoneal immunisations 
with Titremax.  
2. I hypothesised that following an initial full dose immunisation of aggrecan in 
Titremax; subsequent immunisations with a 10-fold reduced dose of aggrecan 
may boost a higher affinity population of B memory cells. Reducing the 
amount of aggrecan with each boost may selectively expand B cells 
expressing a high affinity BCR that is able to recognise small doses of 
immunising aggrecan. To test this theory, mice were immunized initially into 
the flank with a full dose of aggrecan (166 µg) in Titremax followed by two 
subsequent immunizations at 16.6 µg and 1.66 µg respectively. The mice were 
given a fourth final intra-peritoneal boost of aggrecan (166 µg) in alum and 
splenocytes were isolated after 5 days. 
3. In order to be efficient at presenting antigen B cells must take up antigen via 
its antigen-specific BCR and receive co-stimulatory signals from a cognate T 
cell. In addition to this it has been shown by several groups that B cells must 
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receive a third stimulatory signal or „danger signal‟ via pattern recognition 
receptors such as LPS via TLR4. This ensures that the B cells isolated from 
the aggrecan-immunized mice were fully activated and primed to present 
aggrecan to T cells prior to fusion.  In an attempt to stimulate the aggrecan-
specific B cells prior to fusion, cells were cultured with 50 µg/ml 
deglycosylated aggrecan and 50 µg/ml LPS for 48 h before fusing to A20-1HS 
cells.  
 
46 resultant colonies were screened for their ability to present both aggrecan and p84-
103 to the T cell hybridoma 192 using the antigen presentation assays described in 
section 2.12.2 and by flow cytometry for cell surface MHC class II expression. 
Results from representative fusions CW31, CW1, and CW36 are shown in Figure 
3.18. Results revealed that fusions which presented aggrecan more efficiently than the 
A20-1HS fusion partner, also presented peptide more efficiently and showed 
increased MHC class II cell surface expression. These data indicate that although 
several of the fusions generated using this protocol were more efficient at presenting 
aggrecan to the T cell hybridoma 192 this improvement was probably due to 
increased availability of peptide/MHC class II complexes and not due to aggrecan-
specific BCR expression.  
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Figure 3.18 Antigen presentation by fusions generated from 
immunization protocol 2. A20-1 HS or the fusion cells CW1, CW31 and 
CW36 were cultured with aggrecan84-103-specific T cell hybridomas 192 in the 
presence of graded doses of deglycosylated aggrecan or p84-103 for 24 h. Cells 
were killed by freezing at -80
o
C and supernatant was removed for bioassay with 
CTLL-2 cells.  Tritiated thymidine was added for 18 h and T cell responses were 
determined and displayed as 
3
H thymidine cpm +/- SEM. The histograms represent 
cells stained with anti-MHCII antibodies conjugated with PE. The blue histogram 
represents the gated A20-1 HS cell population and the red histogram represents 
different fusion populations. All experiments were carried out at 4
o
C in the 
presence of Fc block. Mean fluorescence intensity values are shown below each 
histogram. Data are representative of three experiments. The asterix represents 
statistical significance determined by students T test where p<0.05. 
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3.3 Discussion 
The aims of this chapter were to generate aggrecan-specific B cells and to assess their 
potential as antigen presenting cells. The generation of aggrecan-specific B cells 
would enable me to assess their role in presenting the candidate rheumatoid arthritis 
autoantigen aggrecan to T cells. Detailed molecular studies could then be performed 
such as how aggrecan is processed by the B cells and how efficiently it is presented in 
comparison to presentation by dendritic cells or macrophages. In this chapter I have 
generated several B cell fusions from aggrecan-immunized mice. These B cell fusions 
have been characterised by flow cytometry to phenotype the BCR that were 
expressed, to assess levels of cell surface MHC class II expression and levels of the 
co-stimulatory molecules B7.1 and B7.2 (Pentcheva-Hoang, Egen et al. 2004). 
Subsequently, the fusion cells were also screened using antigen presentation assays to 
measure their efficiency of aggrecan presentation to several aggrecan-specific T cell 
hybridomas.  
Representative fusions 24 and 53 were selected as potential aggrecan-specific B cells 
and the results obtained using these are discussed below. 
 
3.3.1 Fusion 24  
Flow cytometry analysis showed the expression of a new BCR H chain isotype on 7 
of the fusion cells. All 7 fusions expressed a BCR of the IgM phenotype in addition to 
the IgG2a isotype BCR inherited from the A20-1 HS fusion partner. This data 
suggests that the new IgM BCR inherited from the B cell isolated from the aggrecan-
immunised mice may confer aggrecan-specificity. However, only fusion 24 presented 
aggrecan more efficiently when compared to aggrecan presentation seen by the fusion 
partner A20-1HS. In the early stages of B cell differentiation class switching of the H 
chain constant region occurs by DNA recombination where a functional VDJ unit is 
switched from 1 constant region to another (Harriman, Volk et al. 1993). The 
predominant class of the early response is IgM, hence IgM antibodies / IgM+ BCR 
are generally not as high affinity as the subsequently predominant isotype IgG (Berek 
and Milstein 1988). This may provide an explanation as to why there was only a 10-
fold increase in the efficiency of deglycosylated aggrecan presentation by fusion 24. 
Several groups have previously shown B cell antigen presentation to be improved by 
10,000-fold when the B cell expresses an antigen-specific BCR (Lanzavecchia 1985; 
Knight, Lucocq et al. 1997; Batista and Neuberger 1998). However, these previous 
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studies involved antigen presentation experiments using the small model antigens 
TTCF (50 kDa) and HEL (14 kDa). In this study I used the candidate autoantigen 
aggrecan (250 kDa); this antigen is much larger, is highly glycosylated and is able to 
form large aggregates in the presence of small amounts of hyaluronan (Dudhia 2005).  
Therefore, processing and presentation of this complex molecule may never be as 
efficient as that seen with HEL or tetanus toxin. In addition, my findings concur with 
Leroux et al and Glant et al  that show the multiple glycosaminoglycans hinder 
presentation of the 84-103 epitope and efficiency of aggrecan presentation by fusions 
was much improved following deglycosylation (Leroux, Guerassimov et al. 1996; 
Glant, Buzas et al. 1998). 
 
It is possible, that due to the complex nature of this antigen, fusion 24 may well be 
aggrecan-specific but its low affinity IgM BCR is not sufficient for optimal uptake 
and presentation of aggrecan. An alternate explanation for the observed improvement 
in presentation would be that fusion 24 expresses increased levels of MHC class II. 
Therefore, these cells are equipped to present more aggrecan peptide/ MHC class II 
complexes to the T cell hybridomas improving the efficiency of presentation. 
Although, the levels of B7.1 and B7.2 were found to be higher on fusion 24 than the 
A20-1 HS cells, this may not be a contributing factor to the observed improvement in 
presentation as T cell hybridomas 192 are already primed and should not require 
further stimuli via CD28. Further attempts to verify the specificity of the BCR 
expressed by fusion 24 included ELISA to detect the Ig secreted by the fusions and to 
test its ability to bind to aggrecan. In addition, flow cytometry was used to determine 
if biotinylated aggrecan bound to the surface of these cells. ELISA data revealed that 
IgM is not secreted by fusion 24 so I could not verify whether this was aggrecan-
specific or not. Data from the flow cytometry experiment revealed that aggrecan 
could not be detected binding to the surface of fusion 24. However, there is no 
positive control for this experiment and if the BCR expressed by fusion 24 is 
aggrecan-specific but of low affinity, then this method may not be sensitive enough to 
determine the specificity of the BCR. Therefore, experiments to verify that fusion 24 
is an aggrecan-specific B cells were inconclusive. 
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3.3.2 Fusion 53 
Findings from flow cytometry experiments revealed that fusion 53 expresses a BCR 
of the IgG2a isotype only. As IgG2a is also expressed by the A20-1 HS fusion 
partner, it is not possible to tell from this data whether fusion 53 expresses a new 
aggrecan-specific IgG2a BCR or whether this BCR is simply inherited from the A20-
1 HS cell. IgG2a isotype BCR are generally of a higher affinity than IgM and 
represent events later in the immune response (Berek and Milstein 1988). Therefore, I 
would expect an aggrecan-specific IgG2a BCR to have a higher affinity for aggrecan 
than an IgM BCR and if fusion 53 is aggrecan-specific then it should present aggrecan 
more efficiently than fusion 24. However, this was not the case and fusion 53 presents 
both deglycosylated and glycosylated forms of aggrecan at comparable doses to that 
of fusion 24. An alternate interpretation of the data is that fusion 53 can present 
aggrecan as efficiently as fusion 24 despite expressing much lower levels of MHC 
class II. Therefore, uptake and processing may be more efficient when aggrecan is 
taken up via an IgG2a isotype BCR but presentation to T cells is less efficient due to a 
lower number of peptide/MHC class II complexes expressed on the cell surface of 
fusion 53. Attempts to isolate secreted Ig from fusion 53 and verify its antigen-
specificity by ELISA were unsuccessful. Although levels of IgG2a isotype Ig were 
detected in the supernatant from these cells, I could not detect aggrecan-specificity 
using ELISA. However, this data is still inconclusive as it was not possible to 
determine whether the secreted Ig was inherited from the A20-1 HS cells or inherited 
from the B cell isolated from the aggrecan immunized mice. I have confirmed that 
cultured A20-1 HS cells do secrete their IgG2a Ig into the supernatant and that this is 
detectable by ELISA. Therefore, it is possible that only the A20-1 HS Ig and not 
fusion 53 Ig can be phenotyped by ELISA. Despite the possibility that fusion 53 may 
express a BCR of a higher affinity than fusion 24, I also failed to detect biotinylated 
aggrecan binding to the surface of the fusion 53 cells using flow cytometry. 
Therefore, attempts to verify that fusion 53 is an aggrecan-specific B cell were again 
inconclusive. 
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3.3.3 Problems with verifying the specificity of the fusion BCR. 
One of the weaknesses of this system is the lack of T cell hybridomas recognising 
peptides derived from different regions of aggrecan. As I have described earlier 
aggrecan is a large complex molecule and yet the immune response is almost entirely 
focussed around the G1 domain (Karopoulos, Rowley et al. 1996; Leroux, 
Guerassimov et al. 1996; Zhang, Guerassimov et al. 1998; Li, Zhang et al. 2000). 
Previous studies have shown that when a BCR binds its antigen it can mask this 
region and may directly negatively or positively influence proteolysis once taken up 
inside the B cell. Therefore, if the BCR expressed by the fusions recognises an 
epitope in the G1 domain then it is possible that the region encompassing amino acids 
84-103 is masked, thus preventing the generation of p84-103 for optimal T cell 
hybridoma 192 recognition. To overcome this possibility I attempted to generate T 
cell hybridomas that recognise peptides from an area distinct from G1 (G3). Attempts 
to generate T cell hybridomas that recognised epitopes within the G3 domain resulted 
in the generation of hybridomas that recognise G3 epitopes only when administered in 
their peptide form but not when derived from whole aggrecan. In addition, the 
majority of hybridomas generated from aggrecan-immunized mice responded to the 
peptide p84-103. Therefore, in accordance with previous studies, T cell responses 
were very much focussed around the G1 domain and the generation of alternative T 
cell hybridomas was unsuccessful at establishing the specificity of the B cell fusions. 
 
Another attempt to verify that the fusions express an aggrecan-specific BCR was to 
block aggrecan binding to the BCR using polyclonal anti-IgG2a or anti-IgM 
antibodies. Fusion cells or A20-1 HS were incubated with the antibodies prior to 
incubation with aggrecan or p84-103. If the fusions express an aggrecan-specific BCR 
then prior incubation with anti-Ig antibodies would be expected to inhibit BCR-
improved uptake, processing and presentation of aggrecan (Casten, Lakey et al. 
1985). However, the antibodies should not have any effect on peptide presentation, as 
p84-103 is pre-processed and does not require uptake via the BCR. As expected, 
when anti-MHCII antibodies were added to the antigen presentation assays, 
presentation of both aggrecan and p84-103 was inhibited. However, the inclusion of 
either anti-IgG2a or anti-IgM antibodies did not have any effect on aggrecan 
presentation by the fusions. One possible explanation for this is that these isotype-
specific antibodies are binding to the extracellular constant domain of the BCR and 
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not to the Fab, antigen binding domain and hence do not interfere with aggrecan 
binding or uptake. In conclusion, in the absence of a positive control to show that the 
antibodies are capable of blocking BCR mediated antigen uptake it was not possible 
to draw a positive conclusion from this experiment.  
 
3.3.4 Subsequent fusions. 
Several attempts were made to generate fusion cells following various modifications 
to the immunisation protocol. These included the use of a different adjuvant to 
improve the immune response to aggrecan, immunisation with different aggrecan 
doses to improve the affinity of the B cells prior to isolation and fusion, isolating cells 
at different timepoints after the final aggrecan boost and incubating the ex vivo cells 
with aggrecan and LPS prior to fusion. In addition, Ahmadi et al reported that a 
.population of antigen-specific B cells could be boosted in vitro by culturing the cells 
with CD40L expressing cells in the presence of CsA and IL-4 (Ahmadi, Flies et al. 
2008). I attempted to repeat this result but found that the ex vivo B cells began to lose 
viability after a few days in culture. I also, tried to modify the protocol slightly by 
altering the number of CD40L cells used to produce the co-culture monolayer. 
However, I concluded from these experiments that the isolated B cells were in optimal 
condition when freshly isolated.  The fusion with A20-1 HS cells produced 
considerable cell death and isolated cells must be in optimal condition for successful 
hybridoma generation. Therefore, isolated B cells cultured in this manner were not 
used for fusion or antigen presentation experiments.   
 
3.3.5 B cells isolated from aggrecan-immunized mice used directly in antigen 
presentation experiments. 
The generation of aggrecan-specific B cells was fundamental to this study and I was 
unable to study the molecular mechanisms of aggrecan processing presentation by B 
cells in comparison to other APC. The generation of aggrecan-specific fusions was 
hampered by various technical difficulties and time restraints limited screening of 
multiple batches of fusions. Therefore, this approach for the generation of aggrecan-
specific B cells was not pursued any further.  
 
In a separate attempt to generate aggrecan-specific B cells from mice hyper-
immunized with aggrecan, splenic B cells were isolated using magnetic Microbeads 
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attached to anti-CD43 antibodies. This anti-CD43 isolation is a negative selection 
technique designed to isolate splenic B cells from a population of CD43+ cells (CD43 
is expressed on all leukocytes with the exception of mature B cells) (Miltenyi, Muller 
et al. 1990). The isolated CD43- cells were verified as B220+ cells by flow cytometry 
and used directly in an antigen presentation assays along with LPS to activate the B 
cells, aggrecan or p84-103 and T cell hybridomas 192. A20-1 HS cells or B cells 
isolated from mice immunized with TTCF were used as comparison APC to B cells 
from aggrecan immunized mice. Although, an initial experiment demonstrated that B 
cells isolated from aggrecan–immunized mice showed a 10-fold improvement in 
aggrecan presentation when compared to the other APC, subsequent results were 
variable. Initial work to generate an aggrecan-specific BCR in vitro and transfect it 
into A20-1HS cells to generate stable transfectants looked promising. Therefore, 
focus was moved to Chapter 4 generation of aggrecan-specific B cells by transfection 
of a B cell line with constructed plasmids encoding an aggrecan-specific BCR. 
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3.4 Summary of chapter 3. 
 Several cell lines and clones were generated by fusing B cells from aggrecan-
immunized mice with the HAT sensitive myeloma cell line A20-1 HS in an 
attempt to generate immortalized aggrecan-specific B cells. 
 
 All cell lines were analysed by flow cytometry and tested for their ability to 
present aggrecan to the aggrecan-specific T cell hybridomas 192 in 
comparison to the B lymphoma fusion partner. Several of the fusions tested, 
presented aggrecan (both the glycosylated and the de-glycosylated forms) at 
least 10-fold better than the fusion partner alone.  I have established that the 
newly generated cells consistently present the different forms of aggrecan 
more efficiently than the fusion partner. Fusions 24.14 (IgM) and fusion 53.28 
(IgG2a) are amongst those fusions that consistently present more efficiently 
than the A20-1 HS cells and were chosen for further studies.  
 
 I have carried out an extensive series of experiments to determine if the 
observed improvement in aggrecan presentation was due to the expression of 
an aggrecan-specific BCR. Unfortunately, none of these data have confirmed 
that the newly generated fusions express an aggrecan-specific BCR. 
 
 
 
 
 
 
 
 
 
 
 
 134 
4. Generation of aggrecan-specific B cells by stable transfection of a 
B cell line with constructed plasmids encoding an aggrecan-specific 
BCR. 
4.1 Introduction 
Previous studies have manipulated immunoglobulin (Ig) structure to examine the 
effects on antigen processing and presentation (Knight, Lucocq et al. 1997; O'Neill, 
Shlomchik et al. 2005) and to generate chimeric and/or humanized Ig for use as 
therapeutics (Senolt, Vencovsky et al. 2009; Beck, Wurch et al. 2010). 
 
Therefore, as part of a complimentary approach for the generation of aggrecan-
specific B cells, I wanted to generate an aggrecan-specific BCR by replacing the 
variable region of the heavy chain (VH) and variable region of the light chain (VL) 
from an existing membrane-bound tetanus toxin c fragment (TTCF)-specific BCR 
(Knight, Lucocq et al. 1997) with VH and VL from a newly generated mouse anti-
bovine aggrecan mAb. This would result in an aggrecan-specific BCR that could be 
transfected into the A20-1 HS cell line to generate an aggrecan-specific stable B cell 
line. As the existing TTCF BCR constructs contained the entire Ig sequence isolated 
from an Epstein Barr Virus (EBV) clone 11.3 (Lanzavecchia 1985), this would create 
a chimeric BCR comprising  mouse V region/human C region sequences; an approach 
that has previously been reported (Sahagan 1990; Fan and Leong 2007; Beck, Wurch 
et al. 2010). 
 
In order to generate the aggrecan-specific BCR constructs, I had to first isolate 
cDNAs encoding the VH and VL regions from anti-aggrecan monoclonal antibodies 
for which the sequences are not known. Doenecke et al successfully amplified VH 
and VL sequences from the 5‟ end of cDNA using rapid amplification of cDNA ends 
(RACE) illustrated in Figure 2.1. To verify that this procedure was reproducible, I 
repeated their experiment to isolate the VH cDNA from A20-1 B lymphoma cells and 
confirmed that the isolated sequence was identical to their published data (Doenecke, 
Winnacker et al. 1997).  
Subsequently, using the RACE protocol, I amplified the cDNA encoding the V 
regions of the H and L chains from two independent anti-aggrecan monoclonal 
antibodies. The first monoclonal antibody C71 originated from a heterogeneous 
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population of aggrecan-specific B cell hybridoma (F1.11), generated by A Knight and 
John Robinson prior to the start of this project. The second monoclonal antibody was 
derived from a B cell hybridoma 1-C-6 that recognizes epitopes in the G1 and G2 
domains of reduced and alkylated aggrecan, kindly donated by Dr Bruce Caterson 
(Stevens, Oike et al. 1984; Fosang and Hardingham 1991).  In order to generate an 
aggrecan-specific BCR, I removed the V regions from the plasmids pMCFR TTCF-H 
NI encoding the membrane-anchored TTCF-specific H chain and pMCFR TTCF-L 
hyg encoding the TTCF-specific L chain and replaced them with the C71 and  1-C-6 
aggrecan-specific VH and VL regions respectively.  
 
The plasmids encoding the aggrecan-specific BCR were then transfected into A20-1 
HS and their expression verified by flow cytometry. Subsequently, these aggrecan-
specific B cells could be used as a model to compare the mechanisms of aggrecan-
processing and presentation by B cells to that of dendritic cells and macrophages. 
 
4.1.2 The aims of this chapter: 
 To generate chimeric plasmids encoding aggrecan-specific Ig H and L chains. 
 To transfect the constructs into the A20-1 HS B cell line. 
 To verify that the new aggrecan-specific BCR were expressed on the cell 
surface of the A20-1 HS transfectants. 
 To examine whether the expression of aggrecan-specific BCR improves the 
presentation of aggrecan to the aggrecan-specific T cell hybridomas in 
comparison to untransfected A20-1 HS cells. 
 To generate aggrecan-specific stable B cell lines that could be utilized for 
further mechanistic studies of aggrecan-processing and presentation by B 
cells. 
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4.2 Results 
4.2.1 Characterization of the monoclonal antibodies C71 and I-C-6. 
4.2.1.1 1-C-6  
I-C-6 Ig (IgG1) (kindly donated by Dr B Caterson) that recognises epitopes within the 
aggrecan G1 and G2 domains and requires antigen reduction and alkylation for the 
best exposure of the amino acid sequence QAAY (Fosang and Hardingham 1991).  To 
verify the specificity of the 1-C-6 Ig, 1-C-6 cells were grown to confluence and the 
cell supernatant was removed and screened by ELISA for binding to both 
reduced/alkylated, and deglycosylated forms of aggrecan (data shown in Figure 4.1). 
Data concurs with previous studies that show 1-C-6 Ig binds the reduced/alkylated 
modified form of aggrecan with a higher efficiency than the deglycosylated form.  
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a) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 ELISA to verify the aggrecan-specificity of the 1-C-6 Ig. 1-C-6 cells were 
grown in 2 litres of culture media until confluent. The cells were pelleted and the supernatant was 
removed. Ig was purified from the culture supernatant on protein G columns and titrated on ELISA 
plates coated with either a) 2 μg/ml reduced and alkylated aggrecan or b) deglycosylated 2 μg/ml 
deglycosylated aggrecan. Wells coated with ELISA coating buffer only were used as negative controls 
on both plates). Data is representative of triplicate wells and 2 independent experiments. 
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4.2.1.2 C71 
C71 is an aggrecan-specific B cell hybridoma clone derived from the F1.11 B cell 
hybridoma population. F1.11 aggrecan-specific hybridomas were generated by fusing 
spleen cells isolated from aggrecan-immunized BALB/c mice with the mIg –ve B 
lymphoma NSO immediately prior to this project. F1.11 supernatant was screened by 
ELISA to verify aggrecan-specificity of the Ig. I subsequently transferred the F1.11 
cells from HAT selection medium into HT and finally into hypoxanthine, aminopterin 
and thymidine free RPMI medium. In order to verify that the F1.11 cell population 
had retained their ability to produce aggrecan-specific antibodies I tested the ability of 
supernatants from these cells to bind deglycosylated, glycosylated and denatured 
forms of aggrecan using an ELISA (Figure 4.2). Results revealed that the antibodies 
produced by F1.11 cells bound the deglycosylated form of aggrecan most efficiently. 
Subsequently, the F1.11 supernatant was titrated alongside a dilution of commercially 
available anti-aggrecan antibody (IgG1) as a positive control and screened by ELISA 
(data shown in Figure 4.3). Results showed that the titrated F1.11 supernatant was 
able to bind aggrecan from dilutions ranging from 1:10 to 1:1000.  
 
The F1.11 hybridomas are a heterogeneous population of cells. Therefore, the 
hybridomas were single cell cloned in order to: 
 Select clones secreting anti-aggrecan antibodies, 
and 
 to determine whether F1.11 cells were polyclonal or monoclonal. 
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Figure 4.2 ELISA to determine the aggrecan-specificity of the F1.11 B cell 
hybridomas. F1.11 cells were grown for several days in culture until confluent. Cells were pelleted 
and the supernatant was removed and used un-diluted on ELISA plates coated with either ELISA 
coating buffer only (control), 2 μg/ml glycosylated aggrecan, 2 μg/ml deglycosylated aggrecan  or  2 
μg/ml deglycosylated aggrecan that has been denatured by boiling at 95oC for 10 min. Data is 
representative of triplicate wells and 2 independent experiments. 
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Figure 4.3 ELISA to determine the aggrecan-avidity of the F1.11 Ig. F1.11 cells 
were grown for several days in culture until confluent. Cells were pelleted and the supernatant was 
removed and titrated on an ELISA plate coated with 2 μg/ml deglycosylated aggrecan. Anti-aggrecan 
IgG1 (Serotec) was titrated alongside the F1.11 supernatant as a positive control. Data is 
representative of duplicate wells. 
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In order to clone sequences encoding VH and VL regions that bind aggrecan, I had to 
be confident of a monoclonal single population of cells containing a single VH and 
VL sequence. Therefore, 104 F1.11 single cell clones were generated by limiting 
dilution and the specificity of their secreted Ig was determined by ELISA to identify 
differences in aggrecan binding. 24 out of the 104 F1.11 clones were positive for 
aggrecan binding, yet no significant differences were observed in apparent affinity or 
judged by strength of signal (OD 450 nm). To determine if there were any differences 
between the 24 positive Ig in their ability to bind different forms of aggrecan, I tested 
their binding to deglycosylated, glycosylated and denatured aggrecan. Data shown in 
Figure 4.4 shows that supernatants uniformly bound most efficiently to 
deglycosylated aggrecan. Surprisingly, the binding efficiency was not significantly 
affected by boiling the aggrecan. However, all 24 F1.11 Ig bound to the glycosylated 
form of aggrecan less efficiently implying that the Ig epitope could be masked by 
glycosylation. In a further attempt to identify differences between the Ig secreted by 
the 24 F1.11 clones, the H chain isotype and L chain usage was determined by ELISA 
(not shown). Data revealed no differences between the 24 Ig, all were identified as 
IgG1
+, κ+.  
 
Identifying differences in the specificity of the F1.11 clones Ig would be indicative of 
the presence of individual different clones and may have enabled the generation of B 
cells expressing aggrecan-specific BCRs that recognize different epitopes within the 
aggrecan structure, possibly with different affinities and avidities. By generating a 
panel of different aggrecan-specific B cells I could examine the effects BCR binding 
has on how efficiently the p84-103 epitope is generated and presented to the T cell 
hybridoma 192. However, taken together the results revealed that there were no 
obvious differences observed between the 24 F1.11 clones.   
Therefore, the C71 hybridoma clone was selected as representative of the 24 F1.11 
positive clones detailed above.  Data verifying the aggrecan-specificity of C71 Ig by 
ELISA is shown in Figure 4.5. However, the region of aggrecan bound by C71 Ig is 
not known. 
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Figure 4.4 ELISA to determine the aggrecan-specificity of the 24 F1.11 clones Ig. 
Clones 1-24 (C71 clone 2) were grown for several days in culture until confluent. The cells were 
pelleted and supernatants were removed and used neat on ELISA plates coated with either ELISA 
coating buffer only, 2 μg/ml glycosylated aggrecan (GAg), 2 μg/ml deglycosylated aggrecan (DAg) or 
2 μg/ml deglycosylated aggrecan that has been denatured by boiling at 95oC for 10 min (Denat DAg). 
Data is representative of 2 independent experiments. 
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a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 ELISA to verify the aggrecan-specificity of purified Ig from the F1.11 
clone C71 Ig. C71 cells were grown in 2 litres of culture media until confluent. The cells were 
pelleted and the supernatant was removed. Ig was purified from the culture supernatant on protein G 
columns and titrated on ELISA plates coated with either a) 2 μg/ml deglycosylated aggrecan or b) 2 
μg/ml reduced and alkylated deglycosylated aggrecan. Wells coated with ELISA coating buffer only 
were used as negative controls on both plates. Data is representative of triplicate wells and 2 
independent experiments. 
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4.2.2 Amplification and sequencing of the C71/1-C-6 VH and VL regions.  
 cDNAs encoding the VH and VL regions from the two aggrecan-specific monoclonal 
antibodies (C71 and 1-C-6) were successfully isolated using the RACE procedure 
detailed in section 2.13.4.  Gene-specific primers (GSP1 and GSP2) for both the IgG1 
H chain and kappa L chain of murine Ig were designed based on published sequences 
(Doenecke, Winnacker et al. 1997). First strand cDNA was synthesized from C71 and 
1-C-6 total RNA using reverse transcriptase and the primers, GSP1 (H chain 5'-
ATTTTGTCGACCKYGGTSYTGCTGGCYGGGTG-3' and (L chain 5'-
TTTGGGGTAGAAGTTGTT-3').  cDNA was purified to remove excess nucleotides 
and GSP1 and tailed using TdT.  Tailed cDNA was amplified by PCR using the GSP2 
nested primers (H chain 5'-GCACACYRCTGGACAGGGATCCAGAGTTCC-3' and 
(L chain 5'-TAACTGCTCACTGGATGGTGGGAAGATGGA-3') and an abridged 
anchor primer (5'-GGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG-3') which 
contains a 3‟ sequence complementary to the homopolymeric tail of the TdT tailed 
cDNA.  PCR products were analyzed by agarose gel separation (data shown in Figure 
4.6.) Results show that the C71 and 1-C-6 VH region was successfully amplified at 
around 650 bp and the VL chain region at around 530 bp. 
 
Subsequently, cDNA encoding the C71 and 1-C-6 VH and the VL chain regions were 
purified from agarose gels and ligated into the pCR®-XL-TOPO® vector using T4 
ligase. The ligation mixtures were then transformed into one shot® Top 10 E.coli and 
colonies were selected on ampicillin plates. pCR®-XL-TOPO® vectors containing 
the VH cDNA were isolated by miniprep according to manufacturer‟s instructions. 
The correct VH insert was confirmed by restriction digest with Sac1 and Xho1 
followed by agarose gel separation to confirm a 3.5 kb plasmid vector and 650 bp 
insert. pCR®-XL-TOPO® vectors containing the VL cDNA were isolated and the 
correct insert was verified by restriction digest with EcoR1 followed by agarose gel 
separation to confirm a 3.9 kb plasmid vector and at 526 bp insert.  
 
pCR-XL-TOPO DNA purified from clones containing both VH and VL cDNAs were 
sequenced using the M13 Forward and Reverse primers (M13F 5´-
GTAAAACGACGGCCAG-3´, and M13R 5´-CAGGAAACAGCTATGAC-3´).  
Sequencing revealed 5 independent clones from C71 VH and VL vectors contained 
identical V sequence homology with each other and the conserved framework regions 
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of other published H and L chain sequences. 5 clones containing 1-C-6 VH identical 
regions were also selected (data shown in Figure 4.7).  Aligned sequences of C71, 1-
C-6 and other published H and L chain V regions confirm the integrity of the cDNA 
and that the C71 and 1-C-6 sequences contained similar framework sequences to 
those previously published. Therefore, the next step was to use these amplified C71 
and 1-C-6 V regions to replace those present in pMCFR lymphocyte expression 
vectors described in (Denzin, Robbins et al. 1994) encoding the H and L chains of a 
membrane bound human IgG1 BCR (pMCFR TTCF-H NI and pMCFR TTCF-L 
hyg).  pMCFR TTCF-H NI and pMCFR TTCF-L hyg have been previously shown to 
encode a TTCF-specific BCR and their introduction into B cell lines was 
subsequently shown to improve presentation of TTCF following transfection into B 
cell lines (Knight, Lucocq et al. 1997). Therefore, I hypothesised that exchanging the 
TTCF-specific V regions for aggrecan-specific V regions should enable generation of 
plasmid constructs encoding aggrecan-specific BCR H and L chains for stable 
transfection in A20-1 cells. 
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a) 
 
 
 
b) 
 
      
 
 
Figure 4.6 Agarose gels showing PCR amplified cDNA encoding the V regions 
from the a) H and b) L chains of both the 1-C-6 and C71 anti-aggrecan 
antibodies. Both 1-C-6 and C71 H and L chain V regions were PCR amplified and separated by 
agarose gel (1%) electrophoresis to verify a correct size PCR product of approximately 650 bp (H 
chain) and 530 bp (L chain). on far right shows the migration of molecular weight markers (phiX 174 
HaeIII). 
 
 
 
1-C-6        C71 
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Figure 4.7 C71 and 1-C-6 VH and VL chain sequence alignments. Plasmids encoding C71 and 1-C-6 VH and VL regions were sequenced using the 
universal M13 F and R primers (Cogenics). Sequences were aligned using framework (FR) and complimentary determining regions (CDR) from previously published 
monoclonal antibody sequences 11.3 (human) (Knight, Lucocq et al. 1997), H5 (mouse) (Hackett, Hoff-Velk et al. 1998), H7 (mouse) (Park, Jin et al. 2000), 17-1A (mouse 
(Sun, Curtis et al. 1987), A34L (mouse) (Kwak, Lee et al. 1996).
H chain amino acid alignment 
        
      Leader                FR1       CDR1           FR2                                      
1-C-6 MAVLVLFLCLVAFPSCVLS  QVQLKESGPGLVAPSQSLSITCTVSGFSLT SYGVH         WVRQPPGKGLEWLG   
C71  MAVLVLFLCLVAFPSCVLS  QVQLKESGPGQVAPSQSLSITCTVSGFSLT TFGVH         WVRQPPGKGLEWLG     
11.3  MDWTWSILFLVAAATGAHS  QVQLVQSGVEVKKPGASVKVSCKASGYTFS TYGMS         WVRQAPGQGLEWMG 
H5  MGWSWIFLFLLSVTAGVHS  QVHLQQSGAELVRPGTSVKVSCKASGYAFT NYLIE         WVTQRPGQGLEWIG             
H7  MAWVWTLLFLMAAAQSIQA  QIQLVQSGPELKKPGETVKISCKASGYTFT HYPMH         WVKQAPGKSLKWMG  
17-1A MGWSRVFIFLLSVTAGVHS  QVQLQQSGAGLVRPGTSVKVSCKASGYAFT NYLIE         WVKQRPGQGLEWIG  
        CDR2                FR3         CDR3           FR4 
1-C-6 VIWAGGSTNYNSALMS  RLSISKDNSKSQVFLKMNSLQTDDTAMYYCAR  DQGYGNGGFAY   WGQGTLVTVSA 
C71  VIWPGGSTNYNSALMS  RLSISKDNSKRQVFLKMSSLQTDDTAMYYCAR  EGYWFAY       WGQGTLVTVSA 
11.3  WISAYNGNTNYARNFR  GRITMTTDTSTSTAYMELRSLRSDDTAVYYCAR DGRTVRGFQDLDY WGQGTLVTVSS 
H5    VINPGSDFTYYNEKFKG RATLTADKSSSTAYMQLTSLTSDDSAVYFCAR  TIVTTDYFDY    WGQGTPLTVSS 
H7    WINTKSGVPTYADDFKG RFAFSLETSASTACLQITNLKNEDMATYFCVR  GGLYYDYFYGVDY WGQGTSVTVSS 
17-1A VINPGSGGTNYNEKFKG KATLTADKSSSTAYMQLSSLTSDDSAVYFCAR  DGPWFAY       WGQGTLVTVSA                
              
 
 
 
 
 
 
 
  
                       
L chain amino acid alignment 
 
          Leader                FR1             CDR1            FR2               
1-C-6 MKLPVRLLVLMFWIPASSS    DVVMTQTPLSPVSLGDQASISR  SSQSLVHSNGNTYLH   WYLQKPGQSPKLLIY  
C71   MDFHVQIFSFMLISVTVIL  SSGEIVLTQSPALMAASPGEKV  ITCSVSSSISSSNLH   WYQQKSETSPKPWIY    
H5     MESDTLLLWVLLLWVPGSTG DIVLTQSPASLAVSLGQRATISC RASESVSIRGAGLMH   WYQQKPGYPPKLLIY               
17-1A MESQTLVFISILLWLYGADG NIVMTQSPKSMSMSVGERVTLTC KASQNVVTYVS       WYQQKPEQSPKLLIY                 
H7                         DVVMTQTPLTLSVTIGQPASISC KSSQSLLDSDGETYLN  WLLQRPGQSPKRLIY   
A34L                       DVLMTQTPLSLPVSLGDQASISC RSSQSIVHTNGNTYLE  WYLQKPGQSPKLLIY   
CDR2                      FR3                   CDR3       FR4 
1-C-6     KVSNRFS      GVPDRFSGSGSGTDFTLKISRVEAEDLGVYFC   SQSTHVPP  FGGGTKLEIK 
C71       GTSNLAS      GVPVRFSGSGSGTSYSLTISSMEAEDAATYYC   QQWSTYPLT FGGGTKLEIK 
H5        AASNLES      GVPARFSGRGSGTDFTLNIHPVEEADAATYFC   QQSRRYPYT FGSGTKLEIK 
17-1A     GASNRYT      GVPDRFTGSGSATDFTLTISSVQAEDLADYHC   GQGYSYPYT FGGGTKLEIK 
H7        MVSKLDS      GVPDRFTGSGSGTDFFFTLKISRVEAEDLGVYYC WQGTHFPT  FGSGTKLEIK 
A34L      KVSNRFS      GVPDRFSGSGSGTDFTLKISRVEAEDLGVYYC   FQGSHVPRT FGGGTKLEIK 
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4.2.3 Generation of H chain plasmid constructs pMCFR C7.1/ 1-C-6 NI. 
In order to generate constructs encoding a membrane-bound Ig H chain containing aggrecan-
specific V regions, the next step was to remove the TTCF- specific V region from the 
pMCFR TTCF-H NI plasmid by restriction digestion. 
 
To do this restriction sites Apa1 and Kpn1 were identified 5‟ of sequence encoding TTCF VH 
region and 3‟ of the VH open reading frame (ORF) respectively. However, the digest was 
complicated as the sequence of the pMCFR NI vector is not known. The plasmid pMCFR 
TTCF-H NI was digested with the enzymes Apa1 and Kpn1 followed by agarose gel 
separation. Restriction digest confirmed that the plasmid had digested into several bands 
indicating that it contained more than the one Apa1 site found in the TTCF cDNA. Upon 
further inspection of the TTCF VH and its flanking constant region sequences I attempted to 
remove the V region from the pMCFR TTCF-H NI vector using several different restriction 
enzyme combinations. However, I was unable to find a combination that would allow me to 
remove the V region without digesting the vector. Therefore, as Apa1 had been identified as 
an ideal restriction site with which to remove the V region and a small stretch of sequence 
encoding a few nucleotides from the 5‟ C region, I decided to remove the entire H chain from 
the pMCFR NI vector and ligate it into a vector that was known not to contain an Apa1 site. 
pCMV 2.1 (Invitrogen) was identified as an ideal vector, compatible with the use of an Apa1 
digest to remove the tetanus toxin V region and replace it with cDNA encoding the C71 and 
1-C-6 aggrecan-specific V regions. However, again there were no compatible restriction site 
pairs with which to remove the entire TTCF H chain cDNA from pMCFR NI and ligate it 
directly into the pCMV 2.1 vector. Therefore, the pKS plasmid vector was utilized as a 
vehicle; the H chain cDNA from pMCFR NI was removed using the restriction enzymes 
Kpn1 and Sac1 and ligated with the pKS vector.  
 
Subsequently, cDNA encoding the entire TTCF-specific H chain region was removed from 
pKS (Stratagene) using the enzymes Xho1 and Not1, gel purified and ligated with the vector 
pCMV 2.1 which does not contain an Apa1 site allowing the TTCF V region to be 
subsequently removed without digesting the plasmid vector. The tetanus toxin H chain V 
region only was then removed from the pCMV 2.1 vector by restriction digest with the 
enzymes Xho1 and Apa1. The vector was dephosphorylated using calf intestinal phosphate 
(CIP) to minimize re-ligation and then separated from the TTCF V region by agarose gel 
electrophoresis and gel purification. In parallel, the V regions of C71 and 1-C-6 were 
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amplified from the plasmid DNA pCR 2.1 C71/1-C-6 generated in section 5.3.2 to include 
the restriction sites Apa1 and Xho1. The amplified cDNA was purified from agarose gels and 
ligated into the pCR®-XL-TOPO® vector, transformed into one shot® Top 10 E.coli and 
colonies were selected on ampicillin plates. Plasmids were isolated by miniprep and the 
correct insert was confirmed by restriction digest with Xho1 to linearize the plasmid followed 
by agarose gel separation. Miniprep clones were sequenced using the M13 Forward and 
reverse primers (M13F 5´-GTAAAACGACGGCCAG-3´, and M13R 5´-
CAGGAAACAGCTATGAC-3´). The sequencing results confirmed that the cDNA now 
encodes the 5‟ Xho1 restriction site followed by the entire C71/1-C-6 aggrecan-specific V 
regions, the first few nucleotides of the 5‟ TTCF IgH C region and a 3‟ Apa1 site (data shown 
in Figure 4.8.) Complementary sites in the Xho1 and Apa1 digested pCMV 2.1 vector 
containing the TTCF C region and at the 5‟ and 3‟ ends of the C71/ 1-C-6 V regions now 
enabled the V and C regions to be ligated generating a chimeric mouse V / human C H chain 
sequence.  
 
The pCMV 2.1 vector containing the chimeric H chain was transformed into one shot® Top 
10 E.coli as described previously and colonies were selected on ampicillin plates. Plasmids 
were isolated and amplified by overnight culture followed by maxiprep and the correct 
sequence was verified using the C region primer SEQCH1G3 and the C71/1-C-6 V region 5‟ 
primer including restriction site for Xho1 5'-CTCGAGCCATGGCTGTCCTGGTGCTGTTC-
3'.  
In order to move the newly generated chimeric aggrecan-specific H chain back into the 
lymphocyte expression vector pMCFR NI, the aggrecan-specific H chain was removed from 
the pCMV 2.1 vector by restriction digest with Xho1 and Not 1 and ligated with the pKS 
vector to introduce the restriction sites Kpn1 and Sac1 required for the final ligation with the 
transfection plasmid pMCFR NI. The vector was transformed into one shot® Top 10 Ecoli, 
colonies were selected on ampicillin plates then amplified and isolated as previously 
described. The H chain was then removed from the pKS vector by restriction digest with 
Kpn1 and Sac1 and ligated with the Kpn1 and Sac1 digested pCMFR NI, CIP treated vector. 
This final completed vector was transformed into one shot® Top 10 E.coli and colonies were 
selected on ampicillin plates, amplified and isolated by maxiprep ready for transfection.  
Complete H chain construction is illustrated in Figure 4.9. 
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Heavy chain nucleotide sequencing 
 
C71 VH 
CTCGAGCCATGGCTGTCCTGGTGCTGTTCCTCTGCCTGGTTGCATTTCCAAGCT
GTGTCCTGTCCCAGGTGCAGCTGAAGGAGTCAGGACCTGGCCAGGTGGCGCC
CTCACAGAGCCTGTCCATCACTTGCACTGTCTCTGGGTTTTCATTAACCACCTTT
GGTGTTCACTGGGTTCGCCAGCCTCCAGGAAAGGGTCTGGAGTGGCTGGGAG
TAATATGGCCTGGTGGAAGCACAAATTATAATTCGGCTCTCATGTCCAGACTGA
GCATCAGCAAAGACAACTCCAAGCGCCAAGTTTTCTTAAAAATGAGCAGTCTAC
AAACTGATGACACAGCCATGTACTACTGTGCCAGAGAGGGTTACTGGTTTGCTT
ACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCTGCCTCCACCAAGGGCCC 
 
 
 
 
 
1-C-6 VH 
CTCGAGCCATGGCTGTCCTGGTGCTGTTCCTCTGCCTGGTTGCATTTCCAAGCT
GTGTCCTGTCCCAGGTGCAGCTGAAGGAGTCAGGACCTGGCCTGGTGGCGCC
CTCACAGAGCCTGTCCATCACTTGCACTGTCTCTGGGTTTTCATTAACCAGTTAT
GGTGTACACTGGGTTCGCCAGCCTCCAGGAAAGGGTCTGGAGTGGCTGGGAG
TAATATGGGCTGGTGGAAGCACAAATTATAATTCGGCTCTCATGTCCAGACTGA
GCATCAGCAAAGACAACTCCAAGAGCCAAGTTTTCTTAAAAATGAACAGTCTGC
AAACTGATGACACAGCCATGTACTACTGTGCCAGAGATCAGGGGTATGGTAAC
GGCGGGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCTGCCTC
CACCAAGGGCCC 
 
 
 
Figure 4.8 C71 and 1-C-6 VH regions amplified to include restriction sites. C71 and 1-C-6 
V regions were amplified by PCR to include the restriction sites Xho1, the Kozak sequence and 13 nucleotides 
of the human IgG1 constant region including an Apa1 restriction site. Xho1 site, Kozak sequence (Kozak 1986), 
Human IgG1 constant region, Apa1 site. 
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Figure 4.9 Representation of the pMCFR vector /H chain assembly. The cDNA encoding the 
anti-human TTCF-specific H chain was digested from the plasmid pKSM13 which contains an Apa1 site and 
into the vector pCMV/myc /ER which is Apa1 negative. The cDNA encoding the V region from the TTCF H 
chain (TTCFVH) was removed using Xho1 and Apa1.  1-C-6 and C71 cDNA encoding aggrecan-specific VH 
regions (IC6/C71 VH) were PCR amplified to include Xho1 and Apa1 sites at the 5’ and 3’ ends respectively, 
cloned into the pCR2.1 plasmid and digested using Xho1 and Apa1. IC6/C71 VH cDNA were ligated with the 
digested pCMV/myc/ER vector containing the cDNA encoding the C region from the TTCF-specific H chain 
(hIgG).  The assembled H chain cDNA was digested from pCMV/myc/ER with Xho1 and Not1 and ligated with 
pKSM13 to introduce Kpn1 and Sac1 sites at the 5’ and 3’ ends of the insert respectively. The H chain cDNA 
was digested from pKSM13 with Kpn1 and Sac1 and ligated with the final expression vector pMCFR/NI.  
Plasmids were transformed into E.coli competent cells and cDNA was amplified and isolated at each step by 
maxiprep (Qiagen). 
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4.2.4 Generation of L chain plasmid pMCFR C71/1-C-6 hyg. 
The pMCFR TTCF-L hyg vector contains the TTCF L chain. In order to ligate the TTCF-L 
human kappa C region with the C71 and 1-C-6 aggrecan-specific VL regions, the TTCF VL 
region and the first 13 nucleotides leading up to a restriction site in the CL region would have 
to be removed. Unfortunately, as with the H chain construction, this was complicated by the 
unknown sequence of the pMCFRhyg vector. Several possible restriction site pairs were 
identified to remove the TTCF VL region. However, following restriction digest and 
separation by agarose gel electrophoresis I found that the restriction enzymes were also 
present in the pMCFRhyg vector. The enzymes Xba1 and Bbs1 were identified as ideal 
candidates to remove the VL region from pMCFR hyg. However, as with the H chain, the 
Bbs1 sequences present in the TTCF-L was not unique and was also found to be present in 
the pMCFR hyg vector. Therefore, as described in the H chain construction, the TTCF-L 
cDNA was removed from pMCFR hyg and ligated into the Bbs1 negative plasmid pKS using 
Xba1 and Kpn1.  
 
The pKS /TTCF-L ligation mixture was transformed into one shot® Top 10 E.coli, colonies 
were selected on ampicillin plates, amplified by overnight culture and DNA was isolated. To 
confirm that the TTCF VL region could now be removed, the plasmids were digested with 
Xba1 and Bbs1. The successful removal of the V region was confirmed by agarose gel 
separation.  
 
In parallel, the VL regions of C71 and 1-C-6 were amplified from the plasmid DNA pCR 2.1 
C71/1-C-6 generated in section 5.3.2  to include the restriction sites 5‟ Xba1 and the first  20 
nucleotides encoding the human kappa C region up to and including the 3‟ Bbs1 site. The 
new pCR products were verified by agarose gel separation, ligated with the vector pCR2.1 
and sequenced as described in section 5.3.2.  Sequencing confirmed that the amplified C71/1-
C6- VL regions now contain the 5‟ Xba1 restriction site followed by the C71/1-C-6 VL 
region and the C kappa region up to and including the 3‟ Bbs1 site (data shown in Figure 
4.10.)   
 
The TTCF VL region was then excised from the vector pKS by restriction digest with Xba1 
and Bbs1, the Xba1 and Bbs1 digested pKS vector was treated with CIP and separated from 
the TTCF VL on an agarose gel.  The dephosphorylated vector was then removed from the 
gel, purified and ligated with the new C71/1-C-6 aggrecan-specific VL regions. As there are 
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no compatible restriction enzyme pairs with which to remove the newly constructed L chain 
from the pKS vector and into the final pMCFR hyg lymphocyte expression vector, the entire 
aggrecan-specific L chain was removed by restriction digest with BsshII and ligated into 
BsshII digested plasmid pSL1180 (Invitrogen). The L chain was then transferred from this 
plasmid by restriction digest with Xba1 and Sac1 and ligated into the dephosphorylated Xba1 
and Sac1 digested pCMFR hyg vector. This ligation mixture was then transformed into one 
shot® Top 10 E.coli and colonies were selected on ampicillin plates. DNA from amplified 
colonies was then isolated for transfection.  Complete L chain construction is illustrated in 
Figure 4.11.  
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Light chain nucleotide sequencing 
 
C71 VL 
TCTAGAATGGATTTTCATGTGCAGATTTTCAGCTTCATGCTAATCAGTGTCACAGT
CATATTGTCCAGTGGAGAAATTGTGCTCACCCAGTCTCCAGCACTCATGGCTGCA
TCTCCAGGGGAGAAGGTCACCATCACCTGCAGTGTCAGCTCAAGTATAAGTTCCA
GCAACTTGCACTGGTACCAGCAGAAGTCAGAAACCTCCCCCAAACCCTGGATTT
ATGGCACATCCAACCTGGCTTCTGGAGTCCCTGTTCGCTTCAGTGGCAGTGGATC
TGGGACCTCTTATTCTCTCACAATCAGCAGCATGGAGGCTGAAGATGCTGCCACT
TATTACTGTCAACAGTGGAGTACTTACCCACTCACTTTCGGAGGGGGGACCAAGC
TGGAAATAAAAACTGTGGCTGCACCATCTGTCTTCAT 
 
1-C-6 VL 
TCTAGAATGAAGTTGCCTGTTAGGCTGTTGGTGCTGATGTTCTGGATTCCTGCTTC
CAGCAGTGATGTTGTGATGACCCAAACTCCACTCTCCCTGCCTGTCAGTCTTGGA
GATCAAGCCTCCATCTCTTGCAGATCTAGTCAGAGCCTTGTACACAGTAATGGAA
ACACCTATTTACATTGGTACCTGCAGAAGCCAGGCCAGTCTCCAAAGCTCCTGAT
CTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTCAGTGGCAGTGGA
TCAGGGACAGATTTCACACTCAAGATCAGCAGAGTGGAGGCTGAGGATCTGGGA
GTTTATTTCTGCTCTCAAAGTACACATGTTCCTCCGACGTTCGGTGGAGGCACCA
AGCTGGAAATCAAAACTGTGGCTGCACCATCTGTCTTCAT 
 
 
 
 
Figure 4.10 C71 and 1-C-6 VL regions amplified to include restriction sites. C71 and 1-C-6 
V regions were amplified by PCR to include the restriction sites Xba1 and 20 nucleotides of the human kappa 
constant region including a Bbs1 restriction site. Xba1 site, Human kappa constant region, Bbs1 site. 
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Figure 4.11 Representation of the pMCFR vector/L chain assembly. The cDNA encoding the 
TTCF-specific L chain was digested from the plasmid pMCFR which contains a Bbs1 site and into the vector 
pKSM13 which is Bbs1 site negative. The cDNA encoding the V region from the TTCF L chain (TTCFVL) was 
digested using Xba1 and Bbs1.  cDNA encoding the  1-C-6 and C71 aggrecan-specific VL regions ( 1-C-6/C71 
VL) were PCR amplified to include an Xba1 and Bbs1 site at the 5’ and 3’ ends respectively, cloned into the 
pCR2.1 plasmid and digested using Xba1 and Bbs1.  1-C-6/C71 VL cDNAs were ligated with the digested 
pKSM13 vector containing the cDNA encoding the C region of the TTCF-specific L chain (hIgK).  The 
assembled L chain was digested from the pKSM13 vector with BsshII and ligated with pSL1180 to introduce a 
Sac1 site at the 3’ end of the insert. The L chain cDNA was digested from pSL1180 with Xba1 and Sac1 and 
ligated with the final expression vector pMCFR/hyg.  Plasmids were transformed into E.coli competent cells 
and cDNA was amplified and isolated at each step by maxiprep (Qiagen). 
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4.2.5 Transfection of plasmids encoding aggrecan-specific IgG H and L chains. 
Initially I wanted to verify that the cDNAs contained within the pMCFR plasmids were 
capable of encoding functional H and L chains of a BCR. Our laboratory has previously 
demonstrated that functional IgG BCR can be expressed in non-lymphoid cells (Knight, 
Lucocq et al. 1997) which are comparatively simple to transfect. Therefore, constructs 
containing cDNA encoding both the H and L chains of the new anti-aggrecan-specific BCR 
were transiently transfected in HeLa cells to verify expression. HeLa cells were transfected 
using the Lipofectamine 2000 (Invitrogen) transfection reagent with either the C71/1-C-6 H 
chain only, the L chain only or both H and L. To control for transfection efficiency HeLa 
cells were also transfected with plasmids encoding the original TTCF-specific BCR. Data 
shown in Figure 4.12 revealed that the H chain only transfected cells showed a different 
staining pattern to that of cells transfected with both the H and L chain as previously 
described. This was to be expected as the HeLa cells do not have any endogenous L chain 
and it is known that in the absence of the L chain the H chain is retained in the ER by BiP 
(Knight, Lucocq et al. 1997; Vanhove, Usherwood et al. 2001). However, when the H and L 
chains are co-transfected, expression was observed in cytoplasmic vesicles, indicating a 
correctly assembled BCR trafficking from and to the cell surface (Knight, Lucocq et al. 
1997).  
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                Panel 1                                       Panel 2                                      Panel 3 
  
           pMCFR 1C6 H                                        pMCFR 1C6 H+pMCFR 1C6 L                                       STREP FITC   
 
           pMCFR C71 H                                       pMCFR C71H+pMCFR C71L                                      STREP FITC      
 
           pMCFR TTCF H                                  pMCFR TTCF H +pMCFR TTCF L                             STREP FITC 
 
 
 
Fig 4.12 Indirect Immunofluorescence images of HeLa cells transiently transfected with  
C71 and 1-C-6 constructs. HeLa cells were transiently transfected with the following H chain only (panel 
1) or both H and L chain plasmid constructs (panels 1&2): positive control pMCFR TTCF H/L (anti-TTCF) 
originally used to create the new constructs, pMCFR 1-C-6H/L (anti-aggrecan) or pMCFR C71H/L (anti-
aggrecan). Fixed, permeabilized transfectants were stained with anti-human IgG (H and L) Fab
2 
biotinylated 
antibodies and streptavidin FITC (STREP FITC). The green fluorescence observed in the 1st panel from each 
transfectant shows typical endoplasmic reticulum staining. The 2nd panel shows vesicular staining.  The 3rd 
panel control shows transfectants stained with streptavidin FITC only. Images are representative of 5 fields and 
3 transfections. Magnification is 40x. 
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Subsequently, several attempts were made at transfecting the plasmid constructs into the 
A20-1 HS cell line. Initial attempts using a squareporater and electroporater were 
unsuccessful as the majority of cells were killed during the electroporation process despite 
attempts using both linearized and circular DNA and several different μF and voltage 
combinations. The Amaxa nucleofector system (Lonza) combines the use of electroporation 
with a nucleofection buffer and a pre-programmed voltage, capacitance and resistance 
specific to the cell type. In addition, the Amaxa system transfects DNA directly into the 
nucleus where it is incorporated independent of cell division. Therefore, this system was used 
to transfect the A20-1 HS cells initially with a pMAXgfp plasmid control to test transfection 
efficiency (data shown in Figure 4.13), followed by transfection with the C71/1-C-6 H and L 
chain plasmids discussed below. Results from transfection with the pMAXgfp plasmid 
verified that A20-1 HS could be transfected with plasmid DNA using this method at 
approximately 50% transfection efficiency. 
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Figure 4.13. A20-1 HS pmaxGFP transfection to monitor transfection efficiency. 
A20-1 HS were transfected with 3μg pmaxGFP DNA using the Amaxa nucleofector. Cells were cultured for 48 h 
and screened by a) Immunofluorescence microscopy and b) Flow cytometry to determine the transfection 
efficiency. The Immunofluorescence microscopy experiment was performed twice. The image is representative 
of 5 fields at 20x magnification. The flow cytometry experiment was performed 4 times. 
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4.2.6 Characterisation of A20-1HS C71/1-C-6 transfectants by flow cytometry and antigen 
presentation. 
Two methods were employed to determine whether the Amaxa transfected A20-1 HS cells 
expressed the aggrecan-specific BCR:-  
 
a) Flow cytometry 
b) Antigen presentation assay. 
 
4.2.6.1 Flow cytometry  
A20-1 HS is a murine B cell line and the aggrecan-specific plasmids C71 and 1-C-6 contain 
chimeric cDNA that encode H and L chains containing human C regions. Thus the human 
constant regions were detected by fluorescent labelled antibody against human Ig to 
determine transfection efficiency by flow cytometry by differentiating the transfected BCR 
from the endogenous mouse IgG2a BCR. The A20-1 HS cells transfected with either the 
C71/1-C-6 H and L chain or C71 H or L chain only were screened by flow cytometry for the 
surface expression of a human IgG H+L chain using rabbit anti-human IgG H + L biotin Fab
2
 
followed by incubation with streptavidin FITC 24 h post Amaxa nucleofection. Results 
shown in Figure 4.14  revealed that cells transfected with the C71 or 1-C-6 H and L chain 
constructs contained a population of cells that were now positive for the surface expression of 
the new chimeric aggrecan-specific BCR. However, cells transfected with either the C71 H 
chain or the L chain only, did not show any significant evidence of surface human BCR 
expression. This implies that the chimeric human H chain does not significantly pair with the 
endogenous mouse light chain as it is not expressed on the cell surface in the absence of the 
chimeric light chain. Negative controls, A20-1 HS exposed to the same transfection 
conditions but in the absence of DNA were also negative for surface human BCR expression 
as expected.  
 
Subsequently, I attempted to visualise aggrecan binding to the surface of the transfected A20-
1HS. 48 h post-transfection with the H and L chain constructs (or with the negative control 
DNAs described above) A20-1 HS cells were incubated with biotinylated aggrecan for 1 h at 
4
o
C to prevent BCR/aggrecan internalization. Cells were washed, incubated with streptavidin 
FITC and examined by flow cytometry. Results shown in Figure 4.14 revealed that a 
population of A20-1HS transfected with either the C71 or 1-C-6 H and L chains showed an 
increase in fluorescence intensity indicating aggrecan binding. Importantly, this fluorescence 
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was not seen in A20-1 HS transfected with the C71 H chain only. Surprisingly, A20-1 HS 
transfected with the C71 L chain only showed a slight increase in fluorescence intensity 
following incubation with the biotinylated aggrecan. This indicates that C71 L chain may pair 
with an endogenous mouse H chain and is expressed on the cell surface at sufficient levels 
and with sufficient affinity as to mediate aggrecan binding. 
 
4.2.6.2 Antigen presentation 
As discussed in Chapter 5, several previous studies have shown that antigen-specific BCR 
expression enhances the presentation of antigen to T cells. Therefore, the extent of aggrecan 
presentation by A20-1 HS transfectants to the BALB/c (H-2
d
) aggrecan84-103 -specific T cell 
hybridoma 192, was determined using the antigen presentation assays illustrated in Figure 
3.5. A20-1 HS transfected with both C71/1-C-6 H and L chains, C71 H or L chain only or 
untransfected A20-1 HS were recovered 24 h post transfection and cultured with the T cell 
hybridoma 192 for 24 h in the presence of either graded doses of deglycosylated aggrecan or 
p84-103. T cell hybridoma activation was measured by IL-2 production using CTLL-2. Data 
in Figure 4.15a revealed that A20-1 HS transfected with the C71 H and L chain presented 
aggrecan at least 10
3
 fold more efficiently than untransfected A20-1 HS. In addition, this 
improvement in presentation required the expression of both the C71 H and L chain as A20-1 
HS transfected with either C71 H or L chain only did not show any improvement in 
presentation in comparison to the untransfected A20-1 HS population. However, there was no 
improvement in presentation observed by A20-1 HS transfected with the 1-C-6 H and L 
chains in comparison with untransfected A20-1 HS.  
 
 To confirm that the improvement in presentation by the C71 H and L chain transfected A20-
1 HS is due to aggrecan uptake and processing and not an improvement in surface 
presentation of the epitope 84-103 on H-2
d
, transfected and untransfected A20-1 HS were 
also incubated with graded doses of the synthetic peptide p84-103. Results in Figure 4.15b 
reveal that none of the transfectants showed an improvement in presentation of p84-103 in 
comparison with the untransfected A20-1HS cells. Thus, confirming that the observed 
improvement in aggrecan presentation by the A20-1 HS transfectants is due to enhanced 
aggrecan uptake and/or processing and not merely an improvement in surface presentation of 
84-103.  
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Figure 4.14 Flow cytometry following transient transfection of A20-1 HS with the C71 
and  1-C-6 constructs. Staining of gated A20-1HS cells 48 h post Amaxa nucleofection with   1-C-6 H+L 
chain constructs, C71 H+L chain constructs,  C71 H chain construct, C71 L chain construct or  no DNA 
controls. Cells were stained with either biotinylated anti-human IgG (H+L) Ig or biotinylated aggrecan and the 
secondary reagent streptavidin FITC. Red histograms represent unstained cells and the blue histograms 
represent cells stained for the various markers. All experiments were carried out at 4
o
C. Mean fluorescence 
intensity values are shown adjacent to each histogram. Data is representative of 3 independent experiments. 
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Figure 4.15 Antigen presentation assay following transient transfection of A20-1 HS 
with plasmids encoding- C71 and 1-C-6 BCR. A20-1 HS were transfected with either C71 H+L 
chain constructs, 1-C-6 H+L chain constructs, C71 H chain only construct, C71 L chain only construct or cells 
underwent the Amaxa nucleofection in the absence of DNA. 24 h post transfection (5x10
4
) cells were cultured 
with aggrecan84-103-specific T cell hybridomas 192 (5x10
4
) in the presence of graded doses of a) aggrecan or b) 
peptide for 24 h. Cells were killed by freezing at -80
o
C and supernatant was removed for bioassay with CTLL-2 
cells. 
3
H thymidine was added for 18 h and T cell responses were determined and displayed as 
3
H thymidine 
cpm +/- SEM. Data are representative of triplicate wells and three independent experiments.  
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4.2.7 Generation of stable aggrecan-specific cell lines. 
A20-1 HS were successfully transfected with the C71/1-C-6 plasmids, expression of the BCR 
on the cell surface was verified by flow cytometry and it was shown that the C71 transfected 
A20-1 HS could now present aggrecan at least 10
3
 fold more efficiently. However, variation 
between transfection efficiencies in repeat experiments and limitations on the yield of viable 
cells 48 h post transfection was not optimal for studying the molecular mechanisms by which 
B cells act as aggrecan-specific APC. Therefore, I wanted to generate cells that were stably 
expressing the C71 aggrecan-specific BCR or the 1-C-6 aggrecan-specific BCR. Stable 
aggrecan-specific cell lines would enable me to reproducibly study downstream processing 
events and to examine how efficiently they present aggrecan to T cells in comparison to 
dendritic cells and macrophages. A20-1 HS cells were transfected with the C71 or 1-C-6 H 
and L chain plasmids, the bulk transfected population was screened by flow cytometry and 
antigen presentation 48 h post transfection and the remainder were incubated at 37
o
C, 5% 
CO2 in G418/hygromycin B selection media in 24 well plates until drug resistant colonies 
were visible by eye (approximately 21 days).  Resultant colonies were subsequently screened 
for the expression of a human Ig containing BCR and their ability to retain aggrecan at the 
cell surface by flow cytometry and by antigen presentation assay (as previously described).  
 
4.2.7.1 1-C-6 Transfectants 
1-C-6 Ig is specific for a reduced and alkylated form of aggrecan and does not bind to the 
deglycosylated form in an ELISA shown in Figure 4.1. Therefore, as expected colonies 
resulting from transfection with the 1-C-6 H and L containing plasmids were unable to retain 
deglycosylated aggrecan at the cell surface (data not shown). Therefore, I reduced, alkylated 
and biotinylated aggrecan as described in the materials and methods section 2.1.10. 
 
Subsequently, the 1-C-6 transfected cells were screened by flow cytometry for expression of 
a new BCR and their ability to retain reduced/alkylated aggrecan at the cell surface (Figure 
4.16). Results show that although the 1-C-6 transfectants express a new BCR, I could not 
detect reduced/alkylated aggrecan binding to any of the 1-C-6 transfectants above 
background levels. As a final screen for the 1-C-6 cells it was important to test their ability to 
present the reduced/alkylated aggrecan to the T cell hybridoma 192. I have previously 
determined that A20-1 HS cells do not present this form of aggrecan to T cell hybridoma 192 
data not shown. Therefore, for this experiment the macrophage cell line J774 was used as a 
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positive control. Cells were incubated with graded doses of reduced/alkylated, deglycosylated 
or glycosylated aggrecan or peptide p84-103 (data shown in Figure 4.17). Results show that 
the 1-C-6 transfectants did not present reduced alkylated, deglycosylated, glycosylated or the 
peptide form of aggrecan more efficiently than J774. J774 were the only cell line able to 
efficiently present the reduced /alkylated form of aggrecan to the T cell hybridoma 192 
verifying that the 84-103 epitope could be generated from the reduced/alkylated aggrecan and 
was recognized by the T cell hybridoma 192.  
 
As the specificity of the 1-C-6 BCR is known to be in the G1 and G2 regions it is possible 
that the 1-C-6 BCR is masking the 84-103 epitope and preventing its generation for 
presentation to the T cell hybridomas 192 (Caterson 1987). To overcome this problem 1-C-6 
transfectants were incubated with graded doses of aggrecan and the G3-specific T cell 
hybridomas D9 and D11 generated as described in chapter 3 (data shown in Figure 4.18). 
Results show that 1-C-6 cloned transfectants were unable to generate and/or present the 
epitopes p2373-2387 and p2363-2378 to the G3 specific T cell hybridomas.  However, data 
in Figure 4.17b shows that graded doses of the peptide form of the antigen were efficiently 
presented to both the T cell hybridomas D9 and D11.  
 
To determine whether 1-C-6 was able to mask the 84-103 epitope and prevent its generation 
for presentation on MHC class II, deglycosylated aggrecan was incubated for 24 h with C71 
transfectants, T cell hybridoma 192 and graded doses of soluble 1-C-6 Ig (data shown in 
Figure 4.20). Results show that increasing doses of 1-C-6 Ig had no effect on the efficiency 
of C71 aggrecan presentation to the T cell hybridoma 192 (data shown in Figure 4.20). 
Therefore, as there was no evidence that the 1-C-6 transfectants were aggrecan-specific; no 
further experiments were carried out using the 1-C-6 transfected B cells. 
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Figure 4.16 Flow cytometric analysis of representative  stable A20-1 HS transfectants 
expressing the 1-C-6 BCR Staining of gated representative 1-C-6 transfectants cells 1-C-6-2C3 and 1-C-
6-3F7. Cells were stained with either biotinylated anti-human IgG (H+L) Ig or reduced/alkylated and 
biotinylated aggrecan and the secondary reagent streptavidin APC. Red histograms represent unstained cells 
and the blue histograms represent cells stained for the various markers. All experiments were carried out at 
4
o
C. Data is representative of 3 independent experiments. 
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Figure 4.17 Antigen presentation by stable A20-1 HS transfectants expressing the 1-C-6 
BCR. (5x104) 1-C-6 transfectant, or J774 macrophages were cultured with aggrecan84-103-specific T cell 
hybridomas 192 (5x10
4
) in the presence of graded doses of reduced/alkylated, deglycosylated or glycosylated 
forms of aggrecan or peptide p84-103 for 24 h. Cells were killed by freezing at -80
o
C and supernatant was 
removed for bioassay with CTLL-2 cells. 
3
H thymidine cpm was added for 18 h and T cell responses were 
determined and displayed as 
3
H thymidine cpm +/- SEM. Data are representative of triplicate wells and three 
independent experiments.   
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Figure 4.18 Antigen presentation assay with stable A20-1 HS transfectants expressing 
the 1-C-6 BCR and G3 T cell hybridomas D9 and D11. 1-C-6 cloned stable transfectants 1-C-6 
3F7 and 1-C-6 2C3, A20-1 HS or J774 macrophages (5x10
4
) were cultured with aggrecan2363-2378-specific T cell 
hybridomas D9 or the aggrecan2373-2387 -specific T cell hybridomas D11 (5x10
4
) in the presence of graded doses 
of aggrecan or peptides p2363-2378 or p2373-2387 for 24 h. Cells were killed by freezing at -80
o
C and 
supernatant was removed for bioassay with CTLL-2 cells. 
3
H thymidine was added for 18 h and T cell 
responses were determined and displayed as 
3
H thymidine cpm +/- SEM. Data are representative of triplicate 
wells and three independent experiments.   
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4.2.7.2 C71 Transfectants 
I confirmed by flow cytometry that several A20-1 HS transfectants generated with the C71 
constructs expressed a new BCR and were able to retain aggrecan at the cell surface (data not 
shown). Therefore, it was important to verify that the transfectants also presented aggrecan 
more efficiently than the untransfected A20-1 HS.  Several independent C71 transfectants 
were screened using an antigen presentation assay in the presence of graded doses of 
aggrecan and peptide p84-103 (representative transfectant data is shown in Figure 4.19). 
Data revealed that the C71 stable transfectants were able to present aggrecan and at least 10
4
 
fold more efficiently than the untransfected A20-1 HS cells from aggrecan doses of 0.005nM 
(p<0.001). In addition, C71 D1 transfectants did not present the pre-processed peptide form 
of aggrecan more efficiently than A20-1 HS, indicating that the observed improvement in 
aggrecan presentation is due to more efficient uptake and processing.  
 
It was hypothesised that if the improvement in presentation of aggrecan to the T cell 
hybridoma 192 by the C71 transfectants was due to expression of an aggrecan-specific BCR 
then the observed improvement should be blocked by the addition of the soluble form of the 
receptor i.e C71 Ig. To test this hypothesis, C71-D1 transfectants were incubated with T cell 
hybridoma 192 and aggrecan in the presence of graded doses of C71 Ig. Controls wells 
included C71-D1 incubated with aggrecan and T cell hybridoma 192 in the absence of C71 Ig 
and J774 macrophages incubated with either aggrecan alone or in the presence of graded 
doses of C71 Ig and T cell hybridoma 192 (data shown in Figure 4.20) Results show that 
presentation of aggrecan by C71-D1 is blocked by the presence of soluble C71. However this 
is specific to the C71-D1 transfectants as the C71 Ig had no effect on the ability of J774 
macrophages to efficiently present aggrecan to the T cell hybridoma 192. C71-D1 
transfectants incubated with aggrecan and T cell hybridoma 192 in the absence of C71 Ig 
confirmed that the observed reduction in presentation was due to the addition of C71 Ig.  
Furthermore, the addition of isotype control 1-C-6 Ig (IgG1) did not block presentation of 
aggrecan by the C71-D1 transfectant confirming that the observed attenuation of aggrecan 
presentation by the C71-D1 transfectants is specific to C71 Ig. 
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Figure 4.19 Antigen presentation assay with C71 stable transfectants and T cell 
hybridomas 192. C71 stable transfectants and A20-1 HS controls were expanded and cultured (5x104) with 
aggrecan84-103-specific T cell hybridoma 192 (5x10
4
) in the presence of graded doses of aggrecan or peptide for 
24 h. Cells were killed by freezing at -80
o
C and supernatant was removed for bioassay with CTLL-2 cells. 
3
H 
thymidine was added for 18 h and T cell responses were determined and displayed as 
3
H thymidine cpm +/- 
SEM. Data are representative of triplicate wells and three independent experiments.   
The asterix represents statistical significance determined by one-way ANOVA where p<0.05. 
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Figure 4.20 Antigen presentation assay with C71 D1 stable transfectants and J774 
macrophages in the presence of graded doses of C71 or 1-C-6 Ig. C71 D1 transfectants or J774 
macrophages were incubated with 2 nM deglycosylated aggrecan and the aggrecan84-103-specific T cell 
hybridomas 192 (5x10
4
) in the presence of graded doses of 1-C-6 Ig for 24 h. Cells were killed by freezing at -
80
o
C and supernatant was removed for bioassay with CTLL-2 cells. 
3
H thymidine cpm was added for 18 h and T 
cell responses were determined and displayed as 
3
H thymidine cpm +/- SEM. Data are representative of 
triplicate wells and two independent experiments.   
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The transfectant C71-D1 was chosen as a representative aggrecan-specific population and 
single cell cloned to ensure homogeneity. 
Subsequently, resultant C71 D1 clones and A20-1 HS controls were re-screened by flow 
cytometry for expression of the C71 chimeric BCR, cell surface aggrecan retention, MHC 
class II expression and Fc receptor expression in the presence or absence of Fc block  (data 
shown in Figure 4.21). C71 clones C71-4C5 and C71-5F10 were consistently positive for the 
expression of a new chimeric BCR and their ability to bind aggrecan. MHC class II receptor 
expression was at similar levels on both C71 5F10 and A20-1 HS cells. However, expression 
was 4 fold greater by the C71 4C5 cells. The Fc receptors were efficiently blocked by 2.4G2 
block confirming that positive staining was not due to nonspecific Fc receptor binding. 
Therefore, C71-4C5 and C71-5F10 were chosen as representative aggrecan-specific B cell 
lines for further investigation. 
 
To verify that the improvement in presentation by C71 transfectants C71-4C5 and C71-5F10 
was specific to presentation of aggrecan and not an irrelevant antigen, C71-4C5 and C71-
5F10 cells were screened in an antigen presentation assay with deglycosylated aggrecan, p84-
103 and TTCF.  The TTCF-specific B cells A20 3A5 (Knight, Lucocq et al. 1997)) were used 
as a positive control and presentation to the T cell hybridomas 192 and the TTCF-specific T 
cell hybridoma MC-52 generated by M Ciechomska in our laboratory were examined. APC 
and T cell hybridomas MC-52 or 192 were incubated for 24 h in the presence of graded doses 
of TTCF, deglycosylated aggrecan or p84-103. Data shown in Figure 4.22a revealed that 
C71-4C5 and C71-5F10 B cells are able to present aggrecan to the T cell hybridoma 192 at 
least 10
5
 times more efficiently than the TTCF specific B cell A20 3A5 or A20-1 HS at 
aggrecan doses from 0.005nM (p<0.01). Results in Figure 4.22b shows that the C71-4C5 and 
C71-5F10 cells do not present p84-103 any more efficiently than the A20 3A5 or A20-1 HS 
cells. Importantly, Figure 4.22c shows that C71-4C5, C71-5F10 and A20-1 HS were unable 
to present TTCF to TTCF specific-T cells MC 52, even at doses of up to 100 nM. However, 
TTCF-specific B cells A20 3A5 were able to present TTCF at doses above 0.5 nM (p<0.01). 
These data verify that the C71 4C5 and 5F10 B cells are indeed antigen-specific and are 
highly efficient at the uptake processing and presentation of aggrecan for presentation of the 
84-103 epitope to T cell hybridoma 192. 
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Figure 4.21 Flow cytometry with C71 clones to show BCR expression and aggrecan retention. Staining of A20-1 HS or C71 clones C71-4C5 and 
C71-5F10 with either biotinylated anti-human IgG (H+L) Ig or biotinylated aggrecan and the secondary reagent streptavidin FITC. Anti-MHC II FITC 2.4G2 biotin 
followed by secondary reagent streptavidin APC.  Red histograms represent unstained cells and the blue histograms represent cells stained for the various markers. All 
experiments were carried out at 4
o
C in the presence of Fc block unless otherwise stated. Mean fluorescence intensity values are shown below each histogram. Data is 
representative of 3 independent experiments. 
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Figure 4.22 Antigen presentation assay with C71 clones and the T cell hybridomas 192  
and MC-52. C71 clones C71-4C5 and C71-5F10, A20-1 HS or the TTCF-specific B cell hybridomas A20 
3A5 were cultured with aggrecan84-103-specific T cell hybridoma 192 (5x10
4
) in the presence of graded doses of 
a) aggrecan or b) peptide p84-103 for 24 h. C71 clones C71-4C5 and C71-5F10, A20-1 HS or the TTCF-
specific B cell hybridomas A20 3A5 cultured with c) TTCF-specific T cell hybridomas MC-52 (5x10
4
) in the 
presence of graded doses of TTCF for 24 h, Cells were killed by freezing at -80
o
C and supernatant was removed 
for bioassay with CTLL-2 cells. 
3
H thymidine was added for 18 h and T cell responses were determined and 
displayed as 
3
H thymidine cpm +/- SEM. Data are representative of triplicate wells and three independent 
experiments. The asterix represents statistical significance determined by one-way ANOVA where p<0.05.  
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4.3 Discussion 
The aim of this chapter was to generate plasmid constructs containing cDNA encoding 
aggrecan-specific BCR H and L chains from two independent anti-aggrecan monoclonal 
antibodies (C71 and 1-C-6). Those plasmids were then to be transfected into the B cell line 
A20-1 HS in an attempt to generate aggrecan-specific B cells. Results confirm that I have 
successfully generated both C71 and 1-C-6 H and L chain plasmids and confirmed their cell 
surface expression following transfection into A20-1 HS cells. The new B cell lines have 
been characterised by flow cytometry, to verify the cell surface expression of a chimeric 
mouse/human BCR and their ability to retain biotinylated aggrecan at the cell surface. In 
addition, the transfectants were screened using antigen presentation assays to observe how 
efficiently they could present aggrecan to aggrecan-specific T cell hybridomas. The results 
are discussed below. 
 
4.3.1 H and L chain plasmid construction 
The H and L chain plasmids were constructed by ligating cDNAs predicted to encode 
aggrecan-specific VH and VL regions from the murine aggrecan-specific B cell hybridomas 
C71 and 1-C-6 with cDNAs encoding human H and L chain C regions (Knight, Lucocq et al. 
1997) derived from the human TTCF-specific EBV transformed 11.3 (Lanzavecchia 1985).   
The sequences encoding the H and L chain V regions from C71 and 1-C-6 regions were 
amplified by 5‟ RACE. This technique allows the amplification of DNA where the 5‟ region 
is unsequenced and has successfully been used previously for the amplification of cDNAs 
encoding VH and VL from various monoclonal antibodies. Following successful 
amplification of PCR products of the predicted size, cDNAs encoding both the 1-C-6 and 
C71 VH and VL regions were transformed into competent E.coli and multiple independent 
clones containing the amplified cDNA were sequenced and aligned with other published V 
region sequences.   
 
These data showed that 5 independently isolated C71 and 1-C-6 clones contained identical 
sequences. In addition, similarities were observed between the structural framework regions 
of the C71 and 1-C-6 V H and L chains and previously published sequences. However, I did 
not observe any sequence similarity between the leader sequence of the C71 VL region and 
the leader sequence of 1-C-6 or any of the other published VL sequences shown in Figure 
4.7, despite confirmation that 5 C71 miniprep clones contained this identical sequence. As the 
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leader sequence is required for endoplasmic reticulum (ER) insertion of the C71 VL 
translation product, I was concerned that any errors in the amplification of this region of the 
cDNA would prevent its correct translocation into the ER and the subsequent assembly of the 
C71 BCR (Bergman and Kuehl 1979; Wilkinson, Regnacq et al. 1997). However, later results 
confirmed that the observed improvement in aggrecan presentation by the C71 transfected 
clones required transfection of the A20-1 HS cells with both the C71 H and L chains; 
transfection with plasmids containing the H or L chain only did not improve presentation. 
These data indicate that the C71 L chain had successfully translocated into the ER, assembled 
with its corresponding H chain and was expressed on the cell surface of the A20-1 HS cells.   
 
4.3.2 Transfection 
Following several unsuccessful attempts using other methods, the Amaxa nucleofector 
system was adopted to transfect plasmids encoding the C71 and 1-C-6 BCR into A20-1 HS 
cells.  Subsequently, flow cytometry was used to detect surface expression of the novel C71 
or 1-C-6 chimeric BCR. Anti-human IgG (H and L) Fab
2 
biotin conjugated antibodies and 
streptavidin FITC  were used to detect human H and L C region expression on A20-1 HS 
transfected with the C71 or 1-C-6 H and L chain constructs. As A20-1 HS expresses an 
IgG2a BCR (of unknown specificity), expression of a BCR containing a human C region was 
used to distinguish transfected from endogenous BCR. Anti-human κ L chain antibodies were 
initially used to detect the expression of the introduced L chain. However, these antibodies 
cross-reacted with the endogenous mouse κ L chain. Therefore expression of the C71 or 1-C-
6 light chain by A20-1 HS could not be verified in this way. As I could not verify the 
expression of both the C71 or 1-C-6 H and L chains individually it was not possible to 
determine from this data if the C71 or 1-C-6 H chain had paired with the endogenous A20-1 
HS L chain or if the C71 or 1-C-6 L chain had paired with the endogenous H chain. I 
determined this was not the case by transfecting the C71 H chain plasmid alone and showing 
that these single-chain transfectants did not bind aggrecan at the cell surface or show 
improved presentation of aggrecan. However, this does not exclude the possibility that the 
C71 H and L transfected A20-1 HS express a variety of receptors paired with a combination 
of transfected and endogenous H and L chains.    
Observations that A20-1 HS cells transfected with the C71 H chain alone showed no H chain 
cell surface expression by flow cytometry in the absence of co-transfection with the C71 L 
chain suggested that the H chain did not successfully pair with the endogenous A20-1 HS L 
chain and is retained in the ER. However, I did observe a small increase in the mean 
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fluorescence intensity for A20-1 HS transfected with the C71 L chain only and an increase in 
the mean fluorescence intensity following incubation with biotinylated aggrecan and 
streptavidin FITC. This data suggests that a small percentage of C71 L chains may pair with 
the endogenous A20-1 HS H chain but in the absence of any observed improvement in 
aggrecan presentation this should distract from using these transfectants as a model for 
aggrecan-specific uptake and processing by B cells. It is possible that the transfected A20-1 
HS cells express a variety of mouse and mouse/human BCR on their cell surface. Further 
experiments to analyze this would have been to specifically immunoprecipitate murine Ig and 
Western blot for associated human-Ig.  
 
Inevitably, the A20-1 HS transfectants are not a true reflection of an aggrecan-specific B cells 
in vivo. However, they are an excellent model with which to study the effects of BCR 
mediated uptake and processing and presentation of the candidate joint autoantigen aggrecan. 
In addition, A20-1 cells are representative of activated B cells and have been used by several 
investigators as a model of B cell antigen presentation (Shimonkevitz, Kappler et al. 1983; 
Brennan, Negroiu et al. 1995; Aoi, Nakano et al. 1997). Therefore, aggrecan-specific A20-1 
HS transfectants can be used to examine the unknown processing and presentation events of 
the candidate joint autoantigen aggrecan by antigen-specific B cells and as a comparison to 
the processing and presentation by other APC.  
 
In order to study the activation requirements, proliferation and cytokine production by 
autoreactive aggrecan-specific B cells, a more relevant model would be to transfect ex vivo B 
cells. However, several unsuccessful attempts were made at transfecting freshly isolated B 
cells, including the transfection of LPS activated ex-vivo B cells (Liu, Meckel et al. 2010). 
Ultimately, the generation of a BCR transgenic mouse using the C71 H and L chain 
constructs would enable me to identify the relevance of B cell mediated aggrecan 
presentation on T cell activation and PGIA development. In addition, aggrecan-specific BCR 
transgenic mice would also enable the study of the tolerance mechanisms involved in 
regulating the development of autoreactive aggrecan-specific B cells and the effects of 
aggrecan-specific B cell transfer on PGIA induction (Goodnow 1992) (Gay, Saunders et al. 
1993). Thus, generation of a BCR transgenic mouse maybe an important next step in the 
future development of this study. Therefore for the purpose of this study the A20-1 HS stably 
transfected with the C71 and  1-C-6 H and L chain constructs were used for further 
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experiments to generate preliminary data on aggrecan processing and presentation by 
autoreactive aggrecan-specific B cells.  
 
4.3.3 I-C-6 Cell lines. 
Several stable cell lines were generated from A20-1HS transfected with plasmids encoding 
the 1-C-6 BCR. These cell lines were screened for the expression of a new BCR containing a 
human C region, for their ability to bind deglycosylated and reduced/alkylated forms of 
aggrecan at their surface and to present both forms of aggrecan to the T cell hybridomas 192. 
1-C-6 transfectants were consistently positive for the expression of a BCR containing a 
human C region. However, I did not detect any binding of either forms of aggrecan at the cell 
surface nor did I observe any improvement in presentation of aggrecan in comparison to 
untransfected A20-1 HS.  
 
Possible reasons for these findings may include  
 1-C-6 BCR may contain errors in the cDNA sequence following either V region 
amplification or H or L chain plasmid construction. As the 1-C-6 variable sequence 
has not been published I can only presume from the 12 miniprep clones sequenced 
that their identical sequence similarity is correct. In addition, and in contrast to the 
C71 sequence, both the 1-C-6 VH and VL regions contained a high percentage of 
sequence similarity with other published V regions. It is also possible, that there are 
errors in the construction of the H and L chain plasmids. However, sequencing has 
confirmed that the 1-C-6 V regions appear to be joined to the human Ig C regions 
making this unlikely.  
 As there is no evidence that the 1-C-6 BCR binds with sufficient efficacy to improve 
presentation, it is possible that it also does not bind efficiently enough to be detected 
by flow cytometry. The binding of 1-C-6 Ig to reduced and alkylated aggrecan is 
shown in the ELISA data in Figure 4.1. However, an ELISA is a very sensitive assay 
where aggrecan is bound in a concentrated form to an ELISA plate facilitating 
binding at a low affinity Ig. Indeed sensitivity of ELISA to detect IgG levels was 
demonstrated by Lofgren and colleagues and ranges of 16ng-32μg/ml of antibodies 
were detected which directly correlated with affinity of the Ig (Lofgren, Dhandapani 
et al. 2007). 1-C-6 was detected to bind reduced/alkylated aggrecan in an ELISA at 
concentrations ranging from >1 μg/ml.  Therefore, it is possible that 1-C-6 is a low 
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affinity Ig and the 1-C-6 BCR is incapable of binding sufficient  reduce/alkylated 
aggrecan to improve uptake and processing for presentation to the T cell hybridoma 
192, yet is still positively detected in a more sensitive ELISA. Batista and colleagues 
determined that 10
-6
M is the lowest affinity HEL specific BCR needs to be to show an 
improvement in the presentation to HEL-specific T cell hybridomas (Batista and 
Neuberger 1998). Therefore, as described previously, competition ELISA to 
determine the affinity of the 1-C-6 Ig may clarify whether its affinity dictates its lack 
of improved aggrecan presentation and surface binding.    
 It is possible that reduction and alkylation of the aggrecan may affect the processing 
of 84-103. Therefore, an improvement in presentation may not be detected as the 84-
103 epitope is not optimally generated. C71 transfectants did not present 
reduced/alkylated aggrecan more efficiently than untransfected A20-1 HS. This could 
be due to the C71 BCR no longer recognising its epitope due to destruction of 
conformation or that this represents the optimal generation and presentation of the 84-
103 epitope by B cells when aggrecan is in its reduced and alkylated form. 
Differences in the ability of other APC to present aggrecan more or less efficiently 
when used in a different form was shown later by macrophages that present 
glycosylated aggrecan 10
2
-fold more efficiently than the deglycosylated form (Figure 
5.3). Therefore altering the aggrecan structure may have different effects on 
processing the 84-103 epitope.  
 It is possible that binding of the 1-C-6 BCR prevents the processing of the 84-103 
epitope. However, experiments involving pre-incubation of deglycosylated aggrecan 
with 1-C-6 Ig did not affect the ability of the C71 transfectants to efficiently present it 
to the T cell hybridoma 192. In addition, reduced/alkylated aggrecan was efficiently 
presented by the J774 macrophage cell line to the T cell hybridomas 192. However, 
this data only confirms that the 1-C-6 Ig has no detrimental effects on 
reduced/alkylated aggrecan processing by macrophages and not by B cells. As there is 
no control for improved presentation of reduced/alkylated aggrecan by B cells it is not 
possible to determine whether 1-C-6 has a detrimental effect and to draw any firm 
conclusions on its effects on 84-103 epitope generation by B cells. 
 There is no evidence that the 1-C-6 Ig efficiently recognises the deglycosylated form 
of aggrecan. Therefore it is reasonable to expect that I would not see an improvement 
in its presentation to the T cell hybridomas 192. 
 179 
In conclusion, these data show no evidence for the 1-C-6 transfectant binding or presenting 
aggrecan to the T cell hybridomas 192 used in this study. Therefore for the next chapter all 
mechanistic processing and comparison with other APC experiments were carried out using 
the transfectants C71-4C5 and C71-5F10.  
 
4.3.4 C71 cell lines 
C71 aggrecan-specific B cells were generated and single-cell cloned to ensure homogeneity 
and to identify any potential differences amongst efficient presentation of aggrecan to T cell 
hybridoma 192. Subsequently, clones C71-4C5 and C71-5F10 were chosen as representative 
aggrecan-specific B cells for further studies. Antigen presentation assays confirmed that these 
clones presented aggrecan 10
4
-10
5
 fold more efficiently than the untransfected A20-1 HS 
whilst showing similar efficiency of p84-103 presentation (Figure 4.22). This data indicates 
that aggrecan is taken up and processed more efficiently by the C71-4C5 and C71-5F10 cells 
in comparison to the A20-1 HS and this improvement is not due to the ability of the C71 cells 
to present peptide/MHC class II complexes more efficiently. 
 
 Flow cytometry confirmed the expression of the C71 BCR on the cell surface of the clones. 
However, only low level biotinylated, aggrecan binding was observed by flow cytometry and 
the reasons for this are not fully understood. Flow cytometry experiments were performed on 
cells incubated on ice to prevent uptake of aggrecan once it had been bound by the C71 
aggrecan-specific BCR. Therefore, once the biotinylated aggrecan had bound to the BCR it 
should have been retained at the cell surface and should be detectable by flow cytometry 
following incubation with streptavidin FITC.  This data suggests that either the BCR binding 
site of aggrecan is masked by the biotin molecules or that the BCR is of low affinity. 
However, experiments to verify that biotinylated aggrecan was efficiently processed and 
presented by C71 transfectants were carried out (data not shown) and results showed that 
biotinylation of aggrecan had no effect on the ability of the C71 transfectants to process and 
present aggrecan to the T cell hybridoma 192.  Further experiments to determine the affinity 
of the C71 BCR could have been used such as competition ELISA where affinity of C71 
antibody is determined by the addition of various concentrations of aggrecan required to 
compete with the binding of biotinylated aggrecan to the C71 antibody bound to the ELISA 
plate (Friguet, Chaffotte et al. 1985; Batista and Neuberger 1998).   
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The aggrecan epitope detected by the C71 transfectants is still unknown. To clarify this  
epitope mapping experiments such as Western blotting with MMP digested aggrecan to 
produce aggrecan fragments of known molecular weight followed by incubation with the C71 
Ig may have confirmed C71 specificity. Subsequently, I could have determined whether the 
C71 BCR a) masks the (G1 domain) 84-103 epitope and prevents its destruction and therefore 
improves its presentation to the T cell hybridoma 192 or b) whether it binds to a region 
distinct from 84-103 and improves uptake, leaving 84-103 for processing and optimal peptide 
generation.  
 
Attempts to generate aggrecan-specific T cell hybridomas that recognised alternative epitopes 
within the G3 domain were unsuccessful. I successfully, generated two G3 specific T cell 
hybridomas D9 and D11. However, in antigen presentation assays using A20-1 HS, C71-4C5 
or C71-5F10 as APC they were only able to recognise synthetic peptide containing their G3 
specific epitopes and not those derived from deglycosylated aggrecan. This implies that the 
G3 epitopes are either cryptic and not generated by the B cells, possibly due to destructive 
processing or that the T cells only recognise their epitope when presented in a particular 
MHC class II /peptide conformer such as those described for type B T cells that only 
recognise a peptide form of antigen (Pu, Lovitch et al. 2004). Indeed,  other work in our 
laboratory using the T cell hybridomas D9 and D11 confirmed that the macrophage cell line 
J774 was also only able to present peptide and not deglycosylated aggrecan to the G3-specific 
T cell hybridomas (Andrew Quirk unpublished data). 
 
In summary, C71-5F10 and C71-4C5 consistently presented the candidate joint autoantigen 
aggrecan at least 10
4
 fold more efficiently than the untransfected A20-1 HS cells and are 
therefore good models with which to study aggrecan-specific processing and presentation by 
B cells in comparison to other APC.  
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4.4 Summary  
 Plasmid constructs were generated containing cDNAs predicted to encode aggrecan-
specific H and L chains from two different aggrecan-specific B cell hybridomas C71 
and 1-C-6.  
 Cell lines were generated by transfecting A20-1 HS with plasmid constructs 
containing aggrecan-specific H and L chain cDNA. 
  Expression of new chimeric human/mouse C71/1-C-6 BCRs was confirmed by flow 
cytometry.  
 Flow cytometry confirmed that binding of biotinylated aggrecan was observed by C71 
but not by 1-C-6 transfectants. 
 C71 but not 1-C-6 transfectants showed a 104-105 fold improvement in aggrecan 
presentation in comparison to that of untransfected A20-1 HS. 
  Single cell clones C71-4C5 and C71-5F10 were generated from the parental C71 D1 
stable cell line population. These clones were characterised to verify aggrecan-
specific BCR expression, aggrecan binding and an improvement in aggrecan 
presentation and were chosen for studies into the molecular mechanisms by which 
aggrecan-specific B cells process and present aggrecan to T cells.  
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5. Comparison of aggrecan processing and presentation by aggrecan-
specific B cell transfectants, bone marrow derived dendritic cells and 
macrophages. 
 
5.1 Introduction 
The aim of this chapter was to study the mechanisms by which aggrecan is processed and 
presented by the aggrecan-specific B cells (C71-4C5 and C71-5F10) generated in Chapter 4 
and to make comparisons between this and aggrecan processing and presentation by two 
other major APC, macrophages and dendritic cells.  
 
Initial studies presented in this chapter verified that naïve splenic B cells were poor at 
presenting aggrecan to T cell hybridoma 192 in comparison to presentation by dendritic cells 
and macrophages. I wanted to elucidate whether there was a novel role for aggrecan-specific 
B cells in the processing and presentation of aggrecan. Therefore, I compared the kinetics of 
aggrecan presentation, the ability to present different forms of aggrecan, and differences in 
downstream processing events by the three APC.  
  
Initial studies involved a comparison of presentation of different forms of aggrecan by the 
APC. As previously mentioned in the Introduction Section 1.7.2, aggrecan undergoes various 
proteolytic cleavage events and carbohydrate modifications during the course of RA 
progression (Ortutay, Polgar et al. 2003; Larsson, Lohmander et al. 2009). Furthermore, 
several studies have demonstrated that chondroitin and keratin sulphate side chains must be 
removed from aggrecan in order for it to be used for the induction of PGIA in mice and to 
generate appropriate T cell responses in humans during in vitro recall responses (Leroux, 
Guerassimov et al. 1996; Li, Zhang et al. 2000; Glant and Mikecz 2004). As both the 
immunogenicity and post-translational form of aggrecan is likely to be heterogeneous within 
the joint, I examined T cell hybridoma 192 responses to glycosylated, deglycosylated and 
p84-103 following presentation by the different APC.  
 
Various studies have demonstrated that antigen-specific B cells are efficient APC both when 
and where B cell numbers are low (Lanzavecchia 1985; Byersdorfer, Dipaolo et al. 2004; 
Catron, Itano et al. 2004; Pape, Catron et al. 2007). Therefore, I wanted to investigate the 
nature of this requirement and the mechanisms involved in the presentation of aggrecan by 
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antigen-specific B cells compared to that seen with dendritic cells and macrophages. To do 
this I initially compared both the relative number of APC required to efficiently present 
aggrecan to the T cell hybridomas 192 and the concentration of aggrecan or p84-103 required 
to generate a T cell response. In addition, as previous studies have also shown that B cells are 
involved in the activation of T cells early on in the immune response (Byersdorfer, Dipaolo et 
al. 2004; Catron, Itano et al. 2004; Pape, Catron et al. 2007), I carried out  experiments to 
determine the time kinetics of aggrecan processing by aggrecan-specific B cells C71-4C5 and 
C71-5F10 in comparison to other APC.  
 
The classical pathway of MHC class II restricted antigen presentation involves a series of 
intracellular events that result in antigen degradation and the generation of antigenic 
determinants for loading into the peptide binding groove of newly synthesised MHC class II 
within the MIIC (Neefjes, Stollorz et al. 1990; Robinson and Delvig 2002; Watts 2004). 
MHC class II α and β chains assemble in the ER along with the invariant chain (li). Newly 
generated MHC class II molecules are transported from the ER to MIIC assisted by the li 
which is sequentially degraded by endosomal cysteine and aspartyl proteinases from the 
entire li chain to fragments lip22, lip10 and finally the CLIP fragment which remains bound 
to the peptide binding groove (Roche and Cresswell 1990; Cresswell 1992; Honey and 
Rudensky 2003). Subsequent release of CLIP and loading of antigenic peptides into the 
binding groove of MHC class II is catalyzed by the MHC class like molecule HLA-DM prior 
to MHC class II/ peptide cell surface presentation by APC (Denzin and Cresswell 1995).  An 
alternate pathway involves antigen targeted to early endosomes for loading onto MHC class 
II molecules that are recycled from the cell surface (Pinet, Vergelli et al. 1995; Lindner and 
Unanue 1996; Delvig and Robinson 1998). This pathway is independent of newly synthesised 
MHC class II and the li chain. Cycloheximide blocks protein synthesis (St-Pierre and Watts 
1990) and Brefeldin A prevents egress from the ER (Orci, Tagaya et al. 1991). Therefore, 
both inhibitors should block the classical pathway of antigen presentation by preventing the 
synthesis and transport of MHC class II molecules and should have no effect on the 
presentation of peptides loaded via the recycling pathway. To examine which pathways are 
involved in aggrecan presentation, the different inhibitors of protein synthesis and Golgi 
transport were used and their effects on presentation to T cell hybridoma 192 was examined. 
Early studies have shown that raising the pH of endosomal compartments with ammonium 
chloride can inhibit the processing and presentation of several antigenic epitopes by 
macrophages (Ziegler and Unanue 1981), dendritic cells (Svensson, Stockinger et al. 1997) 
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and B cells (Casten, Lakey et al. 1985). In most cases, efficient antigen processing requires 
both the correct pH and the activation of the appropriate intracellular enzymes.  Although 
intracellular enzymes are present in all endocytic compartments, most require the low pH 
found in late endosomes and lysosomes for removal of the N terminal pro-domain and their 
subsequent activation (Riese and Chapman 2000). Furthermore, HLA-DM peptide exchange 
is itself regulated by HLA-DO and although mechanisms of regulation are not entirely known 
it is thought to be pH dependent, where HLA-DO represses peptide exchange by HLA-DM in 
early endosomes, allowing exchange later in the pathway when pH levels are lower (van 
Ham, van Lith et al. 2000). HLA-DO levels differ between B cells, dendritic cells and 
macrophages and therefore may modulate aggrecan processing differently in the different 
APC (Hornell, Burster et al. 2006). To examine the requirement of endosomal pH for 
efficient aggrecan processing and presentation by the different APC, C71-4C5, C71-5F10, 
macrophages and dendritic cells were incubated with ammonium chloride to lower 
endosomal pH and the effects on aggrecan presentation to T cell hybridoma 192 was 
examined. 
 
The functions of endosomal proteinases include the degradation of protein antigens and 
antigen receptors, the generation and trimming of peptide fragments for MHC class II loading 
and the degradation of the li chain (Honey and Rudensky 2003). The latter function is thought 
to primarily involve cysteine proteinases such as cathepsin S and asparagine endopeptidase 
(AEP) (Shi, Villadangos et al. 1999; Manoury, Mazzeo et al. 2003). MHC class II molecules 
are present in most endocytic compartments and can be loaded with peptide at various stages 
in the pathway (Robinson and Delvig 2002). Previous studies have shown that the route of 
antigen uptake and the type of APC can have differential effects on how antigen is processed 
(Nakagawa, Roth et al. 1998; Shi, Bryant et al. 2000). Therefore, it is possible that different 
APC may have different requirements for the generation of the aggrecan epitope 84-103. 
Possible differences in aggrecan processing include the route of uptake (this could determine 
which intracellular compartment aggrecan is targeted to), different proteinase expression and 
pH dependence for proteinase activation and HLA-DM control by HLA-DO (Denzin, Fallas 
et al. 2005).  In addition, FcR or BCR uptake of antigen may have an effect on how the 
protein is degraded by sequestering various parts of the antigen from proteolysis (Simitsek, 
Campbell et al. 1995). 
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I have used inhibitors of the major proteinase families (cysteine, serine, aspartyl and metallo) 
to identify the proteinase requirements of different APC for the efficient generation and 
presentation of the aggrecan 84-103 epitope to the T cell hybridoma 192. Inhibitor studies 
have helped to elucidate which enzymes were involved in the generation and MHC class II 
loading of 84-103 and to determine any differences in aggrecan processing by aggrecan-
specific B cells, dendritic cells and macrophages.  
Elucidating the mechanisms involved in aggrecan processing by different APC may identify 
novel targets with which to prevent the initiation of an adaptive response against this 
candidate joint autoantigen. 
 
Most of the antigen presentation assays performed in this and earlier chapters have involved 
T cell responses by the T cell hybridoma 192. In order to evaluate the role of the different 
APC in activating aggrecan-specific T cells I isolated T cells from TCR-5/4E8-tg mice that 
express a TCR specific for the aggrecan epitope 84-103. TCR-5/4E8-tg mice develop PGIA 
following immunisation with deglycosylated aggrecan and T cells isolated from TCR-5/4E8-
tg mice can induce disease when adoptively transferred along with deglycosylated aggrecan 
into MHC class II matched SCID mice (Berlo, Guichelaar et al. 2006). PGIA is thought to be 
a Th1- mediated disease dependent on the cytokine IFNγ (Finnegan, Grusby et al. 2002). In 
addition, B cells have been implicated as important mediators of this IFNγ response in the 
PGIA model. Therefore, I was interested in determining whether in vitro presentation of 
aggrecan by aggrecan-specific B cells C71-4C5 and C71-5F10 is able to generate an IFNγ 
response when incubated with aggrecan and the aggrecan-specific T cells 5/4E8 and how this 
compares to IFNγ response following presentation by other APC.   
 
 
5.1.2 The aims of this chapter: 
 To compare aggrecan presentation to T cell hybridomas 192 and T cells isolated from 
TCR-5/4E8 transgenic mice by aggrecan-specific B cell clones C71-4C5 and C71-
5F10 to that seen with other APC. 
 To determine mechanisms of aggrecan-processing by aggrecan-specific B cell clones 
C71-4C5 and C71-5F10 compared to other APC.  
 To determine patterns of cytokine production by T cells in response to aggrecan-
presentation aggrecan-specific B cell clones C71-4C5 and C71-5F10 compared to 
other APC. 
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5.2 Results 
 
5.2.1 Phenotype of bone marrow macrophages and bone marrow dendritic cells 
Bone marrow precursor cells were isolated from BALB/c mice and differentiated into either 
bone marrow derived macrophages or bone marrow derived dendritic cells by culturing the 
cells in media containing MCSF or GMCSF respectively.  Macrophages were activated 
overnight by the addition of 100 ng/ml IFNγ to the culture media. Macrophages and dendritic 
cells were screened by flow cytometry for macrophage cell surface marker F4/80, dendritic 
cell surface marker CD11c and MHC class II. To verify that positive staining was not due to 
antibodies binding to cell surface Fc receptors both macrophages and dendritic cells were 
stained with biotinylated 2.4G2 Fc receptor antibodies and streptavidin APC both in the 
presence and absence of (75 μg/ml) 2.4G2 Fc block (Figure 5.1). As expected macrophages 
expressed F4/80, MHC class II and not the dendritic cell marker CD11c and dendritic cells 
expressed CD11c, MHC class II and not the macrophage cell surface marker F4/80. Positive 
staining with biotinylated 2.4G2 Fc receptor antibodies and streptavidin APC was blocked in 
the presence of 75 μg/ml 2.4G2 Fc block. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 187 
 
 
        
                                 
                                   
                                                                                                        
                                    
                                    
 
Figure 5.1 Phenotyping of bone marrow derived macrophages and dendritic cells by 
flow cytometry.  Bone marrow derived macrophages and bone marrow derived dendritic cells were stained 
with F4/80 FITC, CD11c PE or MHC II FITC. Red histograms represent gated unstained cells and the blue 
histograms represent gated cells stained for the various markers. All experiments were carried out at 4
o
C in the 
presence of (75 μg/ml) 2.4G2 Fc block. To control for the efficiency of 2.4G2 Fc block, cells were stained with 
2.4G2bio and streptavidin APC either in the presence or absence of block. Data is representative of 3 
independent experiments.  
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5.2.2 Kinetics of aggrecan presentation 
 
5.2.2.1 Comparison of aggrecan presentation by dendritic cells, macrophages and splenic 
B cells. 
Initially I set out to compare the efficiency of aggrecan presentation by H-2
d
 expressing 
splenic B cells, bone marrow derived dendritic cells and bone marrow derived macrophages 
all isolated from BALB/c mice. The various APC were cultured with the T cell hybridoma 
192 for 24 h in the presence of either graded doses of aggrecan or peptide p84-103. T cell 
hybridoma activation was measured by IL-2 production using CTLL-2 (results shown in 
Figure 5.2). Data in Figure 5.2a revealed that dendritic cells are the most effective APC, 
presenting aggrecan at a 10
2
 times lower dose than macrophages at doses from 0.3nM 
(p<0.001) and capable of inducing 192 activation at doses of aggrecan at least 10
3
 times 
lower than that seen by splenic B cells. In addition Figure 5.2b shows that dendritic cells are 
also the most efficient APC at presenting the synthetic peptide p84-103 that requires no 
further processing for presentation to the T cell hybridoma 192. Dendritic cells presented 
p84-103 at least 10
2
 times more efficiently than macrophages at doses from 0.0001nM 
(p<0.001) and at least 10
4
 times more efficiently than splenic B cells.  
 
5.3.2.2 Comparison of aggrecan presentation by dendritic cells, macrophages, aggrecan-
specific B cell clones (C71-4C5 and C71-5F10) and A20-1 HS. 
I wanted to determine whether the difference in aggrecan presentation between the various 
APC shown in Figure 5.2a presentation could also be observed between dendritic cells, 
macrophages and aggrecan-specific B cells and whether this difference in aggrecan 
presentation would also become apparent when using other forms of aggrecan. Dendritic 
cells, macrophages, two aggrecan-specific B cell clones C71-4C5 and C71-5F10 and A20-1 
HS (non-specific B cell control) were cultured with the T cell hybridomas 192 for 24 h in the 
presence of either graded doses of deglycosylated aggrecan, glycosylated aggrecan or p84-
103. Data in Figure 5.3a revealed that  aggrecan-specific B cell clone C71-4C5 is as efficient 
as dendritic cells at presenting doses of deglycosylated aggrecan from 0.005nM (p<0.01) to 
the T cell hybridomas 192, 10
2
 more efficient than macrophages and 10
5
 times more efficient 
than A20-1 HS hybridomas p<0.001. C71-5F10 was approximately 10 times less efficient at 
presentation than the C71-4C5 clones. Interestingly, data in Figure 5.3b shows that 
macrophages are the most efficient at presenting the glycosylated form of aggrecan to the T 
cell hybridomas 192 at doses from 0.005nM (p<0.01), followed by dendritic cells which were 
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approximately 10 times more efficient than the C71-4C5 clones and 10
2
 fold more efficient 
than C71-5F10 p<0.001. Data shows that A20-1 HS were not able to present this form of 
aggrecan to the T cell hybridomas 192 even at the highest dose of 200 nM.  Data in Figure 
5.3c shows that p84-103 which requires no further processing by the APC for presentation to 
the T cell hybridoma 192 was most efficiently presented by both dendritic cells and 
macrophages from a dose of 0.001 nM (p<0.001). C71-4C5, C71-5F10 and A20-1 HS all 
presented p84-103 approximately 10
2
 fold less efficiently than dendritic cells and 
macrophages. These data suggest that the improved presentation of deglycosylated and 
glycosylated aggrecan by the C71 clones is due to the improved uptake and processing of 
aggrecan and not surface presentation of the 84-103 epitope. 
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a) 
 
 
 
 
 
 
 
                                                                                                                 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Presentation of aggrecan and p84-103 by splenic B cells, bone marrow 
derived dendritic cells or bone marrow derived macrophages. APC (5x104) were cultured with 
aggrecan84-103-specific T cell hybridoma 192 (5x10
4
) in the presence of graded doses of aggrecan or peptide for 
24 h. Cells were killed by freezing at -80
o
C and supernatant was removed for bioassay with CTLL-2 cells. 
3
H 
thymidine was added for 18 h and T cell responses were determined and displayed as 
3
H thymidine cpm +/- 
SEM. Data are representative of three experiments. The asterix represents statistical significance determined by 
one-way ANOVA where p<0.05.  
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Figure 5.3 Presentation of deglycosylated and glycosylated aggrecan and p84-103 by 
bone marrow derived dendritic cells, bone marrow derived macrophages, aggrecan-
specific B cell transfectants C71-5F10 or C71-4C5 and A20-1 HS.  APC (5x104) were cultured 
with aggrecan84-103-specific T cell hybridoma 192 (5x10
4
) in the presence of graded doses of various forms of 
aggrecan (deglycosylated, glycosylated) or peptide for 24 h. Cells were killed by freezing at -80
o
C and 
supernatant was removed for bioassay with CTLL-2 cells. 
3
H thymidine was added for 18 h and T cell 
responses were determined and displayed as 
3
H thymidine cpm +/- SEM. Data are representative of three 
experiments. The asterix represents statistical significance determined by one-way ANOVA where p<0.05. 
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5.2.2.2 Comparison of aggrecan presentation by a titrated number of dendritic cells, 
macrophage and aggrecan-specific B cell clones (C71-4C5 and C71-5F10). 
 
 Pape et al previously reported that only a small number of B cells are required to accumulate 
antigen following immunization and others have identified the cell surface expression of 
peptide-MHC class II complexes at early timepoints following immunisation suggesting that 
B cells contribute to the early activation of T cells following antigen encounter (Byersdorfer, 
Dipaolo et al. 2004; Catron, Itano et al. 2004; Pape, Catron et al. 2007). However, this 
finding has not been verified for aggrecan presentation. Therefore, I titrated the number of 
APC used in the antigen presentation assays to determine the ratio of aggrecan-specific B 
cells to aggrecan-specific T cells required for T cell activation in comparison with the 
numbers of dendritic cells and macrophages required. A20-1 HS were not included in this 
assay as I have previously verified that 5x10
4
 cells are required to activate the T cell 
hybridoma 192 (data not shown). Graded numbers of the various APC were co-cultured with 
the T cell hybridoma 192 (5x10
4
)
 
for 24 h in the presence of graded doses of deglycosylated 
aggrecan. Data in Figure 5.4 revealed that when APC were cultured at a 1:1 ratio with the T 
cell hybridoma (50,000 APC per well) clones C71-4C5 were the most efficient at antigen 
presentation, presenting aggrecan from doses of 0.0001 nM p<0.001. Macrophages also 
presented aggrecan from doses of 0.0001 nM p<0.001. However, background 
3
H thymidine 
cpm in the absence of antigen was very high in these experiments.  
APC cultured at 1:3 ratio with T cell hybridomas (16,700 APC per well) was enough to 
reduce background 
3
H thymidine cpm. However, this ratio increased the amount of aggrecan 
required to generate a T cell hybridoma response, dendritic cells and clone C71-4C5 
presented aggrecan from doses of 0.001 nM whereas the clone C71-5F10 and macrophages 
required doses of 0.01 nM p<0.001.  
APC cell numbers were titrated down further to a 1:9 ratio with T cell hybridomas (5600 cells 
per well), 1:28 ratio (1800 cells per well) and finally a 1:83 ratio (600 cells per well). Results 
show that as the APC numbers are titrated down the amount of aggrecan required to generate 
T cell activation is elevated to levels of 0.1 nM for  numbers of 600 dendritic cells or clones 
C71-4C5 or C71-5F10 per well. Data from these experiments reveal that the aggrecan-
specific B cell clones C71-4C5 and 5F10 are as efficient at presenting aggrecan at a very low 
cell number (600 cells per well) as dendritic cells and approximately 10 times more efficient 
than macrophages p<0.01.  
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It was shown above that clones C71-4C5 and C71-5F10 do not present p84-103 as efficiently 
as dendritic cells and macrophages (see Figure 5.3c). To repeat this at a reduced cell number, 
APC were titrated as above and cultured with T cell hybridomas 192 (5x10
4
) in the presence 
of graded doses of p84-103 for 24 h (data shown in Figure 5.5). As shown previously for 
aggrecan presentation background 
3
H thymidine cpm were very high when APC were 
cultured at a1:1 ratio (50,000 cells per well) with the T cell hybridomas 192. However, all of 
the APC titrations show that dendritic cells and macrophages are the most efficient at 
presenting the lowest doses of p84-103 to the T cell hybridomas p<0.001. Clones C71-4C5 
and C71-5F10 required 10
3
-10
4
 fold more p84-103 to generate a T cell response at the entire 
APC/T cell ratios tested.  As the APC number was reduced increasing doses of  p84-103 were 
required to generate a T cell response at the lowest cell number of 600 APC per well 
dendritic cells could present 0.01 nM doses of p84-103 whereas clone C71-4C5 and C71-
5F10 required doses of 10 nM p<0.001. 
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Figure 5.4 Aggrecan presentation by titrated numbers of bone marrow derived 
dendritic cells, bone marrow derived macrophages and aggrecan-specific B cell 
transfectants C71-5F10 or C71-4C5. APC were cultured at various different cell numbers with 
aggrecan84-103-specific T cell hybridoma 192 (5x10
4
) in the presence of graded doses of deglycosylated 
aggrecan for 24 h. Cells were killed by freezing at -80
o
C and supernatant was removed for bioassay with 
CTLL-2 cells. 
3
H thymidine was added for 18 h and T cell responses were determined and displayed as 
3
H 
thymidine cpm +/- SEM. Data are representative of two experiments. The asterix represents statistical 
significance determined by one-way ANOVA where p<0.05. 
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Figure 5.5 p84-103 presentation by titrated numbers of bone marrow derived dendritic 
cells, bone marrow derived macrophages and aggrecan-specific B cell transfectants 
C71-5F10 or C71-4C5. APC were cultured at various different cell numbers with aggrecan84-103-specific T 
cell hybridomas 192 (5x10
4
) in the presence of graded doses of peptide for 24 h. Cells were killed by freezing at 
-80
o
C and supernatant was removed for bioassay with CTLL-2 cells. 
3
H thymidine was added for 18 h and T 
cell responses were determined and displayed as 
3
H thymidine cpm +/- SEM. Data are representative of two 
experiments. The asterix represents statistical significance determined by one-way ANOVA where p<0.05.  
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5.2.2.3 Optimisation of the pre fixed APC system. 
Paraformaldehyde fixation of APC has been previously shown to block the internalization 
and processing of antigen (Shimonkevitz, Kappler et al. 1983). Indeed, previous studies in 
our laboratory have shown paraformaldehyde fixation of macrophages and dendritic cells 
leads to recognition of the H-2
d
 /p84-103 epitope by 192 (Lowes 2005).  
 
Prior to experiments involving the pre-fixation of APC I had to optimise the percentage of 
paraformaldehyde required to efficiently fix antigen-specific B cells, whilst still enabling 
surface presentation of previously generated MHC class II/peptide complexes to the T cell 
hybridomas. In addition, in order for inhibitors of antigen processing (utilised in later 
sections) to exert their effects on their individual intracellular targets, they must be added 
prior to the addition of aggrecan. Inhibitors of antigen processing may also have off target or 
toxic effects following a prolonged incubation time with the APC or their inhibitory effects 
may be reversible after a certain length of time. Therefore, I had to optimise the minimum 
amount of time required by the APC for aggrecan uptake, processing and presentation. 
 
Dendritic cells, macrophages, C71-4C5 and C71-5F10 B cells were incubated with different 
doses of antigen at different timepoints to determine the shortest amount of time required for 
aggrecan presentation prior to fixation with different percentage doses of paraformaldehyde. 
The system was found to be optimal by pre-incubating with either aggrecan or p84-103 for 5 
h and APC fixation in 1% paraformaldehyde for 5 min (data not shown). Controls for each 
fixation experiment include APC that were fixed prior to incubation with 200nM aggrecan 
and T cell hybridoma 192 to verify that aggrecan can no longer be taken up and processed by 
the APC for presentation. APC were also fixed and then cultured with p84-103 and T cells to 
verify that this pre-processed form of aggrecan can still be displayed on surface MHC class II 
by fixed APC for presentation to T cell hybridomas and to verify that the fixation process 
does not produce any artefacts that lead to IL-2 production by the T cell hybridoma. 
Representative control data is shown in Figure 5.6.  Data shows that all APC are able to 
efficiently process and present both aggrecan and p84-103 to the T cell hybridomas 192 
following a 5 h incubation period prior to fixation and APC are also able to present p84-103 
to the T cell hybridomas 192 post-fixation. T cell activation was minimal following culture of 
the T cell hybridomas with fixed APC that had been pre-incubated with media only for 5 h  
(fixed no antigen control) or with APC that had been fixed prior to the addition of 200 nM 
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aggrecan.  These data verify that following fixation APC are no longer able to take up and 
process aggrecan for presentation to T cell hybridomas. 
 The positive control, un-fixed APC cultured with the T cell hybridomas 192 for 24 h  in the 
presence of either graded doses of aggrecan or p84-103 was included alongside every fixation 
experiment to verify the integrity of the APC and T cell hybridomas (data not shown).  
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Figure 5.6 Representative controls for post fixation experiments. 
APC were cultured in media only (fixed no antigen), 10 nM p84-103 (peptide then fixed) or 200 nM aggrecan. 
APC were fixed in 1% paraformaldehyde followed by the addition of 0.05% Gly/Gly to halt fixation. APC were 
washed 3 times and cultured (1x10
4
) with aggrecan84-103-specific T cell hybridomas 192 (5x10
4
) for 24 h. 
Alternately cells were fixed as above and cultured (1x10
4
) with aggrecan84-103-specific T cell hybridomas 192 
(5x10
4
) for 24 h in the presence of 10 nM p84-103 (fixed then peptide) or 200 nM Aggrecan (fixed then 
aggrecan). Cells were killed by freezing at -80
o
C and supernatant was removed for bioassay with CTLL-2 cells. 
3
H thymidine was added for 18 h and T cell responses were determined and displayed as 
3
H thymidine cpm +/- 
SEM. Data are representative of >three experiments.   
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5.2.2.4 Kinetics of aggrecan presentation by dendritic cells, macrophages, aggrecan-
specific B cell clones (C71-4C5 and C71-5F10) and A20-1 HS. 
I next wanted to observe whether there were any differences in the time required by the 
different APC to efficiently take up and process aggrecan for presentation of the 84-103 
epitope to the T cell hybridomas 192. Therefore, APC were incubated with aggrecan or p84-
103 for various timepoints, fixed as described previously and cultured with the T cell 
hybridomas 192 for 24 h. Data in Figure 5.7a revealed that dendritic cells, macrophages and 
the C71 clones required at least 5 h incubation with aggrecan to generate a T cell response. 
P<0.05 Interestingly, A20-1 HS were not able to present aggrecan following any of the 
incubation timepoints post-fixation. Optimal presentation of aggrecan required 12 h 
incubation prior to fixation by dendritic cells, macrophages and C71 cells p<0.001. 
Surprisingly after this timepoint the efficiency of presentation by macrophages began to 
decline, whereas the presentation by C71 clones remained stable at 18 h and 24 h incubation 
prior to fixation. Data in Figure 5.7b shows that all APC can present p84-103 following a 1 h 
incubation period p<0.05. However, optimal presentation by dendritic cells, macrophages and 
C71-4C5 required a 5 h incubation period p<0.001.  
 
Interestingly, A20-1HS are the first APC optimally present p84-103 following 1 h incubation, 
C71-5F10 required 2 h whereas the others require 5 h. This data indicates that the fixation 
process may work most efficiently with A20-1 HS. To ensure a minimal yet sufficient pre-
incubation time is given to allow aggrecan processing by the different APC, subsequent 
inhibitor experiments were carried with a 6 h antigen incubation period.  
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Figure 5.7 Kinetics of aggrecan and p84-103 presentation by bone marrow derived 
dendritic cells, bone marrow derived macrophages, aggrecan-specific B cell 
transfectants C71-5F10 or C71-4C5 and A20-1 HS. APC were pulsed for various different 
timepoints with 200 nM deglycosylated aggrecan or 10 nM p84-103. APC were washed 3 times in HBSS to 
remove all unbound antigen. APC were fixed in 1% paraformaldehyde followed by the addition of 0.05% 
Gly/Gly to halt fixation. APC were washed 3 times and cultured (1x10
4
) with aggrecan84-103-specific T cell 
hybridomas 192 (5x10
4
) for 24 h. Cells were killed by freezing at -80
o
C and supernatant was removed for 
bioassay with CTLL-2 cells. 
3
H thymidine was added for 18 h and T cell responses were determined and 
displayed as 
3
H thymidine cpm +/- SEM. Data are representative of three experiments.  The asterix represents 
statistical significance determined by one-way ANOVA where p<0.05. 
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5.2.3 Effect of inhibitors on aggrecan presentation by dendritic cells, macrophages, 
aggrecan-specific B cell clones (C71-4C5 and C71-5F10) and A20-1 HS. 
 
5.2.3.1 Treatment of APC with the inhibitors brefeldin A or cycloheximide to determine 
whether aggrecan epitope 84-103 is presented via the classical or the recycling pathway. 
To determine whether 84-103 is presented via the classical or recycling MHC class II 
pathway dendritic cells, macrophages and aggrecan-specific B cell clones C71-4C5 or C71-
5F10 were treated for 3 h with various doses of cycloheximide or brefeldin A (previously 
determined in our laboratory) to prevent the synthesis or transport of newly synthesised MHC 
class II prior to a 6 h incubation with aggrecan or p84-103.  APC were fixed and 1x10
4
 were 
cultured with T cell hybridoma 192 (5 x 10
4
) for 24 h. Data in Figure 5.8 shows that 
treatment of all APC with 10 μM cycloheximide followed by incubation with aggrecan 
totally inhibited the processing and presentation of aggrecan p<0.001. However, doses above 
10 μM cycloheximide also partially inhibited the presentation of p84-103 implying that 
cycloheximide at doses above this range may cause partial toxicity to the APC.  
 
Data in Figure 5.9 correlates with results from the cycloheximide experiments for both 
dendritic cells and the C71 aggrecan-specific B cells. Results show that presentation of 
aggrecan is totally inhibited by pre-incubation with 2.5 μg/ml brefeldin A for dendritic cells 
and C71-5F10 and 5 μg/ml brefeldin A for C71-4C5 p<0.001. Surprisingly, doses of up to 2 
μg/ml brefeldin had minimal/no effect on aggrecan presentation by macrophages.  
Thus, as expected brefeldin A had no effect on the presentation of the peptide p84-103 by 
dendritic cells, aggrecan-specific B cells C71-4C5, C71-5F10 or macrophages. Data suggest 
that presentation of the 84-103 epitope by dendritic cells, C71-4C5 and C71-5F10 requires 
newly synthesised MHC class II and presentation via the classical pathway. However, 
Brefeldin A data suggests that macrophages may be able to utilise both pathways for 
presentation of the 84-103 epitope. 
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Figure 5.8 Effect of cycloheximide an inhibitor of protein synthesis, on presentation of  
200 nM aggrecan or 10 nM p84-103 to T cell hybridomas 192.  
APC were treated in triplicates with graded doses of cycloheximide for 3 h  prior to 6 h incubation with 200 nM 
deglycosylated aggrecan or 10 nM p84-103. Controls included cells treated with the inhibitor only 
(Background fixed no antigen). APC were washed 3 times in HBSS to remove all inhibitor and unbound 
antigen. APC were fixed in 1% paraformaldehyde followed by the addition of 0.05% Gly/Gly to halt fixation. 
APC were washed 3 times and cultured (1x10
4
) with aggrecan84-103-specific T cell hybridomas 192 (5x10
4
) for 
24 h. Cells were killed by freezing at -80
o
C and supernatant was removed for bioassay with CTLL-2 cells. 
3
H 
thymidine was added for 18 h and T cell responses were determined and displayed as 
3
H thymidine cpm +/- 
SEM. Data are representative of three experiments.  The asterix represents statistical significance comparing 
the aggrecan response in the presence and absence of the lowest dose of inhibitor, determined by one-way 
ANOVA where p<0.05. 
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Figure 5.9 Effect of Brefeldin A, an inhibitor of Golgi transport, on presentation of 200 
nM aggrecan or 10 nM p84-103 to T cell hybridomas 192.  
APC were treated in triplicates with graded doses of brefeldin A for 3 h  prior to 6 h incubation with 200 nM 
deglycosylated aggrecan or 10 nM p84-103. Controls included cells treated with the inhibitor only 
(Background fixed no antigen). APC were washed 3 times in HBSS to remove all inhibitor and unbound 
antigen. APC were fixed in 1% paraformaldehyde followed by the addition of 0.05% Gly/Gly to halt fixation. 
APC were washed 3 times and cultured (1x10
4
) with aggrecan84-103-specific T cell hybridomas 192 (5x10
4
) for 
24 h. Cells were killed by freezing at -80
o
C and supernatant was removed for bioassay with CTLL-2 cells. 
3
H 
thymidine was added for 18 h and T cell responses were determined and displayed as 
3
H thymidine cpm +/- 
SEM. Data are representative of three experiments.  The asterix represents statistical significance determined 
by one-way ANOVA where p<0.05. 
 
 
 
 
Macrophages
0.
25 0.
5 1 2 4
0
100000
200000
300000
400000
0
Brefeldin g/ml
3
H
 T
h
y
m
id
in
e
 c
p
m
* 
* * 
Dendritic cells
0.
25 0.
5 1 2 4
0
100000
200000
300000
400000
200nM Aggrecan
10nM p84-103
Background fixed no antigen
0
Brefeldin g/ml
3
H
 t
h
y
m
id
in
e
 c
p
m
C71 5F10
0.
25 0.
5 1 2 4
0
100000
200000
300000
400000
0
Brefeldin g/ml
3
H
 t
h
y
m
id
in
e
 c
p
m
C71 4C5
0.
25 0.
5 1 2 4
0
100000
200000
300000
400000
0
Brefeldin g/ml
3
H
 t
h
y
m
id
in
e
 c
p
m
 204 
5.2.3.2 Treatment of APC with ammonium chloride to determine the role of endosomal 
acidification in the processing and presentation of the 84-103 epitope. 
To determine the extent of endosomal acidification required by different APC for the 
generation and presentation of the 84-103 epitope, APC were incubated with a dose range of 
ammonium chloride for 3 h (previously determined in our laboratory) to raise the  
intracellular pH prior to a 6 h incubation with aggrecan or p84-103. APC were fixed and 
1x10
4
 were cultured with T cell hybridoma 192 (5 x 10
4
) for 24 h. Data in Figure 5.10 shows 
that doses of 50 mM ammonium chloride inhibited presentation of aggrecan by dendritic cells 
and both C71 clones p<0.001. 50 mM ammonium chloride improved the presentation of 
aggrecan by macrophages p<0.05. However, treatment of macrophages with doses of 100 
mM and above totally inhibited aggrecan presentation p<0.001. This indicates that an acidic 
environment is required for efficient aggrecan processing by dendritic cells and C71 clones 
yet optimal presentation by macrophages may require a slightly less acidic environment 
implying that macrophages may begin to process aggrecan slightly earlier in the endosomal 
pathway.  
 
Doses of 200 mM ammonium chloride completely inhibited peptide p84-103 presentation by 
the C71 clones whereas 400 mM was required to inhibit presentation by dendritic cells. 
Presentation of p84-103 was not inhibited by any of the ammonium chloride doses (up to 400 
mM). This implies that either doses of 200 mM or 400 mM ammonium chloride are toxic to 
C71 clones and dendritic cells respectively or that p84-103 loading of MHC class II 
molecules is inhibited by increasing intracellular pH. 
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Figure 5.10 Effect of ammonium chloride, used to raise endosomal pH, on presentation 
of 200 nM aggrecan or 10 nM p84-103 to T cell hybridomas 192.  
APC were treated in triplicates with graded doses of ammonium chloride for 3 h prior to 6 h incubation with 
200 nM deglycosylated aggrecan or 10 nM p84-103. Controls included cells treated with the inhibitor only 
(Background fixed no antigen). APC were washed 3 times in HBSS to remove all ammonium chloride and 
unbound antigen. APC were fixed in 1% paraformaldehyde followed by the addition of 0.05% Gly/Gly to halt 
fixation. APC were washed 3 times and cultured (1x10
4
) with aggrecan84-103-specific T cell hybridomas 192 
(5x10
4
) for 24 h. Cells were killed by freezing at -80
o
C and supernatant was removed for bioassay with CTLL-2 
cells. 
3
H thymidine was added for 18 h and T cell responses were determined and displayed as 
3
H thymidine 
cpm +/- SEM. Data are representative of three experiments. The asterix represents statistical significance 
determined by one-way ANOVA where p<0.05. 
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5.2.3.3 Treatment of APC with E-64d and pepstatin A to determine the role of cysteine and 
aspartic proteinases in the processing and presentation of the 84-103 epitope. 
I next wanted to determine the role of cysteine and aspartic proteinases in the processing and 
presentation of the 84-103 epitope by the different APC. E-64d is a cell permeable 
irreversible inhibitor of cysteine proteinases including calpain, papain and the cathepsins B, 
H and L (Bond and Butler 1987). Pepstatin A is a highly selective inhibitor of aspartic 
proteinases including cathepsin D, pepsin and rennin (Marciniszyn, Hartsuck et al. 1976).  
 
APC were incubated with graded doses of E-64d, or pepstatin A for 1 h (previously 
determined by our laboratory) prior to a 6 h incubation with aggrecan or p84-103. APC were 
fixed and 1x10
4
 were cultured with T cell hybridoma 192 (5 x 10
4
) for 24 h. Data in Figure 
5.11 shows that pre-treatment of the APC with doses of up to 100 μM of E-64d prior to 
incubation with 200 nM aggrecan had no affect on the presentation of 84-103. In addition to 
this, concentrations as high as 100 μM also failed to have any effect on the presentation of 
peptide p84-103 by all APC types. This data is consistent with experiments previously 
performed by our laboratory that  showed pre-treatment of macrophages with up to 50 μM of 
E-64d had no effect on the presentation of aggrecan to 192. In addition, it was also shown in 
these previous studies that 1.25 μM E-64d did inhibit the presentation of the type II collagen 
epitope 259-273 to collagen specific hybridoma indicating that the inhibitor was functional 
despite having no effect on 84-103 presentation to the T cell hybridoma 192 (Lowes 2005; 
von Delwig, Altmann et al. 2006). 
 
To confirm that the batch of E-64d was functional, I attempted to repeat findings by Shim et 
al from our laboratory who showed previously that the presentation of V antigen by 
macrophages to the V antigen-specific hybridomas 1E10, 1B4 and 2H1 is inhibited by 2.5 
μM E-64d (Shim, Musson et al. 2006).  Unfortunately, I was unable to demonstrate that any 
of the fixed APC were able to present V antigen epitopes to any of the 3 V antigen-specific T 
cells following prior incubation with V antigen. Therefore, although not strictly controlled, I 
had to speculatively conclude that cysteine proteinases are not involved in the endosomal 
processing of aggrecan and the generation of the 84-103 epitope.  
To examine the effects of aspartic proteinases on aggrecan presentation, dendritic cells, 
macrophages and the aggrecan-specific B cell clones C71-4C5 and C71-5F10 were pre-
treated with doses of up to 4 mM of the inhibitor pepstatin A. Data in Figure 5.12 shows that 
the lowest dose of 0.5 mM totally inhibited presentation of aggrecan by both of the C71 
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clones p<0.001. Doses from 1 mM up to 4 mM pepstatin A also inhibited presentation of 
aggrecan by macrophages close to background levels p<0.01. However, doses of up to 4 mM 
pepstatin A only partially reduced aggrecan presentation by dendritic cells.  
 
Pepstatin A did not have substantial affects on the presentation of peptide p84-103 by any of 
the APC. Therefore these data suggest that aspartic proteinases play a major role in aggrecan 
processing and generation of the 84-103 epitope by aggrecan-specific B cells and 
macrophages. However, 84-103 generation and presentation by dendritic cells was not 
completely abolished in the presence of pepstatin A. This implies that dendritic cells require 
aspartic proteinases for optimal generation and presentation of the 84-103 epitope, but are 
still able to process and present aggrecan at a reduced efficiency independently of aspartyl 
proteinases.  
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Figure 5.11 Effect of E-64d, an inhibitor of cysteine proteinases, on presentation of 200 
nM aggrecan or 10 nM p84-103 to T cell hybridomas 192.  
APC were treated in triplicates with graded doses of E-64d for 1 h prior to 6 h incubation with 200nM 
deglycosylated aggrecan or 10nM p84-103. Controls included cells treated with the inhibitor only (Background 
fixed no antigen). APC were washed 3 times in HBSS to remove all inhibitor and unbound antigen. APC were 
fixed in 1% paraformaldehyde followed by the addition of 0.05% Gly/Gly to halt fixation. APC were washed 3 
times and cultured (1x10
4
) with aggrecan84-103-specific T cell hybridomas 192 (5x10
4
) for 24 h. Cells were killed 
by freezing at -80
o
C and supernatant was removed for bioassay with CTLL-2 cells. 
3
H thymidine was added for 
18 h and T cell responses were determined and displayed as 
3
H thymidine cpm +/- SEM. Data are 
representative of three experiments. 
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Figure 5.12 Effect of Pepstatin A an inhibitor of aspartyl proteinases, on presentation of 
200 nM aggrecan or 10 nM p84-103 to T cell hybridomas 192.  
APC were treated in triplicates with graded doses of pepstatin A for 1 h  prior to 6 h incubation with 200 nM 
deglycosylated aggrecan or 10 nM p84-103. Controls included cells treated with the inhibitor only 
(Background fixed no antigen). APC were washed 3 times in HBSS to remove all inhibitor and unbound 
antigen. APC were fixed in 1% paraformaldehyde followed by the addition of 0.05% Gly/Gly to halt fixation. 
APC were washed 3 times and cultured (1x10
4
) with aggrecan84-103-specific T cell hybridomas 192 (5x10
4
) for 
24 h. Cells were killed by freezing at -80
o
C and supernatant was removed for bioassay with CTLL-2 cells. 
3
H 
thymidine was added for 18 h and T cell responses were determined and displayed as 
3
H thymidine cpm +/- 
SEM. Data are representative of three experiments. The asterix represents statistical significance determined 
by one-way ANOVA where p<0.05.  
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5.2.3.4 Treatment of APC with 3,4-DCI and leupeptin to determine the role of cysteine and 
serine  proteinases in the processing and presentation of the 84-103 epitope. 
3,4- dichloroisocoumarin  (3,4-DCI) is an irreversible broad range serine proteinase inhibitor 
(Harper, Hemmi et al. 1985). Leupeptin is a reversible competitive inhibitor of serine and 
cysteine proteinases including plasmin, trypsin, papain and cathepsin B (Aoyagi, Takeuchi et 
al. 1969). To determine the role of cysteine and serine proteinases in the processing and 
presentation of 84-103 by the different APC, APC were incubated with various doses of 3,4-
DCI, or leupeptin for 1 h prior to a 6 h incubation with aggrecan or p84-103. APC were fixed 
and 1x10
4
 were cultured with T cell hybridoma 192 (5 x 10
4
) for 24 h. Data in Figure 5.13 
shows that pre-treatment with doses greater than 10 μM 3,4-DCI prior to incubation with 200 
nM aggrecan completely abolished presentation to T cell hybridomas 192 by both of the C71 
clones p<0.001. Pre-treatment with >20 μM 3,4-DCI completely abolished presentation of 
aggrecan by dendritic cells p<0.001. However, macrophages required a much larger dose of 
80μM 3,4-DCI to completely inhibit aggrecan  presentation p<0.001.  
 
Pre-treatment of dendritic cells with doses of up to 80 μM 3,4-DCI had no effect on the 
presentation of the peptide p84-103 by dendritic cells. Pre-treatment of C71-5F10 with 20 
μM 3,4-DCI improved presentation of p84-103 yet an increased dose of 80 μM 3,4-DCI 
reduced p84-103 presentation. Pre-treatment of C71-4C5 with up to 40 μM had no effect on 
p84-103 presentation but an increased dose of 80μM reduced presentation to near background 
levels. Interestingly, presentation of p84-103 by macrophages was enhanced by pre-
incubation with doses of 20 μM 3,4-DCI and above.  
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Figure 5.13 Effect of DCI, an inhibitor of serine proteinases, on presentation of 200 nM 
aggrecan or 10 nM p84-103 to T cell hybridomas 192.  
APC were treated in triplicates with graded doses of DCI for 1 h prior to 6 h incubation with 200 nM 
deglycosylated aggrecan or 10 nM p84-103. Controls included cells treated with the inhibitor only 
(Background fixed no antigen). APC were washed 3 times in HBSS to remove all inhibitor and unbound 
antigen. APC were fixed in 1% paraformaldehyde followed by the addition of 0.05% Gly/Gly to halt fixation. 
APC were washed 3 times and cultured (1x10
4
) with aggrecan84-103-specific T cell hybridomas 192 (5x10
4
) for 
24 h. Cells were killed by freezing at -80
o
C and supernatant was removed for bioassay with CTLL-2 cells. 
3
H 
thymidine was added for 18 h and T cell responses were determined and displayed as 
3
H thymidine cpm +/- 
SEM. Data are representative of three experiments. The asterix represents statistical significance determined by 
one-way ANOVA where p<0.05. 
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Data in Figure 5.14 shows that pre-treatment of the C71 clones with 2.5 μM of the 
cysteine/serine inhibitor leupeptin prior to incubation with 200 nM aggrecan totally inhibited 
presentation to the T cell hybridomas 192 p<0.001. However, doses of up to 20 μM leupeptin 
did not reduce presentation of aggrecan by dendritic cells and macrophages to background 
levels. Interestingly, lower doses of 2.5 μM and 5 μM began by reducing aggrecan 
presentation by macrophages, and larger doses leupeptin (10 μM-20 μM) recovered and 
began to improve presentation.  
 
Presentation of the peptide p84-103 was also reduced close to background levels by both of 
the C71 clones suggesting that leupeptin may be toxic to these cells. Presentation of p84-103 
by dendritic cells was not affected by any of the leupeptin doses tested (2.5-20 μM). In 
correlation with the pattern of presentation of observed with the 84-103 epitope, presentation 
of peptide p84-103 by macrophages was reduced at doses of 5μM leupeptin followed by a 
recovery to untreated levels of p84-103 presentation at 20μM.  
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Figure 5.14 Effect of Leupeptin an inhibitor of serine and cysteine proteinases on 
presentation of 200 nM aggrecan or 10 nM p84-103 to T cell hybridomas 192.  
APC were treated in triplicates with graded doses of leupeptin for 1 h  prior to 6 h  incubation with 200 nM 
deglycosylated aggrecan or 10 nM p84-103. Controls included cells treated with the inhibitor only 
(Background fixed no antigen). APC were washed 3 times in HBSS to remove all inhibitor and unbound 
antigen. APC were fixed in 1% paraformaldehyde followed by the addition of 0.05% Gly/Gly to halt fixation. 
APC were washed 3 times and cultured (1x10
4
) with aggrecan84-103-specific T cell hybridomas 192 (5x10
4
) for 
24 h. Cells were killed by freezing at -80
o
C and supernatant was removed for bioassay with CTLL-2 cells. 
3
H 
thymidine was added for 18 h and T cell responses were determined and displayed as 
3
H thymidine cpm +/- 
SEM. Data are representative of three experiments.  The asterix represents statistical significance determined 
by one-way ANOVA where p<0.05. 
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5.2.3.5 Treatment of APC with phenanthroline to determine the role of metalloproteinases 
in the presentation of the 84-103 epitope. 
Phenanthroline is a broad spectrum metalloproteinase inhibitor (Takahashi, Cease et al. 
1989). To determine the role of metalloproteinases in the processing and presentation of 84-
103, APC were incubated with various doses of phenanthroline for 1 h prior to a 6 h 
incubation with aggrecan or p84-103. APC were fixed and 1x10
4
 were cultured with T cell 
hybridoma 192 (5 x 10
4
) for 24 h. Data in Figure 5.15 shows that pre-treatment of the four 
APC with doses of >800 μM phenanthroline prior to incubation with 200 nM aggrecan 
completely abolished presentation to the T cell hybridomas 192 by dendritic cells and the 
C71 clones C71-5F10 p<0.001. Increasing doses of >200 μM phenanthroline had a gradual 
effect on lowering the efficiency of aggrecan presentation by the C71-5F10 clone. 
Interestingly, phenanthroline had a slightly different effect on aggrecan presentation by the 
C71 clone C71-4C5. C71-4C5 clones, required doses of 1600 μM phenanthroline to 
completely abolish aggrecan presentation and lower doses had no effect on aggrecan 
presentation to the T cell hybridomas 192 p<0.001. Macrophages began to show a reduction 
in their efficiency to present aggrecan following pre-treatment with >400 μM phenanthroline. 
However, even when used at the highest dose of 1600 μM phenanthroline did not reduce 
aggrecan presentation to the T cell hybridomas 192 by macrophages back down to 
background levels.  
 
Presentation of p84-103 by dendritic cells, macrophages or the C71-4C5 cells was not 
affected by even the highest 1600 μM dose of phenanthroline. However, presentation of p84-
103 by the C71-5F10 clones was reduced from >200 μM doses of phenanthroline. 
Surprisingly this reduction in p84-103 presentation by C71-5F10 was recovered by pre-
treatment with the highest dose of phenanthroline 1600 μM. Data suggests that 
metalloproteinases play a major role in the processing and presentation of 84-103 by 
aggrecan-specific B cells and dendritic cells and to a lesser extent in macrophages.  
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Figure 5.15 Effect of phenanthroline, an inhibitor of metalloproteinases, on presentation 
of 200 nM aggrecan or 10 nM p84-103 to T cell hybridomas 192.  
APC were treated in triplicates with graded doses of phenanthroline for 1 h prior to 6 h incubation with 200 nM 
deglycosylated aggrecan or 10 nM p84-103. Controls included cells treated with the inhibitor only 
(Background fixed no antigen). APC were washed 3 times in HBSS to remove all inhibitor and unbound 
antigen. APC were fixed in 1% paraformaldehyde followed by the addition of 0.05% Gly/Gly to halt fixation. 
APC were washed 3 times and cultured (1x10
4
) with aggrecan84-103-specific T cell hybridomas 192 (5x10
4
) for 
24 h. Cells were killed by freezing at -80
o
C and supernatant was removed for bioassay with CTLL-2 cells. 
3
H 
thymidine was added for 18 h and T cell responses were determined and displayed as 
3
H thymidine cpm +/- 
SEM. Data are representative of three experiments. The asterix represents statistical significance determined by 
one-way ANOVA where p<0.05. 
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5.2.4 A comparison of aggrecan presentation by the different APC to aggrecan-specific T 
cells isolated from TCR-5/4E8-tg mice.   
So far I have shown that aggrecan-specific B cells are efficient APC capable of aggrecan 
presentation comparable to that of dendritic cells and at a far greater efficiency to that of non-
specific B cells. I next wanted to examine aggrecan presentation by the different APC to 
another population of aggrecan-specific T cells (5/4E8) isolated from TCR-5/4E8-transgenic 
mice.  
 
5.2.4.1 Phenotype of T cells from TCR-5/4E8 transgenic mice.  
Therefore, I isolated 5/4E8 T cells from the spleens of TCR-5/4E8 transgenic mice. 5/4E8 
CD4+ T cells express a functional TCR specific for the aggrecan epitope 
ATEGRVRVNSAYQDK found within the epitope 84-103. The TCR is composed of Vα1.1 
and Vβ4 chains. To verify the purity of the CD4+ T cells isolated from spleens of these mice, 
CD4 expression was detected along with TCRαβ by flow cytometry. The percentage of Vβ4+ 
cells was also evaluated by flow cytometry as a marker of aggrecan-specific TCR expression 
(Figure 5.16).  
Results confirm that 97.7% of CD4+ isolated cells are indeed CD4+ and 94.2% of the 
isolated CD4+ cells express a Vβ+ TCR.     
 
5.2.4.2 Aggrecan presentation to T cells from TCR-5/4E8 transgenic mice. 
Dendritic cells, macrophages, C71-4C5, C71-5F10 B cells and A20-1HS B cells were 
cultured with the 5/4E8 T cells for 72 h in the presence of either deglycosylated aggrecan or 
p84-103. Isolated T cells alone (no APC) were used as a negative control to determine 
whether a small percentage of contaminating APC from MACS separation is enough to 
generate an IL-2 response to aggrecan. Activation of transgenic T cells was measured by IL-2 
production using CTLL-2. Results in Figure 5.17a showed that C71-4C5 were the most 
efficient at presenting low dose (0.01nM) aggrecan to the T cells 5/4E8 p<0.01. Macrophages 
required around 10-fold more aggrecan (0.1 nM) for efficient presentation to the T cells 
5/4E8 and A20-1 HS were unable to generate a T cell response above the level of the no APC 
control. Surprisingly, the addition of A20-1-HS generated slightly reduced IL-2 production 
compared to the no APC control. The no APC control required >10nM doses of aggrecan to 
generate an IL-2 response indicating that either the low levels of contaminating APC present 
in the isolated T cell population are sufficient to present high doses of aggrecan to the T cells 
5/4E8 or that the T cells 5/4E8 produce IL-2 in the presence of high increasing doses of 
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aggrecan without the requirement for antigen presentation. Data in Figure 5.17b shows that 
dendritic cells are most efficient at presenting >0.05 nM p84-103 to the 5/4E8 T cells 
p<0.001 followed by macrophages and C71-4C5 and C71-5F10 B cells which require 
approximately 10 times more p84-103 for efficient presentation. The no APC and A20-1 HS 
controls showed weak responses to >1 nM p84-103. Surprisingly, increasing the dose of p84-
103 to 10nM reduced presentation by A20-1 HS to just above background.   
 
5.2.5 Cytokine analysis of CD4+ T cells from TCR-5/4E8-tg mice.  
PGIA is thought to be reliant on a Th1 response, mediated by the cytokine IFNγ (Hollo, Glant 
et al. 2000). Therefore, I wanted to investigate if there were any differences in the cytokine 
profile of the 5/4E8 T cells when they were activated in vitro by the different types of APC. It 
is possible that APC are able to promote an anti-inflammatory response following antigen 
presentation to the 5/4E8 aggrecan-specific T cells. To address this possibility I wanted to 
determine whether any of the APC promoted a regulatory type IL-10 response following 
aggrecan presentation to the 5/4E8 T cells. 
 
Therefore, supernatant from the above antigen presentation assays was examined by ELISA 
to determine the cytokines produced by the CD4+ TCR-5/4E8 T cells in response to p84-103 
or aggrecan presentation by the different APC populations. Controls for this experiment 
included blank wells coated with capture antibody and subsequently incubated with media 
only. Supernatant from wells cultured with T cells and antigen only (no APC) and 
supernatant from wells cultured with APC and antigen only. The concentration of IL-10 or 
IFNγ in the supernatant was calculated from standard curves using recombinant IL-10 and 
IFNγ. Results in Figure 5.18a showed that increasing amounts of IFNγ (up to 9.4 ng/ml) was 
detected in the supernatant taken from 5/4E8 T cells cultured with C71-4C5 and doses of 
aggrecan  >0.5 nM. IFNγ was detected from wells containing 5/4E8 T cells and C71-5F10, 
dendritic cells or macrophages and higher doses of 1 nM aggrecan. However, there were 
much higher doses of 4.7 ng/ml IFNγ detected in wells containing the C71-5F10 cells around 
5 times higher than that detected in response to aggrecan presentation by dendritic cells 1.5 
ng/ml or macrophages 1.3 ng/ml. No IFNγ was detected in supernatant taken from wells 
containing A20-1 HS and 5/4E8 T cells or the no APC control. Data indicates that aggrecan 
presentation by aggrecan-specific B cells C71-4C5 and C71-5F10 produces a much greater 
IFNγ response than presentation by dendritic cells or macrophages.  
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Surprisingly the same result was not obtained when 5/4E8 T cells were cultured with APC in 
the presence of graded doses of p84-103. Figure 5.18b shows that IFNγ responses are highest 
when 5/4E8 T cells are cultured with macrophages and p84-103. IFNγ was detected in the 
supernatant taken from wells containing 5/4E8 T cells cultured with macrophages and >0.1 
nM p84-103. Dendritic cells produced IFNγ responses from around 1 nM, whereas C71-4C5 
required 5 nM 50 times more p84-103 than macrophages to produce an IFNγ response and 
C71-5F10 required 10 nM 100 times more p84-103. IFNγ was not detected in supernatant 
taken from wells containing A20-1 HS or the no APC control. Results in Figures 5.18 c and 
d show that IL-10 was not detected in the supernatant taken from any of the antigen 
presentation conditions indicating that aggrecan and p84-103 presentation to 5/4E8 T cells by 
APC in vitro does not result in a regulatory IL-10 response. However, presentation of 
aggrecan to 5/4E8 T cells by aggrecan-specific B cells C71-4C5 and C71-5F10 results in a 
high level of IFNγ production indicative of a Th1 type response. 
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Figure 5.16 Flow cytometry of isolated spleen cells and CD4+ separated cell populations 
with CD4, TCRαβ and Vβ4-specific antibodies. Staining of isolated spleen cells or CD4+ MACS 
separated cells with CD4, TCRαβ or Vβ4 antibodies. All experiments were carried out at 4oC in the presence of 
Fc block. Data is representative of 2 independent experiments. The percentage of cells per quadrant is 
indicated. 
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Figure 5.17 Aggrecan and p84-103 presentation to 5/4E8 CD4+  T cells by bone marrow 
derived dendritic cells, bone marrow derived macrophages, aggrecan-specific B cell 
transfectants C71-5F10 or C71-4C5 and A20-1 HS. Aggrecan-specific 5/4E8 CD4+ T cells were 
isolated from the spleens of transgenic mice and separated on an LS separation column in the magnetic field of 
the VarioMacs separator using CD4 (L3T4) microbeads. 5x10
4
 isolated T cells were cultured with APC (1x10
4
) 
in the presence of graded doses of aggrecan or p84-103 for 72 h. Cells were killed by freezing at -80
o
C and 
supernatant was removed for bioassay with CTLL-2 cells. Tritiated thymidine was added for 18 h and T cell 
responses were determined and displayed as 
3
H thymidine cpm +/- SEM. Data are representative of two 
experiments.  The asterix represents statistical significance determined by one-way ANOVA where p<0.05. 
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Figure 5.18 IFNγ and IL-10 levels detected in the supernatant 5/4E8 T cells cultured 
with aggrecan or p84-103 and the different APC. Aggrecan-specific CD4+ T cells 5/4E8 (5x104) 
were cultured  in the presence of graded doses of aggrecan or p84-103 and APC (1x10
4
)  for 72 h. Cells were 
killed by freezing at -80
oC and supernatant was removed for IFNγ and IL-10 detection by ELISA.  Data are 
representative of two experiments. The asterix represents statistical significance determined by one-way 
ANOVA where p<0.05.  
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5.3 Discussion 
The aim of this chapter was to examine the kinetics and mechanisms of aggrecan processing 
and presentation by the aggrecan-specific B cell clones C71-4C5 and C71-5F10 in 
comparison to that seen in dendritic cells and macrophages. Results from the kinetics study 
confirm the optimal time required by the various APC, the number of APC required and dose 
of aggrecan required for efficient presentation to the aggrecan-specific T cell hybridoma 192. 
In addition, the different APC were incubated with aggrecan in the presence of a number of 
reagents that have previously been demonstrated to have profound effects on antigen 
processing. This enabled dissection of the different components of the aggrecan processing 
and presentation pathway and established which steps were important or indeed vital in 
generating the 84-103 immunodominant arthritogenic epitope from this important candidate 
joint autoantigen. In addition to detecting 84-103 recognition by a well characterized T cell 
hybridoma (192), I have also examined the effects of 84-103 presentation by the various APC 
on naïve T cells isolated from transgenic mice expressing the 5/4E8 aggrecan 84-103-specific 
TCR. APC were cultured with the aggrecan-specific T cells 5/4E8 and graded doses of 
aggrecan or p84-103 to establish which APC were the most efficient at presenting aggrecan 
to ex vivo aggrecan-specific CD4+ T cells. These experiments also demonstrated the levels of 
both the pro-inflammatory cytokine IFNγ and the anti-inflammatory cytokine IL-10 produced 
in response to aggrecan/p84-103 presentation by the 4 different APC. The results are 
discussed below. 
 
5.3.1 Kinetics of aggrecan presentation  
The kinetics of antigen processing by B cells has been extensively studied. To summarize, 
presentation of HEL (14 kDa) is presented with different efficiencies dependent on the 
antigen/BCR interaction. B cells expressing anti-HEL BCR with high affinity  (Ka 5 x10
10
 M
-
1 
) for example, are capable of presenting HEL at concentrations as low as 0.5nM, whereas 
those B cells expressing a BCR with a low affinity (Ka 3 x10
8
 M
-1
 ) require approximately  
10 times more HEL for equivalent T cell stimulation (Batista and Neuberger 1998). Using a 
different model antigen (TTCF; 47 kDa) Lanzavecchia demonstrated that TTCF-specific B 
cells require 10
4
 fold lower concentrations of TTCF (10
-11
-10
-12
M) than non-specific B cells 
(Lanzavecchia 1985). Casten and colleagues have studied the presentation kinetics of the 
globular antigen pigeon cytochrome c (PCC; ~12 kDa) by non-specific B cells and when 
PCC is targeted to the BCR via PCC linkage to anti-Ig fragments. Data from the PCC kinetics 
study revealed that specific uptake via the BCR requires 10
3
 times less PCC than nonspecific 
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B cell for T cell presentation (Casten, Kaumaya et al. 1988). The consensus from these and 
other studies is that B cells that do not have an antigen- specific BCR require 10
3
-10
4
 more 
antigen for efficient presentation to T cells (Rock, Benacerraf et al. 1984; Abbas, Haber et al. 
1985; Lanzavecchia 1990). Hapten-linked proteins have also been used to define the antigen 
uptake and kinetics of a variety of antigens using a single hapten-specific B cell line. Using 
this method antigens can be linked via haptens such as 2,4,6 trinitrophenol (TNP), 4-hydroxy-
3-nitro-phenol-acetyl (NP) or fragments of anti-Ig antibodies (Abbas, Haber et al. 1985; 
Casten and Pierce 1988). Hapten-linked proteins are a good model for defining B cell uptake, 
activation and signalling in response to BCR-ligand binding. However, the effects on 
modifying antigen in an unphysiological way such as linking of haptens may have an effect 
on antigen processing by the APC by preventing access to various proteolytic sites.  
 
Thus, most previously described reports have involved the study of the presentation of simple 
model antigens and not a large (250 kDa) complex candidate autoantigen such as aggrecan. 
However, there are several lines of evidence to suggest that B cells play a role in the 
presentation of this candidate RA autoantigen (Brennan, Mikecz et al. 1995; O'Neill, 
Shlomchik et al. 2005; O'Neill S, Cao et al. 2007). Indeed, elegant studies by O‟Neill et al 
confirmed that B cells are essential for the induction and transfer of PGIA (O'Neill, 
Shlomchik et al. 2005). Furthermore, they demonstrated that the role of B cells was not only 
antibody production but also as an essential population of antigen-specific APC. Therefore, in 
an attempt to identify novel aspects of antigen presentation by aggrecan-specific B cells, I 
optimised a series of experiments allowing me to dissect aggrecan processing and 
presentation by different APC types.   
 
As the induction of PGIA requires immunisation with deglycosylated aggrecan in adjuvant, I 
wanted to confirm which APC were proficient at presenting both this form of aggrecan and 
it‟s fully glycosylated form. Interestingly, results confirmed that aggrecan-specific B cells 
(C71-4C5) were as efficient as dendritic cells and more efficient than macrophages at 
presenting deglycosylated aggrecan to T cell hybridomas 192. However, it was macrophages 
that were the most efficient APC when presenting the glycosylated form of aggrecan. This is 
possibly due to the high expression of carbohydrate receptors by macrophages such as CD44 
which triggers phagoctosis of large antigens (Sterling, Saginario et al. 1998; Taylor, 
Martinez-Pomares et al. 2005). Presentation of the synthetic peptide p84-103 by dendritic 
cells and macrophages was at least 10
2
 times more efficient than that of aggrecan-specific B 
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cells (Figure 5.3). These findings imply that the efficient presentation of deglycosylated 
aggrecan by B cells is due to recognition of the aggrecan structure and efficient uptake and 
processing as modifications such as glycosylation reduce the presentation capacity of the 
aggrecan-specific B cells. In addition, as the aggrecan-specific B cells are relatively poor at 
presenting peptide p84-103 which does not require any further processing to be presented by 
APC this implies that the efficiency of aggrecan-specific B cells as APC lies in their ability to 
very efficiently take up and process aggrecan. Therefore it is possible that the results from 
O‟Neill and colleagues could be explained by the fact that aggrecan-specific B cells are 
extremely efficient APC at presenting the immunogenic deglycosylated form of aggrecan and 
are required in this capacity to generate an immune response against aggrecan and a severe 
form of PGIA (O'Neill, Shlomchik et al. 2005; O'Neill S, Cao et al. 2007).  
 
Furthermore, it has been shown that B cells can divert the immune response from one epitope 
to another by the paradigm known as „molecular mimicry‟. Molecular mimicry describes a 
process where foreign peptides resembling a self protein can initiate an immune response 
against self antigens. An example of this is rheumatic fever where B cells can recognise and 
promote an antibody response toward streptococcal M protein that also recognises and cross 
reacts with cardiac myosin (Liang and Mamula 2000). Indeed, this phenomenon is also 
typical for autoimmune disease models for example primary billiary cirrhosis (PBC) in mice 
is only induced with the antigen pyruvate dehydrogenase complex (PDC) from other species, 
or if mouse PDC is modified e.g. by biotinylation it will induce antibodies that cross-react to 
non- biotinylated mouse PDC (Palmer, Robe et al. 2004). Therefore, as PGIA is only initiated 
by the immunisation of deglycosylated human or bovine aggrecan and not mouse aggrecan, it 
is possible that B cells are involved in efficiently taking up the aggrecan and presenting 
different epitopes that lead to a break in self- tolerance.  
 
Recent data has confirmed a citrullinated form of aggrecan p84-103 was able to generate 
responses in T cells isolated from RA patients (von Delwig, Locke et al. 2010). Therefore, 
time permitting it would have been interesting to investigate the processing and presentation 
of citrullinated whole aggrecan as an alternate modified autoantigen. This coupled with the 
finding that ~70% RA patients have antibodies to cyclic citrullinated peptides makes this an 
exciting prospect for future studies (Nishimura, Sugiyama et al. 2007). 
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Studies have shown that small numbers of antigen-specific B cells residing in lymphoid 
follicles are sufficient to present low amounts of antigen, early in the immune response 
(Curtsinger, Schmidt et al. 1999). To investigate the amount of aggrecan-specific B cells 
required to generate a T cell response in comparison to dendritic cells and macrophages, APC 
numbers were titrated and cultured with T cell hybridoma 192 in the presence of graded 
doses of either aggrecan or p84-103 (Figures 5.4 and 5.5). Results confirmed that 600 
dendritic cells, macrophages or aggrecan-specific B cells were sufficient to present aggrecan 
or p84-103 to 5x10
4
 T cell hybridoma 192. Reducing the number of APC had no effect on the 
differences between the efficiency of aggrecan or p84-103 presentation by the different APC 
observed in earlier experiments (see Figure 5.3). What is interesting to note is that 600 
aggrecan-specific B cells can efficiently process and present >0.01 nM of deglycosylated 
aggrecan to the T cell hybridomas 192, whereas they require >1nM p84-103 that requires no 
further processing for presentation. However, dendritic cells and macrophages can present 
>0.01 nM doses of either antigen efficiently.  These data imply that optimal MHC class II 
loading of the 84-103 epitope requires its generation within the endosomal pathway by 
aggrecan-specific B cells. One possibility is that following BCR ligation there is an 
upregulation or more rapid turnover of MHC class II on the surface of the aggrecan-specific 
B cells. It has been shown that MHC class II surface expression is regulated via the ubiquitin 
system (Matsuki, Ohmura-Hoshino et al. 2007). Therefore, it is possible that BCR signalling 
is involved in this regulation. Indeed it has also been previously shown that BCR signaling 
triggers the re-organization of MHC class II molecules and influence the site of antigen 
processing (Siemasko, Eisfelder et al. 1998). An increase in MHC class II surface expression 
or intracellular re-organization could have been established by examining expression by flow 
cytometry both prior to and following aggrecan-specific B cell culture with aggrecan for 24 
h.  
 
Fixation of APC to study antigen processing by APC has been previously described 
(Shimonkevitz, Kappler et al. 1983).  Once the APC is fixed it is metabolically inactive and 
can no longer process or transport antigen. Therefore, APC can be incubated with antigen and 
processing can be halted at various timepoints to determine the length of time required for 
efficient antigen processing and presentation. Alternately, APC can be pre-incubated with 
modulators of intracellular pH, inhibitors of protein synthesis, ER egress, and various 
proteinase inhibitors to examine the antigen processing pathway required by the different 
APC. An essential control for all the fixation experiments in this project, was to fix the APC 
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prior to incubation with aggrecan and p84-103, if the cell is sufficiently fixed aggrecan will 
not be presented yet p84-103 will bind to MHC class II already on the APC cell surface and 
should still be efficiently presented following 24 h culture with the T cell hybridoma 192. 
Using this fixation system a timecourse of aggrecan and peptide presentation by the different 
APC was established. I confirmed that macrophages required a minimum of 6 h to efficiently 
process aggrecan and generate 84-103-MHC class II complexes, yet aggrecan-specific B cells 
C71-4C5 and dendritic cells began to process aggrecan and generate 84-103-MHC class II 
complexes after 2 h incubation with aggrecan implying faster kinetics and possible peptide 
loading of recycling molecules. The 5 h required to present the 84-103 epitope suggests that 
transport of newly synthesised MHC class II that takes around this time (Delvig and 
Robinson 1998; Musson, Hayward et al. 2002). 
 
Expectedly p84-103 required less time for presentation and 84-103-MHC class II complexes 
were generated following <1 h incubation with p84-103. Interestingly A20-1 HS were the 
most efficient at generating 84-103-MHC class II complexes (maximal following 1 h 
incubation with p84-103) despite being unable to present native aggrecan following post-
fixation, whereas dendritic cells and macrophages require 5 h before 84-103-MHC class II 
generation is optimal. These data imply that A20-1 HS cells are less sensitive to the fixation 
process than dendritic cells and macrophages possibly due to the cell morphology. In support 
of this the aggrecan-specific B cells C71-5F10 only required 2 h. However, C71-4C5 also 
required 5 h for efficient p84-103 presentation and reason for the observed differences 
between the 2 aggrecan-specific B cell clones is not known.  
 
Despite the observation that optimal 84-103-MHC class II generation occurs in dendritic 
cells, macrophages and the two aggrecan-specific B cells tested following a 12 h incubation 
period with aggrecan, this timepoint is too long for optimal use in these assays as the 
inhibitors used may loose function during this extended period prior to fixation. In support of 
this, Katie Lowes in our laboratory previously optimised the timepoint required for 
macrophage processing of aggrecan (Lowes 2005). Therefore the minimum 6 h timepoint 
was chosen for inhibitor studies. 
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5.3.2 Effect of inhibiting steps in the antigen processing pathway 
 
Inhibitor Dendritic 
cells 
macrophages C71-4C5/ 
C71-5F10 
Cycloheximide 
(protein synthesis) 
inhibited inhibited inhibited 
Brefeldin A 
(Golgi transport) 
inhibited Partially 
inhibited 
inhibited 
Ammonium chloride 
(raise Ph) 
inhibited inhibited inhibited 
E-64d 
(cysteine proteinases) 
no effect no effect no effect 
3’4-DCI 
(serine proteinases) 
inhibited inhibited inhibited 
Leupeptin 
(cysteine and serine 
proteinases) 
Partially 
inhibited 
Partially 
inhibited 
inhibited 
Pepstatin A 
(aspartyl proteinases) 
Partially 
inhibited  
inhibited inhibited 
Phenanthroline 
(metalloproteinases) 
inhibited Partially 
inhibited 
inhibited 
 
Table 5.1 Summary of inhibitor data 
The table summarizes whether the different inhibitors of antigen processing inhibited the processing and 
presentation of the 84-103 epitope to T cell hybridomas 192.  
 
5.3.2.1 Inhibitors of protein synthesis and transport 
In order to determine whether efficient aggrecan presentation by dendritic cells, macrophages 
or aggrecan-specific B cells required the synthesis and transport of newly synthesised MHC 
class II,  APC were pre-incubated with inhibitors of protein synthesis (cycloheximide) and 
Golgi transport (brefeldin A). Data collected using cycloheximide, suggests that newly 
synthesised MHC class II molecules are required for efficient generation of 84-103/MHC 
class II complexes following aggrecan processing by dendritic cells, macrophages and 
aggrecan-specific B cells (Figure 5.8). However, contrasting data was obtained for 
macrophages using the Golgi transport inhibitor brefeldin A (Figure 5.9). Cycloheximide 
completely abolished the generation of 84-103-MHC class II complexes following aggrecan 
processing by dendritic cells, macrophages and aggrecan-specific B cells. However, brefeldin 
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A only abolished 84-103-MHC class II complex generation by dendritic cells and aggrecan-
specific B cells but had minimal effects on macrophages.  
 
One possible explanation for this observation is that the lowest dose of cycloheximide (10 
μM) also had quite a profound effect on the generation of 84-103 MHC class II complexes 
following incubation of macrophages with p84-103 and a less profound effect following 
incubation of dendritic cells and aggrecan-specific B cells with p84-103. Therefore, 
cycloheximide may be toxic to macrophages and the observed effects on aggrecan 
presentation may be anomalies. Taken this into account it is possible that macrophages and 
not dendritic cells or aggrecan-specific B cells may present the 84-103 epitope on recycling 
MHC class II molecules independently of newly synthesised MHC class II.  Indeed, greater 
molar doses of ammonium chloride used to lower intracellular pH were also required to 
prevent aggrecan presentation by macrophages in comparison to dendritic cells and B cells 
(Figure 5.10). This implies that macrophages may be able to process aggrecan in a higher pH 
environment such as those found in the early endosomes of the recycling pathway. Further 
titrations of cycloheximide may have determined a lower dose able to inhibit aggrecan 
presentation and not p84-103 presentation by macrophages. Alternately different inhibitors of 
the classical pathway of presentation such as emetine (protein synthesis inhibitor) or 
monensin (Golgi transport inhibitor) may have clarified the conflicting macrophage results.   
 
5.3.2.2 Ammonium chloride 
Raising intracellular pH is known to reduce antigen processing and MHC class II loading of 
epitopes derived from antigens such as HEL and the matrix protein of influenza virus 
(Griffin, Chu et al. 1997; Pinet and Long 1998). As the antigen travels through the various 
intracellular compartments the environment becomes increasingly acidic early endosomes 
6.0-6.5, late endosomes 5.0-6.0 and lysosomes 4.5-5.0 (Berzofsky, Brett et al. 1988).  Low 
pH found in late endosomes/lysosomes is required for the activation of various intracellular 
proteinases cathepsin D and dissociation of HLA-DO to allow peptide exchange by HLA-DM 
(Yamashiro and Maxfield 1987; Liljedahl, Winqvist et al. 1998). To assess the requirement 
for low intracellular pH for aggrecan processing dendritic cells, macrophages and aggrecan-
specific B cells C71-4C5 and C71-5F10 were pre-treated with ammonium chloride to raise 
intracellular pH prior to culture with aggrecan. Ammonium chloride inhibited the generation 
of 84-103 MHC class II complexes following aggrecan and not p84-103 processing by 
dendritic cells (Figure 5.10) and aggrecan-specific B cells. This data suggests that a low 
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endosomal pH is required for efficient peptide generation and/or MHC class II loading in 
these APC. The observed effects are not due to toxicity as ammonium chloride had no effect 
on the presentation of p84-103 by these APC.  
Interestingly, macrophages required twice as much ammonium chloride to abolish the 
generation of 84-103 MHC class II complexes following aggrecan processing. This concurs 
with my brefeldin A data that suggests that following aggrecan processing 84-103 may be 
loaded onto recycling epitopes earlier in the endosomal pathway where the pH is higher, thus 
requiring more ammonium chloride to have a substantial effect on the pH environment within 
this compartment. Ammonium chloride had no effect on the generation of 84-103 MHC class 
II complexes following incubation with p84-103 with macrophages. Therefore the observed 
effects were not due to ammonium chloride toxicity.  
 
5.3.2.3 Cysteine proteinase inhibitors 
Cysteine proteinases such as members of the cathepsin family have been shown to play a role 
in both antigen processing and removal of the li chain from the peptide binding groove of 
MHC class II molecules (Honey and Rudensky 2003). To determine the role of cysteine 
proteinases in the generation of 84-103 MHC class II complexes following aggrecan 
processing by dendritic cells, macrophages and aggrecan-specific B cells, APC were pre-
treated with the broad spectrum cysteine proteinase inhibitor E-64d.  
Results showed that pre-incubation of APC with E-64d had no effect on the (Figure 5.11) 
generation of 84-103 MHC class II complexes following incubation with either aggrecan or 
p84-103 by any of the APC. It has been previously shown that 2.5 μM of E-64d is sufficient 
to prevent the presentation of V antigen to V antigen-specific T cells by macrophages (Shim, 
Musson et al. 2006). However, doses up to 100 μM had no effect on the presentation of 
aggrecan by any of the APC. It is possible that the inhibitor was no longer active, and to test 
this I attempted to repeat the findings of Shim et al using the V antigen-specific T cells and 
APC pre-treated with various doses of E-64d and V antigen. However, I was unable to 
optimise this antigen presentation system. Although it is possible that the E64-d inhibitor was 
not active, this is unlikely as several different batches were tested and the observation that 
E64-d has no effect on aggrecan processing by macrophages has been previously shown 
(Lowes 2005). Therefore, these data concur that cysteine proteinases do not play a role in the 
generation of 84-103 MHC class II complexes by macrophages, or by dendritic cells or B 
cells.  
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5.3.2.4 Aspartic proteinases 
Another of the proteinase family implicated as playing a role in both antigen processing and 
li chain removal are the aspartic proteinases including cathepsins D and E (Villadangos, 
Bryant et al. 1999). To investigate the role of aspartic proteinases in the generation of 84-103 
MHC class II complexes following aggrecan processing by dendritic cells, macrophages and 
aggrecan-specific B cells, APC were pre-treated with the aspartic proteinase inhibitor 
Pepstatin A. Pepstatin A abolished aggrecan presentation by aggrecan-specific B cells and 
macrophages suggesting that aspartic proteinases are essential in the generation of 84-103 
complexes by these APC (Figure 5.12). Interestingly, presentation of p84-103 was slightly 
increased in these APC following pre-treatment with pepstatin A. This suggests that aspartic 
proteinases may have a destructive effect on p84-103 processing. Presentation by dendritic 
cells was only partially blocked suggesting that aspartic proteinases are not absolutely 
required by dendritic cells for the generation of the 84-103 epitope and subsequent MHC 
class II loading. In addition pepstatin A did not have any effect on p84-103 presentation by 
dendritic cells suggesting that aggrecan processing by dendritic cells differs in its requirement 
for aspartic proteinases. E64-d data suggests that dendritic cells do not require cysteine 
proteinases for aggrecan processing. Therefore, in the absence of cysteine and aspartic 
proteinases there is still efficient li chain degradation to allow aggrecan presentation by 
dendritic cells. Future work may therefore uncover novel mechanisms of aggrecan processing 
by dendritic cells. 
 
5.3.2.5 Serine proteinases  
Serine proteinases have been implicated in the extracellular or cell surface processing of 
antigens at a neutral pH (von Delwig, Musson et al. 2003). To investigate the role of serine 
proteinases in the generation of 84-103 MHC class II complexes following aggrecan 
processing by dendritic cells, macrophages and aggrecan-specific B cells, APC were pre-
treated with the broad spectrum serine inhibitor DCI or the cysteine and serine inhibitor 
leupeptin. Results showed that DCI abrogated aggrecan presentation by aggrecan-specific B 
cells at a low dose of 10 μM (Figure 5.13). However, dendritic cells required twice this 
amount to abrogate aggrecan presentation and macrophages required 4 times this amount. 
Despite these differences aggrecan presentation and not p84-103 presentation was eventually 
abolished in dendritic cells and macrophages suggesting a role for serine proteinases in the 
optimal presentation of aggrecan by all APC types. p84-103 presentation was slightly 
enhanced following the pre-treatment of aggrecan-specific B cells and macrophages but not 
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dendritic cells with 20 μM of DCI. These data imply that serine proteinases can mediate 
destructive processing of p84-103 and yet are absolutely required for the optimal processing 
of aggrecan in aggrecan-specific B cells and macrophages.  
 
Results from leupeptin inhibition of serine and cysteine proteinases revealed an abrogation in 
both peptide and aggrecan presentation by aggrecan-specific B cells, partial abrogation of 
aggrecan and not p84-103 presentation by dendritic cells and partial abrogation of aggrecan 
and p84-103 presentation by macrophages at a lower leupeptin dose that was recovered at a 
higher dose of 20 μM (Figure 5.14). Leupeptin is a broad range inhibitor and its use is 
difficult to interpret. However, from my results using E64-d (cysteine) and DCI (serine) 
inhibitors, it is most likely that leupeptin is having its effect on serine proteinases for the 
abrogation of aggrecan presentation by the different APC. The finding that it also abrogates 
p84-103 presentation by aggrecan-specific B cells may be due to toxic effects on B cells and 
further optimisation of leupeptin dose may have overcome this problem. The recovery of 
aggrecan and p84-103 presentation by high doses of leupeptin in macrophages may be due to 
the inhibition of proteinases that require a high dose of leupeptin and mediate destructive 
processing of 84-103 in macrophages which is abolished by doses of >20 μM. 
 
5.3.2.6 Metalloproteinases  
Metalloproteinases are a class of proteolytic enzymes shown to regulate the extra-cellular 
environment including normal turnover of the ECM of joint cartilage at a neutral pH 
(Cawston and Young 2010). However, matrix metalloproteinases play a significant 
pathological role in the degradation of cartilage in the inflamed synovium of RA patients 
most likely due to a lack of balance between their own expression and that of their 
endogenous inhibitors TIMPs (Yoshihara, Nakamura et al. 2000). It has been previously 
shown that dendritic cells, macrophages and B cells can secrete these proteinases into the 
extracellular environment possibly contributing to the breakdown of ECM components in 
inflammatory conditions such as RA as well as being involved in the breakdown of the 
basement membrane and cell migration (Kouwenhoven, Ozenci et al. 2002; Melamed, 
Messika et al. 2006; West, Prescott et al. 2008; Elkington, Green et al. 2009). As these 
important APC are equipped to degrade joint components it is possible that they can also 
begin to „process‟ joint autoantigens such as aggrecan extracellularly and prior to uptake for 
presentation to T cells. 
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To investigate the role of metalloproteinases in the generation of 84-103 MHC class II 
complexes following aggrecan processing by dendritic cells, macrophages and aggrecan-
specific B cells, APC were pre-treated with the broad metalloproteinase inhibitor 
phenanthroline.  Results showed that 1000 μM phenanthroline abrogated aggrecan and not 
peptide p84-103 presentation by dendritic cells and aggrecan-specific B cells, yet only 
partially inhibited aggrecan presentation by macrophages. These data suggest a major role for 
metalloproteinases in aggrecan processing by dendritic cells and aggrecan-specific B cells 
and an involvement in aggrecan processing by macrophages. 
A full screen of MMP expression by the different APC types in response to inflammatory 
stimuli such as the exposure to synovial fluid from PGIA diseased mice may confirm which 
MMP are important in a disease scenario. Identification of MMPs involved in antigen 
processing is a novel concept with great scope for further investigation such as how their 
expression is regulated, whether the APC also secrete TIMPs and how is this balanced during 
inflammation. These could be studied by examining APC processing and presentation in 
MMP knockout mice. Furthermore, MMP cleavage sites in candidate autoantigens such as 
aggrecan and collagen II have been identified (see Figure 1.5). Therefore, by identifying 
specific MMP involved in antigen processing their effects on site-specific joint autoantigen 
cleavage can be analysed and possibly even targeted to prevent presentation of arthritogenic 
epitopes and induction of PGIA. 
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5.3.3 Presentation to the 5/4E8 transgenic T cells 
In order to further investigate the efficiency and mechanisms of aggrecan presentation by 
dendritic cells, macrophages and aggrecan-specific B cells I wanted to investigate the 
consequence of antigen presentation and cytokine production in response to presentation to 
the aggrecan-specific TCR transgenic T cells 5/4E8.  All of the previous studies had been 
performed using T cell hybridomas. The disadvantage of T cell hybridomas is that it is not 
entirely clear how typically representative T cells that form hybridomas are. In addition, the 
contribution of oncogenes and cell surface proteins provided by the BW5147 fusion partner 
may not sufficiently represent a physiological situation in vivo. 5/4E8 T cells are efficient at 
mediating PGIA in mice with a susceptible background and 5/4E8 T cells were shown to 
differentiate into Th1 phenotype T cells by the secretion of IL-2 and IFNγ and not IL-4 in 
response to stimulation with aggrecan (Buzas, Brennan et al. 1995; Berlo, van Kooten et al. 
2005; Berlo, Guichelaar et al. 2006). I have confirmed that aggrecan-specific B cells C71-
4C5 were the most efficient at presenting aggrecan to the 5/4E8 T cells, around 5 times more 
efficient than dendritic cells, around 10 fold more efficient than macrophages and 10
3
 fold 
more efficient than the non-specific B cells A20-1 HS (Figure 5.17). The isolated T cell 
population contained a small population of class II positive cells (5%) that mediate 
background proliferation in response to p84-103 or aggrecan. Interestingly, the addition of 
A20-1 HS B cells slightly reduces this background proliferation in response to both p84-103 
and aggrecan. A possible explanation for this is that the A20-1 HS do not contribute to 
aggrecan/p84-103 presentation to 5/4E8 T cells but are able to internalize IL-2. Alternately, 
proliferating A20-1 HS cells are reducing IL-2 responses by physically crowding the wells 
and impeding optimal antigen presentation by contaminating APC.  
 
Cytokine production in response to aggrecan or peptide presentation by the different APC to 
5/4E8 T cells was investigated (Figure 5.18).  Low levels of the anti-inflammatory cytokine 
IL-10 were detected in wells containing 5/4E8 T cells and macrophages, dendritic cells or 
aggrecan-specific B cells. However higher levels were detected in the wells containing A20-1 
HS which do not express a BCR specific for aggrecan.  
Interestingly the opposite effect was found in wells containing p84-103. IL-10 production in 
wells containing p84-103 was higher for dendritic cells, macrophages and aggrecan-specific 
B cells and lowest in wells containing A20-1 HS. As the wells lacking in antigen are just as 
high, the levels of IL-10 were not dependent on aggrecan or p84-103 dose and therefore not 
incremental with antigen presentation. Therefore, it was not possible to conclude whether IL-
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10 detected in the supernatant represents background levels of the assay or non-specific 
levels of IL-10 production from the cells. 
 
High levels of the Th1 cytokine IFNγ were detected in wells containing aggrecan-specific 
clones C71-4C5 and C71-5F10 and increasing levels were detected at higher aggrecan doses 
(up to 10 ng/ml IFNγ), whereas IFNγ levels in wells containing dendritic cells or 
macrophages were low (<2 ng/ml IFNγ) with no IFNγ detected in wells containing A20-1 
HS.  These data imply that the major APC responsible for Th1 responses to aggrecan are 
aggrecan-specific B cells. This is further justified by lower production of IFNγ in response to 
C71-5F10 than C71-4C5 as C71-4C5 is more efficient at aggrecan presentation to the 5/4E8 
T cells. A20-1 HS which are poor at aggrecan presentation to 5/4E8 T cells did not produce 
any IFNγ response. Interestingly, the opposite effect was observed in response to p84-103 
presentation to 5/4E8 T cells. In these experiments macrophages produce the largest IFNγ 
response up to 6ng/ml. Dendritic cells and C71-4C5 produced low levels in response to >1nm 
p84-103 and A20-1 HS and C71-5F10 did not produce any IFNγ. Again IFNγ responses by 
macrophages, dendritic cells and C71-4C5 were dose dependent implying that production is 
in response to antigen presentation. Control wells containing APC and antigen only were 
carried out for each cytokine and no IL-10 or IFNγ was detected, implying that either the 
cytokines are produced by T cells or by APC following T cell interaction. Indeed, Harris and 
colleagues have demonstrated that B cells are able to produce IFNγ in response to Th1 cell 
interaction or in response to the cytokines IL-12 and IL-18 (Harris, Goodrich et al. 2005). 
Therefore, the IFNγ response detected in wells containing aggrecan, C71-4C5 and 5/4E8 T 
cells may be a result of IFNγ production by 5/4E8 T cells which is then amplified by more 
IFNγ produced by C71-4C5 cells.  It would be interesting to extend the study to a full screen 
of Th1, Th2 and Th17 cytokines, and controls such as non-aggrecan-specific T cells would 
have confirmed that the cytokine data was dependent on aggrecan or p84-103 presentation to 
5/4E8 aggrecan-specific T cells.  However, aggrecan-presentation by the aggrecan-specific B 
cells was as efficient as that of dendritic cells and produced more of the pro-inflammatory 
cytokine IFNγ, highlighting an important role for aggrecan-specific B cells not only as highly 
efficient aggrecan presenting cells but also in mediating the IFNγ Th1 phenotype observed in 
the PGIA model. 
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5.4 Summary  
 Aggrecan-specific B cells are as efficient as dendritic cells at presenting low doses 
<0.001 nM deglycosylated aggrecan to the T cell hybridoma 192. They are 10
2
 fold 
more efficient than macrophages and at least 10
4
-10
5
 fold more efficient than A20-1 
HS non-specific B cells. 
 Aggrecan presentation by dendritic cells and aggrecan-specific B cells is dependent 
on the „classical‟ pathway of MHC class II presentation. My data also provides 
evidence that macrophages utilise both the „classical‟ and the „recycling‟ pathways of 
antigen presentation. 
 Aggrecan presentation by dendritic cells, macrophages and aggrecan-specific B cells 
does not require cysteine proteinases.  
 Aggrecan presentation by dendritic cells and aggrecan-specific B cells is dependent 
on serine and metalloproteinases. Macrophages are reliant on serine proteinases yet 
only require metalloproteinases for optimal aggrecan presentation.  
 Aggrecan presentation by aggrecan-specific B cells and macrophages is dependent on 
aspartyl proteinases. Dendritic cells only require aspartyl proteinases for optimal 
aggrecan presentation.  
 Aggrecan-specific B cell clones C71-4C5 are the most efficient APC type at 
presenting aggrecan to T cells isolated from TCR-5/4E8 transgenic mice. 
 High IFNγ responses are detected in assay supernatant when aggrecan is presented to 
T cells isolated from TCR-5/4E8 transgenic mice by aggrecan-specific B cells in 
comparison to dendritic cells macrophages and nonspecific B cells. 
  IL-10 (up to 4ng/ml) is detected in assay supernatant when p84-103 is presented to T 
cells isolated from TCR-5/4E8 transgenic mice by macrophages, dendritic cells, 
aggrecan-specific B cells and A20-1HS.  IL-10 produced does not appear to be 
dependent on p84-103 dose.  
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6. General discussion 
Studies over the past few years have identified elevated levels of aggrecan cleavage products, 
aggrecan-specific antibodies and aggrecan-specific T cells in RA patients (Poole and Dieppe 
1994; Zou, Zhang et al. 2003; Vynios, Tsagaraki et al. 2006). In addition, germinal centre 
like structures, containing proliferating B and T cells have been found in many RA patients 
(Weyand, Goronzy et al. 2000). Rituximab is an anti-CD20 therapy that depletes both pre and 
mature B cells and has been used successfully to treat RA patients where other therapies have 
failed (Edwards and Cambridge 2006). This evidence, taken together with an abundance of 
data collected from mouse models of rheumatoid arthritis implicate a role for aggrecan and 
autoreactive aggrecan-specific T and B cells in the perpetuation of RA. Future studies to 
verify the mechanisms of aggrecan processing and presentation by B cells may uncover 
future therapeutic targets with which to ameliorate antigen-specific autoimmune diseases. 
 
Therefore, the aims of this project were very much focussed on investigating a role for 
antigen-specific B cells as APC in a model of rheumatoid arthritis and examining the 
mechanisms by which B cells process and present the candidate rheumatoid arthritis 
autoantigen aggrecan.   
 
I have successfully isolated aggrecan from bovine cartilage and removed chondroitin and 
keratanase sidechains to generate both glycosylated and deglycosylated forms. In addition I 
have modified deglycosylated aggrecan by the addition of biotin molecules for use as a 
molecular tool with which to determine the binding efficiency of both aggrecan-specific 
antibodies and aggrecan-specific BCRs. Finally, I have generated a reduced and alkylated 
form of aggrecan with which to study the binding efficiency of a previously generated anti-
aggrecan antibody 1-C-6 (kindly donated by Dr Bruce Caterson) and the 1-C-6 BCR 
construct that I have generated during this project. In addition, this reduced and alkylated 
form of aggrecan has enabled me to determine the importance of structural integrity of 
aggrecan and the effects of this loss of structure on the recognition by antibody and BCR 
against native intact aggrecan.  
 
To develop and in vitro aggrecan presentation system I have also generated bone marrow 
derived dendritic cells and macrophages from BALB/c (H-2
d
) mice to use as APC for 
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presentation to both previously generated as well as several newly generated T cell  
hybridomas that recognise the various epitopes within the G1 and G3  domains of aggrecan. 
 
Importantly, I have also generated several cloned aggrecan-specific B cell line able to present 
the immunogenic deglycosylated form of aggrecan at least as efficiently as the „professional‟ 
APC dendritic cells, 10
2 
fold more efficiently than macrophages and 10
4
-10
5
 fold more 
efficiently than non-specific B cells. Upon examination of the kinetics of aggrecan 
presentation by these aggrecan-specific cell lines, I have determined that aggrecan-specific B 
cells are again as efficient as dendritic cells at presenting aggrecan at a low APC: T cell ratio 
of 1:83 and both require at least 5 h for optimal aggrecan presentation.  
 
To determine the mechanisms by which APC process and present aggrecan to 84-103 specific 
T cell hybridomas I have optimised the fixation conditions for dendritic cells, macrophages 
and aggrecan-specific B cells. Using a panel of known inhibitors of antigen processing I have 
established that both dendritic cells and aggrecan-specific B cells present aggrecan via the 
„classical pathway‟ on newly synthesised MHC class II molecules with a requirement for a 
low pH environment indicative of the classical pathway and processing within late 
endosomes. However, although aggrecan presentation by macrophages was inhibited by 
cycloheximide, implying a requirement for newly synthesised MHC class II, inhibition of 
presentation was less efficient using brefeldin A to prevent Golgi transport of MHC II and 
higher doses of ammonium chloride required to raise pH. Therefore, it is possible that in 
contrast to dendritic cells and aggrecan-specific B cells, macrophages are able to present 
aggrecan on recycling MHC class II earlier in the endosomal pathway. 
 
Inhibitors of cysteine, aspartyl, serine and metalloproteinases were used to determine the 
families of proteolytic enzymes involved in aggrecan processing by the different APC types. 
Data from these experiments revealed the requirement of aspartyl proteinases by 
macrophages and aggrecan-specific B cells. However, dendritic cells showed only a partial 
requirement for aspartyl proteinases. In addition, none of the APC showed any requirement 
for cysteine proteinases for aggrecan processing and presentation. Interestingly, I have found 
that serine proteinases are essential for the generation of the 84-103 epitope by all APC types. 
Serine proteinases are extracellular enzymes that function at neutral pH, which strongly 
implicates a role for extracellular processing of aggrecan by all APC types. Furthermore, 
generation of the 84-103 epitope by dendritic cells and aggrecan-specific B cells was 
 238 
completely reliant on metalloproteinases and partially required by macrophages which again 
are extracellular enzymes active at a neutral pH. This finding in conjunction with previous 
studies in our laboratory is novel and suggests that aggrecan processing begins in the 
extracellular environment and not following antigen uptake.  Indeed, as the RA synovium is 
rich in inflammatory mediators it is easy to envisage a scenario where initial aggrecan 
cleavage by MMPs releases fragments into the extracellular milieu containing infiltrating 
immune cells including T cells, B cells, dendritic cells and macrophages. In this environment 
APC activated by the pro-inflammatory stimuli are required to secrete additional MMP to 
further breakdown these large matrix degradatitve fragments prior to their uptake and 
processing within the cell. Furthermore, as this cascade is dependent on an initial localised 
inflammatory episode within the joint, under non-diseased circumstances there would be 
limited inflammatory cell infiltrate, hence no APC activation, secretion of MMP or 
presentation of this important joint autoantigen. Also, it is possible that other joint 
components such as the candidate autoantigen collagen II are processed by similar 
mechanisms but further investigation is required to clarify the role of MMP in the 
presentation of other joint components.  
 
Time prevailing, expression profiling of aggrecan-specific B cells, dendritic cells and 
macrophages to define MMP or ADAMTS production under either resting, aggrecan 
stimulated or proinflammatory stimuli  may have given some idea of their relative 
contribution to aggrecan processing. Following from this particular MMP or ADAMTS 
shown to be significantly upregulated could be investigated more closely to determine a) The 
level of secretion into the extracellular environment and b) the effects on aggrecan processing 
in vitro via MMP-aggrecan co-culture followed by Western blotting. In addition, I would 
have liked to determine the half-life of any MMP secreted by aggrecan-specific B cells, as 
another possibility is that local production of MMP in B cell rich environments such as 
ectopic germinal centres observed in some RA patients may have a contributing effect on the 
breakdown of cartilage directly. This could be examined in patients with ectopic germinal 
centres in comparison with those that have either none or diffuse T and B cell aggregates. 
 
Although thus far I have elucidated that aggrecan-specific B cells are as efficient as dendritic 
cells and appear to process aggrecan in a similar way, I have not elucidated a novel role for B 
cells in the processing and presentation of aggrecan. However, studies using the PGIA mouse 
model of arthritis have implicated B cells as essential mediators of disease required for 
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optimal T cell activation and severe disease progression aside from there ability to produce 
antibodies. Therefore, as I have examined aggrecan presentation kinetics and processing 
requirements, another possibility for the importance of B cells in PGIA mice was cytokine 
production either directly by the B cells themselves or as a result of antigen presentation to 
aggrecan-specific B cells. 
 
To examine this possibility I examined aggrecan presentation by the different APC to isolated 
T cells from 5/4E8 TCR transgenic mice expressing an aggrecan-specific TCR for the epitope 
84-103. (These T cells represent a fair approximation of a physiological scenario of aggrecan 
presentation to naïve aggrecan-specific T cells). Data from these experiments concurred with 
my findings using the T cell hybridomas 192 that confirmed aggrecan-specific B cells were 
as efficient at presenting aggrecan to T cells as dendritic cells. However, upon examination of 
the amount of pro-inflammatory cytokine IFNγ present in supernatants following aggrecan 
presentation by the different APC, I found that aggrecan presentation by aggrecan-specific B 
cells promoted a 4-fold greater IFNγ response than that of dendritic cells, macrophages or 
nonspecific B cells. 
 
PGIA is reportedly dependent on IFNγ and indeed levels of this pro-inflammatory cytokine 
can mediate the balance between T cell responses in mouse models.   
Therefore, I have found  a novel role for aggrecan-specific B cells as important APC involved 
in aggrecan-presentation and in mediating a Th1 response in vitro, as well as elucidating a 
novel role for MMPs in aggrecan processing and presentation by APC. 
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